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ABSTRACT 
Autism spectrum disorders (ASDs) are neurodevelopmental conditions diagnosed by 
atypical behaviours in social interaction and communication, along with stereotyped, restricted 
and repetitive behaviours. The exact cause of ASDs is unclear but is likely from a combination 
of genetic and environmental influences. Various clinical studies have identified an association 
between irregular lipid signalling and ASDs. 
Lipids are major components of brain cells and serve as a supply for signalling molecules 
such as prostaglandin E2 (PGE2). Cyclooxygenase-2 (COX-2) is the key enzyme responsible for 
PGE2 production in the brain. The COX-2/PGE2 signalling pathway is essential for development 
and maintenance of healthy neural functions. Genetic defects or exposure to various 
environmental agents—such as infections or drugs—can disrupt the levels of PGE2.  
However, investigation into the molecular mechanisms by which disrupted COX-2/PGE2 
signalling or irregular PGE2 levels might affect the development of the nervous system and 
contribute to the pathogenesis of ASDs is sparse. Addressing this gap in knowledge was the main 
purpose of this dissertation. We found that PGE2 interacts with the key developmental Wnt 
signalling pathway in vitro by affecting neuroectodermal stem cell motility and proliferation 
(Study 1) and by promoting their differentiation into neurons (Study 2). In addition, prenatal 
PGE2 exposure disrupted cell density and increased migration in ASD-implicated areas of the 
mouse brain (Study 3). Decreased PGE2 (via COX-2-deficiency) or increased PGE2 in mice also 
led to abnormal microglial density and morphology (Study 4). Lastly, behavioural outcomes 
related to ASDs were quantified in COX-2-deficient and PGE2-exposed mice (Study 5 and 6). 
Our findings support epidemiological and clinical reports implicating the COX-2/PGE2 
pathway in ASDs. We provide novel evidence that disturbances in the COX-2/PGE2 pathway 
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results in aberrant neurodevelopment, including molecular, cellular, and behavioural differences 
analogous to those described in ASDs. Importantly, this array of research studies is one of the 
first to investigate mechanisms related to ASDs in both males and females and at various 
developmental stages, which is greatly underrepresented in the current literature. Altogether, this 
dissertation exposes the COX-2/PGE2 pathway as an autism candidate pathway and offers 
important insight into the complex, unknown etiology of ASDs. 
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CHAPTER 1. 
1.1. General Introduction  
Lipids serve as important building blocks in the brain and are essential for the production 
of crucial developmental signalling molecules such as prostaglandin E2 (PGE2). Endogenous 
production of PGE2 in the brain is predominately controlled through the enzymatic activity of 
cyclooxygenase-2 (COX-2), which expression is both constitutive and inducible in the nervous 
system (Kirkby et al., 2016).  Insufficient dietary supplementation, genetic defects, or influence 
of various environmental agents such as exposure to infections, pesticides, air pollution, or 
specific drugs have all been shown to cause abnormal lipid metabolism and disrupt the levels of 
PGE2 (Wong et al., 2015, Wong and Crawford, 2014). These same factors have also been 
associated with Autism Spectrum Disorders (ASDs). For example, clinical studies have revealed 
that prenatal exposure to the drug misoprostol, an analogue to PGE2, during the first trimester of 
pregnancy may lead to neurodevelopmental aberrations, including Mobius sequence and ASDs 
(Miller et al., 2005, Bandim et al., 2003, Schuler et al., 1999, Costa, 1998, Gonzalez et al., 1998). 
Polymorphisms of the gene that encodes COX-2 called Ptgs2 have been associated with ASDs 
and related core symptoms including abnormalities in communication, social interaction, and 
overactivity (Yoo et al., 2008). Despite clinical and epidemiological evidence that the COX-
2/PGE2 signalling pathway may have etiological significance to the pathogenesis of ASDs (see 
Chapter 2 for review of literature), basic research surrounding the function of PGE2 in the 
developing brain and its potential implications in ASDs are sparse. The studies presented in this 
dissertation provide a range of molecular, cellular, and behavioural research conducted in cell 
and mice model systems, revealing mechanisms by which abnormalities of the COX-2/PGE2 
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pathway can influence brain development and result in pathologies that may contribute to the 
cause of ASDs. 
 
1.2. Objectives and Hypothesis 
The studies of this dissertation in its entirety aim to address the overarching objectives:   
To discover the molecular mechanisms by which abnormal signalling of lipid mediators, 
specifically prostaglandin E2 (PGE2), may affect brain development and contribute to ASDs-
related pathologies. Another important objective was to describe sex differences in mouse 
studies, which are often overlooked although critical for understanding disorders such as ASDs. 
Overall Hypothesis: Abnormalities to the COX-2/PGE2 lipid signalling pathway disrupts normal 
brain development that leads to molecular characteristics and behaviours associated with ASDs 
in a sex-dependent manner.  
 
Specific objectives of the current dissertation were:         
Using an in vitro cell model (Study 1 and 2):              
1)  To study the effects of PGE2 exposure on the proliferation and migration of early 
neuroectodermal (NE-4C) stem cells. 
2)  To determine if an elevated PGE2 level influences the differentiation of NE-4C stem cells. 
3) To investigate the possible interaction between the PGE2 pathway and a major 
developmental pathway of the nervous system called the Wnt signalling pathway. 
Using an in vivo mouse model (Study 3 thourgh 6): 
4)  To verify in vitro findings and study the consequences of elevated maternal PGE2 levels on 
cell proliferation and neuronal migration in the developing brain of offspring mice. 
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5) To describe if altered COX-2/PGE2 signalling disrupts microglial density and morphology 
in the developing brain. 
6)  To examine the behavioural outcomes of COX-2-deficient and PGE2-exposed mice. 
 
1.3. Dissertation Layout 
The general introduction (Chapter 1) is followed by a literature review (Chapter 2) on 
lipid signalling with a focus on major lipid metabolite PGE2 and its significance in ASDs. To 
address the objectives of my dissertation, six studies were conducted and are presented in 
manuscript style in the subsequent chapters. The first two studies utilized NE-4C stem cells as an 
in vitro model to study the fundamental roles of PGE2 on neuronal cell function. The next four 
studies were completed in vivo to examine the sex-dependent molecular, cellular, and 
behavioural consequences of altered COX-2/PGE2 levels during early brain development.  
The first study (Chapter 3) examined the possible interaction of PGE2 and Wnt signalling, 
as well as the resulting effects on cell motility and proliferation. The second study (Chapter 4) 
focused on the effects of increased PGE2 in neuronal differentiation. The third study (Chapter 5) 
explored the consequence of PGE2 exposure on neuronal cell density and neocortical migration 
in the mouse brain. The fourth study (Chapter 6) investigated how elevated PGE2 (in a PGE2-
injected model) and decreased PGE2 (in a COX-2-deficient model) levels effect microglial 
density and morphology. Lastly, the fifth and sixth studies (Chapter 7 and 8) described the 
behavioural outcomes of PGE2 exposure and COX-2-deficiency in mouse offspring. 
The closing chapter of this dissertation (Chapter 9) provides an overview of the key novel 
findings across all studies and our contributions to the existing literature on ASDs. This chapter 
will also discuss the influence of abnormal COX-2/PGE2 signalling on neurogenesis during brain 
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development, the convergence of the COX-2/PGE2 and Wnt signalling pathways, and its distinct 
role in the male and female brain at various developmental ages. Our findings confirm what has 
been suggested in various clinical studies by providing new scientific evidence for the link 
between the COX-2/PGE2 pathway and the etiology of ASDs.  
 
1.4. Overview of Experimental Models  
 Over 90% of the mouse and human genomes are analogous (Waterston et al., 2002) 
indicating that the mouse model can serve as a valuable model for studying human processes 
such as early development. The studies within this dissertation utilize murine cell (Study 1 and 2) 
and animal (Study 2, 3, 4, 5, and 6) models.  
 
In vitro model for Study 1 and 2: The complete gestational period of a mouse is around 20 days 
(Xu et al., 2010, Lanman and Seidman, 1977). At the 8-9th day of gestation, pluripotent stem 
cells specialize into tissue-specific neural stem cells, which are destined to become neuronal and 
glial cells. Neuroectodermal (NE-4C) stem cells originate from prenatal day 9 of the mouse 
embryo (Schlett and Madarasz, 1997). They undergo in vitro migration, aggregation, 
neurosphere formation, and differentiation similar to processes that occur in the developing brain 
(Kelava and Lancaster, 2016) and thus serve as an appropriate model to investigate the effect of 
abnormal PGE2 signalling on neuronal function.  
 
In vivo model for Study 2, 3, 4, 5, and 6: To study the molecular, cellular, and behavioural 
effects of altered PGE2 signalling in the animal model, mice offspring prenatally exposed to 
PGE2 or deficient in the PGE2-producing enzyme, COX-2, were examined.  
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In the PGE2-exposed mouse model, C57bl/6 pregnant mice were subcutaneously injected 
with 16, 16-dimethyl prostaglandin E2 (dmPGE2) on embryonic day 11 (E11). A subcutaneous 
injection was administered to the mother to mimic an increase in PGE2 levels in the maternal 
environment that would result from exposure to infections or inflammation (Sugimoto and 
Narumiya, 2007). dmPGE2 is a stable analog of PGE2 that is often used in vivo (Cook et al., 
2016, Cruz Duarte et al., 2012, Ohno et al., 1978). It also better mimics the increase of PGE2 that 
may arise due to factors that have been associated with ASDs, including inflammation, 
infections, and oxidative stress. E11 was chosen as the day of dmPGE2 administration for two 
reasons. First, the onset of neurogenesis in the mouse brain occurs at this time point (Zhang and 
Jiao, 2015). Second, this period corresponds to the time reported in human studies in which 
misoprostol, a PGE2 analog, was misused for the termination of pregnancy resulting in the 
manifestation of Moebius syndrome and autism symptoms (Bos-Thompson et al., 2008, Miller et 
al., 2005, Bandim et al., 2003, Schuler et al., 1999, Costa, 1998, Gonzalez et al., 1998, Pastuszak 
et al., 1998). The PGE2-exposed mouse model was used in Study 2, 3, 4, and 6. 
 COX-2-deficient mice exhibit a decrease in the level of PGE2 in the brain (Bosetti et al., 
2004). COX-2- knockin (KI) mice, also known as B6.129S6(FVB)-Ptgs2 tm1.1Fun/J mice, were 
investigated. COX-2- KI mice are a genetic mouse model for selective COX-2 inactivation. They 
were made by a targeted point mutation of the Ptgs2 gene, specifically, a substitution of the 
Y385F amino acid. This mutation leads to the complete inhibition of COX-2 activity (and its 
production of PGE2) but downstream peroxidase activity remains unaltered (Yu et al., 2006). 
COX-2- KI founder mice were backcrossed for at least 5 generations to wild-type 
129S6/SvEvTac mice to generate the COX-2-deficient mouse model used in Study 4 and 5.  
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 Handling and behavioural testing of all mouse subjects were conducted by the same 
female researcher to avoid increased stress levels in rodents reported when handling is done by 
male researchers (Sorge et al., 2014). 
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CHAPTER 2.   
Literature Review: Lipid Signalling in Autism Spectrum Disorders  
 
Manuscript 1 Citation:  Wong C. and Crawford DA. (2014). Lipid signalling in the Pathology 
of Autism. In: Patel V., Martin C., Preedy V. (Eds.) Comprehensive Guide to Autism: Springer 
Reference. Springer-Verlag Berlin Heidelberg. Pages 1259-1283. 
 
Manuscript 2 Citation:  Wong C., Wais J., and Crawford DA. (2015). Prenatal exposure to 
common environmental factors affects brain lipids and increases risk of developing Autism 
Spectrum Disorders. European Journal of Neuroscience. 42(10):2742-2760. 
 
Components of this review have been published in a book chapter with the publisher, 
Springer Reference, and in an invited review in the journal, European Journal of 
Neuroscience. All writings presented in this section were composed by Christine T. Wong 
and edited by Dr. Dorota A. Crawford. Copyright permissions can be found in Appendix B.  
 
The research in our lab stems from the clinical studies presented in the two published 
manuscripts. Our main objective was to review the environmental and genetic risk factors that 
affect lipid signalling and result in Autism Spectrum Disorders (ASDs). The important role of 
lipids in the brain is summarized, followed by an introduction to the signalling pathway of a 
major lipid-derived molecule, prostaglandin E2 (PGE2). The current literature on the connection 
between the PGE2 signalling pathway and ASDs will then be presented, including topics such as 
genetic abnormalities, oxidative stress, immunological factors, and exposure to common 
environmental agents. This chapter will provide an overview of key findings and concepts 
related to the field of research in this dissertation. 
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2.1. Introduction to Autism Spectrum Disorders 
Autism is a neurodevelopmental disorder that is categorized under the umbrella term 
Autism Spectrum Disorders (ASDs), which also includes Asperger’s and Fragile X syndrome. 
Over recent years, there has been a dramatic increase in the prevalence of ASDs in children. 
Autism is behaviourally defined by a combination of qualitative impairments in social 
interaction, reciprocal communication, and abnormalities in restrictive and stereotyped patterns 
of behaviours that typically emerge at 3 years of age (Pelphrey et al., 2014, Folstein and Rosen-
Sheidley, 2001). However, increasing lines of evidence suggest that differences between children 
with autism and typically developing children are already present at the time of birth (Nelson et 
al., 2001). The Centers for Disease Control and Prevention reported that 1 in 88 children had an 
ASD in 2008 (CDC, 2012) and in 2010 the prevalence increased to 1 in 68 children (CDC, 
2014). Furthermore, school-aged boys were more than four times as likely to have an ASD 
compared to their female counterparts (Blumberg et al., 2013). Although some argue that the 
increased prevalence is the result of changes in diagnostic criteria, this cannot fully explain the 
observed increases (Hertz-Picciotto and Delwiche, 2009). ASDs are heterogeneous disorders, 
etiologically and phenotypically, and it is well established that the etiology of ASDs involves the 
complex interaction of genetic composition and exposure to environmental factors (Kim and 
Leventhal, 2015, Banerjee et al., 2014, Hall and Kelley, 2014, Rossignol et al., 2014, Tordjman 
et al., 2014, Meek et al., 2013, Herbert, 2010, Muhle et al., 2004). Since genes do not evolve 
very rapidly in evolution, influence of environmental factors might contribute to the 
developmental differences in ASDs through modifications in gene expression. 
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2.1.2 Development of ASDs 
Emerging literature suggests the pathogenesis of autism may occur as early as prenatal 
development (Croen et al., 2011, Atladottir et al., 2010, Brown et al., 2008, Arndt et al., 2005). 
The critical period of brain development occurs prenatally and during this period, gross changes 
are occurring throughout the body, particularly in the nervous system. Neural stem cells 
proliferate, migrate and differentiate into specialized neurons and astrocytes (Kornblum, 2007). 
The rapid changes in the nervous system involve carefully guided coordination, accomplished by 
tightly regulated signalling molecules (Vaccarino et al., 2001), including PGE2 and Wnt. For 
these reasons, the critical period is particularly sensitive to environmental insults that might 
influence the level of these important molecules. Major congenital anomalies, such as neural 
tube defects and mental retardation, could occur as a result of exposure to harmful environmental 
agents during the first trimester of pregnancy (Moore and Persaud, 1998). 
 
2.1.3. Genetic and Environmental Contributions to ASDs 
 
Family and twin studies have provided support for a strong genetic component in the 
etiology of ASDs. The first twin study examining autism was in 1977 and provided breakthrough 
evidence on the involvement of genetics in the disorder (Folstein and Rutter, 1977). It reported 
that a much higher concordance was seen in monozygotic twins compared to dizygotic twins, 
and it has since been verified in several studies (Hu et al., 2006, Bailey et al., 1995). Moreover, 
the risk for siblings of individuals with autism to be affected or to display milder autistic 
behaviours is higher than the average population (Constantino et al., 2010). Further support for a 
genetic contribution to ASDs comes from a study that suggests relatives may be at a higher risk 
of being affected by difficulties related to autistic behaviours (Bailey et al., 1998). There has 
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been no single gene associated with autism, but instead it is likely that multiple genes are 
involved (Muhle et al., 2004). Candidate genes have been identified through various techniques 
such as genome screening (Risch et al., 1999), homozygous haplotype mapping (Casey et al., 
2012) and using various in vivo and in vitro models (Kumar et al., 2011, Meehan et al., 2011). 
Genetic variations could be inherited or de novo and these genetic differences as well as possible 
deviations in gene expression could be promoted by environmental factors. Human studies have 
provided evidence for candidate genes, while animal studies performed in vivo and in vitro have 
enabled further biological characterization of these genes. 
Although twin studies have provided evidence for the heritability of ASDs, the most 
recent evidence suggests that in monozygotic twins (MTs) that share the same genetic material, 
the concordance rates range from 43-88% (Ronald and Hoekstra, 2014, Hallmayer et al., 2011, 
Lichtenstein et al., 2010, Stilp et al., 2010, Rosenberg et al., 2009). Additionally, MTs that are 
diagnosed with ASDs often display different subsets of autism symptoms (Mitchell et al., 2009, 
Belmonte and Carper, 2006, Kates et al., 2004, Kates et al., 1998). Furthermore, the concordance 
rates for dizygotic twins are around double that of non-twin siblings, suggesting that the uterine 
and maternal environment likely contributes to autism concordance rates (Bohm et al., 2013). 
This suggests that investigations beyond heritable genetic differences should be taken to uncover 
the etiologies of ASDs. Various studies on ASDs using animal models and human samples have 
shown significant differences in gene expression during pre- and postnatal brain development 
(Gupta et al., 2014, Bhogal et al., 2013, Garbett et al., 2008). Gene expression studies in 
individuals with ASDs have revealed dysregulation of particular pathways, including those 
involved with the immune response, cell communication and motility, and neuronal 
differentiation (Gupta et al., 2014, Garbett et al., 2008). Given that the expression of genes as a 
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result of gene-environment interactions determine phenotype outcomes (Kanherkar et al., 2014), 
exposure to environmental risk factors during vulnerable developmental periods may alter gene 
expression and contribute to the phenotypes of ASDs. The exponential rise in the prevalence of 
ASDs and the increasing evidence for the contribution of environmental factors in the etiology of 
these disorders has prompted urgency in determining the potential exogenous causes and 
underlying mechanisms involved (Landrigan et al., 2012). Environmental factors such as 
increased oxidative stress (which could be due to infections and inflammation or exposure to 
toxins), dietary imbalances of omega-3 and -6, and use of the drug misoprostol (prostaglandin 
type E analogue) can interfere with the homeostasis of lipid metabolism (Tamiji and Crawford, 
2010). Lipids are particularly important to brain development and will be reviewed in Chapter 
2.2. 
The development of the human brain and nervous system is extraordinarily complex, 
involving time-sensitive events that are impacted by an ongoing interplay of genetic and 
environmental factors. Human brain development begins in the 3rd week of gestation and 
continues after birth through to adolescence, and arguably into adulthood (Stiles and Jernigan, 
2010). Normal prenatal development of the brain—including events like cell fate specification 
and axon guidance—requires highly specific signalling from key biological pathways (Charron 
and Tessier-Lavigne, 2005).  These pathways carefully regulate the expression of genes, which 
can be turned on or off during different stages of development and expressed in specific 
concentration gradients (Charron and Tessier-Lavigne, 2005). The environment, endogenous 
signals found within the brain and exogenous agents originating outside the body, can influence 
gene expression during development (Andersen, 2003). Exposure to exogenous insults can 
perturb the normal developmental trajectory during the critical prenatal and perinatal period 
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(Andersen, 2003). The foundations for brain formation are being established during this period, 
making it particularly susceptible to harmful environmental agents that may occur through 
maternal exposure (Tannahill et al., 2005, Moore and Persaud, 1998).  
Since the human brain contains high lipid content, healthy development of the brain relies 
on the supply and function of these macromolecules (Calderon and Kim, 2004). Fatty acids are 
the simplest form of lipids that serve as the building blocks for more complex lipids such as 
phospholipids, cholesterol, and vitamin E. A sufficient supply and balance of fatty acids is 
integral to cell membrane integrity, which is an indicator for healthy development, maintenance, 
and function of the nervous system (Lawrence, 2010). Environmental factors such as diet, 
increased levels of oxidative stress, and exposure to infections and inflammation can lead to 
altered lipid metabolism (Wong and Crawford, 2014, Tamiji and Crawford, 2010, Adibhatla and 
Hatcher, 2008). Lipid mediators such as prostaglandin E2 (PGE2) are key molecules important in 
the development and function of the human brain (Carlson, 2009, Innis, 2007, Uauy and 
Dangous, 2006).  
 
2.2. Introduction to Lipids 
Fatty acids are the simplest type of lipids that serve as building blocks for more complex 
lipids such as phospholipids, cholesterol, and vitamin E, which are integral to cell membranes 
(Fig. 2-1). Abnormal metabolism and imbalances of these three complex lipids have all been 
associated with autism spectrum disorders (ASDs) and will be outlined in following sections. 
Fatty acids can be saturated, monounsaturated, or polyunsaturated; the latter will be elaborated 
upon due to its link with ASDs. Essential fatty acids (EFAs), also called polyunsaturated fatty 
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acids (PUFAs), play an important role in maintaining the structural and functional integrity of 
the central nervous system (CNS). They serve as major components of neural cell membrane 
phospholipids and are necessary for the modulation of ion channels, enzymes, and receptor 
activity (Boland et al., 2009, Guizy et al., 2008). PUFAs must be obtained through the diet since 
the ability to synthesize them is limited. The two major types of PUFAs are omega-6 linoleic 
acid (LA; 18:2n-6) and omega-3 α-linolenic acid (ALA; 18:3n-3), which are converted to 
arachidonic acid (AA, 20:4n-6) and to eicosapentaenoic acid (EPA, 20:5n-3) or docosahexaenoic 
acid (DHA, 22:6n-3), respectively (Haag, 2003) (Figs. 2-1 and 2-2). 
One  of  the  most  commonly  derived  PUFAs  from  cell  membranes  is  AA. Through 
the action of phospholipase A2 (PLA2), an enzyme important for cell membrane maintenance, 
AA is cleaved from membrane phospholipids and further metabolized to potent bioactive 
messengers including prostaglandins, thromboxanes, leukotrienes, lipoxins, and cannabinoids. 
The metabolic products of AA are collectively known as eicosanoids. 
 
2.2.1. The Importance of Lipids in the Brain 
Compared to all organs other than adipose tissue, the human brain has the highest 
percentage of lipids by mass, with approximately 60 % of its dry mass being lipids – specifically 
phospholipids and PUFAs (Lawrence, 2010). AA and DHA/EPA are the most abundant PUFAs 
in the brain (Sastry, 1985), and a sufficient supply of and balance between omega-6 and omega-3 
fatty acids are important for plasma membrane integrity, which is tightly integrated with healthy 
development, maintenance, and function of the nervous system (Lawrence, 2010). An extensive 
body of research has been devoted to determining the role of fatty acids in the nervous system. 
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Rapid brain growth begins during prenatal fetal development and continues postnatally 
for 2 years following birth. The majority of brain growth occurs during the fetal stage, and at 
birth, a newborn’s brain is already 70 % the size of the adult brain (Clandinin et al., 1994). There 
is a high PUFA demand during the brain growth spurt (Lauritzen et al., 2001), and during this 
period, the omega-6 and omega-3 fatty acid content in grey and white matter increases 
significantly (Martinez, 1992). The importance of PUFAs in fetal development is emphasized by 
the high lipid content found in breast milk, as well as the increasing proportions of PUFAs in the 
phospholipids when comparing levels found in the maternal blood to the placenta and to the fetal 
brain (Crawford et al., 1981). This process ensures that the high concentrations of long-chain 
PUFAs necessary for the developing brain can be acquired (Crawford et al., 1989). 
Healthy development of the human brain relies greatly on the functions of lipids 
(Calderon and Kim, 2004). For example, AA and DHA are important for retinal development 
and vision (Hoffman et al., 2009), neuroplasticity and signal transduction (Wu et al., 2008), 
inflammation (Ferrucci et al., 2006), learning and memory (Su, 2010), and sleep (Ladesich et al., 
2011). The final structure and breakdown of phospholipids (AA and DHA precursors) represent 
a unique interaction between genetic and environmental factors. Proper brain functioning relies 
on the supply of dietary PUFAs and the release of their metabolites from membrane 
phospholipids through the activity of enzymes such as PLA2 (Yehuda et al., 1999) (Fig. 2-3). 
Therefore, alterations in phospholipid metabolism may affect normal functions of the CNS. 
Anomalies in lipid concentrations due to insufficient dietary intake or aberrant lipid regulation 
may lead to irregular lipid profiles and signalling and could be highly detrimental to the 
developing brain. Recent literature provides sufficient evidence that dysregulation of the lipid 
metabolic pathway may be an underlying biological component involved in the pathophysiology 
17 
 
of ASDs. Abnormalities at multiple sites of this pathway have been associated with ASDs and 
will be further discussed in proceeding sections. 
 
2.3. Lipid Imbalances in ASDs 
2.3.1. Essential Fatty Acid Profiles in ASDs 
Current literature suggests that imbalances in the lipid profiles of omega-6 (i.e., AA) and 
omega-3 (i.e., DHA and EPA) fatty acids may be an underlying mechanism to the manifestation 
of autistic-like behaviours. Specifically, several studies have reported altered AA, DHA, and 
EPA levels in patients with autism. Investigation of blood samples revealed that children with 
autism have a higher AA: DHA ratio (Meguid et al., 2008) and a higher AA: EPA ratio (Bell et 
al., 2010) compared to healthy controls. Other studies have reported significantly lower than 
normal levels of AA and DHA in the blood plasma of individuals with autism (Wiest et al., 2009, 
Vancassel et al., 2001). Another study revealed an increase in plasma DHA levels in high-
functioning males with autism (Sliwinski et al., 2006). Though the causes of atypical PUFA 
levels have yet to be fully understood at the molecular level, potential reasons include defects in 
the enzymes that convert dietary PUFAs into longer and highly unsaturated derivatives, 
inadequacy in the integration of PUFAs into membrane phospholipids, or deficient dietary intake 
of PUFA precursors (Vancassel et al., 2001). Moreover, aberrant activity of fatty acid 
desaturase-1 and fatty acid desaturase-2 (FADS1 and FADS2), the enzymes that catalyze the 
breakdown of LA and ALA into AA and DHA, can lead to irregular lipid profiles (Morales et al., 
2011) and may be involved in lipid imbalances reported in autism (Figs. 2-1 and 2-3). Notably, 
the chromosomal locations of FADS1 and FADS2 are in close proximity to an autism-candidate 
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linkage peak on chromosome 11q22 (Ma et al., 2007, Craddock and Lendon, 1999). The 
presence of altered lipid composition and its potential contribution to the behavioural outcomes 
of ASDs have been conveyed in animal studies using rodent models, which revealed that altered 
brain phospholipid composition induced by environmental agents, including enteric bacteria and 
diet, can lead to the appearance of autism-like behaviour (Thomas et al., 2010, Shultz et al., 
2009). Altogether, these studies provide evidence that irregular lipid profiles are a common 
characteristic of ASDs. 
 
2.3.2. Insufficient Dietary Fatty Acids and Autism 
The availability of fatty acids for brain development can be heavily impacted by the 
maternal diet during the prenatal stage and by the infant’s diet (i.e., breast milk or formula) in the 
postnatal stage. Since abnormal lipid profiles have commonly been characterized in individuals 
with ASDs, the ability to alter lipid concentrations through dietary means is encouraging. 
Healthy infants fed with PUFA-supplemented milk formula showed improvements in infant 
cognitive scores compared to infants on a no-PUFA formula, suggesting that inadequate intake 
of dietary PUFAs during early development may be associated with altered cognition (Willatts et 
al., 1998). Considering that higher problem-solving scores in infancy have been associated with 
higher childhood IQ scores, PUFA supplementation may modify the development of childhood 
intelligence. There is also a significantly higher likelihood for infants to develop autism if they 
were not breastfed or not supplemented with PUFAs (Schultz et al., 2006), and administration of 
PUFA supplementation has been shown to restore normal fatty acid profiles and improve 
behavioural outcomes in children with autism. For example, when diet was supplemented with 
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fish oils high in omega fatty acids for 6 months, children with autism or Asperger’s syndrome 
exhibited reduced omega-6:omega-3 and AA: EPA ratios compared to supplementation-naïve 
autistic controls (Bell et al., 2010). Another study found that supplementation of omega-6 and 
omega-3 fatty acids in children with autism led to elevated levels of fatty acids in the blood, 
decreased AA: DHA ratio, and improvements in several autism-affected behavioural domains 
such as eye contact, concentration, language development, and motor skills (Meguid et al., 
2008). Another group revealed that stereotypy and hyperactivity associated with autism were 
mitigated with omega-3 fatty acid supplementation (Amminger et al., 2007). Such 
supplementation also led to improvements in basic language and learning skills in children with 
autism (Patrick and Salik, 2005). 
A case study on a child with autism and associated high levels of anxiety and agitation 
showed the elimination of irregular fatty acid levels and the complete resolution of anxiety and 
agitation after EPA supplementation was administered (Johnson and Hollander, 2003). A better 
quality of life was also reported in the study. Additionally, these improvements in fatty acid 
levels and behaviour were stable at the 8-month follow-up. In contrast, a study investigating 
young adults (18–40 years old) with autism revealed that omega-3 fatty acid supplementation did 
not lead to significant improvements in behaviour (Politi et al., 2008), which suggests that there 
may be a specific time window for the potential beneficial effects of supplementation. 
Furthermore, cholesterols are lipids that are important components of cell membranes 
(Fig. 2-1) involved in the induction of normal motor and mental capacity (Gilbert, 2003). 
Cholesterol is needed for proper embryonic and fetal development as well. Specifically, it is 
necessary for the Sonic Hedgehog signal transduction pathways, which are crucial for the 
induction of brain formation, neural patterning, mood regulation, and cerebral development 
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(Gilbert, 2003). Cholesterol affects the availability of essential lipid molecules, and as such, its 
insufficient consumption by the mother could lead to unhealthy metabolic deficiencies that may 
contribute to the development of autism in the offspring (Tallberg et al., 2011). Imbalances in 
cholesterol levels have also been associated with ASDs (Tierney et al., 2006). Prevailing 
evidence for this stems from studies on Smith-Lemli-Opitz Syndrome (SLOS), which is a genetic 
condition of impaired cholesterol biosynthesis (Bukelis et al., 2007, Sikora et al., 2006). 
Cholesterol treatment in individuals with SLOS resulted in a decrease in autism-related 
behaviours, infections, and symptoms of irritability and hyperactivity, as well as improvements 
in physical growth, sleep, and social interactions (Aneja and Tierney, 2008). It is interesting to 
note that cholesterol supplementation also improved other behaviours such as aggression, self-
injury, temper outbursts, and trichotillomania (Aneja and Tierney, 2008). 
Taken together, the existing literature indicates that dietary imbalances in lipids and fatty 
acids may influence the development of autism-related behavioural outcomes. However, the 
molecular mechanisms of lipid dysregulation in ASDs still have to be determined. This would 
aid in establishing recommended dietary supplementation for individuals with ASDs. 
 
2.4. Association of Prostaglandin Metabolic Pathway with ASDs 
While PUFAs such as AA or DHA are crucial for membrane structure and function, their 
metabolites, such as bioactive prostanoids, are very important for the normal functioning of the 
brain (Tassoni et al., 2008). Upon the release of AA from membrane phospholipids via the action 
of PLA2, cyclooxygenase-1 (COX-1) or cyclooxygenase-2 (COX-2) converts AA into an 
unstable intermediate, PGG2, which is then metabolized to the prostanoid precursor, PGH2 (Fig. 
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2-3). Prostaglandin (PG) or thromboxane synthases convert PGH2 to active lipid signalling 
messengers including prostanoids, PGs (PGE2, PGF2a, PGD2, PGI2), and thromboxane A2 
(TXA2) (Tamiji and Crawford, 2010). Prostanoids can elicit cellular effects by binding to their 
respective G-protein-coupled receptors called E-prostanoid (EP), FP, DP, IP, and TP receptors, 
respectively (Breyer et al., 2001) (Fig. 2-3). 
 
2.4.1. Phospholipase A2 
Phospholipases are enzymatic molecules that break down phospholipids, which are 
precursors of important lipid mediators such as PGs. Phospholipase A2 (PLA2) is of particular 
interest since it is an upstream regulator of a wide range of physiologic functions. PLA2 
selectively hydrolyzes the sn-2 fatty acid ester bond of phospholipids to produce free fatty acids 
such as AA (Murakami and Kudo, 2002). PLA2 activation and the subsequent release of AA and 
its metabolites can be stimulated by various neurotransmitters such as glutamate (Marin et al., 
1997). Alternatively, the presence of other stimuli, such as cytokines activated during 
inflammation, can cause the release of AA and DHA from phospholipid membranes (Farooqui et 
al., 2007). 
The PLA2 protein family has been associated with autism. Specifically, clinical studies 
have reported significantly higher concentrations of PLA2 in the red blood cells of individuals 
with autism and Asperger’s syndrome compared to healthy controls (Bell et al., 2004) (Fig. 2-3). 
The increased activity of PLA2 in patients with ASDs could interfere with the proper 
maintenance of membrane phospholipids, and this may contribute to their abnormal PUFA 
profiles. Current literature provides support for a link between aberrant PLA2 enzyme activity or 
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concentrations and ASDs, reinforcing the hypothesis that abnormal lipid metabolism may play a 
role in the pathophysiology of these disorders. 
 
2.4.2. COX Enzymes 
The enzymes cyclooxygenases-1 and -2 (COX-1, -2) catalyze the reaction of oxygen with 
PUFAs, producing bioactive lipid substances, such as prostaglandins (PGs), from AA (Sang and 
Chen, 2006). Collectively, these lipid metabolites are known as eicosanoids, each of which is 
formed by a different sequence of enzyme- catalyzed reactions. Both COX enzymes assist in the 
production of autoregulatory and homeostatic prostanoids, which may be released during 
inflammation. The enzymatic activity of COX can be inhibited by nonsteroidal anti-
inflammatory drugs, consequently inhibiting the biosynthesis of PGs (Vane, 1971). 
COX-1, the constitutive form, is expressed in nearly all human tissues including the 
brain, lung, kidney, and stomach (O'Neill and Ford-Hutchinson, 1993). Although most 
commonly known as a mediator of housekeeping functions, new evidence shows that COX-1 
may also be important in developmental and inflammatory functions (Loftin et al., 2002). For 
example, COX-1 activity may alter progenitor cell proliferation and hippocampal neurogenesis 
(Russo et al., 2011), neuroinflammation (Shukuri et al., 2011), as well as parturition (Gross et al., 
1998). COX-2, the inducible form, is heavily involved with the inflammatory response. It is 
normally found in low levels, but various stimuli such as growth factors (Hinz and Brune, 2002), 
inflammation due to injury or infection (Ricciotti and FitzGerald, 2011), synaptic activity 
(Yamagata et al., 1993), and oxidative stress (Kwiecien et al., 2012) can trigger its up-regulation. 
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Interestingly, COX-2 plays important roles in the CNS, gastrointestinal tract, and pain 
perception (Hinz and Brune, 2002) via the production of downstream signalling metabolites such 
as PGE2. Abnormalities in the CNS, GI, and nociception have been reported in cases of ASDs 
(Gorrindo et al., 2012, Kohane et al., 2012, Dubois et al., 2010) increasing lines of evidence 
demonstrates that these abnormalities are associated with alterations in the COX-2/PGE2 
pathway (Fig. 2-3). The activity and production of COX-2 are induced by cytokines and 
proinflammatory agents, and irregular immune responses have been characterized in patients 
with ASDs (Ashwood et al., 2006). Additionally, COX-2 is a key contributor to 
neurodevelopment. COX-2 is richly expressed in the dendrites of neurons (Yamagata et al., 
1993). However, its distribution pattern is anomalous in the brain tissue of individuals with Rett 
syndrome, a form of ASD (Kaufmann et al., 1997). Furthermore, ASDs have been associated 
with a polymorphism in PTGS2, the gene encoding for the COX-2 protein (Yoo et al., 2008). 
 
2.4.3. Prostaglandin E2 during Development 
PUFAs are essential structural components of cell membranes, while eicosanoids are 
crucial metabolites required for the normal functioning of the brain (Tassoni et al., 2008). PGE2 
is an eicosanoid that is generated from the metabolism of PGH2 by the enzymatic action of PG 
synthase. PGE2 diffuses rapidly through membranes, exerting its signalling effects by binding to 
E-prostanoid receptors (EP1-4). 
EP receptors are G-protein-coupled receptors and are expressed differentially across 
varying tissue types (Sugimoto and Narumiya, 2007). PGE2 is an important lipid mediator that 
typically acts within the local microenvironment, providing autocrine and paracrine stimulation 
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to a number of signalling pathways in the nervous system (Legler et al., 2010) and regulating the 
function of many immune cell types, thus mediating the inflammatory response in the brain 
(Zhang and Rivest, 2001). Evidence shows that it is also involved in dendritic spine formation 
(Burks et al., 2007), synaptic plasticity (Koch et al., 2010), pain transmission (Harvey et al., 
2004), and cell survival (Jiang et al., 2010) or death (Jonakait and Ni, 2009). In early prenatal 
development, there is an increase in the number of COX-2 and PG synthase transcripts (Saint-
Dizier et al., 2011), as well as elevated levels of EP receptor transcripts (Tamiji and Crawford, 
2010), suggesting that PGE2 is involved in early development. The PGE2 pathway is summarized 
in Fig. 2-4. 
Clinical studies have revealed a connection between misuse of the drug misoprostol 
during the first trimester of pregnancy and neurodevelopmental aberrations, including Mobius 
sequence and ASDs (Bandim et al., 2003) (Fig. 2-3). Misoprostol is an analogue of prostaglandin 
type E, which has been proven to bind and activate EP receptors activating the PGE2 pathway 
(Tamiji and Crawford, 2010) (Fig. 2-4). It was initially used to treat stomach ulcers and has since 
been used also to induce labour and to terminate pregnancy (Lin et al., 2011). During the early 
stages of pregnancy (5–6 weeks after fertilization), the embryo is the most vulnerable to 
misoprostol exposure (Genest et al., 1999). Exposure to this drug during early embryonic 
development may alter the PGE2 signalling pathway and have toxic effects on the developing 
nervous system. Misoprostol and PGE2 can increase the intracellular level and fluctuation 
amplitude of calcium in neuronal growth cones, as well as reduce the number and length of 
neurite extensions through the activation of EP receptors (Tamiji and Crawford, 2010, Tamiji 
and Crawford, 2010). Dysfunctional calcium regulation has been previously suggested in the 
etiology of ASDs (Krey and Dolmetsch, 2007). When considering these studies together, they 
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demonstrate that abnormalities in the PGE2 pathway through misoprostol exposure could lead to 
neurotoxic effects on the development and communication of neurons. 
The importance of the PGE2 signalling pathway during early development is further 
established through the significantly increased expression of four EP receptors transcripts – EP1, 
EP2, EP3b, and EP4 – during early neurogenesis (embryonic day 11–15) in the mouse (Tamiji 
and Crawford, 2010). It is intriguing that this embryonic period marks the development of many 
brain structures (Rice and Barone, 2000) including the cerebellum, amygdala, hippocampus, and 
caudate nucleus of the basal ganglia, which have been reported to be abnormal in individuals 
with autism (Amaral et al., 2008). However, it is still unclear how COX-2/PGE2 signalling may 
directly affect the development of these brain areas. 
There is growing evidence supporting an interaction between the PGE2 and the Wnt 
(wingless) pathways (Evans, 2009). PGE2-dependent signalling may converge with the Wnt 
pathway at the level of β-catenin through EP1-4 receptors, including the  association  of  the  Gαs  
subunit  with  axin,  the  stimulation  of  the cAMP/PKA pathway, or the phosphorylation of 
GSK-3β by PI-3K (Buchanan and DuBois, 2006) (Fig. 2-5). Such an interaction is of particular 
interest since Wnts are morphogens necessary for the formation of a healthy nervous system 
(Ciani and Salinas, 2005). They are signalling molecules that act through Frizzled (FZD) 
transmembrane receptors and are vital to embryonic development, participating in the 
determination of cell fates through activating transcription of various target genes (Buechling 
and Boutros, 2011). Cross talk and joint regulation between these pathways have been reported 
previously in various non-neuronal cells. For example, in osteocytes, PGE2 interacts with β-
catenin to modulate bone mass and density (Genetos et al., 2011), as well as apoptosis following 
induced stress (Kitase et al., 2010). The COX-2/PGE2 signalling pathway is highly stimulated in 
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gastric cancer cells, which results in significantly increased levels of PGE2 and subsequent 
activation of Wnt (Oshima et al., 2009). In these cells, PGE2 and Wnt signalling cooperated to 
cause dysplastic growth and development (Oshima and Oshima, 2010), while a dose-dependent 
effect of PGE2 on Wnt activation in bone and prostate cancer cells has been reported (Liu et al., 
2010). Furthermore, in colon cancer cells, PGE2 induces a decrease in β-catenin phosphorylation, 
which increases the activation of TCF/LEF transcription factors and up-regulates certain genes, 
resulting in increased proliferation (Castellone et al., 2005). Wnt and PGE2 also collaborate to 
promote the survival and proliferation of zebra fish hematopoietic stem cells (Goessling et al., 
2009). Through this model, it was also demonstrated that PGE2 and Wnt are important in the 
regulation of vertebrate regeneration and recovery. 
Although the interaction between these two pathways in the nervous system still remains 
elusive, our current studies have shown that PGE2 can modulate the expression of Wnt-target 
genes and change the proliferation and migration behaviour of neuroectodermal (NE-4C) stem 
cells (Wong et al., 2016, Wong et al., 2014). Wnt signalling proteins are also essential for 
neuronal precursor proliferation (Zhou et al., 2006), radial migration of cortical neurons (Zhou et 
al., 2004), and synapse formation (Sahores and Salinas, 2011), all of which are cellular events 
driven by calcium signalling. Therefore, calcium fluctuations induced by PGE2 or misoprostol as 
demonstrated by Tamiji and Crawford (2010) may interfere with the Wnt signalling pathway, 
influencing its various functions. For example, calcium signalling triggered by neuronal activity 
mediates the CREB-dependent transcription of Wnt-2 as well as the production and secretion of 
its corresponding protein. Wnt-2, one of many wingless genes, contributes to proper dendritic 
outgrowth and branching (Wayman et al., 2006). Notably, this gene is located in the 
chromosome region 7q31-33, which has been linked to autism, and its polymorphisms have been 
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associated with speech delay inherent in ASDs (Lin et al., 2012, Lennon et al., 2007). Moreover, 
Wnt signalling participates in the formation of the cerebellum (Hall et al., 2000), hippocampus 
(Galceran et al., 1999), and amygdala (Abu-Khalil et al., 2004). As mentioned earlier, structural 
deviations in these brain areas have been implicated in autism. Misguided neuronal migration 
resulting in misplaced neurons, especially Purkinje cells, has also been connected to autism 
(Wegiel et al., 2010). Given that Wnts are crucial regulators of cell fate specification, cell 
proliferation, and cell migration during development (Buechling and Boutros, 2011), PGE2-
dependent dysregulation of Wnt signalling could result in brain abnormalities and contribute to 
autism. These lines of evidence validate the increasing interest in investigating the molecular 
mechanisms underlying the interaction between the COX-2/PGE2 and Wnt signalling pathways 
and its link to autism. 
 
2.5. Oxidative Stress and Lipid Peroxidation in ASDs 
Under normal conditions, there is a dynamic equilibrium between the production of 
reactive oxygen species (ROS) and the rate at which they are neutralized by antioxidants. 
Oxidative stress occurs when there is an imbalance in this equilibrium and the level of ROS 
produced by a cell exceeds its antioxidant capacity. ROS such as oxygen ions, free radicals, and 
peroxides are highly reactive molecules that can damage the cell by targeting lipids, key building 
blocks of cells (Choe, 2010). Elevated levels of free radicals and reduced antioxidant defense 
mechanisms are the prime initiators of oxidative stress (Sies, 1997). The activity of ROS can 
lead to altered cell function due to abnormal lipid metabolism affecting proliferation and 
differentiation during neurodevelopment and can even cause cell death (Filomeni and Ciriolo, 
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2006). The PUFAs from membrane phospholipids are the primary targets of ROS because they 
contain many double bonds, making them particularly vulnerable to lipid peroxidation, which is 
the oxidative breakdown of lipids (Adibhatla and Hatcher, 2008). This results in increased 
metabolism of AA and activates the PGE2 signalling pathway (Pepicelli et al., 2005). A number 
of neurological disorders, such as autism, schizophrenia, and Alzheimer’s, have been associated 
with dysregulation of lipid metabolism and increased levels of oxidative stress. A combination of 
genetic and environmental factors influencing lipid peroxidation may contribute to the etiology 
of autism (Deth et al., 2008). 
An imbalance between the oxidative and antioxidative stress systems due to increased 
oxidative damage and decreased antioxidant neutralization has been reported in individuals with 
autism (Ghanizadeh et al., 2012). The brain is particularly vulnerable to oxidative stress and 
consequent lipid peroxidation because lipids are the primary component of the human brain 
(Adibhatla and Hatcher, 2008), and because the brain uses a great amount of oxygen, generating 
potentially elevated levels of harmful reactive by-products. The high oxygen requirement of the 
brain is exemplified by the fact that although the human brain is approximately 2 % of an 
individual’s total body mass, it uses around 20 % of the available body oxygen (Shulman et al., 
2004). The brain also has limited antioxidant defense mechanisms because neurons cannot 
produce glutathione (GSH), one of the most important antioxidants for the free radical 
neutralization of environmental toxins (Shulman et al., 2004). As the majority of the energy 
consumed in the brain is used by neurons, they are the first cells to be affected by reduced 
antioxidant levels and thus in the most danger. Infants who are in a sensitive period of 
development are more vulnerable than adults to oxidative stress because they have naturally 
lower levels of GSH (Ono et al., 2001), which may suggest greater risk of oxidative stress. 
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Children with  autism  have  been  reported  to  have  lower  levels  of  GSH  and  a deficiency in 
GSH precursors, methionine, and cysteine, which indicate their increased susceptibility to 
oxidative stress and the associated risk of developing brain disorders (Al-Gadani et al., 2009, 
James et al., 2004). The diminished antioxidant capacity could amplify oxidative damage to the 
cells. Several studies have also discovered genetic variances (allele deletions and 
polymorphisms) that directly impact methionine and GSH metabolism in individuals with autism 
(Ming et al., 2010, Williams et al., 2007, Buyske et al., 2006), hinting at the influence of genetics 
in the abnormalities of lipid peroxidation observed in ASDs. In addition to GSH, aberrations in a 
number of other antioxidants have been reported in several studies. Protein antioxidants, 
ceruloplasmin, and transferrin levels were significantly reduced, and lipid peroxidation was 
significantly elevated in the plasma samples of children with autism compared to controls 
(Chauhan et al., 2004). 
Current literature also provides support for the connection between elevated oxidative 
damage and lipid/prostanoid metabolites in cases of autism. Two protein adducts, carboxyethyl 
pyrrole (CEP) and iso[4]levuglandin (iso[4]LG)E2 (Fig. 2-1), are uniquely formed through the 
peroxidation of DHA- and AA-containing lipids, respectively, and are markers of oxidative 
damage. Significantly increased fluorescent immunoreactivity of these compounds was detected 
in the cortical tissue of subjects with ASD compared to healthy controls (Evans et al., 2008). 
Moreover, a distinct expression pattern specific to the autistic brain was also visualized – 
significant staining was found in white and grey matter. Increased levels of lipid peroxidation 
markers 2, 3-dinor-thromboxane (TXB2) and 6-ketoprostaglandin PGF1a (6-keto-PGF1a), which 
are metabolites of TXA2 and PGI2, respectively (Fig. 2-3), were quantified in urine samples of 
children with autism (Yao et al., 2006). Likewise, elevated levels of 8-isoprostane-F2a(8-iso-
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PGF2a) and isoprostane F2a- VI (iPF2a-VI), by-products of PGF2a peroxidation via the oxidation 
of AA (Fig. 2-3), have been measured in the urine of children with autism compared to healthy 
controls (Yao et al., 2006). A significantly higher concentration of iPF2a was also reported in 
plasma samples of children with autism (Mostafa et al., 2010) and patients with Rett syndrome 
(De Felice et al., 2009). Under normal conditions, the accumulation of F2-isoprostanes induces 
platelet aggregation and vasoconstriction (Pratico et al., 2001). However, when the accumulation 
becomes abnormal, as evident in the blood and urine samples from individuals with autism, it 
may contribute to the altered platelet reactivity and vascular irregularities reported in these 
patients (Yao et al., 2006). 
There has also been mounting evidence that links abnormalities in vitamin E and the 
pathology of ASDs. Vitamin E, a lipid and a powerful antioxidant capable of protecting cells and 
tissues from oxidative damage, is important in the regulation of lipid peroxidation. It is a key 
component of cell membranes (Fig. 2-1) that is also stored in fat and liver for future mobilization 
during elevated levels of oxidative stress (Lawrence, 2010). Deficient levels of vitamin E have 
been reported in blood samples of children with autism (Al-Gadani et al., 2009). 
Supplementation of PUFAs and vitamin E led to dramatic improvements in a number of areas 
including speech, imitation, coordination, eye contact, behaviour, sensory issues, and the 
development of pain sensation in 97 % of 187 ASD-affected children (Morris and Agin, 2009). 
When the supplementation was halted, speech and coordination regressed in some children, 
suggesting that abnormal fatty acid metabolism may contribute to the manifestation of these 
autism-associated traits. 
In summary, the reported findings provide additional evidence for irregular lipid 
biogenesis in ASDs. Current publications reveal altered antioxidant capacity and increased 
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oxidative stress markers in individuals with autism. Lipids are the prime targets for oxidative 
stress, suggesting that abnormal lipid signalling may be associated with the development and/or 
expression of symptomatic deficits in affected individuals. 
 
2.6. Immunological Factors Contributing to Lipid Dysregulation 
Immunological events associated with infections in early fetal life through alterations in 
the vasculature and maternal-fetal immune responses may play a role in the initiation of 
neurological disorders such as autism, epilepsy, and schizophrenia (Stolp et al., 2012, Atladottir 
et al., 2010, Brown and Derkits, 2010). Immune dysfunctions and insults during sensitive periods 
of brain development could predispose the developing nervous system to potential failures in 
subsequent cell migration, target selection, and synapse maturation (Harvey and Boksa, 2012). 
During embryonic and fetal life, the immune system is still immature. This may be an adaptive 
measure to safeguard the fetus from premature maternal immune rejection, which could lead to 
fetal damage or even death (France de La Cochetiere et al., 2007). Paradoxically, this beneficial 
adaption also increases the risk for the fetus to acquire an infection. 
Although autism is a disorder that primarily affects brain function, many cases have 
shown that other systems, such as the immune system, are also affected. Clinical studies and case 
reports have revealed the potential contribution that viral infections and aberrant immune 
responses have towards the pathology of ASDs (Libbey et al., 2005). Additionally, women who 
develop a fever while pregnant may be more than twice as likely to have a child with an ASD or 
some other form of developmental delay (Zerbo et al., 2013). Research by various scientists 
utilizing animal models has demonstrated that certain pre- and postnatal infections can induce 
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gene alterations in the brain, morphological changes in cells and brain regions, immunological 
deviations in offspring, and irregular behaviours analogous to those characterized in ASDs (Shi 
et al., 2009, Fatemi et al., 2008, Ponzio et al., 2007, Fatemi et al., 2005, Shi et al., 2003, Fatemi 
et al., 2002). 
Although the direct molecular mechanisms by which infections and inflammation may 
lead to the pathological outcomes of autism through the COX-2/PGE2 lipid signalling pathway 
remain to be fully elucidated, existing literature supplies indirect evidence of their possible roles. 
Eicosanoids derived from omega-6 and omega-3 PUFAs are central regulators of the immune 
and inflammatory responses (Wall et al. 2010). Specifically, AA (omega-6 metabolite) has 
proinflammatory and immunoactive properties, while EPA and DHA (omega-3 metabolites) 
have anti-inflammatory roles. Cyclooxygenase-derived mediators, such as the lipid signalling 
molecule PGE2, are significantly elevated during infections and the inflammatory response 
(Fitzgerald et al., 2012), especially if the viral or bacterial exposure occurs during pregnancy 
(Christiaens et al., 2008). PGE2, the most abundantly produced eicosanoid derived from AA, can 
modulate the sensitivity of sensory nerves and functions as a mediator to induce fever 
(Lawrence, 2010). Heightened PGE2-related inflammatory responses during early development 
may produce developmental defects in the nervous system. The inflammatory response in the 
brain can be mediated by PGE2 since it regulates the function of many immune cell types (Zhang 
and Rivest, 2001). It promotes the production of cytokines (Legler et al., 2010), which are 
compounds made and secreted by leukocytes at the site of inflammation. Cytokines, along with 
other products of immune activation, have widespread effects on neuronal pathways, which may 
contribute to common features of ASDs (Ashwood and Van de Water, 2004). They also 
represent the primary mediators of communication between the brain and the immune system. 
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Cytokines act locally as signalling molecules between immune cells, but they may also enter the 
bloodstream and target remote structures including the brain (Rothwell and Hopkins, 1995). The 
activation of endothelial cells associated with the blood brain barrier is responsible for the 
subsequent release of second messengers such as prostaglandins that act on specific brain targets 
(de Vries et al., 1996). Cytokines are also involved in many aspects of CNS function and 
development as well. They are of particular importance during early neural development, 
including the induction of the neuroepithelium (Gaulden and Reiter, 2008). They are also critical 
modulators of neuronal and glial migration (Zhu et al., 2002), differentiation (Soleymaninejadian 
et al., 2012), and selective pruning or programmed cell death to acquire proper neural 
connections (Sedel et al., 2004). Taken altogether, studies demonstrate that infections and the 
resultant inflammatory responses could disturb several processes involved in brain development 
and potentially be in part responsible for the abnormalities of autism. Additional studies are 
necessary to establish a direct link between the effects of immunological factors and the COX-
2/PGE2 pathway, and how consequent alterations are manifested in the molecular and 
behavioural outcomes of ASDs. 
 
2.7. Exposure to Common Environmental Factors with ASDs 
Exposure to various exogenous risk factors  during prenatal and perinatal development 
can disrupt important neurodevelopmental processes, such as the patterning and growth of the 
brain, by altering normal gene expression and cell function (Jurewicz et al., 2013, Braw-Tal, 
2010, Grandjean and Landrigan, 2006, Weiss, 2000). The maternal environment can have direct 
consequences on the developing embryo and fetus. It is known that molecules found in the 
maternal system, such as lipids, can be passed into the developing embryo or fetus during 
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pregnancy and to the growing infant through breast milk following birth (Lassek and Gaulin, 
2006). Exposure to natural and manmade chemicals occurs on a daily basis through the air, soil, 
foods, water, and consumer products. Transmission of these chemicals into the body can occur 
via inhalation, ingestion, or contact with skin and it has been reported that accumulations of 
chemicals can be found in organs (Johnson-Restrepo et al., 2005); predominately in fatty tissues 
(De Saeger S. et al., 2005). A greater buildup of toxins in the mother could increase the 
likelihood of exposure to the developing fetus or child. Goldman and Koduru reported that 
approximately 85,000 chemicals were manufactured in the United States (U.S.) in year 2000 and 
with each following year, about 2,000-3,000 new chemicals are reviewed by the U.S. 
Environmental Protection Agency (Goldman and Koduru, 2000). In this year, roughly 2,800 
chemicals were used in high volumes with over one million pounds produced annually. They 
also state that nearly 80% of these chemicals lacked screening for developmental toxicity and 
almost half that were found in consumer products had no test data for developmental toxicity. 
Moreover, a study by the Environmental Working Group in the U.S. found that 287 of the 413 
toxic substances tested were present in the umbilical cord of newborns (Houlihan, 2005). These 
chemicals include heavy metals, numerous pesticides, and estrogen-like endocrine disrupting 
chemicals (EEDCs). Alarmingly, 157 of these chemicals were found to affect the brain and 
nervous system and are related to developmental defects (Houlihan, 2005). This striking 
information gives precedence to the investigation of potentially harmful chemicals—including 
air pollutants, pesticides, and toxins in consumer products—that could impact the developing 
baby.  
Below we describe how these environmental risk factors are capable of directly affecting 
the PGE2 signalling pathway during early brain development. Moreover, we reveal how air 
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pollutants, pesticides, and toxins in consumer products may indirectly affect the PGE2 signalling 
pathway by elevating levels of inflammation, increasing levels of oxidative stress, and acting as 
EEDCs that can affect PGE2 signalling. We also discuss how these exogenous chemicals have 
been associated with increased risk for ASDs.  
 
2.7.1. Air Pollution and Heavy Metals 
Exposure to air pollution has been shown to induce increased levels of inflammation and 
oxidative stress in the brains of children, adolescents and adults (Calderon-Garciduenas et al., 
2014, Moller et al., 2014, Calderon-Garciduenas et al., 2007). Moreover, sustained exposure 
could lead to DNA damage and pathologies in the brain (Calderon-Garciduenas et al., 2014, 
Moller et al., 2014, Calderon-Garciduenas et al., 2007). In turn, inflammation is highly 
associated with increased levels of PGE2 (Nakanishi and Rosenberg, 2013, Andreasson, 2010). 
PGE2 is the most abundant prostaglandin and can induce fever (Lawrence, 2010) and promote 
the production of cytokines (Legler et al., 2010). Immune activation and the production of 
cytokines can cause disturbances in the development of neuronal pathways that have been 
associated with ASDs (Ashwood and Van de Water, 2004). Increased levels of oxidative stress 
can cause lipid peroxidation of cell membranes, including membranes of endothelial cells in the 
blood-brain barrier (BBB), which leads to the subsequent release of second messengers like 
prostaglandins (de Vries et al., 1997, de Vries et al., 1996). In fact, exposure to air pollution 
particles and common air pollutant, sulfur dioxide (SO2), have been found to elevate PGE2 levels 
in macrophages (Schneider et al., 2005), lung fibroblasts (Alfaro-Moreno et al., 2002), and 
neurons (Sang et al., 2011).  
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Toxic air pollutants can arise from human activity—such as vehicles, factories, and 
household cleaning solvents—and from natural activity including volcano eruptions. Toxic air 
pollutants are fine particles that can be found in diesel exhaust, tobacco smoke, and industrial 
emission. They include organic compounds like styrene, and metals like mercury, lead, and 
cadmium. Metals are of concern because they stay in the body for prolonged periods of time 
(Wang and Du, 2013, Suwazono et al., 2009). For example, the biological half-life of cadmium 
in humans is between 13-24 years (Wang and Du, 2013, Suwazono et al., 2009). They are 
especially dangerous to the developing brain because upon inhalation and entry into the 
circulation, many metals can translocate across various tissues including the BBB or can result in 
increased systemic levels of inflammation and oxidative stress that can also be measured in the 
brain (Jomova and Valko, 2011, Lopez et al., 2006, Peters et al., 2006, Valko et al., 2005).  
Elevation in inflammation (Nakanishi and Rosenberg, 2013, Andreasson, 2010) and oxidative 
stress (de Vries et al., 1997, de Vries et al., 1996) can also lead to abnormal PGE2 production. 
A number of extensive case-control studies completed in recent years across the U.S. 
investigated the possible association of exposure to toxicants in the air and the risk of 
neurodevelopmental disorders such as ASDs. Each child’s residential area was compared to the 
exposure of surrounding air pollutants which included metals, particulates, and volatile organic 
compounds. They report that exposure to metals (antimony, arsenic, cadmium, chromium, lead, 
mercury, manganese, nickel) (Roberts et al., 2013, Palmer et al., 2009, Roberts et al., 2007, 
Windham et al., 2006), diesel particulates (Volk et al., 2014, Roberts et al., 2013, Windham et 
al., 2006), methylene chloride  (Roberts et al., 2013, Kalkbrenner et al., 2010, Windham et al., 
2006), vinyl chloride (Windham et al., 2006), styrene (Kalkbrenner et al., 2010), and 
trichloroethylene (Windham et al., 2006) are associated with increased risk of ASDs. 
37 
 
Additionally, reviews from the U.S. Environmental Protection Agency have reported that each of 
these pollutants has been demonstrated to have adverse effects on the developing fetus in clinical 
and animals studies (Environmental Protection Agency, 2013). Interestingly, stronger 
associations were observed in boys compared to girls for most air pollutants, indicating a sex-
specific interaction similar to that found in autism (Roberts et al., 2013). 
Porphyrin levels in the urine are often used as a biomarker for heavy metal toxicity from 
air pollution, including mercury and lead. Numerous independent studies have found that 
children with ASDs have significantly elevated levels of urinary porphyrins, which are indicative 
of greater symptom severity (Kern et al., 2011, Kern et al., 2010, Youn et al., 2010, Geier et al., 
2009, Austin and Shandley, 2008, Geier and Geier, 2007, Geier and Geier, 2006). Although 
measuring porphyrins levels might not be a valid diagnostic tool for ASDs on its own (Shandley 
et al., 2014), it may help identify a subgroup of ASDs subjects (Heyer et al., 2012). 
Individuals having a genetic variant in the promoter region (rs1858830 “C” allele) of the 
MET receptor tyrosine kinase gene and who are exposed to high levels of air pollutants were at a 
greater risk of ASDs (Volk et al., 2014). A polymorphism in the delta-aminolevulinic acid 
dehydratase (ALAD), which is associated with heavy metal toxicity and elevated levels of 
oxidative stress, has also been associated with autism (Rose S. et al., 2008 ). This suggests that 
individuals with ASDs may have a decreased ability to eliminate heavy metals from the body 
due to a genetic etiology (Kern et al., 2007). Furthermore, individuals with ASDs have 
impairments in detoxification and have lower levels of antioxidants, such as glutathione-s-
transferase and vitamin E (Alabdali et al., 2014). This may cause these individuals to be more 
susceptible to the accumulation of toxic metals such as mercury and lead. Altogether, many 
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studies report that perinatal exposure to air pollutants, in combination with genetic susceptibility, 
may increase risk for ASDs.  
 
2.7.2. Pesticides 
Pesticides are chemical agents that are distributed widely throughout our environment for 
two common uses: to eradicate or discourage the involvement of pests and to protect plants in 
agriculture. Exposure to pesticides is of great concern since they are capable of passing the 
placental barrier and the BBB through specific transporters, such as the OAT3 transporter, which 
normally transport PGE2. Furthermore, many pesticides can act as EEDCs, estrogen-like 
compounds that can result in hormonal disturbances (Kojima et al., 2004, Soto et al., 1994). In 
rodent models, exposure to estrogen compounds have been shown to induce PGE2 production 
during development causing permanent changes, such as masculinization of the brain and sexual 
behaviour (Amateau and McCarthy, 2004). Given that pesticides are EEDCs that are capable of 
crossing protective barriers, it is probable that pesticides may directly or indirectly disrupt the 
PGE2 lipid signalling pathway during development. Moreover, many pesticides have been found 
to induce oxidative stress (Abdollahi et al., 2004), which can lead to abnormal increases of PGE2 
levels that may disturb sensitive periods of neurodevelopment. 
The general population, including pregnant women, is exposed to these types of 
compounds from a wide variety of sources including household products, food with pesticide 
residue or their metabolites, and air from areas where agricultural or urban spraying has occurred 
(Shelton et al., 2012). Maternal exposure to various pesticides during pregnancy has been 
associated with adverse effects in cognitive development in children (Bouchard et al., 2011) and 
increased risk of ASDs (Shelton et al., 2012, Roberts et al., 2007). Numerous pesticides have 
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been shown to disrupt critical neurodevelopmental signalling pathways—such as the γ-
aminobutyric acid (GABA) and acetylcholine (ACh) pathways—and important hormones, 
including thyroid hormones (reviewed in (Shelton et al., 2012)). Interestingly, dysregulation of 
GABA, ACh, and thyroid hormone signalling have been associated with ASDs (Khan et al., 
2014, Coghlan et al., 2012, Deutsch et al., 2010). Moreover, pesticides can increase levels of 
oxidative stress and the production of reactive oxygen species (Franco et al., 2009). This leads to 
a decline in mitochondrial function (Cui et al., 2012), which has been associated with ASDs 
(Rossignol and Frye, 2014). Considering that pesticides have the potential to impair 
neurodevelopment, we review the three most widely used pesticides: organochlorine pesticides 
(OCPs), organophosphate pesticides (OPPs), and pyrethrins and pyrethroids (PPs). 
OCPs are a group of pesticides that was used widely across the globe for agricultural 
purposes. Due to its low biodegradability, toxicity, and incorporation into food webs, the use of 
these pesticides has been banned in many countries, including the U.S. and Canada. However, 
their levels remain persistent in the environment and continue to pose a risk to human health 
(Crinnion, 2009, Brun et al., 2008).  In fact, a recent study conducted in the U.S. found that the 
presence of OCPs were detected in all of the pregnant women tested (Woodruff et al., 2011). In 
addition to their lasting presence in the environment, OCPS are able to cross the intestinal 
barrier, BBB, and skin barrier (Escuder-Gilabert et al., 2009). Examples of OCPs include 
dichlorodiphenyltrichloroethane (DDT), endosulfan, and dicofol. Many OCPs are EEDCs, which 
mimic endogenous estrogen that can affect calcium signalling (Wozniak et al., 2005) and PGE2 
signalling (Amateau and McCarthy, 2004). Moreover, in a large scale case-control study on 
children, prenatal exposure to OCPs during the first trimester was reported to increase the risk of 
children developing ASDs (Roberts et al., 2007). Another study identified two critical periods of 
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vulnerability for exposure to OCPs that were associated with ASDs: from 1 month prior to 
conception to 5 months post conception, and approximately 2 months to 8 months after birth 
(Roberts and English, 2013).     
OPPs are another group of pesticides that were originally manufactured to replace 
numerous banned OCPs. Examples of commonly used OPPs include chlorpyrifos, dichlorvos, 
and malathion. OPPs act on the enzyme acetylcholinesterase and inhibit its function, causing 
nerve damage to unwanted pests (Costa, 2006). Unfortunately, OPPs also pose a potential risk to 
human health. Children whose mothers reside near application sites of OPPs during gestation 
were at a greater risk for ASDs (Shelton et al., 2014). Furthermore, a prospective cohort study by 
Rauh and colleagues found that higher concentrations of chlorpyrifos in the umbilical cord 
plasma was associated with a greater likelihood to develop symptoms of pervasive 
developmental disorder by 3 years of age (Rauh et al., 2011). Another investigation by the same 
group utilized magnetic resonance imaging to show that children with increased concentrations 
of chlorpyrifos had structural changes in brain areas associated with attention, social cognition, 
and receptive language processing (Rauh et al., 2012). Exposure to OPPs, including those which 
are commonly used to deter mosquitos and fruit flies, has been shown to induce oxidative stress, 
mitochondrial dysfunction, and cytotoxicity to neurons and liver cells (Moore et al., 2010, Kaur 
et al., 2007). As mentioned earlier, oxidative stress and mitochondrial dysfunction has been 
reported in ASDs cases (Rossignol and Frye, 2014). Additionally, the effects of OPPs, such as 
impaired cognition and altered neurochemistry, have been reported to be more severe in males 
than females (Levin et al., 2010), comparable again to the trend found with ASDs. Similar to the 
findings regarding heavy metals, there have been various reports about the possibility of genetic 
susceptibility to OPP toxicity (reviewed in (Costa, 2006)). This greater susceptibility would 
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decrease the ability to excrete OPPs and their metabolites (Costa, 2006). A study by Pasca and 
associates found that children with ASDs may be affected more harshly by OPPs due to 
relatively less active paroxonases; the enzymes responsible for metabolizing OPPs (Pasca et al., 
2006).  
A third group of pesticides are the naturally-derived pyrethrins and synthetically-adapted 
pyrethroids. Pyrethrins and pyrethroids (PPs) have been reported by the U.S. Environmental 
Protection Agency to be found in over 3,500 products in the U.S. (Environmental Protection 
Agency, 2013). Substantial increases in the use of PPs have been observed since 2000, when 
household use of OPPs was banned in the U.S. (Williams et al., 2008). 88% of women surveyed 
between 2000 and 2008, reported the use of PPs during their pregnancy, with 55% reporting 
high-exposure use including professional pesticide application of PPs (Williams et al., 2008). 
Even though PPs are short-lived, their metabolites have been found in over 75% of American 
children and adults, and 80% in adolescence (Barr et al., 2010). This suggests that utilization of 
PPs in daily living likely occurs in the majority of Americans. PPs and their metabolites could 
have toxic effects on humans since they can alter calcium signalling, induce oxidative stress, and 
affect voltage-sensitive sodium channels (Soderlund, 2012, Shafer et al., 2005). PPs have also 
been shown to cause neurotoxic developmental effects. For example, permethrin is a pyrethroid 
that is commonly found in treatment creams against lice and is also used as an agricultural 
pesticide. Studies show that permethrin increases oxidative stress leading to immunotoxic effects 
and neural apoptosis (Shi et al., 2011, Gabbianelli et al., 2009). Cyfluthrin is another example of 
a common household pyrethroid. It was found to modulate the production and signalling of 
interleukin-6 and interferon-γ (Mense et al., 2006), cytokines associated with ASDs (Li et al., 
2009). Furthermore, the authors highlighted its potential to disrupt brain development (Mense et 
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al., 2006). In addition, maternal proximity to agricultural sites (that use PPs) just prior to 
conception or during the third trimester was associated with an increased risk for both ASDs and 
developmental delay (Shelton et al., 2014). 
Taken together, these studies reveal that all three major groups of pesticides (OPPs, 
OCPs, and PPs) can lead to neurodevelopmental disturbances, including increased risk for 
developing ASDs.  
 
2.7.3. Consumer Products 
The daily use of consumer products potentially containing chemicals that accumulate 
within fatty tissues due to their lipophilic nature has become a concern for the human population. 
Many of these chemicals in consumer products have been shown to cross into the body and 
bloodstream through the skin, as well as through the protective barriers between a pregnant 
mother and fetus. Recent literature presented here reveals examples of chemicals that elicit 
physiological changes including aberrant fluctuations and dysregulation of PGE2 signalling, 
hormone activity, and calcium function that may lead to developmental abnormalities. Examples 
of some consumer products that may contain harmful chemicals include lubricants, fire 
retardants, plastic containers, flooring and building materials, lotions, cosmetics, and fragrances. 
Persistent use of such products could potentially lead to absorption and bioaccumulation of 
certain compounds in the body. 
Halogenated aromatic hydrocarbons (HAHs) are toxic compounds that are resistant to 
degradation and have been found in consumer products. Polychlorinated bisphenyls (PCBs) and 
polybrominated diphenyl ethers (PBDEs) are two examples of HAHs that were used in lubricants 
(for industrial pipelines, cables, scientific equipment, etc.) and flame retardants (compounds 
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added to wood and manufactured materials such as plastics and textiles), respectively (Goines 
and Ashwood, 2013). Despite being banned in many industrial countries after it was discovered 
that they can cause serious adverse health effects on both wildlife and humans, PCBs and PBDEs 
still remain present in human tissues and breast milk (Daniels et al., 2010, Johnson-Restrepo et 
al., 2005). Exposure to PCBs and PBDEs has been shown to increase levels of PGE2 in uterine 
and placental cells leading to proinflammatory responses (Peltier et al., 2012, Wrobel et al., 
2010, Wang et al., 2008). Interestingly, the immune systems of children with ASDs react 
uniquely to PBDEs compared to typically developing children: peripheral blood cell samples of 
ASDs subjects displayed an increased cytokine response compared to control subjects indicating 
an overactive immune system in ASDs (Ashwood et al., 2009). This is important since the tight 
connection existing between the development of the immune system and central nervous system 
suggests that aberrations in immune responses may contribute to neurobehavioural disorders 
(Goines and Ashwood, 2013, Hertz-Picciotto et al., 2008). This is in line with other studies, 
which have found that exposure to PCBs and PBDEs can disrupt normal neuronal development 
(Kimura-Kuroda et al., 2007) and result in behavioural deficits observed with ASDs in the 
human population (Eskenazi et al., 2013) and animal model (Jolous-Jamshidi et al., 2010), such 
as social impairments . Additionally, maternal exposure to PBDEs in rats has been associated 
with hormonal disruptions as well as cognitive and behavioural abnormalities in the offspring 
(Kodavanti et al., 2010). PCBs and PBDEs have also been found to cause disruptive effects on 
the endocrine system (Lema et al., 2008, Morse et al., 1993) and cause dysfunction of calcium 
homeostasis (Wayman et al., 2012, Pessah et al., 2010); a potential marker for 
neurodevelopmental disorders like autism (Wayman et al., 2012).  
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Phthalate esters, also referred to as phthalates for short, are synthetic compounds that 
have been used as plasticizers for a variety of consumer products such as polyvinyl chloride 
(PVC) flooring material and building materials, children’s toys, plastic containers, and personal 
care products (e.g. cosmetics, lotions, and fragrances) (Crinnion, 2010, Witorsch and Thomas, 
2010). Phthalates found in food packaging, plastic containers, polluted soil, and polluted water 
can contaminate our foods and beverages; this is concerning because ingesting trace amounts of 
phthalates may have health consequences (Serrano et al., 2014, Schecter et al., 2013).  In fact, 
phthalates are widely present in foods from the U.S. with high concentrations found in poultry, 
pork, cooking oils, and cream-based dairy products (Serrano et al., 2014, Schecter et al., 2013).  
Although, phthalates are short-lived chemicals that do not bio-accumulate and are rapidly 
excreted from the body (Heudorf et al., 2007), they still present a potential risk to human health 
since they are EEDCs. As EEDCs, they mimic endogenous estrogen by activating estrogen 
receptors and by acting as an antagonist to androgen receptors (Sharpe, 2008, Takeuchi et al., 
2005). Moreover, exposure to phthalates has been shown to disrupt the levels of prostaglandins, 
including PGE2, in uterine and amniotic cells (Wang et al., 2010, Pavan et al., 2001). It has been 
found through retrospective case and clinical studies that phthalate exposure is linked to 
behavioural abnormalities and developmental disorders including ADHD and ASDs (Testa et al., 
2012, Miodovnik et al., 2011, Engel et al., 2010, Larsson et al., 2009). A study conducted in 
Sweden investigating potential harmful indoor environmental factors found that if PVC flooring 
was present in the parents’ or children’s room, which is a source of airborne phthalates, the child 
was at an increased risk of developing ASDs compared to wood flooring (Larsson et al., 2009). 
Prenatal exposure to phthalates during the third trimester of pregnancy (determined by urine 
samples) has been associated with adverse effects on childhood behaviour and executive 
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functioning, with behavioural outcomes commonly found in children with ADHD (Engel et al., 
2010). Since phthalates are expelled quickly from the body, detection of phthalates in the urine 
indicates that daily phthalate exposure is likely occurring. Another study also measuring the 
urine samples of pregnant women in their third trimester found that phthalate exposure was 
associated with deficits in social behaviour, communication, social awareness, and social 
cognition (Miodovnik et al., 2011). In a study examining the phthalate levels in children, a 
significant increase in the urinary concentrations of phthalate metabolites were detected in 
children with ASDs compared to control children (Testa et al., 2012). Strikingly, the authors of 
this study were able to identify ASDs subjects with 91.1% specificity through the measurement 
of phthalate metabolite, 5-oxo-MEHP. In summary, these studies provide evidence that prenatal 
and postnatal exposure to phthalates has been associated with behavioural differences and 
developmental disorders like ASDs.  
Bisphenol A (BPA) has been used to make epoxy resins and polycarbonate plastics, both 
of which are used in many household products including reusable plastic food containers, the 
internal lining of tin cans, food packaging materials, and cash register receipts (Biedermann et 
al., 2010, vom Saal and Hughes, 2005). BPA can enter the body through the skin, eating or 
drinking contaminated sources, hand-to-mouth contact, and manufacturer workplace exposure 
(CDC, 2013, Biedermann et al., 2010). Leaching of BPA molecules from consumer product 
sources has been shown to be increased when washing polycarbonate plastics and heating BPA-
containing containers to sterilize foods (Howdeshell et al., 2003, Kang et al., 2003).  
Furthermore, it has been shown that BPA can leach from landfills into surrounding ecosystems, 
affecting drinking and bathing water (Coors et al., 2003). In a national health and nutrition 
examination study conducted by the Centre for Disease Control and Prevention in the U.S. in 
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2003-2004, nearly all individuals tested had BPA in the urine, suggesting widespread BPA 
exposure (CDC, 2013). Similarly, a study conducted by Statistics Canada in 2009-2011 found 
that BPA was detected in the urine of 95% of Canadians between the ages of 3 to 79 years old, 
with the highest levels of BPA measured in children between the ages of 3 to 5 and 6 to 11 years 
old (Statistics-Canada, 2013). Because BPA has been found to be rapidly metabolized (Volkel et 
al., 2002), this suggests that human exposure occurs in a continuous manner most likely from 
multiple sources. BPA has been found in various human body fluids, such as fetal serum and 
full-term amniotic fluid (Ikezuki et al., 2002), indicating that BPA has the ability to pass through 
the placenta that acts as a maternal-fetal protective barrier. 
Exposure to BPA has been shown to alter the human uterine microenvironment by 
disrupting PGE2 production in the endometrium and corpus luteum, which could disturb 
embryonic and fetal development (Mannelli et al., 2014, Romani et al., 2013). BPA is also 
known as a common EEDC (vom Saal and Hughes, 2005) that can exert its toxic affects at low 
human-relevant doses (Welshons et al., 2003). Studies completed on mouse and rat models found 
that prenatal and perinatal exposure to BPA can affect the offspring by up-regulating the immune 
response (Yoshino et al., 2004), altering social behaviours and expression of estrogen receptors 
(Wolstenholme et al., 2012), increasing hyperactive behaviour (Ishido et al., 2004), impairing 
neural pathways involving fear and learning (Negishi et al., 2004), decreasing levels of sonic 
hedgehog (Shh), a crucial developmental signalling molecules, and affecting dopaminergic 
neuron development (Miyagawa et al., 2007), and changing levels of DNA methyltransferases in 
the cortex, suggesting the possibility of epigenetic and transgenerational effects (Kundakovic et 
al., 2013). A clinical prospective study found that gestational BPA exposure was associated with 
deficits in behavioural and emotional regulation in children at 3 years of age (Braun et al., 2011). 
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Postnatal exposure to BPA in animal model studies reveal that exposure led to elevated levels of 
reactive oxygen species and lipid peroxidation and decreased levels of antioxidant enzymes 
(Chitra et al., 2003), higher estrogen receptor levels in the brain (Aloisi et al., 2001), and 
increased calcium signalling in hippocampal neurons (Tanabe et al., 2006). To summarize, 
prenatal and postnatal BPA exposure was found to be toxic by altering gene expression, 
disrupting immunological and neural pathways, and altering behaviours later in life. 
Cosmetics are another group of consumer products that possesses chemicals that may be 
harmful to human health. For example, cosmetic eyelash growth products often include 
ingredients bimatoprost or dechloro ethylcloprostenolamide, which are prostaglandin analogues 
that can activate prostaglandin receptors (Alm et al., 2008, Choy and Lin, 2008, Toris et al., 
2008), and thus are capable of disrupting normal prostaglandin signalling. Furthermore, 
siloxanes and parabens are chemicals that are often found in cosmetics that have been contested 
as substances that put human health at risk. Siloxanes (cyclic and linear) are used in cosmetics as 
spreading agents (Nair and Cosmetic Ingredients Review Expert, 2003). They are of concern 
since they can accumulate in fatty tissues and are EEDCs that are able to elicit estrogenic activity 
(He et al., 2003, Luu and Hutter, 2001, McKim et al., 2001) and indirectly disrupt PGE2 levels 
(Amateau and McCarthy, 2004). Additionally, they may cause adverse effects on the nervous 
system by disrupting normal dopamine neurotransmission (Alexeeff, 2007). Parabens are largely 
used as antimicrobial preservatives in products such as cosmetics, pharmaceuticals, and on foods 
(Crinnion, 2010) and can also increase estrogenic activity (Darbre and Harvey, 2008). As 
mentioned earlier, elevated estrogenic activity can disturb regular PGE2 signalling during 
development. Taken altogether, a variety of chemicals that can be found in the environment and 
in consumer products are capable of bio-accumulating in human tissue and are capable of 
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altering the signalling of important developmental pathways, such as the lipid mediator PGE2 
signalling pathway (Fig. 2-6). In addition to the chemicals mentioned above, Health Canada has 
published a science-based document, an “Ingredient Hotlist” containing a list of prohibited and 
restricted substances for use in cosmetics due to their hazardous properties (Government of 
Canada, 2014).  Given that these chemicals are considered dangerous to the health of an adult, 
they could produce profound disturbances on the developing brain, which starts prenatally and 
continues into adolescence.  
 
2.8. Literature Review Summary 
In closing, lipids and lipid signalling pathways, such as PGE2, are crucial in the 
development of the brain. There are several lines of research that provide evidence supporting 
the involvement of abnormal lipid metabolism in individuals with ASDs. Lipid signalling 
participates in the development of the nervous system, oxidative balance, immune function, as 
well as gastrointestinal repair and sleep behaviour consistent with reported medical 
complications in some children with autism. The COX-2/PGE2 signalling pathway can become 
defective due to genetic aberrations or environmental conditions, such as exposure to drugs, 
infections, or common environmental agents and toxic chemicals. There is evidence linking the 
impairment of this pathway at various steps and the development of ASDs. Collectively, the 
available literature suggests that lipid signalling may have a crucial impact during pre- and 
postnatal periods. Anomalous changes along this pathway can be detrimental to the development 
of the nervous system and may contribute to the pathogenesis and symptomatic manifestations of 
autism. Considering that ASDs are complex neurodevelopment disorders characterized by a wide 
range of behaviours, dysregulation at different points of the lipid signalling pathways discussed 
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herein might provide some explanation to the diverse behavioural outcomes of ASDs. Current 
research gives compelling evidence that lipid irregularities may be a potential underlying cause 
of autism. However, additional investigation into the various genetic and environmental factors 
involved with lipid signalling in autism is essential for understanding the molecular mechanisms 
of the disorder and may aid in the development of novel diagnostic and therapeutic tools as well 
as preventative strategies for ASDs. 
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2.9. Figures 
 
 
 
Fig. 2-1: Cell membrane lipid components implicated in ASDs.  
Irregularities in PUFAs and complex lipids have been associated with ASDs (dashed arrows 
indicate an increase or decrease level in individuals with an ASD; asterisks indicate a link to 
ASDs). 
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Fig. 2-2 : Omega polyunsaturated fatty acids.  
The essential PUFAs are long carbon chain molecules that have an acidic (COOH) end and a 
methyl (CH3) end. The location of the first double bond, at the sixth or third carbon atom, 
determines whether the PUFA is an o-6 or o-3 fatty acid, respectively. 
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Fig. 2-3: Defects in lipid derivatives and prostanoids.  
Prostanoids (PGE2, PGF2a, PGD2, PGI2) and thromboxane A2 (TXA2) are bioactive lipid 
metabolites that elicit cellular events through the action of their respective receptors (EP, FP, DP, 
IP, and TP) (dashed arrows indicate an increase or decrease level in individuals with an ASD; 
asterisks indicate a link to ASDs). 
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Fig 2-4: The PGE2 signalling pathway.  
Stimulation of EP1-4 via PGE2 or misoprostol acid leads to activation of PKC, PKA, or PI-3K, 
resulting in gene transcription. Abnormal deviations indicated by the asterisks have been 
associated with ASDs. 
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Fig. 2-5: The interaction between Wnt and PGE2 signalling pathways.  
Wnt and PGE2 signalling have been implicated in ASDs, and an interaction between these 
pathways has been determined in various cell types as indicated by the dotted lines. 
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Fig. 2-6: Common environmental factors affecting the COX-2/ PGE2 signalling pathway.  
Environmental factors, such as exposure to chemicals in drugs, air pollution, pesticides and 
consumer products, can disrupt normal lipid signalling pathways, such as the PGE2 pathway. 
They can act as analogs, antagonists and EEDCs that interfere with PGE2 signalling and result in 
altered gene expression, thereby influencing the function and development of brain cells. 
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CHAPTER 3.  
Study 1: Prostaglandin E2 alters Wnt-dependent migration and proliferation in 
neuroectodermal stem cells: implications for autism spectrum disorders. 
 
Manuscript 3 Citation (Copyright Permission in Appendix B.):  
Wong, C. T., Ahmad, E., Li, H., & Crawford, D. A. (2014). Prostaglandin E2 alters Wnt-
dependent migration and proliferation in neuroectodermal stem cells: implications for autism 
spectrum disorders. Cell Communication and Signaling : 12, 19. 
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Ahmad assisted in gene expression experiments. Dr. Hongyan Li provided administrative and 
technical support and proofread the manuscript. Dr. Dorota A. Crawford supervised the design of 
the study and was involved with editing the manuscript.  
 
Objectives and Hypotheses: The primary aim of this first study was to investigate the potential 
interaction between the PGE2 and Wnt (a crucial morphogen) signalling pathways. Our major 
objectives were to determine how PGE2 affects the motility (final distance, path length, and 
average speed) and proliferation behaviour of Wnt-activated NE-4C stem cells. We also aimed to 
identify the molecules downstream from PGE2 receptors that interfere with the Wnt signalling 
pathway. I hypothesized that crosstalk between the PGE2 and Wnt signalling pathways alters the 
motility and proliferation of NE-4C stem cells through downstream effectors such as protein 
kinase A (PKA) and phosphatidylinositide 3-kinase (PI-3K). 
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3.1. Chapter Summary 
Prostaglandin E2 (PGE2) is a natural lipid-derived molecule that is involved in important 
physiological functions. Abnormal PGE2 signalling has been associated with pathologies of the 
nervous system. Previous studies provide evidence for the interaction of PGE2 and canonical 
Wnt signalling pathways in non-neuronal cells. Since the Wnt pathway is crucial in the 
development and organization of the brain, the main goal of this study is to determine whether 
collaboration between these pathways exists in neuronal cell types. We report that PGE2 interacts 
with canonical Wnt signalling through PKA and PI-3K in neuroectodermal (NE-4C) stem cells. 
We used time-lapse microscopy to determine that PGE2 increases the final distance from origin, 
path length travelled, and the average speed of migration in Wnt-activated cells. Furthermore, 
PGE2 alters distinct cellular phenotypes that are characteristic of Wnt-induced NE-4C cells, 
which corresponds to the modified splitting behaviour of the cells. We also found that in Wnt-
induced cells the level of β-catenin protein was increased and the expression levels of Wnt-target 
genes (Ctnnb1, Ptgs2, Ccnd1, Mmp9) was significantly upregulated in response to PGE2 
treatment. This confirms that PGE2 activated the canonical Wnt signalling pathway. 
Furthermore, the upregulated genes have been previously associated with ASDs. Our findings 
show, for the first time, evidence for cross-talk between PGE2 and Wnt signalling in neuronal 
cells, where PKA and PI-3K might act as mediators between the two pathways. Given the 
importance of PGE2 and Wnt signalling in prenatal development of the nervous system, our 
study provides insight into how interaction between these two pathways may influence 
neurodevelopment. 
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3.2. Introduction  
The plasma membrane phospholipids play a fundamental role in the nervous system and 
act as a reservoir for second messenger molecules important for the development and normal 
functioning of the brain. Prostaglandin E2 (PGE2) is a bioactive fatty acid that is derived from 
arachidonic acid, a major structural component of plasma membrane phospholipids, through the 
enzymatic metabolism of cyclooxygenases-1 and -2 (COX-1,-2) and then prostaglandin 
synthases (Breyer et al., 2001). Extracellular stimuli such as immunological and infectious 
agents (Brown, 2012, Patterson, 2011, Parker-Athill and Tan, 2010), environmental toxins such 
as mercury and lead (Grandjean and Landrigan, 2006), and exposure to drugs including 
misoprostol and valproic acid (Arndt et al., 2005) can trigger the local production of PGE2 via 
specific biosynthetic pathways, resulting in altered cell signal transmission that modulates 
biological functions such as sleep, fever, inflammation, and pain (Sugimoto and Narumiya, 
2007).  
The diverse action of PGE2 is achieved through the activation of 4 different G-protein 
coupled E-prostanoid receptors (EP1 through 4) (Furuyashiki and Narumiya, 2011, Coleman et 
al., 1994). The divergent role of PGE2 is amplified by the variety of different kinase- mediated 
signalling cascades that can be activated through its EP receptors, such as the protein kinase A 
(PKA), phosphatidylinositide 3-kinases (PI-3K), and protein kinase C (PKC) pathways 
(Andreasson, 2010).  
During the early stages of pregnancy, there are elevated levels of COX-2 and PGE 
synthases, enzymes responsible for the production of PGE2, which is indicative of the 
involvement of PGE2 in prenatal development (Saint-Dizier et al., 2011). We have previously 
shown that the expression profiles of EP receptors during mouse embryonic development 
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changes depending on the embryonic stage, with EP receptor expression highest during E7 
(Embryonic day 7) and E15, which corresponds to peak periods of neurogenesis (Tamiji and 
Crawford, 2010). It has been shown that PGE2 plays a regulatory role in membrane excitability 
and synaptic transmission in neurons (Chen and Bazan, 2005). PGE2 increases the dendritic 
length and complexity of Purkinje neurons, and can also alter neuronal firing activity in the 
developing brain (Dean et al., 2012). PGE2 is involved in synaptic plasticity and neuroprotection 
(Chen and Bazan, 2005), and can also be involved in neuronal cell death and apoptosis 
(Miyagishi et al., 2013, Shimamura et al., 2013). Prostaglandins have also been reported to 
induce the differentiation of neuronal cells (Choi et al., 2001). Moreover, the inhibition of COX-
2, can suppress neurogenesis and proliferation of neural progenitor cells (Goncalves et al., 2010). 
These studies show the important role PGE2 can play during normal development of the nervous 
system. Furthermore, previous research found that PGE2 can exert various effects on cell 
development, proliferation, and migration in a diversity of cell lines. It has been shown that 
PGE2 stimulates cell growth and motility in osteoblasts (Raisz et al., 1993), prostate cancer cells 
(Tjandrawinata et al., 1997), and pancreatic stellate cells (Charo et al., 2013). The migration of 
vascular smooth muscle cells (Lin et al., 2012), intestinal subepithelial myofibroblasts (Iwanaga 
et al., 2012), dendritic cells (Joo et al., 2012), hepatocellular carcinoma cells (Mayoral et al., 
2005), and mesangial cells (Jaffer et al., 1995) can all be regulated by PGE2. However, the 
effects of PGE2 on neural stem cell behaviour and movement are not well characterized. Our 
previous studies provide some insight into the molecular mechanisms of abnormal PGE2 
signalling on neuronal cells. We have found that exposure to PGE2 results in the retraction of 
neurites and the elevation of calcium amplitude fluctuations in growth cones of differentiated 
Neuro-2A cells (Tamiji and Crawford, 2010, Tamiji and Crawford, 2010) 
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Abnormal fatty acid metabolism through the PGE2 pathway may contribute to the 
pathology of neurodevelopmental disorders such as Autism Spectrum Disorders (ASDs) (Tamiji 
and Crawford, 2010). Abnormal levels of PGE2 and other fatty acid metabolites have been 
identified as potential biomarkers for ASDs (El-Ansary and Al-Ayadhi, 2012). PGE2 can act as 
an endogenous modulator for cerebellar development in the rat brain affecting social interaction 
and sensory behaviour, which are characteristic behaviours altered in ASDs (Dean et al., 2012). 
Clinical studies have shown that maternal exposure to the drug misoprostol (prostaglandin E 
analogue), has been associated with the development of Moebius syndrome and autistic-like 
symptoms (Miller, 2007, Miller et al., 2005, Bandim et al., 2003).  
Current literature also provides evidence that PGE2 signalling interacts with another 
crucial developmental pathway, the canonical Wnt (wingless-related MMTV integration site) 
signalling pathway in various non-neuronal cells (Wong and Crawford, 2014) such as osteocytes 
(Kitase et al., 2010), prostate and colon cancer cells (Liu et al., 2010), hematopoietic stem cells  
(Goessling et al., 2009), and mesenchymal stem cells (Kleiveland et al., 2008). Wnt signalling is 
tightly regulated in early development and is required for the formation of the nervous system 
(Ciani and Salinas, 2005). The canonical Wnt signalling pathway is composed of a network of 
proteins that modify cell communication and interactions with other cells. Wnt proteins bind to 
cell surface Frizzled (FZD) receptors, where the signal is then transduced to β-catenin, activating 
the transcription of Wnt-target genes. The Wnt molecules are vital to embryonic development 
since they can moderate cell proliferation and differentiation by participating in the 
determination of cell fates (Buechling and Boutros, 2011). Previous literature shows that 
convergence of PGE2-dependent signalling with the canonical Wnt pathway can occur at the 
level of β-catenin through EP1-4 receptors, including the association of the Gαs subunit with 
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Axin, the stimulation of the cAMP/PKA pathway, or the phosphorylation of GSK-3β by PI-3K 
(Buchanan and DuBois, 2006). However, the interaction of PGE2 and Wnt signalling is not well-
characterized in the nervous system. To activate and study canonical Wnt signalling in an in vitro 
model system, Wnt Agonist (WntA), 2-amino-4-[3,4-(methylene- dioxy)benzylamino]-6-(3-
methoxyphenyl) pyrimidine, can serve as a useful reagent. WntA is a cell-permeable pyrimidine 
compound that mimics the effects of Wnt by functioning through the canonical pathway via 
upregulating TCF-activity without inhibiting the activity of GSK-3β (Liu et al., 2005). This is 
important because GSK-3β plays a regulatory role in many signalling pathways other than Wnt 
so an agonist that blocks GSK-3β could have disparate effects in cellular models. 
This study investigates the effects of PGE2 interaction with the Wnt signalling pathway 
on the behaviour of murine neuroectodermal (NE-4C) stem cells. We demonstrate that PGE2 
modifies canonical Wnt signalling in NE-4C stem cells by altering components of cell motility 
such as final distance travelled, path length travelled, average speed of migration, as well as cell 
splitting behaviour. We also reveal that PGE2 can alter the protein expression of non-phospho 
(active) β-catenin (Ser33/37/ Thr41), as well as the expression of specific Wnt-target genes. 
Interestingly, the genes implicated in our study have been previously associated with ASDs. To 
our knowledge, we show for the first time, that PGE2 signalling interacts with the Wnt pathway 
in neural stem cells to affect cell behaviour and gene transcription. Our study furthers our 
understanding of the possible mechanisms by which intracellular cross-talk between PGE2 and 
Wnt signalling may contribute to cell migration and proliferation during prenatal development of 
the nervous system. 
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3.3. Methods 
Cell culture 
Mouse NE-4C cells were obtained from American Tissue Culture Collection 
(ATCC) and grown in Minimum Essential Medium (MEM) supplemented with 10% fetal 
bovine serum, 2 mM glutamine, 1 X penicillin-streptomycin mixture (Invitrogen). Cells were 
maintained in an incubator containing 5% CO2 at 95% humidity 37°C. Cells were plated on 
0.01% poly-L-lysine (Sigma) coated 100 mm culture plates (BD Falcon) and were 
subcultured at a 1:10 ratio. Supplemented MEM was changed every 2–3 days. 
 
Cell culture treatments 
NE-4C cells (ATCC) were dissociated with 0.05% trypsin-EDTA, pelleted and 
resuspended in complete medium as described above. The cells were plated on poly-L-
lysine 0.01% (Sigma, MW 70000–150000 kDa) on 35 mm tissue culture dishes (Sarstedt). 
Plated cells were incubated in 5% CO2 at 95% humidity 37°C overnight before treatment 
with Wnt Agonist (WntA,  Calbiochem),  prostaglandin E2 (PGE2, Sigma) and/or blockers. 
WntA (2 μM), PGE2 (1 μM), H89 dihydrochloride hydrate (H89, 10 μM, Sigma), 
Wortmannin (WORT, 1 μM, Sigma) or an equivalent volume of vehicle were added to each 
well. Cells were treated for 24 hours. 
 
Reverse transcription and real-time PCR 
Total RNA was extracted from NE-4C cells using the NucleoSpin RNA/Protein Kit 
(Macherey-Nagel) and was reverse-transcribed into cDNA using MMuLV reverse 
transcriptase (New England Biolabs) according to manufacturer’s instructions. Primer3 
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Input software (v. 0.4.0) was used to design forward and reverse primers for EP receptors 
and have been previously noted (Tamiji and Crawford, 2010). Selection of Wnt-target genes 
was determined using Custom TaqMan® Array Plates (Life Technologies) as a screening tool 
(data not shown). Genes that had a greater than 1.8 fold-change were selected for further 
validation and forward and reverse primers were designed (Table 3-1). Real-time PCR was 
performed using the 7500 Fast Real-time PCR system (Applied Biosystems) and the ΔΔCT 
method was applied to calculate the expression of transcripts. Hypoxanthine phosphoribosyl 
transferase (Hprt) and Phosphoglycerate Kinase 1 (Pgk1) served as endogenous controls. 
The relative quantification (RQ) ratios were determined from the average of three technical 
replicates from three biological replicates. 
 
Table 3-1: qRT-PCR Primers for undifferentiated NE-4C stem cells 
 
 
Name Primer Primer Sequence (5’-3’) Base pair Length 
Hprt Forward TCCATTCCTATGACTGTAGATTTTATCAG 29 
 Reverse AACTTTTATGTCCCCCGTTGACT 23 
Pgk1 Forward CAGTTGCTGCTGAACTCAAATCTC 24 
 Reverse GCCCACACAATCCTTCAAGAA 21 
Ptgs2 Forward CAGCCAGGCAGCAAATCC 18 
 Reverse TTATACTGGTCAAATCCTGTGCTCAT 26 
Ctnnb1 Forward GGACGTTCACAACCGGATTG 20 
 Reverse GAGAATAAAGCAACTGCACAAACAA 25 
Ccnd1 Forward GCACTTTCTTTCCAGAGTCATCAA 24 
 Reverse CTCCAGAAGGGCTTCAATCTGT 22 
Mmp9 Forward TCGCGTGGATAAGGAGTTCTCT 22 
 Reverse ATAGGCTTTGTCTTGGTACTGGAAGA 26 
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Western blot analysis 
Total protein was extracted from NE-4C cells using the NucleoSpin RNA/Protein Kit 
(Macherey-Nagel). Samples were separated by polyacrylamide gel electrophoresis (PAGE). 
Primary antibodies used for EP expression levels include rabbit polyclonal anti-EP1, -EP2, 
-EP3, -EP4 (1:200; Santa Cruz Biotechnology). Detection of rabbit monoclonal anti-
Phospho-Histone H3 (Ser10) (1:1000; Cell Signaling) was used as a measure of cell 
splitting behaviour. Primary antibodies used for β-catenin expression levels were rabbit 
monoclonal anti-non-phospho (Active) β-catenin (Ser33/37/Thr41) and rabbit polyclonal 
anti-phospho-β-catenin (Ser552) (1:1000; Cell Signaling). Blots were reprobed with mouse 
monoclonal anti-β-Actin (1:10,000; Abcam). Visualization of bound anti-rabbit and anti-
mouse horseradish peroxidise-conjugated secondary antibodies was achieved by incubation 
with ECL Prime Western Blotting Detection Reagent (GE Healthcare) and detection by 
Geliance 600 Imaging System (Perkin Elmer). 
 
Immunocytochemistry 
 NE-4C cells were seeded onto 35 mm culture plates containing poly-L-lysine 
coated coverslips and grown overnight at 37°C. The cells were fixed with 50% acetone and 
50% methanol for 20 minutes at −20°C and washed with phosphate buffered saline (4.3 
mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, 1.4 mM KH2PO4). Cells were then 
incubated with primary antibodies in PBS with 0.3% Triton-X 100 and 2% Normal Goat 
Serum. Cellular localization of the EP receptors was determined by incubation with anti-EP 
primary antibodies as described above along with mouse monoclonal anti-Lamin A + C 
nuclear envelope marker (1:200;  Abcam), anti-58 K Golgi marker [58 K-9] (1:100; 
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Abcam), anti-PDI endoplasmic reticulum marker [RL90] (1:100; Abcam) or β-Actin 
(1:1000; Abcam) at room temperature for 1 hour. Following primary antibody incubation, 
cells were washed three times with PBS-T for 15 min and incubated with secondary 
antibodies in PBS-T and 2% NGS for 1 hour at room temperature in the dark. Secondary 
antibodies used were anti-rabbit fluorescein isothiocyanate (FITC) (1:100; Jackson 
ImmunoResearch Laboratories) and anti-mouse TexasRed (1:200;   Jackson   ImmunoResearch 
Laboratories). Cells were then washed twice with PBS-T for 10 min, followed by a 20 minute 
incubation of 4′,6-diamidino-2-phenylindole (DAPI) (1:2000; Molecular Probes) at room 
temperature. Cells were washed twice with PBS-T for 5 min and coverslips were mounted 
on glass microscope slides with mounting media (Vectashield). The staining was 
visualized and captured using an Eclipse 80i upright fluorescent microscope with DS-5MC 
camera (Nikon). 
 
Time-lapse imaging and analysis 
Cell behaviour was recorded using Nikon Eclipse Ti-E microscope. Three biological 
replicates of each treatment condition were performed (N=3), where an average of 150 cells 
were tracked. Micrographs were automatically captured every 10 minutes for a 24 hour 
period from a minimum of three fields. To maintain conditions physiologically suitable for 
the cells, an enclosed chamber was mounted to the microscope, which was equipped with 
CO2 supply and temperature thermostat. Cells were kept at 5% CO2, 95% humidity, 37°C. 
Measurements were completed using NIS Elements software, including a specialized 
tracking module. Final distance from origin, path length, and average speed were tracked 
and calculated from an average of 150 cells per treatment condition. The final distance was 
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defined as the distance between the initial and final positions of the cell, represented as a straight 
line distance. The path length was the total distance travelled from the initial to the final cell 
position. The average speed of a cell was calculated by dividing the total distance travelled by 
the time it took to travel between the two positions. 
Initial and final cell counts were used to determine fold change as a measurement of 
proliferation. Split percentage was quantified as a measurement of proliferation behaviour. 
Split percentage was defined as the percentage of cells that fulfilled the complete cell 
cycle, which was evaluated based on whether the parent cell could successfully split into 
two daughter cells. 
 
Cell viability analysis 
Cells were disassociated and diluted with equal volumes of trypan blue dye (4%). 
Cell count averages were taken from a minimum of four hemacytometer squares to 
determine cell number and viability. 
 
Statistical analysis 
All numerical data were presented as mean + SEM of three individual experiments. 
Statistical analysis was performed using student t-test or one-way analysis of variance 
(ANOVA) followed by Tukey post-hoc comparisons or Dunnett t-test (2-sided). 
Differences were considered statistically significant at *p < 0.05, **p < 0.01, or 
***p < 0.001. 
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3.4. Results 
Expression of EP1-4 receptors in NE-4C cells 
To determine whether NE-4C cells endogenously express the receptors of PGE2, we 
performed real-time quantitative PCR assay, Western blot analysis, and immunocytochemistry. 
Our results show that in NE-4C cells, EP2 had the highest mRNA expression followed by EP3γ 
and EP4 receptors. Endogenous EP1 and EP3β receptor expression was considerably low in NE-
4C cells, while the EP3α transcript level was nearly absent and may be considered negligible. 
The relative quantity (RQ = 1) values of EP1, EP2, EP3α, EP3β, EP3γ, and EP4 transcripts 
expression were 3, 542, 0, 1, 391, and 15, respectively (Fig. 3-1A). Western blot results confirm 
the expression of all four EP receptors in NE-4C cells (Fig. 3-1B). The localization of the EP 
receptors in NE- 4C cells was also detected with immunocytochemistry using EP1-4 specific 
antibodies along with antibodies against various cellular organelles including the nuclear 
envelope, Golgi apparatus, the endoplasmic reticulum, and β-Actin (Fig. 3-1C). Our results show 
that EP1 receptors were localized in the ER membrane, EP2 receptors were uniformly expressed 
around the nucleus and co-localized with the nuclear envelope marker, EP3 receptors were 
located at the plasma membrane, and EP4 receptors at the Golgi apparatus. Hence, NE-4C cells 
can act as an appropriate experimental model to study PGE2 signalling. 
 
Prostaglandin E2 increases the cell motility of Wnt-induced NE-4C cell migration 
The effect of PGE2 on Wnt-dependent migration of NE-4C cells was determined using 
Nikon Eclipse Ti-E microscope with NIS Elements time-lapse tracking software over a 24 hour 
period. Final distance, path length, and average speed were quantified after exposure to 1 μM 
PGE2, 2 μM Wnt Agonist (WntA), or 2 μM WntA with the addition of 1 μM PGE2.  
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The results show that untreated NE-4C cells moved an average final distance of 65.6 μm 
following a 24 hour period (Fig. 3-2A). The addition of PGE2 to the cells resulted in a final 
distance of 56.2 μm which was not significantly different from the untreated control (65.6 μm). 
WntA only treatment resulted in a significant decrease in final distance of 21.3 μm (p = 0.00242) 
when compared to the control. The addition of PGE2 to WntA-treated cells resulted in a final 
distance of 45.0 μm, which is an increase by 23.6 μm (p = 0.04371), as compared to WntA only-
treated cells. It represents a 211% increase from the WntA-regulated movement. Visualization of 
final distance through dispersion XY position plots clearly illustrates that PGE2 signalling 
restores the Wnt-regulated suppression of cell movement (Fig. 3-2B, WntA + PGE2). 
The quantification of path length (Fig. 3-3A) revealed the same pattern. The path length 
of untreated cells was 458.9 μm. As compared to untreated cells, PGE2 only treatment did not 
result in a significant change (408.6 μm), but WntA treatment significantly decreased the path 
length to 103.3 μm (p = 0.00189). Addition of PGE2 to WntA-treated cells led to a path length of 
362.1 μm. This is a 350% increase (p = 0.00928) compared to WntA only-treated cells. 
Quantification of average speed showed that PGE2 treated cells travelled at a speed of 
10.5 nm/s, which was not significantly different from untreated NE-4C cells that moved at a 
speed of 11.0 nm/s (Fig. 3-3B). WntA only treatment resulted in a decreased average cell speed 
of 1.65 nm/s (p = 0.00065). Addition of PGE2 to WntA- treated cells resulted in an average speed 
of 7.34 nm/s. This suggests that addition of PGE2 elevated the average speed by 439%; an 
increase of 5.59 nm/s (p = 0.00946) when compared to WntA only-treatment. 
In summary, administration of PGE2 treatment leads to significant changes in WntA-
regulated cell behaviours such as final distance, path length, and average speed. PGE2 treatment 
significantly restored the cell kinematic measures which were suppressed by WntA treatment.b 
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Prostaglandin E2 modulates Wnt-induced cell behaviour through PKA and PI-3K kinases 
Previous studies in embryonic kidney and colon cancer cells determined that the 
convergence of PGE2 signalling on the Wnt pathway occurred through the activation of PKA or 
PI-3K (Castellone et al., 2005, Fujino et al., 2002, Sheng et al., 2001). To determine whether 
PGE2 treatment alters Wnt-induced cell migration behaviour via these kinases in NE-4C cells, 
we used dihydrochloride hydrate (H89) to block PKA and Wortmannin (Wort) to block PI-3K. 
Our results show a trend across final distance, path length, and average speed (Fig. 3-2 and 3-3). 
With the addition of H89 to WntA + PGE2 treated cells, all cell motility measures significantly 
decreased compared to the WntA + PGE2 treated cells, resulting in movement profiles that were 
not statistically different from the WntA-only condition. Specifically, H89-treated cells travelled 
a final distance of 20.32 μm from the origin (p = 0.02477), path length of 116.01 μm (p = 
0.00567), and at an average speed of 1.37 nm/s (p = 0.00073) (Fig. 3-2A and 3-2B). 
With the addition of Wort to WntA + PGE2 treated cells, there was a decreasing trend in 
final distance and path length but it was not significantly different from PGE2 + WntA treated 
cells. Only average speed significantly decreased to 2.76 nm/s (N = 3; p = 0.00422) compared to 
the WntA + PGE2 treatment. Post hoc Dunnett t-test revealed that measurements from the H89 
and Wort conditions were not significantly different from the WntA-only treatment, indicating 
that H89 and Wort significantly diminished the effect of PGE2 on WntA- treated cells. This 
indicates that PGE2 likely acts through PKA and PI-3K to elicit effects on the WntA-dependent 
cell motility. However, it appears that H89 may have had a greater effect, suggesting that PGE2 
may predominately act through PKA. 
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Prostaglandin E2 alters cell proliferation behaviour of NE-4C cells induced by Wnt agonist 
treatment 
Previous literature reveals that PGE2 may also affect cell proliferation via the Wnt 
signalling pathway in prostate and colon cancer cells (Liu et al., 2010) and hematopoietic 
(Goessling et al., 2009) and mesenchymal (Kleiveland et al., 2008) stem cells. We studied the 
effects of PGE2 on NE-4C cell proliferation using NIS Elements software. The cells were 
exposed to 1 μM PGE2, 2 μM WntA, or 2 μM WntA with the addition of 1 μM PGE2. 
Furthermore, H89 or Wort was added to PGE2 + WntA treated cells to determine the effective 
role of these kinases. The initial number of cells was compared to the final number of cells 
following 24 hours treatment. PGE2 treatment led to an increase in cell number by 4.60-fold, 
which was not significantly different from the untreated cells that proliferated by a 4.59 fold-
increase (Fig. 3-4A). Administration of WntA resulted in a fold- change of 0.86 (p < 0.001) 
which was significantly lower than untreated cells. Addition of PGE2 to WntA-treated cells 
(WntA + PGE2) resulted in a fold-change of 1.03, which was not significant from the WntA only 
treated condition. Although we observed lower levels of proliferation in the WntA, WntA + 
PGE2 and WntA + PGE2 + blocker conditions, we confirmed no change in cell viability between 
the conditions tested (Fig. 3-4B). 
However, we observed distinct differences in cell phenotype between the WntA, WntA + 
PGE2 and WntA + PGE2 with H89 or Wort treatment. A majority of the cells treated with WntA 
adopted a shiny circular shape (indicated by black arrows, Fig. 3-4D). This was not as prevalent 
in the WntA + PGE2 condition. However, the cells treated with WntA + PGE2 and Wort blocker, 
adopted the shiny circular phenotype seen in the WntA condition. Cells treated with WntA + 
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PGE2 and H89 blocker adopted a circular appearance as well but a smaller population of these 
round cells were shiny. 
Our experiments showed that cell viability was not affected but a distinct shiny circular 
cell appearance was observed, which is characteristic of a cell just prior to splitting into two 
daughter cells. Therefore, we also quantified the split percentage, defined as the percentage of 
cells that successfully divided into two daughter cells during the recorded time period. As 
expected, the NE-4C untreated cells demonstrated a split percentage of 100% (Fig. 3-4C), 
indicating that all cells entering a mitotic phase resulted in cell division. A similar pattern was 
seen in PGE2-treated cells (97.5%). However, treatment of WntA resulted in a significant 
decrease of split percentage to 0% (p < 0.001), where mitotic cells appeared to become arrested 
in a round stage denoted in Fig. 3-4D (WntA Image) with black arrows. The addition of 1 μM 
PGE2 to WntA-treated cells produced a significant increase in split percentage to 14.7% (p < 
0.001, Fig. 3-4C) as compared to WntA only treatment. The cells appear to resume their flat 
morphology. These results suggest that PGE2 treatment can modify Wnt-induced proliferation 
behaviour such as split percentage. Following treatment with either H89 or Wort, cells returned 
to a split percentage of 0% as seen with WntA only treatment (Fig. 3-4C, -4D). This again 
indicates that PGE2 likely acts on the Wnt pathway through PKA and PI-3K to modify cell 
proliferation. 
To further confirm our results of the cell splitting behaviour, we measured the level of 
Phospho-Histone H3 (Ser10) (Fig. 3-5) since phosphorylation at Ser10 is tightly associated with 
chromosome condensation and segregation that occurs during mitosis (Liokatis et al., 2012, 
Nowak and Corces, 2004, Goto et al., 1999). Compared to untreated cells, PGE2 only-treated 
cells did not display a significant difference. However, when compared to untreated NE-4C cells, 
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cells treated with WntA, WntA + PGE2 and WntA + PGE2 with H89 or Wort treatment led to a 
significance increase  in Phospho-Histone H3 (Ser10) expression. RQ values were 1.35 (p = 
0.033), 1.52 (p = 0.001), 1.36 (p = 0.027), and 1.58 (p = 0.005), respectively. This revealed that 
although cell numbers were lower under these conditions, the relative expression of Phospho-
Histone H3 (Ser10) was significantly higher, indicating that a greater percentage of cells were 
undergoing mitosis when exposed to these treatments compared to untreated cells. This 
correlates with our finding that a larger proportion of cells under these conditions adopts and 
seems to be arrested in a round stage characteristic of cells undergoing mitosis. 
 
Prostaglandin E2 increases active β-catenin expression in Wnt-induced NE-4C cells 
β-catenin is a key effector in the canonical Wnt signalling pathway that regulates 
downstream gene transcription (Cadigan and Nusse, 1997). β-catenin levels can be intricately 
regulated at multiple phosphorylation sites. Phosphorylation at Ser33, Ser37, and Thr41 leads to 
its destabilization and primes it for degradation (Wu and He, 2006), while phosphorylation at 
Ser552 has been correlated with β-catenin nuclear accumulation (Fang et al., 2007, He et al., 
2007). We tested the levels of non-phospho-(the active form) β-catenin (Ser33/37/Thr41) and 
phospho-β-catenin (Ser552). The addition of PGE2 only to NE-4C cells did not significantly 
change the levels of either form of β-catenin (Fig. 3-6A and -6B). However, adding PGE2 to 
WntA-induced NE-4C cells lead to a significant 2.1 fold increase in non-phospho-(active) β-
catenin (Ser33/37/ Thr41) levels compared to the WntA only treated condition (Fig. 3-7A). 
There was no significant difference in Phospho-β-catenin (Ser552) levels between the sample 
conditions (Fig. 3-7B), suggesting that phosphorylation of β-catenin at Ser552 is likely not 
involved with the behavioural differences in NE-4C cells described earlier. These results indicate 
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that PGE2 may interact with the canonical Wnt signalling pathway by regulation of non-
phospho- (active) β-catenin (Ser33/37/Thr41) levels. 
 
Prostaglandin E2 regulates expression of Wnt-target genes in Wnt-induced NE-4C cells 
To investigate whether the addition of PGE2 can influence gene transcription relevant to 
the canonical Wnt pathway, we screened 29 target genes using Custom TaqMan® Array Plates. 
We found that Ctnnb1, Ptgs2, Ccnd1, and Mmp9 were differentially regulated (data not shown). 
Their expression was confirmed with real-time PCR using RNA derived from the same treatment 
conditions used for behavioural analyses, which includes 1 μM PGE2, 2 μM Wnt Agonist 
(WntA), or 2 μM WntA with the addition of 1 μM PGE2. Kinase blockers (H89 or Wort) were 
added to PGE2 + WntA treated cells to determine the potential contribution of PKA and PI3K 
activity via PGE2 signalling. Our real-time PCR results indicate that PGE2 affects the expression 
levels of all Wnt-target genes tested (Fig. 3-8). 
Ctnnb1 (beta-catenin) levels were not altered with the addition of PGE2 when compared 
to untreated NE-4C cells, but cells treated with WntA showed a significant increase of RQ value 
1.25 (p = 0.0372). Addition of PGE2 to WntA-induced cells led to a further increase of Ctnnb1 
level to an RQ value of 1.55, which was significantly different from the WntA-only condition (p 
= 0.0131). This pattern was consistent with the expression of phospho (active) β-catenin 
(Ser33/37/Thr41) protein quantified earlier using Western blot analysis. Addition of H89 or Wort 
to PGE2 + WntA treated cells resulted in RQ values to 0.83 and 0.60, respectively, compared to 
untreated cells which was a significant decrease compared to the PGE2 + WntA condition (p < 
0.001, p < 0.001). The PKA and PI3K blockers, H89 and Wort, appeared to remove the effect   
of PGE2 on Ctnnb1 expression in WntA-induced cells, while also reversing the influence on 
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Ctnnb1 levels from WntA-only treatment. This suggests that PKA and PI3K signalling may 
modify Ctnnb1 expression through PGE2 signalling. 
NE-4C cells treated with PGE2 alone had a significant decrease in Ptgs2 (prostaglandin-
endoperoxide synthase 2; gene encoding COX-2) mRNA levels compared to untreated cells (RQ 
= 0.56, p < 0.001), while cells treated with WntA had a significant increase of RQ value 2.99 (p 
= 0.00286). In contrast, when PGE2 was added to WntA-induced NE-4C cells, Ptgs2 expression 
was further elevated with an RQ value of 4.59 compared to untreated. This value was 
significantly different from the PGE2 + WntA condition (p = 0.015). Addition of H89 or Wort to 
PGE2 + WntA treated cells resulted in RQ values of 2.16 and 4.22, but only the H89 treatment 
was significantly different from the PGE2 + WntA condition (p < 0.001). This suggests that the 
effect of PGE2 on WntA-induced cells may be through PKA. 
Expression of Ccnd1 (cyclin D1) was also altered. Administration of PGE2 treatment to 
NE-4C cells  correlated with a  significant increase of an RQ value to 3.68 (p = 0.045) compared 
to untreated cells, while WntA-treated cells had a significant increase of RQ value to 1.50 (p = 
0.048). Addition of PGE2 to WntA-activated cells was associated with a further increase of 
Ccnd1 expression, with an RQ value 1.99 compared to untreated cells, which was significantly 
different from WntA-only treated cells (p = 0.047). H89 or Wort added to PGE2 + WntA treated 
cells had RQ values of 0.74 and 1.42, respectively, which was significantly different from the 
PGE2 + WntA condition (p = 0.0054, p = 0.0078). The blockers, H89 and Wort, seemed to 
attenuate the increase of Ccnd1 levels associated with the addition of PGE2 to WntA-induced 
cells. 
In comparison to untreated NE-4C cells, PGE2 treatment did not change levels of Mmp9 
(matrix metalloproteinase 9). However, when compared to WntA-induced NE-4C cells, addition 
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of PGE2 treatment to WntA-treated cells caused a significant increase in expression level (p < 
0.001). Specifically, with WntA treatment, Mmp9 expression was significantly elevated to an RQ 
value of 2.19 (p < 0.001) compared to untreated cells, but addition of PGE2 to WntA-induced 
cells resulted in a further rise of Mmp9 expression with an RQ value of 3.00. H89 and Wort were 
added to PGE2 + WntA treated cells and RQ values for Mmp9 were 2.16 and 2.68, respectively, 
compared to the untreated condition. These values were significantly different from the PGE2 + 
WntA condition. This indicates that the use of H89 and Wort diminished the increase in Mmp9 
expression as a result of PGE2 treatment on WntA-induced cells. 
Overall, these results demonstrate that PGE2 can raise the expression of Wnt-target genes, 
specifically, Ctnnb1, Ptgs2, Ccnd1, and Mmp9, in WntA-induced NE-4C cells. Since H89 and 
Wort attenuated the changes caused by PGE2, PKA and PI3K likely serve as a molecular link for 
the interaction between the PGE2 and canonical Wnt signalling pathways. 
 
3.5. Discussion 
Cell migration and proliferation are crucial components of neural development. Previous 
studies have shown that elevated levels of PGE2 can result in increased cell motility and 
proliferation in various non-neuronal cells (Aso et al., 2013, Bai et al., 2009, Yen et al., 2008, 
Sheng et al., 2001). Recent evidence indicates that abnormalities in cell behaviour can result 
from the interaction between PGE2 with Wnt signalling pathways (Oshima and Oshima, 2013, 
Castellone et al., 2005).  Our current study provides evidence, for the first time, for the cross-talk 
between these two pathways in neural stem cells. We report that PGE2 treatment elicits changes 
in cell behaviour such as an increase in components of cell motility and proliferation, as well as 
expression of Wnt-target genes, in Wnt-activated NE-4C stem cells. Moreover, the stimulatory 
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effects of PGE2 are subdued through the inhibition of downstream pathway kinases, PKA and PI-
3K, suggesting that PGE2 acts through these particular kinases to converge with the Wnt 
pathway. 
Previous studies have shown that PGE2 can increase or decrease the activity of canonical 
Wnt signalling. PGE2 activates several components of the canonical Wnt pathway in colorectal 
cancer cells (Buchanan and DuBois, 2006). Specifically in these cells, PGE2 stimulated a 
significant increase in the activity of Wnt transcription factors, T cell factor-4 (Tcf-4), as well as 
elevated protein levels of Wnt-target genes (Shao et al., 2005). PGE2 acted through its EP2 
receptor to modulate β-catenin activity of the Wnt pathway, promoting the growth of colon 
cancer cells (Castellone et al., 2005). Wnt activation induced by PGE2 also contributed to 
abnormal proliferation resulting in enhanced gastric tumorigenesis (Oshima and Oshima, 2013). 
Furthermore, PGE2–regulated Wnt signalling had a hepatoprotective effect, aiding in liver 
regeneration (North et al., 2010). In pre-osteoblastic cells, concentration-dependent treatment of 
PGE2 modulated Wnt signalling by altering protein expression of pathway activators, β-catenin 
and low-density lipoprotein receptor-related protein 5/6 (LRP 5/6), as well as Wnt inhibitor, 
dickkopf-1 (DKK-1); low doses of PGE2 promoted the Wnt pathway while high doses inhibited 
it (Liu et al., 2010). PGE2 also modified Tcf-luciferase activity of Wnt signalling through the 
same dose effect (Liu et al., 2010). Additionally, in human colorectal adenoma and carcinoma 
cells, PGE2 treatment upregulated the protein expression of the Wnt target gene, leucine-rich G-
protein coupled receptor 5 (LGR5), which internalizes FZD co-receptor LRP6 and decreases 
Wnt activity (Al-Kharusi et al., 2013). 
Altogether, these studies reveal that the interaction between PGE2 and Wnt signalling can 
have different effects depending on the dose of PGE2 administered and the specific cell type. 
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We reveal that PGE2 increases the final distance and path length travelled, as well as the average 
speed of migration in Wnt-activated neuroectodermal stem NE-4C cells. We also show that 
PGE2 alters the phenotype of Wnt-treated cells, which corresponds to an increase in split 
percentage. Aberrations in cell motility and proliferation behaviour could have detrimental 
effects to early development of the nervous system. This is because proper neural development 
requires an orchestrated system of cellular events, such as migration and proliferation, to occur 
over particular windows of time (Stiles and Jernigan, 2010). Careful control of these crucial 
neurobiological processes during prenatal development is required for the formation of complex 
layered structures in the brain like the cerebral cortex, hippocampus, and cerebellum (Evsyukova 
et al., 2013, Hatten, 1999). 
Our study adds to the current body of research by showing that PGE2 interferes with the 
Wnt pathway by attenuating Wnt-dependent cell behaviour in NE-4C cells. This is important 
because Wnt signalling is involved in a myriad of regulatory processes important for the 
development and organization of the nervous system (Ille and Sommer, 2005). It is thoroughly 
established that Wnt signalling is instrumental to normal anterior-posterior patterning of the 
embryo (Arkell et al., 2013). Wnt proteins are key regulators for the formation of the neural tube, 
as well as neuronal migration and differentiation (Ciani and Salinas, 2005, Ille and Sommer, 
2005). Wnt signalling also modulates neurite outgrowth (Lu et al., 2004), axon growth and 
guidance (Bovolenta et al., 2006, Sanchez-Camacho et al., 2005, Zou, 2004, Lyuksyutova et al., 
2003), dendritic development and arborization (Wayman et al., 2006, Rosso et al., 2005), radial 
migration (Zhou et al., 2004), and synapse formation and plasticity (Gogolla et al., 2009, Chen et 
al., 2006). Moreover, Wnt signalling is crucial in neuronal fate determination, particularly in the 
specification and differentiation of neuronal precursors in the midbrain (Prakash et al., 2006) and 
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forebrain (Zhou et al., 2006, Hirabayashi and Gotoh, 2005). Furthermore, epithelial stem cells 
require Wnt/β-catenin signalling for proliferation and quiescent division (Lowry et al., 2005) and 
the balance between re-entry and exit of the cell cycle can be altered by Wnt/β-catenin signalling 
(Chenn and Walsh, 2002). Additionally, aberrant cortical progenitor cell proliferation patterns 
and defective hippocampus development can result due to abnormal Wnt signalling (Lee et al., 
2000). Interestingly, recent findings provide evidence that defective Wnt signalling could 
contribute to the pathogenesis of psychiatric disorders like schizophrenia and ASDs (Kalkman, 
2012, Okerlund and Cheyette, 2011, Cotter et al., 1998). Specifically, Wnt2, located in the 
putative speech and language region at chromosome 7q31-33, has been identified as a 
susceptibility gene for autism. (Lin et al., 2012, Wassink et al., 2001). Given the importance of 
Wnt signalling in prenatal development and the existing interaction between Wnt and PGE2 
pathways in NE-4C stem cells, alterations in levels of PGE2 via endogenous and exogenous 
means may have profound effects on nervous system development. 
In addition to quantifying cell behaviour, we also demonstrate that PGE2 can affect the 
expression of non-phospho (active) β-catenin (Ser33/37/Thr41). Wnt/β-catenin signalling occurs 
through a complex, highly regulated pathway that involves the phosphorylation of multiple sites 
on β-catenin, which may promote its degradation or activation and subsequent nuclear 
internalization. For instance, the phosphorylation of sites Ser33, 37, and Thr41 targets β-catenin 
for ubiquitination and proteasomal degradation (Kimelman and Xu, 2006, Liu et al., 2002). 
Quantification of β-catenin that is non-phosphorylated at these sites has become a common 
measurement for active or stabilized β-catenin expression. Phosphorylation of β-catenin at the 
site Ser552 has also been correlated with increased β-catenin/TCF mediated transcriptional 
activity (Zhao et al., 2010, Taurin et al., 2006). We found that PGE2 treatment administered to 
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Wnt-activated cells increased the expression of non-phospho (active) β-catenin (Ser33/37/Thr41) 
protein. In contrast, the phospho-β-catenin (Ser552) levels remained unchanged. It has been 
established that the regulation of glycogen synthase kinase 3 beta (GSK3β) activity may control 
stabilization of β-catenin and increased levels of non-phospho (active) β-catenin 
(Ser33/37/Thr41) protein (Gao et al., 2014). It is possible that PGE2 signalling may modify 
GSK3β activity but this remains to be determined. Nonetheless, the increased levels of non-
phospho (active) β-catenin (Ser33/37/Thr41) quantified were in line with our gene expression 
results that also showed an increase in Ctnnb1 expression as well as other Wnt-target genes. 
Ctnnb1 encodes for the β-catenin protein, which can regulate cell growth and adhesion and is 
also a key downstream component of the canonical Wnt pathway. It has also been shown to 
regulate cortical size; enlarged cortices with increased cortical folds were observed in Ctnnb1 
transgenic mice (Chenn and Walsh, 2002). Interestingly, brain overgrowth and abnormal excess 
in number of neurons was measured in children with autism (Courchesne et al., 2011). Gene 
expression of Ctnnb1 was altered in both young and adult autistic cases (Chow et al., 2012). 
Furthermore, de novo mutations of this gene and its relevant network have been ranked 
significantly as potential autism candidate genes (Krumm et al., 2014, O'Roak et al., 2012).  
Within the canonical Wnt pathway, the β-catenin/TCF complex can promote the 
transcription of target genes including Ptgs2 (Nunez et al., 2011), Ccnd1 (Klein and Assoian, 
2008, Shtutman et al., 1999), and Mmp9 (Ingraham et al., 2011, Wu et al., 2007). Expression of 
these genes was increased as an effect of elevated PGE2 signalling in our study, and 
interestingly, previous studies have reported a link between these genes and ASDs as described 
below. Ptgs2, also known as COX-2, is the key enzyme in prostaglandin biosynthesis, including 
the production of PGE2. COX-2 is a crucial mediator of inflammation and prostanoid signalling 
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(Chen, 2010, Seibert and Masferrer, 1994). Polymorphism of Ptgs2 has been associated with 
ASDs (Yoo et al., 2008). A recent clinical study proved the efficacy of a COX-2 inhibitor drug, 
celecoxib, as an adjunctive therapy in the treatment of autism: the treatment was superior for 
treating irritability, social withdrawal, and stereotypy of children with autism (Asadabadi et al., 
2013). 
Another gene affected was Ccnd1. This gene encodes for a protein in the cyclin family, 
which are important regulators in cell cycle progression, transcription, and neuronal function 
(Lim and Kaldis, 2013, Bloom and Cross, 2007). The increased levels of Ccnd1, as a result of 
added PGE2, may be involved with the altered proliferation behaviour visualized in this study. 
Aberrant Ccnd1 levels have also been associated with ASDs. In autistic rat pups (model 
encompassed administration of valproic acid), Ccnd1 expression was atypical in the cerebellum 
compared to controls (Kim et al., 2013). Another study showed that the dysregulation of Ccnd1 
lead to abnormal cell cycle and proliferation, neuronal and network excitability and behaviour, 
and revealed its potential link to human neuro-cardio-facial-cutaneous and related syndromes, 
which are associated with developmental abnormalities, cognitive deficits, and autism 
(Pucilowska et al., 2012). Diminished expression of 22q11 genes, which disrupts cortical 
neurogenesis and cell migration, led to alterations in Ccnd1 levels (Meechan et al., 2009). 
The authors explain that a developmental disruption, as such, may alter cortical circuitry and 
establish vulnerability for developmental disorders, including schizophrenia and autism. 
Mmp9 is a membrane of the matrix metalloproteinase (MMP) family, which can 
target many extracellular proteins including proteases, growth factors, and adhesion 
molecules (McCawley and Matrisian, 2001) and are involved with the breakdown of the 
extracellular matrix in normal physiological processes such as embryonic development and 
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tissue remodelling (Vu and Werb, 2000). MMPs are also important in neuronal 
development, plasticity, and maintenance of neuronal health (Fujioka et al., 2012). Mmp9 
has also been shown to regulate the proliferation and migration of embryonic neural stem 
cells (Ingraham et al., 2011) and participate in neuronal differentiation by regulating neurite 
elongation and neuronal cell migration (Shubayev and Myers, 2004, Chambaut-Guerin et 
al., 2000, Ferguson and Muir, 2000). Therefore, altered Mmp9 expression may contribute to 
the deviant behaviour observed in our study. Mmp9 has also been associated with ASDs 
(Abdallah and Michel, 2013). Elevated levels of MMP9 protein were found in the amniotic 
fluid of ASD cases compared to controls (Abdallah et al., 2012). Findings from this study 
provide evidence that molecular and physiological abnormalities in ASDs may begin 
prenatally. Mmp9 has also been implicated in Fragile X syndrome (FXS) (Janusz et al., 2013), 
which is characterized by behaviours at the extreme of the autistic spectrum. Using a 
mouse model of fragile x (Fmr1 KO), levels of MMP9 was found to be elevated in the 
hippocampus of Fmr1 KO mice (Bilousova et al., 2009). Furthermore, Minocycline, a drug 
that inhibits MMP9 activity, has been shown to promote dendrite spine maturation and 
improve behavioural performance in Fmr1 KO mice (Bilousova et al., 2009). These 
researchers continued their work in human trials and found that Minocycline taken as a daily 
dose for 8 weeks led to behavioural improvements in FXS patients. This was consistent with 
their fmr1 KO mouse model results, indicating that MMP9 activity alters underlying neural 
defects that contribute to behavioural abnormalities seen in ASDs (Paribello et al., 2010). 
Taken altogether, our gene expression results not only show a potential interaction 
of the PGE2 and canonical Wnt pathway in the nervous system, but also provide further 
evidence for a link to ASDs. 
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We show that PGE2 interacts with canonical Wnt signalling through PKA and PI-3K 
to produce the reported behavioural changes in cell motility and proliferation, as well as 
gene expression. Specifically, we found that inhibiting these PGE2 downstream pathway 
kinases, PKA and PI-3K with H89 and Wort respectively, reduced the effect of PGE2. This 
is in line with previous literature, which found that the convergence of PGE2-dependent 
effects and the Wnt pathway can occur through the stimulation of PKA or PI-3K in 
embryonic kidney cells and colon cancer cells (Castellone et al., 2005, Fujino et al., 2002, 
Sheng et al., 2001). Moreover, similar stimulatory effects on cell migration induced by 
PGE2 in Wnt-activated NE-4C cells from our study were also exhibited in prostate cancer 
cells through the activation of PI-3K (Vo et al., 2013). Our results revealed that H89 had a 
stronger effect than Wort, suggesting that PGE2 may predominately act through PKA; but 
future studies are needed to determine which EP receptors are involved. A proposed model 
is provided in Fig. 3-9. 
Increasing evidence for the contribution of environmental factors in the etiology of 
neurodevelopmental disorders like ASDs has prompted urgency to reveal their potential 
exogenous causes and underlying mechanisms (Landrigan et al., 2012). Environmental 
factors like exposure to drugs, toxins or infectious agents cause disruptions in PGE2 
signalling by increasing the levels of oxidative stress, consequent lipid peroxidation, and the 
immunological response; these factors and consequences that disturb normal PGE2 
signalling have all been linked to ASDs (Ecker et al., 2013). We show that increased PGE2 
signalling can modify cell migration, proliferation behaviour, and gene expression in Wnt-
activated NE-4C stem cells. Aberrant cell migration and proliferation are pathophysiologic 
mechanisms that impact the brain broadly, and could be possible factors that contribute to 
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the origination of neurodevelopment disorders. Abnormalities in structure, organization, and 
connectivity of the brain are all indicators of irregular neural cell migration and 
proliferation. Local distortions in neural cytoarchitecture, dysplasia, and hypoplasia have 
been described in brains of autistic subjects (Wegiel et al., 2010). Moreover, structural 
abnormalities and atypical connectivity of the brain in ASDs have been identified by a 
number of research groups (Abrams et al., 2013, Aoki et al., 2013, Ecker et al., 2013, 
Minshew and Williams, 2007, Belmonte et al., 2004). Noteworthy, areas of the brain that 
would be most impacted by dysregulation in neuronal migration and proliferation— that is 
the cerebellum, cerebral cortex, and hippocampus— are also implicated in ASDs (Penzes et 
al., 2013, Cauda et al., 2011, Wegiel et al., 2010, Hashimoto et al., 1995). Despite the 
assumptions that can be made from our in vitro results,   in vivo models must be employed 
to further describe the possible effects of PGE2 and its interaction with morphogenic 
signalling pathways, such as Wnt, during prenatal development. 
 
3.6. Conclusions 
PGE2 is an important lipid signalling molecule and its interaction with the Wnt signalling 
pathway could have significant effects on prenatal development. We showed that PGE2 can 
affect Wnt-dependent cell behaviours and gene expression in neuroectodermal stem cells through 
PKA and PI-3K. Aberrant PGE2 and Wnt signalling have been linked to ASDs, and altered 
migration and proliferation due to irregular gene expression during embryonic development in 
ASDs have been suggested in previous studies. Our in vitro study provided further evidence that 
these aberrations may be potential mechanisms in the genesis of neurodevelopmental disorders 
like ASDs.  
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3.7. Figures 
 
 
Fig. 3-1: Expression of EP receptors’ mRNA and protein in NE-4C cells.  
(A) Real-time PCR was used to determine the RQ value for EP1, EP2, EP3α, EP3β, EP3γ and 
EP4 receptors, which was found to be 2, 16, 1, 2, 46 and 46 respectively. The error bars 
represent + SEM. (B) Western blot analysis of the EP1, EP2, EP3 and EP4 receptors expression 
(65, 68, 62 and 53 kDa, respectively). β-Actin was used to indicate equal loading. (C) 
Immunocytochemistry revealed the subcellular localization of EP1-4 receptors with specific 
organelles visualized through the use of anti-PDI endoplasmic reticulum marker, anti-Lamin A + 
C nuclear envelope marker, β-Actin cell membrane marker, and anti-58 K Golgi marker. The 
scale bar represents 10 μm  
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Fig. 3-2: PGE2 -dependent effect on final distance travelled from origin. 
(A) Final distance from origin was 65.6, 56.2, 21.3, 45.0 μm, respectively. The error bars 
represent + SEM and values were considered significant at *p<0.05, **p<0.01. (B) The 
Dispersion XY position plots illustrate the effect of PGE2 on Wnt-induced behaviour, where 
addition of PGE2 to Wnt-activated cells increased the final distance. Addition of H89 (PKA 
blocker) and Wort (PI-3K) blocker reduces the effect PGE2. Measurements represent an average 
of 150 cells from three independent experiments (N = 3).  
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Fig. 3-3: PGE2 -dependent effect on path length and average speed.  
(A) Path length travelled was 459, 409, 103, 362 μm, respectively. (B) Average speed of 
migration was 11.0, 10.5, 1.7, 7.2 nm/s, respectively. The error bars represent + SEM, **p< 0.01, 
***p<0.001. Results represent an average of 150 cells from three independent experiments (N = 
3). 
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Fig. 3-4: PGE2 -dependent effect on proliferation behaviour.  
(A) Over the experimental duration of 24 hours, the number of cells changed by a fold of 4.60, 
4.59, 0.86, 1.03, respectively. (B) Cell viability across treatment conditions was not significantly 
different. (C) Percentage of successful split ratio was 100%, 98%, 0%, 15%, 0%, and 0% 
respectively. The error bars represent + SEM, ***p< 0.001. Measurements represent an average 
of 150 cells from three independent experiments (N = 3). (D) WntA treatment resulted in an 
arrested state indicted by the black arrows and corresponded with a significant decrease in cell 
proliferation (***p< 0.001). Scale bar represents 100 μm. 
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Fig. 3-5 : PGE2 -dependent effect on phospho-histone H3 (Ser10) expression.  
Western blot analysis was used to determine Phospho-Histone H3 (Ser10) protein (17 kDa). The 
expression of Phospho-Histone H3 (Ser10) represented in fold change was 1, 1.04, 1.35, 1.52, 
1.36, and 1.58, respectively. The error bars represent + SEM and values were considered 
significantly different from untreated *p<0.05, **p<0.01. Average measurements represent 
protein from three independent experiments (N = 3). β-Actin was used to indicate equal loading. 
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Fig. 3-6: PGE2 -dependent effect on β-catenin expression in NE-4C cells.  
Western blot analysis was used to determine two forms of active β-catenin: (A) non-phospho-
(active) β-catenin (Ser33/37/Thr41) and (B) phospho-β-catenin (Ser552) (92 kDa). Addition of 
PGE2 to NE-4C cells did not yield a significant difference in levels of either active form of  
β-catenin compared to control. The error bars represent + SEM and values were considered 
significantly different from control at *p<0.05, **p<0.01. Average measurements represent 
protein from three independent experiments (N = 3). β-Actin was used to indicate equal loading. 
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Fig. 3-7: PGE2 -dependent effect on β-catenin expression in Wnt-activated NE-4C cells.  
Western blot analysis was used to determine two forms of active β-catenin: non-phospho-(active) 
β-catenin (Ser33/37/Thr41) and phospho-β-catenin (Ser552) (92 kDa). (A) The expression of 
active β-catenin represented in fold change was 1, 2.09, 1.61, and 1.98, respectively. The error 
bars represent + SEM and values were considered significantly different from control at *p<0.05. 
Only PGE2 +WntA condition was significantly different from WntA only condition. (B) There 
was no significant difference in phospho-β-catenin (Ser552) expression between the conditions. 
Average measurements represent protein from three independent experiments (N = 3). β-Actin 
was used to indicate equal loading. 
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Fig. 3-8: PGE2 -dependent effect on Wnt-target genes.  
Real-time PCR was used to determine the RQ value for Ctnnb1, Ptgs2, Ccnd1, and Mmp9. The 
expression of Ctnnb1 represented in fold change was 1, 0.97, 1.25, 1.55, 0.84, and 0.60, 
respectively. The fold change expression of Ptgs2 was 1, 0.56, 2.99, 4.59, 2.16, and 4.22. The 
fold change expression of Ccnd1 was 1, 3.68, 1.50, 1.99, 0.74, and 1.42. Mmp9 fold change 
expression was 1, 1.08, 2.19, 3.00, 2.16, and 2.68, respectively. The error bars represent + SEM 
and values were considered significantly different from control at *p < 0.05, **p < 0.01, and 
***p < 0.001. Average measurements are from three independent experiments (N = 3). 
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Fig. 3-9: A proposed model for PGE2 -Wnt interactions in Wnt-induced NE-4C cells. From 
the compilation of our results (bolded) and other studies, a schematic model is drawn of the 
mechanism by which PGE2 might interact with the canonical Wnt pathway. 
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CHAPTER 4. 
Study 2: Prostaglandin E2 promotes neural proliferation and differentiation and regulates 
Wnt target gene expression. 
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Objectives and Hypotheses: The second study was predominately completed in vitro with an in 
vivo component. The main purpose was to investigate whether an elevated level of PGE2 affects 
the proliferation and differentiation of NE-4C stem cells into neurons. We aimed to determine if 
PGE2 alters the formation of neural stem cell clusters (neurospheres), if the expression of genes 
involved in neuronal differentiation is affected, and if PGE2 influences the expression of genes 
from the canonical Wnt signalling pathway. I hypothesized that PGE2 would effect the 
differentiation of NE-4C cells by altering the progression of neurosphere formation, as well as 
their size and roundness. Moreover, I hypothesized that PGE2 would change the expression of 
Wnt signalling regulator, β-catenin, as well as the expression of Wnt-target genes.  
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4.1. Chapter Summary 
Prostaglandin E2 (PGE2) is an endogenous lipid molecule that regulates important 
physiological functions including calcium signalling, neuronal plasticity, and immune responses. 
Exogenous factors such as diet, exposure to immunological agents, toxic chemicals, and drugs 
can influence PGE2 levels in the developing brain and have been associated with autism 
disorders. The main goals of this study were to determine if changes in PGE2 level can alter the 
behavior of undifferentiated and differentiating neuroectodermal (NE-4C) stem cells and whether 
PGE2 signalling impinges with the Wnt/β-catenin pathway. We show that PGE2 increases 
proliferation of undifferentiated NE-4C stem cells. PGE2 also promotes the progression of NE-
4C stem cell differentiation into neuronal lineage cells, which is apparent by accelerated 
appearance of neuronal clusters (neurospheres) and earlier expression of neuronal marker, Mapt. 
Furthermore, PGE2 alters the expression of downstream Wnt-regulated genes previously 
associated with neurodevelopmental disorders. In undifferentiated stem cells, PGE2 
downregulates Ptgs2 expression and upregulates Mmp9 and Ccnd1 expression. In differentiating 
neuronal cells, PGE2 causes upregulation of Wnt3, Tcf4, and Ccnd1. The convergence of the 
PGE2 and Wnt pathways is also apparent through increased expression of active β-catenin, a key 
signalling component of the Wnt/β-catenin pathway. The results of this study provide novel 
evidence that PGE2 may influence progression of neuronal development and influence Wnt-
target gene expression. We discuss how these findings could have potential implications for 
neurodevelopmental disorders such as autism. 
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4.2. Introduction 
The human brain is highly composed of lipids and the availability and metabolism of 
these lipids are tightly integrated with healthy development, maintenance, and function of the 
nervous system (Lawrence, 2010). Prostaglandin E2 (PGE2) is a bioactive lipid molecule derived 
from plasma membrane phospholipids through the enzymatic activity of phospholipase A2 and 
cyclooxygenase-1, -2 (COX-1, -2). PGE2 binds to four E-prostanoid receptor subtypes (EP1, 
EP2, EP3, EP4) to regulate various functions in the developing nervous system including 
memory formation and synaptic plasticity (Furuyashiki and Narumiya, 2011), thermoregulation 
and immune response modulation (Lazarus, 2006), and neurotransmitter release (Bezzi et al. 
1998). Furthermore, various studies have linked abnormalities in the PGE2 pathway to 
neurodevelopmental disorders, such as Autism Spectrum Disorders (ASDs) (Wong and 
Crawford, 2014). Altered PGE2 signalling due to environmental factors has been reported in 
many cases of ASDs (Landrigan, 2010, Tamiji and Crawford, 2010b). For example, exogenous 
stimuli that affect PGE2 levels, such as immunological agents (Patterson, 2011), toxic chemicals 
(Schwartzer et al., 2013), and exposure to drugs (Arndt et al., 2005), have all been associated 
with ASDs.  
Although the molecular mechanisms by which PGE2 affects brain development are still 
not well understood, we have shown that an increased level of PGE2 augments the migration of 
neuronal stem cells (Wong et al., 2014), retracts neuronal extensions (Tamiji and Crawford, 
2010c) and elevates calcium levels in the cytosol and growth cones (Tamiji and Crawford, 
2010a). Recent research shows emerging evidence for cross-talk between PGE2 signalling and 
the major developmental pathway called Wingless-Type MMTV Integration Site Family (Wnt) 
pathway. Interestingly, the Wnt pathway has also been associated with ASDs (Kalkman 2012, 
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Zhang et al., 2014). Previous literature in different cell types has provided some evidence for the 
interaction of COX/PGE2 signalling with the Wnt pathway via protein kinase A (PKA) and 
phosphoinositide 3-kinase (PI-3K) (Buchanan and DuBois, 2006, Evans, 2009, Wong et al., 
2014). Wnt signalling plays a pivotal role in embryogenesis (Solis et al., 2013). Wnt ligands are 
present in specific concentration gradients and modulate expression of target genes that regulate 
cell proliferation, differentiation, and migration during development of the nervous system 
(Logan and Nusse, 2004).  
In this study, our goal was to further determine if PGE2 affects proliferation and neuronal 
differentiation of neuroectodermal (NE-4C) stem cells as well as the expression of important 
developmental genes. We found that PGE2 increases the proliferation of NE-4C stem cells and 
accelerates their differentiation. We also determined that PGE2 modifies the expression of 
downstream Wnt-regulated genes, including Ptgs2, Mmp9, Ccnd1 in undifferentiated NE-4C 
stem cells and Wnt3, Tcf4, and Ccnd1 in differentiating cells. We found that the expression of the 
common gene, Ccnd1, is also altered in the brain of C57BL/6 mouse offspring prenatally 
exposed to PGE2. Finally, we examined potential implications of these findings for neuronal 
pathology and neurodevelopment, including the possible link to ASDs. 
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4.3. Materials and Methods 
Cell Culture 
Mouse NE-4C (ATCC CRL-2925) cells were grown in Gibco Minimal Essential Medium 
(MEM), supplemented with 10% Fetal Bovine Serum, 2mM L-glutamine, 1×Penicillin 
Streptomycin, and 1mM Sodium Pyruvate (Gibco). Cells were cultured according to ATCC 
culture method guidelines and maintained in an incubator at 37°C, 5% CO2, 95% humidity. Cells 
were plated on 0.01% poly-L-lysine (Sigma) coated culture plates. Supplemented MEM was 
changed every 2 days. 
 
Cell culture treatments of Undifferentiated NE-4C stem cells 
NE-4C cells were dissociated with 0.05% trypsin-EDTA and resuspended in 
supplemented MEM described above. The cells were plated on poly-L-lysine (Sigma) coated 60 
mm culture dishes (BD Falcon). The plated cells were then cultured in the supplemented MEM 
at 37°C and 5% CO2 for 24 hours before treatment with 1µM prostaglandin E2 (PGE2; Sigma), 
10µM PGE2, or an equivalent volume of vehicle. Cells were incubated in designated treatments 
for 24 hours before being lysed for collection. 
 
Proliferation Assay 
60mm cell culture plates were seeded with 4 x 106 cells and kept at 37°C and 5% CO2 for 
24 hours before addition of vehicle, 1µM PGE2, or 10µM PGE2 treatment. Following 24 hour 
incubation of treatment conditions, undifferentiated NE-4C stem cells were extracted and diluted 
with equal volumes of trypan blue dye (4%). Cell count averages were taken from a minimum of 
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four hemacytometer squares to determine the number of cells per treatment sample. Three 
independent experiments were completed for each treatment condition. 
 
Cell Differentiation and PGE2 treatment 
NE-4C cells were dissociated with 0.05% trypsin-EDTA and plated onto poly-L-lysine 
(Sigma) pre-coated plates at 2.5×103/cm2. Plated cells were cultured in supplemented MEM (as 
above) overnight before neuronal differentiation induction. Differentiation was induced by 
replacing the MEM with Serum-Free Medium (SFM); Day 0 in the differentiation schedule. 
SFM has been previously shown to promote and support the differentiation of stem cells into 
neurons (Brewer,  1995, Schulz et al., 2004). SFM contained Neurobasal Medium, 2mM L-
glutamine, 1×Penicillin Streptomycin, and 1×B-27 (Gibco). SFM was subsequently replaced 
every other day and cells differentiated for a total of 8 days. For PGE2-treated conditions, 1μM 
PGE2 (Cayman Chemical) was added to the fresh SFM preparation with each replacement. 
Lysates were collected on day 0, 6, and 8 for extraction of total RNA and protein. 
 
Microscope Imaging and Analysis 
Imaging of cell behaviour was completed by Nikon Eclipse Ti-E microscope. 
Micrographs were taken at 10X objective from 125 fields every 48 hours for duration of 8 days 
(Day 0, 2, 4, 6, 8). Measurements were determined from a minimum of three independent 
experiments for each day during two differentiation conditions: SFM or SFM+PGE2. Area, 
perimeter, and roundness of neurospheres were calculated from approximately 1,000 
neurospheres per respective day. Neurospheres were manually selected using NIS-Elements 
software, which computed the area and perimeter of objects selected. The area represents the 
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space occupied by the neurosphere, while the perimeter represents the bordering length of the 
neurosphere. The formula used for roundness was: Roundness = 4×π×Area/(Perimeter)2. A 
roundness measure of 1 is indicative of a perfect circle, while a lower value is indicative of an 
object other than a circle. Hence the lower the value, the less round the neurosphere is; the closer 
the value is to 1, the closer the neurosphere is to a perfect round shape. 
 
Polymerase Chain Reaction of Cell Differentiation Markers 
Octamer-binding transcription factor (Oct4) and microtubule-associated protein tau 
(Mapt) were used as early and late neuronal markers. Glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) was used as a positive control for measuring cDNA synthesis efficiency. 
4 µg of total RNA was converted to cDNA and then amplified using gene specific primers 
designed using Primer3 Input software v.0.4.0. (Primer3, RRID:SCR_003139) (Table 4-1) and 
cycling parameters: 94°C for 1 min, 55°C for 30s, 72°C for 30s for 30 cycles followed by 72°C 
for 5min. The presence or absence of these markers was visualized on a 1% agarose gel. 
Polymerase chain reaction also confirmed an absence of the glial marker, glial fibrillary acidic 
protein (Gfap) during SFM differentiation of NE-4C stem cells (data not shown). 
Table 4-1: PCR primers used for neural cell marker genes 
Name Primer Primer Sequence (5’-3’) Base pair Length 
Gapdh Forward TTCACCACCATGGAGAAGGC 20 
 Reverse GGCATGGACTGTGGTCATGA 20 
Gfap Forward TCAATCAGTGCTAAGCTTCATA 22 
 Reverse TGCAGCCAGGAATAGACCTT 20 
Mapt Forward TGAGATTGCTTGCGTTGTGG 20 
 Reverse ACAGCAACAGTCAGTGTAGA 20 
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RNA isolation and quantitative real-time polymerase chain reaction 
Total RNA isolation was completed using the NucleoSpin®RNA/Protein-Kit (Macherey-
Nagel) and was reverse-transcribed into cDNA using MMuLV reverse transcriptase (New 
England Biolabs) following the manufacturer‘s instructions. Custom Taqman® Array 96 Well 
FAST plates (Applied Biosystems) were used to screen the expression of 29 developmental 
genes available by the manufacturer (Shh, Gli1, Gli2, Gli3, Bmp2, Bmp4, Bmp7, Smad4, Wnt1, 
Wnt2, Wnt3, Wnt3a, Wnt5a, Wnt7a, Wnt8a, Ctnnb1, Lef1, Tcf7, Tcf3, Tcf4, Ptgs2, Axin1, Gsk3b, 
Axin2, Ccnd1, Mmp2, Mmp9, Mmp7, Myc), along with 3 housekeeping genes (18S, Gusb, Hprt). 
Genes with expression ±1.5 RQ were further analyzed. All these genes were further validated 
using SYBER Green quantitative real-time polymerase chain reaction (qRT-PCR). Forward and 
reverse primers for the indicated genes (Table 4-2) were designed using Primer Express® 
Software v3.0. qRT-PCR was conlebducted with a 7500 Fast Real-time PCR system (Applied 
Biosystems) and the ΔΔCT method was used to calculate transcript expression as we previously 
described (Tamiji and Crawford, 2010a, Tamiji and Crawford, 2010c, Wong et al., 2014). 
Hypoxanthine phosphoribosyl transferase (Hprt) and Phosphoglycerate Kinase 1 (Pgk1) were 
used as endogenous controls. The relative quantification (RQ) ratios for each gene were 
determined from the average of three independent experiments. Genes that were differentially 
expressed due to PGE2 treatment by an RQ of 2 or higher were further validated through protein 
expression analysis described below. 
 
 
Oct4 Forward CTGGCTAAGCTTCCAAGGGC 20 
 Reverse CCAGGGTCTCCGATTTGCAT 20 
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Table 4-2: qRT-PCR primers for gene expression quantification in NE-4C stem cells 
 
 
Protein isolation and Western blot analysis 
Total protein was isolated using the NucleoSpin®RNA/Protein-Kit (Macherey-Nagel). 
Samples were resolved by SDS-PAGE and transferred to nitrocellulose membranes. Protein 
bands were detected using Mouse monoclonal primary anti-Cyclin D1 (DCS6) (1:2000, Cell 
Signaling Technology Cat#2926P Lot#10 RRID:AB_10828124) or Rabbit monoclonal primary 
anti-Non-phospho (Active) β-catenin (Ser33/37/Thr41) (D13A1) (1:1000, Cell Signaling 
Technology Cat#8814S Lot#3 RRID:AB_11127203), followed by  goat anti-mouse horseradish 
peroxidase-conjugated secondary antibody (1:10,000, Abcam Cat# ab6789 RRID:AB_955439) 
Name Primer Primer Sequence (5’-3’) Base pair Length 
Hprt Forward TCCATTCCTATGACTGTAGATTTTATCAG 29 
 Reverse AACTTTTATGTCCCCCGTTGACT 23 
Pgk1 Forward CAGTTGCTGCTGAACTCAAATCTC 24 
 Reverse GCCCACACAATCCTTCAAGAA 21 
Cdh2 Forward CCACTTATGGCCTTTCAAACACA 23 
 Reverse CCGTAGAAAGTCATGGCAGTAAACT 25 
Ccnd1 Forward GCACTTTCTTTCCAGAGTCATCAA 24 
 Reverse CTCCAGAAGGGCTTCAATCTGT 22 
Mmp9 Forward TCGCGTGGATAAGGAGTTCTCT 22 
 Reverse ATAGGCTTTGTCTTGGTACTGGAAGA 26 
Ptgs2 Forward CCGTAGAAAGTCATGGCAGTAAACT 25 
 Reverse TTATACTGGTCAAATCCTGTGCTCAT 26 
Tcf4 Forward GGGTTTGCCGTCTTCAGTCTAC 22 
 Reverse GCCTGGCGAGTCCCTGT 17 
Wnt3 Forward AATGCCATTGCGTCTTCCA 19 
 Reverse AGTGCCCTGGCTCACTACTTG 21 
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or goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:10,000, Abcam 
Cat# ab6721 Lot#GR150215-3, RRID:AB_955447). Blots were then reprobed with mouse 
monoclonal anti-β-Actin [AC-15] (1:10,000; Abcam Cat#ab6276 Lot#634267 
RRID:AB_2223210) or mouse monoclonal anti-GAPDH (1:5,000, Abcam Cat#ab8245 
Lot#GR232949-5 RRID:AB_2107448) for quantitative analysis. ECL Prime Western Blotting 
Detection Reagent (GE Healthcare) was used for visualization with Geliance 600 Imaging 
System (Perkin Elmer). GeneSnap and GeneTools (Perkin Elmer) software was used to capture 
blot images and quantify band intensities, respectively. Band intensities for proteins of interest 
were first normalized to GAPDH or β-Actin than compared to the control group for each 
respective experiment.  
 
Animals for Ccnd1 quantification 
Male and female mice (C57BL/6) were obtained from Charles River Laboratories. Upon 
arrival, they were maintained at the animal facility at York University, kept at a 12 h light/dark 
cycle, and provided with unlimited food and water. All protocols for animal procedures used in 
this study were approved by the Animal Care Committee (ACC) at York University. Samples 
were obtained from a current ongoing in vivo study in our laboratory (Rai-Bhogal et al., 
unpublished). In brief, on embryonic day 11 (E11), the pregnant females were injected 
subcutaneously with 0.2mg/kg concentration of 16,16-dimethyl prostaglandin E2 (dmPGE2; 
Cayman Chemical) in saline. Controls were injected with saline only. dmPGE2 has a prolonged 
half-life in vivo since it is resistant to metabolism by prostaglandin-inactivating enzyme, 15-
hydroxyprostaglandin dehydrogenase (Ohno et al., 1978). Brain tissue samples were collected 
from all pups of each litter, at embryonic day 16 (E16) and embryonic day 19 (E19) with 
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maternal treatment of saline or dmPGE2. Total RNA and protein were extracted from brain tissue 
using the trizol (Sigma) method for further quantification of mRNA and protein quantification 
using qRT-PCR and western blot, respectively. At least 3 whole litters were collected from each 
condition. The mean value for the E16 saline condition represents 35 pups, E16 dmPGE2 
represents 21 pups, E19 saline represents 20 pups, and E19 dmPGE2 represents 20 pups.  
 
Statistical Analysis 
All numerical data have been presented as mean with SEM bars representing a minimum 
of three individual experiments for each sample condition and time point of interest. For in vitro 
undifferentiated system, statistical analysis was performed with one-way ANOVA followed by 
Tukey post-hoc comparisons. For the in vitro differentiating system, two-way ANOVA followed 
by Tukey post-hoc tests were conducted to determine statistical significance of neurosphere 
characteristics and T-tests were used for Wnt-target expression. T-test was conducted to compare 
the dmPGE2-treated condition to the saline-treated condition for each embryonic stage.  A value 
of *p<0.05, **p<0.01, ***p<0.001, was considered statistically significant. One-way ANOVA 
with Tukey post-hoc tests were used for β-catenin expression. Statistical tests were conducted 
using IBM SPSS Statistics 23.0 software (SPSS, RRID:SCR_002865). 
 
4.4. Results 
Prostaglandin E2 increases proliferation of NE-4C stem cells 
The NE-4C stem cell line is used in this study as an in vitro model for embryonic 
development. They derive from the brain of 9-day-old mouse embryos at the onset of 
neurogenesis and their behaviour is known to mimic cellular events that occur in the brain such 
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as proliferation, migration, aggregation and differentiation into neuronal cells (Schlett and 
Madarasz, 1997). To assess the effect of PGE2 treatment on the proliferation of the stem cells, 
we conducted a proliferation assay (Fig. 4-1). We applied 1µM or 10µM PGE2 concentrations, 
which represent a range widely tested in various neural cell types (Koch et al. 2015, Ma, 2010, 
Simm et al., 2016, St-Jacques and Ma, 2013, Tamiji and Crawford, 2010c). Plates were seeded 
with 4.0x105 cells (0hr) and were incubated overnight to allow cells to settle. Cells were then 
incubated for 24 hours under each condition. The control condition (Control 24hr) proliferated to 
an average cell number of 1.80 x 106 cells (n=3). The 1µM PGE2 treatment condition resulted in 
a significantly greater number of cells compared to the control condition, with an average of 2.33 
x 106 cells, F(2,6)=18.488, n=3, p=0.00258. Similarly, the 10µM PGE2 treatment condition 
yielded 2.19 x 106 cells, which was greater than the control condition F(2,6)=18.488, n=3, 
p=0.0125. However, there was no significant difference between the 1µM and 10µM PGE2 
treatment conditions (p=0.3092). 
 
PGE2 treatment results in a shift in the formation of neurospheres 
NE-4C stem cells are able to differentiate into neurons through formation of neural cell 
clusters (neurospheres) (Bez et al., 2003, Schlett et al., 1997, Tarnok et al., 2002). Moreover, the 
formation of neurospheres is considered a physiologically relevant in vitro model for studying 
neurogenesis or neural development (Vangipuram et al., 2008, Zhou et al., 2011). Neuronal 
differentiation of NE-4C stem cells was induced by SFM on Day 0 and continued for 8 days (see 
methods). Micrographs taken throughout the differentiation of NE-4C cells revealed that PGE2-
treated cells showed an earlier switch in morphology, causing an accelerated formation of 
neurospheres (Fig. 4-2). We observed that NE-4C stem cells normally undergo time and stage 
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specific changes prior to differentiation: proliferation (Day 2), followed by aggregation and 
inward migration (Day 4, 6), and neurosphere formation (Day 8) (Fig. 4-2A). On Day 2, there 
were no observable differences in cell proliferation between SFM and SFM+PGE2 conditions. 
However, on Day 4, large aggregates migrated inwards becoming rounder in shape in the PGE2 
condition as compared to SFM-only condition. More distinct differences were noticeable on Day 
6, where the SFM+PGE2 condition showed an earlier formation of neurospheres (Fig. 4-2B) 
whereas clear neurosphere formation with the absence of aggregates occurred on Day 8 for the 
SFM-only condition (Fig. 4-2A). Treatment with PGE2 resulted in earlier formation of 
aggregates and neurosphere clusters (Fig. 4-2B). Neurospheres appeared larger and rounder in 
the SFM+PGE2 compared to the SFM-only condition on the same respective day. Further 
quantification of differences in neurosphere morphology is described below. In summary, these 
results show that PGE2 also affected the differentiation process of NE-4C stem cells. We 
observed accelerated neurosphere formation in the PGE2-treated condition compared to the 
SFM-only control, indicative of earlier initiation of differentiation. 
 
PGE2 alters the expression timeline of neuronal cell differentiation markers 
To validate the changes in differentiation phenotype described above, we studied two 
commonly used cell type markers: Oct4 as a stem cell marker (Yamada et al., 2013) and Mapt as 
a neuronal differentiation marker (Cardozo et al., 2012). Oct4 stem cell marker was observed 
throughout the experiment in the SFM-only condition (Fig. 4-2C, left), but was only present from 
Day 0 to 4 in the SFM+PGE2 condition (Fig. 4-2D, left) suggesting that the cells underwent an 
earlier molecular switch due to the treatment of PGE2. The expression of Mapt neuronal marker 
complimented our findings for Oct4 expression. In the SFM-only condition, Mapt expression 
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appeared on Day 8 (Fig. 4-2C, right) along with Oct4, indicating the presence of both stem cells 
and differentiating neuronal cells. In the PGE2-treated cells, the Mapt neuronal marker was 
observed earlier, at Day 6 and thereafter (Fig. 4-2D, right). More importantly, there was also a 
distinct absence of Oct4 expression on Day 6 and 8 in the PGE2-treated condition, demonstrating 
that a genetic switch during differentiation occurs earlier with an increased level of PGE2. The 
presence of the neuronal marker on Day 6 and 8 in the PGE2-treated condition also suggests that 
PGE2 accelerated the differentiation process of NE-4C stem cells into neuronal lineage cells. 
 
PGE2 increases the expression of neurosphere adhesion marker cadherin-2 (Cdh2) 
The above experiments showed earlier initiation of differentiation and distinct differences 
in neurospheres formation in the presence of PGE2 on Day 6 and 8. We used qRT-PCR to show 
the difference in expression of cadherin-2 (Cdh2), an important neural adhesion molecule that is 
commonly used as a marker for neurosphere formation (Chen et al., 2006, Sheng et al., 2012) on 
Day 6 and 8. Day 0 was used as a baseline for relative quantification values and statistical 
comparisons were made between the two conditions (SFM and SFM+PGE2). A two-way 
ANOVA followed by Tukey post-hoc comparisons were conducted to examine the effect of 
treatment and differentiation day on the expression of Cdh2. There was no interaction between 
the effect of treatment and day, F(1,11)=1.323, p=0.2745. However, Tukey post-hoc 
comparisons revealed that on Day 6, the Cdh2 expression was significantly higher in the 
presence of PGE2 compared to the SFM-only condition (Fig. 4-3A, left). The RQ value in the 
SFM-only condition was 6.95±0.615 (n=3), while in the PGE2-treated condition, it increased to 
an RQ of 24.33±4.83, F(3,9)=3.387, n=6, p=0.0016. On Day 8, there was no significant 
difference in Cdh2 expression between the conditions, (p=0.052); the RQ values were 
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15.92±1.04 (n=3) and 23.11±2.41 (n=3) in the SFM-only and SFM-PGE2-treated conditions, 
respectively. 
Notably, in the SFM-only condition the formation of neurospheres continued from Day 6 
to 8 as indicated by increased Cdh2 expression  F(3,11)=1.323, p<0.001 (Fig. 4-3A, right). This 
was also evident by the continuous presence of Oct4, the stem cell marker shown above (Fig. 4-
2C, right). However, the Cdh2 expression in the PGE2-treated condition reached a plateau and 
with no difference from Day 6 to Day 8, suggesting saturation in the formation of neuronal 
clusters. These results complement our Oct4 and Mapt data shown above, where no expression 
of Oct4 and only the presence of Mapt detected on Day 6 and 8 (Fig. 4-2D) in the PGE2-treated 
condition. 
 
PGE2 modifies the area, perimeter, and roundness of neurospheres 
Since phenotype differences in the progression of differentiation were visibly apparent 
between the SFM-only and SFM+PGE2 treatment conditions on Day 6 of differentiation (Fig. 4-
2) we quantified the measurements of area, perimeter, and roundness of neurospheres on Day 6 
and 8 (see methods for definitions). These measures are physiologically relevant since 
neurosphere size (area and perimeter) is correlated with cell proliferation (Moors et al., 2009) 
and roundness is an indicator of coalescence and cell migration (Vangipuram et al., 2008). A 
two-way ANOVA followed by Tukey post-hoc comparisons were conducted to examine the 
effect of treatment and differentiation day on the area of neurospheres. There was a significant 
interaction between the effect of treatment and day, F(1,9)=92.886, p<0.001. In the control SFM 
samples, the average area of neurosphere-like structures on Day 6 was 2.96±0.27 ×104 µm2, 
number of neurospheres (N)=936, number of independent samples (n)=3. PGE2-treated samples 
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on Day 6 had a significantly smaller neurosphere area of 2.41±0.09 ×104 µm2, F(3,9)=287.460, 
N=1221, n=3 p=0.03354 (Fig. 4-3B, left). On Day 8 of the SFM condition, the area of 
neurosphere structures was 4.78±0.25 ×104 µm2 (N=991, n=3) and the SFM+PGE2 treatment 
condition had a significantly larger area of 6.36± 0.14 ×104 µm2, F(3,9)=287.460, N=1286, n=4, 
p<0.001. Analysis of the neurosphere area is represented in line graphs for each individual 
condition (Fig. 4-3B, right). SFM-only samples show a significant increase in area of 161% 
(F(3,9)=287.460, p<0.001) from Day 6 to 8 whereas in the SFM+PGE2 samples, area increased 
by 264% (F(3,9)=287.460, p<0.001). 
PGE2 treatment had a similar effect on the perimeter of neurospheres as it did on the area 
(Fig. 4-3C, left). A two-way ANOVA followed by Tukey post-hoc comparisons were conducted, 
which examined the effect of treatment and differentiation day on the perimeter of neurospheres. 
There was also a significant interaction between the effect of treatment and day, F(1,9)=56.670, 
p<0.001. On Day 6, the perimeter in the SFM condition was 750.2±68.5µm (N=936, n=3) and 
became significantly smaller in the SFM+ PGE2 condition with an average perimeter of 
548.7±33.5 µm, F(3,9)=54.318, N=1221, n=3, p<0.001. On Day 8 the results were reverse. The 
perimeter was 795.2±10.3µm (N=991, n=3) in the SFM-only condition and increased 
significantly in the SFM+ PGE2 condition to 901.7±8.4 µm, F(3,9)=54.318, N=1286, n=4, 
p=0.018. Analysis of trend lines (Fig. 4-3C, right) show that there is no significant difference in 
perimeter in SFM-only condition from Day 6 to Day 8 (p=0.473), but in the SFM+PGE2 
condition, there is a significant increase of 164%, F(3,9)=54.318, p<0.001. 
A two-way ANOVA followed by Tukey post-hoc comparisons were also conducted to 
examine the effect of treatment and day of differentiation on the roundness of neurospheres. A 
significant interaction between the effect of treatment and day was found, F(1,9)=10.104, 
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p=0.01121. The roundness of the neurospheres in the SFM condition was 0.64±0.041 (N=936, 
n=3) on Day 6, while in the PGE2 condition, neurospheres were significantly rounder, with a 
roundness ratio of 0.83±0.063, F(3,9)=29.262, N=1221, n=3, p<0.001 (Fig. 4-3D, left). This 
indicates that on Day 6, the neurospheres were closer to a perfect round shape in the PGE2 -
treated condition compared to the SFM-only condition, suggesting that cells were further along 
in differentiation under PGE2 treatment. However, the roundness between treatment conditions 
on Day 8 was not significant (p=0.220); SFM condition neurospheres had a roundness ratio of 
0.83±0.005 (N=991, n=3), while SFM+PGE2 condition had a roundness ratio of 0.89±0.014 
(N=1286, n=4). Trend lines for each individual condition (Fig. 4-3D, right) show that there is a 
significant increase in roundness of 130% in the SFM-only condition from Day 6 to Day 8 
(F(3,9)=29.262, p<0.001) but there was no difference in roundness between these days in the 
SFM+PGE2 condition (p=0.166). 
Taken together, the PGE2 treated samples had significantly different morphological 
measurements of area, perimeter, and roundness when compared to the control sample on the 
respective day. On Day 6, the PGE2-treated condition had neurospheres (containing 
differentiating neurons only, as indicated above) that were smaller in size but rounder as 
compared to larger and more irregular neurospheres (containing a mixture of stem cells and 
differentiating neurons) seen in SFM-only control cells. Neurospheres under the PGE2-treated 
condition had already undergone inward migration to form round neurospheres on Day 6, 
whereas in the control condition, the stage of inward migration took place on Day 8. This 
indicates that PGE2 can affect the differentiation behaviour of NE-4C stem cells by modulating 
the shape and composition of neurospheres. 
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PGE2 altered expression of Wnt signalling target genes in undifferentiated NE-4C stem cells 
We previously established that NE-4C stem cells express all four of the EP receptors 
(Wong et al., 2014), enabling the investigation of how elevated levels of PGE2 affect NE-4C 
stem cells. In this study, we tested the expression level of various developmental genes in 
undifferentiated NE-4C stem cells using Custom TaqMan® Arrays and determined that 
PGE2 modified the expression of three downstream Wnt-target genes: Ptgs2 (encodes for COX-
2), Mmp9 (encodes for Matrix Metalloproteinase 9), and Ccnd1 (encodes for Cyclin D1). qRT-
PCR was completed to confirm the expression level of these genes (Fig. 4-4A,-4B,-4C). One-
way ANOVA followed by Tukey post-hoc comparisons were used for statistical analyses. 
Treatment with 1µM and 10µM PGE2 resulted in a reduced expression of Ptgs2, with RQ 
values of 0.56±0.012 (F(2,6)=164.774, n=3, p<0.001) and 0.89±0.029 (F(2,6)=164.774, n=3, 
p=0.011), respectively, compared to the base line in untreated cells (control). The effect of PGE2 
on Ptgs2 expression appeared to be significantly more prominent with 1µM PGE2 treatment 
compared to 10µM treatment (F(2,6)=164.774, n=3, p<0.001). Mmp9 expression was 
significantly altered only by 10 µM PGE2 treatment. We detected an increase of Mmp9 
expression with an RQ value of 1.37±0.041 (F(2,6)=25.909, n=3, p=0.0012) compared to 
control. Ccnd1 expression increased with either 1µM or 10µM PGE2 with RQ values of 
3.68±0.93 (F(2,6)=9.136, n=3, p=0.033) and 4.08±0.25 (F(2,6)=9.136, n=3, p=0.018), 
respectively. Ccnd1 expression was not significantly different between 1µM and 10µM PGE2 
treatment conditions (p=0.868). 
The PGE2 treatment caused more than 300% increase in Ccnd1 expression level, which 
met the cutoff of RQ value 2 (see methods). The level of Ccnd1 was further validated through 
protein expression analysis using western blot. When compared to the untreated control 
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condition, Ccnd1 protein levels increased by a fold change of 1.45±0.017 (F(2,6)=42.260, n=3, 
p=0.00212) and 1.66±0.089 (F(2,6)=42.260, n=3, p<0.001), when treated with 1µM or 10µM 
PGE2 (Fig. 4-4D). There was no significant concentration-dependent effect (p=0.0624). This was 
consistent with the increase in the mRNA expression. The significant upregulation of Ccnd1 in 
NE-4C stem cells due to elevated PGE2 is also in line with the increases in cell proliferation (as 
indicated in Fig. 4-1). 
 
PGE2 increases the expression of Wnt-target genes during neurosphere formation 
Since Day 6 of NE-4C cell differentiation marked a significant phenotype difference 
between the SFM and SFM+1µMPGE2 conditions, these samples were used to screen for various 
developmental genes using the Custom TaqMan® Array Plates (as described above). We found 
differentially regulated Wnt-target genes with a RQ greater than 1.5, namely, Wnt3 (Wingless-
Type MMTV Integration Site Family, member 3), Tcf4 (transcription factor T-cell factor 4), and 
Ccnd1, which was also upregulated in undifferentiated NE-4C stem cells. qRT-PCR was used to 
confirm the expression of these genes in differentiating cells from Day 6 and Day 8. The SFM-
only control condition for each time point of interest was considered as the basal expression for 
relative quantification (RQ) values, where RQ=1 (Fig. 4-5A,-5B,-5C). 
Wnt3 expression on Day 6 increased with PGE2 treatment to an RQ of 1.97±0.189 in 
PGE2-treated cells (t(4)=-7.210, n=3, p=0.00196), while on Day 8 Wnt3 expression between 
SFM-only and SFM+1µMPGE2 conditions was not significant (p=0.126546). The RQ value for 
Tcf4 expression increased to 1.93±0.104 in PGE2-treated cells on Day 6, t(4)=-7.210, n=3, 
p=0.00196. Tcf4 expression was not affected by PGE2 on Day 8 (p=0.0762). RQ values for 
Ccnd1 expression on Day 6 PGE2 samples had an increased RQ of 2.32±0.208, t(4)=-8.180, n=3, 
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p=0.00382. On Day 8, Ccnd1 expression also increased to an RQ of 2.94±0.121 in PGE2-treated 
cells, t(4)=-8.180, n=3, p<0.001. 
The expression of Ccnd1 gene expression increased by an RQ value greater than 2 (cutoff 
used), thus was further confirmed by determining the level of protein expression using western 
blot technique. When compared to the SFM samples, the protein expression of Ccnd1 in PGE2 
treated samples significantly increased by a fold change of 1.66±0.054 (t(4)=-12.208, n=3, 
p<0.001) on Day 6 and 2.48±0.045 (t(4)=-32.368, n=3, p<0.001) on Day 8 (Fig. 4-5D). This 
trend was similar to the gene expression of Ccnd1 and consistent with the results obtained in 
undifferentiated cells. 
 
Maternal injection of PGE2 changes Ccnd1 expression in mouse offspring 
We observed that PGE2-dependent expression of Ccnd1 mRNA and protein was 
increased in both undifferentiated and differentiating NE-4C stem cells, therefore we also tested 
its expression in vivo. From a separate ongoing study in our lab, we had available samples from 
mouse offspring affected with PGE2 during prenatal development (Rai-Bhogal et al., 
unpublished). Pregnant mice were subcutaneously injected with dmPGE2 (see methods) on 
Embryonic Day 11 (E11), which is normally the beginning of neurogenesis (Takahashi et al., 
1996, Zhang and Jiao, 2014). mRNA and protein from brain tissues at E16 and E19 were used 
for quantification of Ccnd1 expression. We observed that the average transcript level of Ccnd1 in 
dmPGE2-injected mouse off-springs significantly increased at E16 by a RQ of 1.37±0.025 (t(4)= 
-14.826161, n=3 litters, p=0.00452) compared to saline-injected mice but there was no 
significant difference at E19 (p=0.8855) (Fig. 4-6A). Protein analysis revealed that mice 
prenatally exposed to dmPGE2 had an increased expression of Ccnd1 at E16 with a RQ of 
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1.83±0.271, t(6)= -2.309328, n=5 litters, p=0.0369 (Fig. 4-6B). At E19, dmPGE2-exposed mice 
had a decrease in Ccnd1 expression level with a fold change of 0.552±0.038, t(4)=11.88, n=3 
litters, p<0.001. These results show that a single exposure to elevated levels of PGE2 during an 
early critical time point in prenatal development can result in stage-specific changes (E16 vs 
E19) of Ccnd1 expression. 
 
PGE2 increases protein expression of β-catenin in differentiating NE-4C stem cells 
In our previous study, we showed that PGE2 can increase the level of non-phospho-
(active) β-catenin (Ser33/37/Thr41) in Wnt-activated NE-4C stem cells (Wong et al., 2014). In 
this study we tested if PGE2 also interacts with the canonical Wnt signalling pathway in 
differentiating NE-4C cells by regulation of active β-catenin (Ser33/37/Thr41) levels. We show 
that PGE2 can influence the Wnt/β-catenin pathway in differentiating neuronal NE-4C cells by 
increasing the level of active β-catenin (Fig. 4-7). Western blot results revealed that on Day 6 of 
differentiation, the expression of active β-catenin increased by a fold change value (FC) of 
1.42±0.0243 in SFM control cells (n=3) and 2.14±0.194 in SFM+PGE2-treated cells (n=3) in 
comparison to Day 0 NE-4C stem cells (n=3). On Day 8 of differentiation, β-catenin protein 
expression had an FC of 1.75±0.166 for the SFM condition (n=3) and 1.76± 0.113 in the 
SFM+PGE2 condition (n=3). Compared to the SFM condition, PGE2 treatment resulted in a 
significant increase in β-catenin protein expression on Day 6 (F(4,10)=11.616, p=0.0156), 
corresponding to the stage with the observed phenotype shift shown in Figure 4-2. 
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4.5. Discussion 
Our study investigated a general hypothesis whether PGE2 can interfere with normal 
neural cell behaviour and alter expression of developmental genes in neuroectodermal NE-4C 
stem cells. We showed that PGE2 can promote NE-4C stem cell proliferation and accelerate their 
lineage progression into neurons. We also determined that PGE2 modified the expression level of 
specific downstream Wnt-target genes in undifferentiated and differentiating NE-4C stem cells. 
Moreover, we review the association of all the affected genes with neurodevelopmental 
disorders. The findings of this study show that PGE2 may influence early neuronal development 
and alter expression of specific Wnt-target genes (Fig. 4-8).  
We first found that PGE2 increased cell proliferation in undifferentiated NE-4C stem cells 
and promoted neuronal differentiation in SFM-induced NE-4C stem cells. Disruptions in these 
two key biological processes could result in neurodevelopmental pathologies, such as 
acceleration of brain growth in early childhood (Redcay and Courchesne, 2005), minicolumn 
irregularities in the brain (Casanova et al., 2002, Casanova et al., 2006), and abnormalities in 
brain cytoarchitecture (Bailey et al., 1998), which have all been reported in autism spectrum 
disorders (ASDs). 
We also analyzed markers for early stem cell gene Oct4 (Okuda et al., 2004, Pesce and 
Scholer, 2001, Yamada et al., 2013) and late neuronal cell gene Mapt (Cardozo et al., 2012, 
Chambaut-Guerin et al., 2000) to determine the effects of PGE2 on neuronal differentiation. Our 
results indicated that PGE2 promotes earlier acquisition of neuronal characteristics. PGE2 
treatment during NE-4C differentiation also increased the expression of Cdh2, an essential 
adhesion molecular that serves as a key neurosphere marker (Chen et al., 2006, Kim et al., 2010, 
Sheng et al., 2012). This corresponds with the earlier appearance of neurospheres and neuronal 
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marker, Mapt, observed in the PGE2 treatment condition. Moreover, increased levels of Cdh2 
could have potential implications in vivo. Alterations in Cdh2 levels can interrupt or misguide 
important prenatal processes of the brain (Derycke and Bracke, 2004, Garcia-Castro et al., 2000, 
Radice et al., 1997, Warga and Kane, 2007). It is feasible that altered Cdh2 expression is a 
mechanism through which some structural and behavioural phenotypes of ASDs emerge. For 
example, abnormal white matter integrity in children with ASDs (Weinstein et al., 2011) is 
indicative of aberrant axonal growth, which is regulated by Cdh2 (Bekirov et al., 2008). 
Additionally, dysregulation of Cdh2, which guides left-right symmetry (Garcia-Castro et al., 
2000), may contribute to asymmetrical development of the ventricles (Miles and Hillman, 2000) 
and altered synaptic connectivity patterns (Monk et al., 2009) recorded in ASDs. Synaptic 
communication and plasticity is central to learning and memory and disturbances in relevant 
systems have been described in ASDs (Goh and Peterson, 2012). Considering PGE2 may play a 
role in the regulation of adhesion molecules such as Cdh2, irregular PGE2 signalling could have 
serious consequences in development. 
Furthermore, we found that exposure to PGE2 affects neurosphere formation such as the 
area, perimeter, and roundness. In our study, PGE2 treatment accelerated aggregation and 
neurosphere formation. Neurosphere size and roundness was modified by PGE2, suggesting that 
cell proliferation (Moors et al., 2009) and migration (Vangipuram et al., 2008) was affected, 
respectively. Neurospheres are composed of differentiating neural cell clusters and are 
considered dynamic spherical structures that contain distinct gradients of cell proliferation and 
survival (Bez et al., 2003). Since the fate of neural progenitor cells is dependent on its position 
within the neuroepithelium and the time at which the cell initiates differentiation (Stiles and 
Jernigan, 2010), it can be inferred from our findings that altered PGE2 levels may influence 
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neural cell fate and patterning.  This could have significant implications for the developing brain. 
In fact, improper neural cell migration has been previously associated with autism (Wegiel et al., 
2010) and schizophrenia (Deutsch et al., 2010). 
Along with our cell behavioural findings, we also screened for developmental genes—
belonging to the Bmp, Shh and Wnt pathway—that may be affected by PGE2 treatment. 
Interestingly, in both undifferentiated and differentiating NE-4C cells, PGE2 caused significant 
changes specifically in the expression of Wnt-target genes. In undifferentiated cells, PGE2 
decreased Ptgs2 and increased Mmp9 and Ccnd1 expression. We also determined that a different 
subset of Wnt-target genes was affected by PGE2 in differentiating NE-4C cells; PGE2 increased 
the levels of Wnt3, Tcf4, and Ccnd1. Since Ccnd1 was commonly affected in both 
undifferentiated and differentiated cells, we confirmed that Ccnd1 expression was also altered in 
vivo. Compellingly, all of these genes have been implicated in neurodevelopmental disorders. 
The alteration of Ptgs2 expression is particularly interesting. This is because the Wnt-target 
gene, Ptgs2, is also known as COX-2 and is responsible for the enzymatic biosynthesis of 
prostaglandins including PGE2. Our results show that the collaboration between the PGE2 and 
Wnt/β-catenin signalling pathways may occur through regulation of Ptgs2 via a feedback loop 
mechanism. This adds to our previous research, which found that cross-talk occurs between the 
PGE2 and Wnt/β-catenin pathways through protein kinase A (PKA) and phosphoinositide 3-
kinase (PI-3K) (Wong et al., 2014) (Fig. 4-8). Furthermore, polymorphism of Ptgs2 has been 
previously reported in individuals with ASDs (Yoo et al., 2008). 
We established that elevated levels of PGE2 resulted in a general upregulation of 
canonical Wnt/β-catenin pathway genes including, Wnt3, Tcf4, Mmp9 and, Ccnd1. Wnt3 
expression is normally associated with neurogenesis (David et al., 2010), which is in line with 
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our results that showed PGE2 accelerates neural stem cell differentiation and increases Wnt3 
expression. Additionally, Wnt3 is required for normal forebrain formation (Mattes et al., 2012). 
Wnt3 also regulates the development of neuromuscular (Henriquez et al., 2008) and sensory 
(Krylova et al., 2002) neurons. Considering atypical forebrains have been reported in autism 
patients (Riva et al., 2011) and motor skill deficits (Chukoskie et al., 2013, Cook et al., 2013) 
and sensory integration difficulties (Green et al., 2013, Hazen et al., 2014) are pervasive across 
age in ASDs, deviations in Wnt3 expression due to increased PGE2 signalling may contribute to 
behavioural manifestations of ASDs. 
Tcf4 is a transcription factor and major downstream effector of canonical Wnt signalling 
(Faro et al., 2009). Abnormal increases in Tcf4 expression due to increased PGE2 exposure could 
have profound developmental effects since Tcf4 is important in normal nervous system 
development (de Pontual et al., 2009). Moreover, disruptions in Tcf4 expression have been 
linked to neurodevelopmental disorders, including Pitt-Hopkins syndrome (Sweatt, 2013) and 
schizophrenia (Navarrete et al., 2013). Additionally, the Tcf4 gene is located on chromosome 
18q21.2, which is an autism susceptibility locus. 
The matrix metalloproteinase (Mmp) family is important in numerous neurobiological 
processes, such as learning and memory (Fujioka et al., 2012). Mmp9 has been previously shown 
to increase neural stem cell proliferation and migration (Ingraham et al., 2011). Thus, the PGE2-
dependent increase in NE-4C stem cell proliferation found in this study may be influenced by the 
correlating elevation in Mmp9 expression. Mmp9 is expressed in the hippocampus, cortex and 
cerebellum (Yong, 2005). Mmp9-deficient mice show abnormalities in cell accumulation, 
migration, and programmed cell death in the cerebellum (Vaillant et al., 2003).  Interestingly, the 
cerebellum, hippocampus, and cortex are all brain regions that are commonly abnormal in ASDs. 
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Additionally, Mmp9 has been directly associated with ASDs (Abdallah and Michel, 2013, 
Abdallah et al., 2012). Therefore, increases in Mmp9 expression due to elevated PGE2 levels 
during critical prenatal periods may be disruptive to normal brain development. 
Increased PGE2 levels also resulted in upregulation of Ccnd1 transcript and protein 
expression in vitro and in vivo. Ccnd1 encodes for the Cyclin D1 (Ccnd1) protein, which has 
been shown to regulate cell cycle progression and neuronal function, as well as promote 
differentiation and neurogenesis (Lim and Kaldis, 2013, Lukaszewicz and Anderson, 2011). This 
supports our results, where in parallel with the increases in Ccnd1 expression, we also found that 
PGE2 led to increased proliferation of undifferentiated NE-4C stem cells and accelerated 
neuronal differentiation in SFM-induced NE-4C stem cells. 
Although previous studies in hematopoietic and colorectal cells have determined that 
PGE2 can interact with Wnt signalling through β-catenin (Evans, 2009, Goessling et al., 2009, 
Greenhough et al., 2009), investigation into whether a similar interaction exists in neuronal cells 
is limited. We previously determined that PGE2 can interact with the Wnt/β-catenin signalling 
pathway in undifferentiated NE-4C stem cells by modulating the expression of β-catenin and 
Wnt-regulated genes (Wong et al., 2014). In this study, we have now determined that PGE2 can 
also increase β-catenin expression in differentiating neuronal NE-4C cells. 
Normally without the Wnt ligand in an in vitro model, GSK-3β (part of the β-catenin 
destruction complex) destabilizes β-catenin by phosphorylating it at the Ser33/Ser37/Thr41 sites, 
which marks it for degradation (Wu and He, 2006). In this study, we saw a lower level of non-
phospho-(active) β-catenin (Ser33/37/Thr41) in untreated cells compared to PGE2-treated cells 
on Day 6 of differentiation. This corresponds with the stage where altered neurosphere 
phenotype was observed. This suggests that these PGE2-induced changes in differentiating 
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neuronal cells may occur through the collaboration of both the PGE2 and Wnt/β-catenin 
pathways. 
Various studies have described abnormalities in either PGE2 or Wnt signalling in ASDs 
(Kalkman, 2012, Landrigan, 2010, Tamiji and Crawford, 2010b, Wong and Crawford, 2014, 
Zhang et al., 2014). The cross-talk between PGE2 and Wnt pathways might be important for 
normal early development. Exogenous stimuli that affect PGE2 levels, including exposure to 
immunological agents (Patterson, 2011), toxic chemicals (Schwartzer et al., 2013), and drugs 
(Arndt et al., 2005), have all been associated with ASDs. Moreover, the misuse of misoprostol, a 
prostaglandin E analogue, during early pregnancy is linked to characteristics of ASDs and 
Moebius syndrome (Bandim et al., 2003). In rodent males, disrupted PGE2 signalling via 
exposure to COX-inhibitors led to social and sensory abnormalities (Dean et al., 2012). This is of 
importance since social deficits and sensory sensitivity are frequently described in ASDs 
(Robertson and Simmons, 2013) and males have a higher risk of developing an ASD (Lai et al., 
2014). What still remains to be determined is whether or not the described changes in PGE2 
levels due to environmental influences can result in Wnt-dependent pathologies of the 
developing brain. 
 
4.6. Conclusions 
Overall our current study provides molecular evidence that the PGE2 pathway can alter 
signalling from the Wnt/β-catenin pathway—which are both autism candidate signalling 
pathways—in neural cells and can affect the expression of genes previously associated with 
developmental disorders. Importantly, our study provides novel evidence that changes in the 
level of PGE2 may disrupt the proliferation and differentiation of neural stem cells, which 
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normally occurs during early development of the nervous system. In vivo experiments currently 
conducted in our lab using injection and knock-out mouse model systems may shed more light 
on the involvement of PGE2 signalling in pathologies of the developing brain. 
 
4.7. Figures 
 
 
 
Fig. 4-1: PGE2 increased the proliferation of NE-4C stem cells.  
Representative images and quantification data of cell proliferation assay. Data are mean with 
SEM bars from three independent experiments. Statistical significance was assessed by one-way 
ANOVA, followed by Tukey’s post hoc comparison. *P <0.05, **P <0.01. Scale bars = 100 μm. 
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Fig. 4-2: Morphological characteristics and expression time line of neuronal markers in 
differentiating NE-4C cells exposed to 1 μM PGE2.  
(A,B): Morphology in SFM-only- and PGE2-treated cells differentiated over an 8-day duration. 
Arrows highlight neurosphere structures. (C,D): Gene expression of early Oct4 and late Mapt 
neuronal markers visualized via PCR for samples from days 2, 4, 6, and 8 of differentiation. 
Gapdh was used as a housekeeping gene control for PCR. Images are representative of three 
independent experiments. Gfap marker shows absence of astrocytes and confirms the presence of 
neuronal lineage. Whole adult mouse brain was used for specificity of the Gfap marker. Scale 
bars = 200 μm. 
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Fig. 4-3: PGE2 affected neurosphere formation during SFM differentiation of NE-4C cells. 
(A): Expression of neurosphere-specific adhesion molecule, Cdh2, quantified by RT-PCR. The 
expression level is represented as RQ values compared with day 0 (RQ = 1). (B,C): PGE2 treatment 
resulted in a decrease in neurosphere area and perimeter on day 6 but an increase in these parameters 
on day 8. (D): PGE2-treated condition had significantly rounder neurospheres on day 6. Line graphs 
(A–D at right) depict changes in Cdh2 expression and the increasing trend of area, perimeter, and 
roundness in each individual condition from day 6 to day 8. Each average determined for 
neurosphere area, perimeter, and roundness represents a total of ~1,000 neurospheres, captured from 
a minimum of three independent experiments. Statistical significance was assessed by two-way 
ANOVA, followed by Tukey’s post hoc comparison; error bars represent SEM. *P < 0.05, **P < 
0.01, ***P < 0.001. 
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Fig. 4-4: PGE2 affected Wnt-target genes in undifferentiated NE-4C stem cells.  
Gene expression levels are displayed as RQ values compared with control untreated NE-4C stem 
cells. (A): Downregulation of Ptgs2 gene expression. (B): Upregulation of Mmp9 gene 
expression. (C,D): Increased expression of Ccnd1 transcript and protein. Data are mean with 
SEM bars from three independent experiments. Statistical significance was assessed by one-way 
ANOVA, followed by Tukey’s post hoc comparison. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Fig. 4-5: PGE2 increased the expression of Wnt-target genes in differentiating NE-4C stem 
cells. Gene expression levels are displayed as RQ values compared with the untreated SFM 
condition. (A): Increased Wnt3 expression. (B): Increased Tcf4 expression. (C,D): Elevated 
expression of Ccnd1 transcript and protein. Data are mean with SEM bars from three 
independent experiments. Statistical significance was assessed by t-test. *P < 0.05, **P < 0.01, 
***P < 0.001. 
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Fig. 4- 6: Ccnd1 expression in C57BL/6 mouse offspring at E16 and E19.  
(A): Prenatally dmPGE2-exposed mice have increased Ccnd1 expression at E16. (B): Ccnd1 
protein expression increased at E16 and decreased at E19 in prenatally dmPGE2-exposed mice. 
Data are mean with SEM bars from three independent experiments. The number of animals used 
in each experimental group is described in the Methods. Statistical significance was assessed by 
t-test. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Fig. 4-7: PGE2 increased the level of b-catenin in differentiating NE- 4C stem cells.  
RQ values were compared with untreated NE-4C stem cells. Data are mean with SEM bars from 
three independent experiments. Statistical significance was assessed by one-way ANOVA, 
followed by Tukey’s post hoc comparison. *P < 0.05. 
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Fig. 4-8: Proposed model of the cross-talk between the PGE2 and the Wnt/b-catenin 
signalling pathways. Previous literature has provided evidence for the interaction of COX-2/ 
PGE2 signalling with the Wnt pathway via PKA and PI-3K (Wong et al., 2014). Our current 
study adds that elevated levels of PGE2 promote the proliferation and differentiation of NE-4C 
stem cells and alter the expression Wnt-regulated genes through increased levels of β-catenin. A 
feedback loop for the regulation of PGE2 and Wnt signalling may occur through the expression 
of Ptgs2, a Wnt-target gene that codes for COX-2 and that is responsible for the production of 
PGE2. 
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CHAPTER 5. 
Study 3: Prenatal exposure to prostaglandin E2 leads to abnormal cell density and 
migration in the mouse brain 
 
Manuscript 5 Citation (in preparation):  
Wong, C. T., Bestard Lorigados I., and Crawford DA. (in prepareation, 2019). Prenatal 
exposure to prostaglandin E2 leads to abnormal cell density and migration in the mouse brain. 
 
Parts of this work have been presented as a poster at a conference: 
Wong, C.T., Bestard Lorigados I., and Crawford D.A. 2019, May. Prenatal exposure to 
prostaglandin E2 leads to abnormal cell density and migration in the mouse brain – link to 
autism. Abstract # 1-Cluster-240. Presented at the Canadian Association of Neuroscience (CAN) 
Conference. Toronto, ON, Canada. 
 
Contributions: Christine T. Wong designed and performed all experiments, collected samples, 
acquired and analyzed the data, made all figures and tables, and prepared the manuscript. Isabel 
Bestard Lorigados assisted in the acquisition of RNA samples and data. Dr. Dorota A. Crawford 
supervised the design of the study and was involved with editing the manuscript.  
 
Objectives and hypotheses: The first and second studies (Chapter 3 and 4) showed that PGE2 
affects cell movement, proliferation, and differentiation in vitro, which led us to our third study 
to determine if neuronal cell migration and density were also influenced by PGE2 in vivo. Our 
main objectives were to study if PGE2 alters cell density in the cerebellum, hippocampus, 
olfactory bulb, and neocortex, and if neocortical cell migration is also affected. I hypothesized                      
that PGE2 would alter neuronal cell density, neocortical migration, and the expresson of cell 
growth and motility genes in a sex-dependent manner.  
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5.1. Chapter Summary 
The prostaglandin E2 (PGE2) pathway is important for developmental processes in the 
brain such as neuronal proliferation and migration. Abnormal PGE2 signalling affected by 
various environmental or genetic risk factors has been linked to autism spectrum disorders 
(ASDs). We previously found that a single maternal injection of PGE2 during pregnancy, 
embryonic day 11 (E11), can lead to autism-related behaviours in male and female mouse 
offspring. Using the same model system in this new study, we investigated the impact of 
maternal PGE2 exposure on proliferation and migration of two cell cohorts originating from E11 
or E16. We quantified cell density in the cerebellum, hippocampus, olfactory bulb, and 
neocortex, as well as cortical cell migration at postnatal day 8. PGE2-exposed mice compared to 
controls had significantly lower cell densities in the cerebellum and neocortex, while the 
opposite effect was observed in the olfactory bulb. Sex-dependent analyses revealed that cell 
density differences seen in the neocortex were specific to PGE2-exposed females, while 
differences in the olfactory bulb were only detected in PGE2-exposed males. Moreover, WT or 
PGE2-exposed females had an overall greater cell density in the cerebellum, hippocampus, and 
neocortex compared to matched males. Normal neocortical cell migration was also disrupted, 
with greater cell migration in PGE2-exposed mice. Irregular expression of cell growth and 
motility genes, beta-actin (Actb) and spinophilin (Spn), were also exhibited in PGE2-exposed 
mice compared to controls in a sex-specific manner. Overall, our findings demonstrate that 
aberrant PGE2 signalling during prenatal development may affect normal cell proliferation and 
migration in brain areas that have been implicated in ASDs.  
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5.2. Introduction 
Prostaglandins are important endogenous, lipid-derived signalling molecules that have 
several biological roles including inflammatory regulation and various homeostatic functions. 
Prostaglandin E2 (PGE2) is the most abundant prostaglandin and is also involved in 
neurodevelopmental processes such as cell proliferation, migration, differentiation, and 
synaptogenesis (Wong et al. 2016, Wong et al. 2014, Tassoni et al. 2008, Chen and Bazan 2005). 
PGE2 is a derivative of arachidonic acid from cell membranes and is generated through the 
subsequent enzymatic activity of phospholipase A2 and cyclooxygenase-1, -2 (COX-1,-2). PGE2 
elicits its diverse functions through four receptors, EP1 through EP4 (Narumiya 2007). 
Abnormal levels of PGE2 due to various genetic and environmental factors, including exposure 
to chemicals in pesticides, pollution, consumer products, and drugs like misoprostol and 
acetaminophen have been associated with an increased risk for autism spectrum disorders 
(ASDs) (Avella-Garcia et al. 2016, Liew et al. 2016, Wong et al. 2015, Wong and Crawford 
2014, Brandlistuen et al. 2013). Maternal exposure to Misoprostol, a drug structurally analogous 
to PGE2, has been linked to the neurodevelopmental conditions: ASDs and Moebius syndrome 
(Bos-Thompson et al. 2008, Bandim et al. 2003, Pastuszak et al. 1998). 
Our previous in vitro studies showed the PGE2 disrupts the proliferation, migration, and 
differentiation of neuronal stem cells (Wong et al. 2016, Wong et al. 2014). Furthermore, 
research in rodent models has determined that perinatal PGE2 exposure can also affect brain 
development by influencing neuron branching, spine density, male sex behaviour, and male play 
behaviour (Hoffman et al. 2016, Wright and McCarthy 2009, Amateau and McCarthy 2004). We 
also recently determined that a single injection of PGE2 to pregnant mice at embryonic day 11 
(E11) resulted in autism-like behaviours in offspring, as well as alterations in the expression of 
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autism-linked genes (Rai-Bhogal et al. 2018). However, in vivo investigations into the potential 
effect of prenatal PGE2-exposure on the cell density of ASD-associated brain regions and 
neuronal migration in the cortex have not yet been conducted.  
In this current study, we aimed to study the sex-dependent effect of PGE2 signalling on 
neural proliferation and migration by investigating postnatal day 8 (P8) mouse offspring that had 
maternal exposure to PGE2 at E11. We measured the density of cells originating from two 
separate cohorts (E11 and E16) in various brain regions including the cerebral cortex, 
hippocampus, cerebellum, and olfactory bulb since they have been previously implicated in 
ASDs (Courchesne et al. 2019, Becker and Stoodley 2013, Courchesne et al. 2011, Brang and 
Ramachandran 2010, Wegiel et al. 2010, Dager et al. 2007, Raymond et al. 1996). We also 
examined the effect of PGE2 on neocortical cell migration. Additionally, the expression of cell 
growth and migration genes—spinophilin (Spn), beta-actin (Actb), and cyclin D1 (Ccnd1)—was 
quantified. This study shows for the first time that elevated maternal PGE2 at a single time point 
during pregnancy alters the density and migration of cells in various brain regions as well as 
transcript expression of Spn and Actb in male and female offspring.  
 
5.3. Methods 
Animals  
 C57bl/6 mice were obtained from Charles River Laboratories. All animals were bred and 
maintained at York University animal facility on a 12-hour light/dark cycle. Whole brain 
samples were extracted at postnatal day 8 (P8), where birth was considered postnatal day 0. P8 in 
mice is analogous to infanthood in humans (Auvin and Pressler 2013, Semple et al. 2013), which 
is when symptoms of ASDs are first observed. All experiments and protocols followed the York 
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University Animal Care Committee ethics guidelines and have been approved by the Research 
Ethics Board of York University. 
 
Maternal Injection for PGE2-exposed mouse model 
Male and female mice were housed together for breeding overnight. Every morning, 
females were inspected for a vaginal plug, which was noted as embryonic day 1 (E1, 
Supplementary Fig. 5-S1). Upon occurrence of a vaginal plus, females were separated and 
housed individually for the entirety of their pregnancy. On E11, pregnant females were weighed 
and given a single subcutaneous injection of 0.2 μg/g concentration of 16, 16-dimethyl 
prostaglandin E2 (dmPGE2; Cayman Chemical) diluted in saline as used in previous studies 
(Rai-Bhogal et al. 2018, Okamoto et al. 2011, Ma 2010, Tessner et al. 2004). The metabolic rate 
of dmPGE2 is slower and thus considered a stable analogue of PGE2 (Ohno et al. 1985, 
Steffenrud 1980). E11 was used as the injection time-point since it coincides with the beginning 
of neurogenesis in embryonic mice. E11 also corresponds to the time when misoprostol was 
taken in human cases resulting in Moebius syndrome and autism characteristics (Bandim et al. 
2003, Pastuszak et al. 1998). Maternal exposure of dmPGE2 at E11 was also shown in earlier 
studies to lead to autism-like behaviours and alteration of autism-linked gene expression (Rai-
Bhogal et al. 2018, Wong et al. 2017). Herein, mouse offspring subjected to maternal exposure 
of dmPGE2 will be referred to as “PGE2 mice”. 
 
CldU and IdU labelling 
Two cell subpopulations of different ages were labelled in each sample utilizing a method 
that detects sequential incorporation of different thymidine analogues (CldU and IdU) into the 
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dual helix of any cell actively synthesizing DNA during the specific time-point when the 
thymidine marker is injected (Tuttle 2010). Through this technique, the later fate of a specific 
cohort of cells can be studied. For both control and PGE2-exposed animals, subcutaneous 
injections of 5-Chloro-2’- deoxyuridine (CldU) or 5-Iodo-2’deoxyurdine (IdU) (Sigma) were 
administered at 50μg/g dissolved in saline to pregnant mice. In the mouse, the neuronogenetic 
interval extends from embryonic day 11 (E11) through early E17 (Takahashi et al. 1995). For 
dual labelling of early- and late-born cohorts of neural cells, an injection of CldU at E11 and IdU 
at E16 were given, and animals were sacrificed at P8 (Supplementary Fig. 5-S1). For the PGE2-
exposed group, pregnant mice were given a single co-injection of CldU and PGE2 at E11 at 
described concentrations. Cells born on E11 and E16 are likely neuronal cells since neurons are 
predominately produced from E10 to E18 in rodents, while astrocytes and oligodendrocytes are 
generated at later time points around E18 and postnatally, respectively (Reemst et al. 2016, 
Miller and Gauthier 2007, Bayer and Altman 1991). 
 
Immunohistochemistry (IHC) 
Left hemisphere brain samples were carefully extracted and fixed in 4% 
paraformaldehype (PFA) in PBS at 4°C for 48 hrs for histological staining. Paraffin-embedding 
and serial slicing from the mid-sagittal plane onwards at 4μm thickness was completed by The 
Centre for Phenogenomics (Toronto, Canada). Immunohistochemistry was performed as 
previously described (Tuttle et al. 2010). In brief, paraffin removal from samples was completed 
by xylene incubation, followed by rehydration through subsequent ethanol incubations. Cell 
permeabilization was completed by 0.2% Triton X-100 in PBS. An antigen retrieval step was 
performed using 0.01M pH 6.0 sodium citrate buffer followed by a 1.5N HCl incubation. 
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Sections were then circled using a liquid blocking super PAP pen (Cedarlane). Sections were 
treated with 0.25% trypsin EDTA in a pre-warmed hydration chamber at 37°C for 3 min. All 
subsequent steps were then completed in a hydration chamber. Samples were blocked in 5% goat 
serum diluted in PBS, followed by 4°C overnight incubation of the primary antibody for CldU 
called Rat anti-BrdU (1:100, ab6326, Abcam), diluted in 5% goat serum in PBS. Samples were 
then incubated in a high stringency wash of low salt TBST buffer (36 mMTris, 50mM NaCl, 
0.5% tween-20; pH 8.0) at 37°C with agitation for 20 min at 225 rpm. Next, samples were 
incubated overnight at 4°C overnight with the primary antibody for IdU, Mouse anti-IdU (1:100, 
ab181664, Abcam). Secondary antibody incubation was completed in the dark with Alexa Fluor 
555 goat anti-mouse (1:500, ab150118, Abcam) and Alexa Fluor 488 goat anti-rat goat anti-rat 
(1:500, ab150165, Abcam). Coverslips were mounted with ProLong Gold Antifade Mountant 
(ThermoFisher).  
 
Cell Density and Neocortical Cell Migration Analysis 
CldU and IdU staining was visualized and captured using an Eclipse 80i upright 
fluorescent microscope with DS-5MC camera (Nikon). The cerebellum, hippocampus, olfactory 
bulb, and neocortex were investigated. Estimated cell density measurements for each brain 
region were calculated by dividing the total number of cells counted by the area of each specific 
brain region. Neocortical cell migration distances from the subplate to the labelled cells were 
measured in the cortex. The migration percentage for each cell was calculated by taking its 
migration distance and dividing it by the total distance between the subplate and cortical pial 
surface. Image analysis was completed using NIS-Elements software (Nikon). All analyses were 
completed blind to the condition. 
202 
 
RNA Isolation and quantitative Real-Time Polymerase Chain Reaction 
Right hemisphere brain samples were extracted at postnatal day 8 and homogenized in 
Trizol (Sigma) using a Polytron power homogenizer. The standard Trizol (Sigma) method was 
conducted for total RNA isolation. MMuLV reverse transcriptase (New England Biolabs, 
Ipswich, MA) was used following manufacturer’s protocol to convert total RNA into cDNA. 
Quantitative real-time polymerase chain reaction (qRT-PCR) using SYBER green master mixes 
in a 7500 FAST RT-PCR system (Applied Biosystem, Foster City, CA) was performed on the 
cDNA samples. Transcript expression represented by relative quantification (RQ) values was 
calculated using the ΔΔCt method. Primer Express v3.0 (ThermoFisher Scientific, Waltham, 
MA) was used to design the primers for genes investigated: Spinophilin (Spn), Beta-Actin 
(Actb), Cyclin D1 (Ccnd1) (Table 5-1). Hypoxanthine phosphoribosyl transferase (Hprt) and 
phosphoglycerate kinase 1 (Pgk1) were quantified as housekeeping controls for the qRT-PCR 
experiments. The RQ means were calculated from the RQ values of at least three individuals 
from different litters determined in independent experiments.  
Table 5-1: qRT-PCR primers for cell growth and migration gene expression 
Name Primer Primer Sequence (5’-3’) Base pair Length 
Hprt Forward TCCATTCCTATGACTGTAGATTTTATCAG 29 
 Reverse AACTTTTATGTCCCCCGTTGACT 23 
Pgk1 Forward CAGTTGCTGCTGAACTCAAATCTC 24 
 Reverse GCCCACACAATCCTTCAAGAA 21 
Spn Forward CAAGGACTACCAGCAAAAGGAGAT 24 
 Reverse CCTGGCTAGCTCCGACTCTTC 21 
Actb Forward GCTTCTTTGCAGCTCCTTCGT 21 
 Reverse AGCGCAGCGATATCGTCAT 19 
Ccnd1 Forward GCACTTTCTTTCCAGAGTCATCAA 24 
 Reverse CTCCAGAAGGGCTTCAATCTGT 22 
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Statistical Analysis 
Numerical data are reported as mean±standard error of the mean (SEM), which 
represents the average of individuals from a minimum of three separate litters. Two-way 
ANOVA followed by post-hoc Bonferroni comparisons were conducted to determine if there 
were significance differences between PGE2-exposed and wildtype (WT) control groups and 
between males and females. Independent t-test was performed to determine if there were 
differences in gene expression. Significance was identified for p values less than 0.05. 
 
5.4. Results 
Cerebellar Cell Density 
 Cells originating from E11 and E16 were counted in P8 cerebellum samples (Fig. 5-1A, 
1B). Two-way ANOVA analysis on E11 cell density values (cells/mm2) were conducted (Fig. 5-
1C, F(3,10)=27.23, p=0.00004). There was a lower cerebellar cell density in PGE2-exposed mice 
compared to WT controls for males (Fig. 5-1C, p=0.005233; WT=339.5±21.9, 
PGE2=156.2±19.5) and for females (Fig. 5-1C, p=0.000084; WT=595.0±23.3, 
PGE2=267.6±72.0). Sex differences were seen between WT mice, where males had a lower cell 
density than females (Fig. 5-1C, p=0.000324; M=339.5±21.9, F=595.0±23.3). 
 Two-way ANOVA analysis on cerebellar E16 cell density values were also performed 
(Fig. 5-1D, F(3,10)=13.83, p=0.000685). PGE2-exposed mice also had a lower cerebellar cell 
density of E16-originating cells than WT controls for males (Fig. 5-1D, p=0.01066; 
WT=546.8±24.6, PGE2=356.4±11.0). There was no significant difference between PGE2-
exposed and control females (Fig. 5-1D, p=0.366; WT=1652.1±332.2, PGE2=948.3±117.5). Sex-
dependent differences were seen in both the WT and PGE2-exposed groups. WT males had a 
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lower cell density than WT females (Fig. 5-1D, p=0.000262). Similarly, PGE2-exposed male also 
had a lower cell density than PGE2-exposed females Sex differences were only seen between WT 
mice, where males had a lower cell density than females (Fig. 5-1D, p=0.02501). 
 Overall, PGE2-exposed males had lower cerebellar cell densities compared to WT males 
for E11 and E16 cell cohorts. PGE2-exposed females also had lower cell densities compared to 
WT controls for only E11-labelled cells. In general, females had greater cerebellar cell densities 
for E11 and E16-originating cells than males.  
 
Hippocampal Cell Density 
Hippocampal cells originating from E11 and E16 were counted in P8 samples (Fig. 5-2A, 
2B). Two-way ANOVA analysis on E11 cell density values (cells/mm2) were completed (Fig. 5-
2C, F(3,11)=4.236, p=0.032). There were no significant differences in hippocampal E11 cell 
densities between PGE2-exposed mice compared to WT controls for males (Fig. 5-2C, p=0.898; 
WT=262.4±47.4, PGE2=288.2±65.1) and for females (Fig. 5-2C, p=0.059; WT=735.3±128.7, 
PGE2=397.671±45.9). Sex differences were only seen between WT mice, where males had a 
lower cell density than females (Fig. 5-2C, p=0.026741). 
 Two-way ANOVA analysis on hippocampal E16 cell density values were also conducted 
(Fig. 5-2D, F(3,11)=7.135, p=0.006253). There were also no significant differences in E16 
hippocampal cell densities between PGE2-exposed mice compared to WT controls for males 
(Fig. 5-2D, p=0.223; WT=643.7±85.6, PGE2=437.4±142.5) and for females (Fig. 5-2D, p=0.346; 
WT=1067.9±110.4, PGE2=922.4±63.3). Sex-dependent differences were observed in the WT 
and PGE2-exposed groups. WT males had a lower E16 hippocampal cell density than WT 
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females (Fig. 5-2D, p=0.02243). PGE2-exposed males also had a lower cell density than PGE2-
exposed females (Fig. 5-2D, p=0.007376).  
In summary, PGE2 exposure did not have a significant impact on hippocampal cell 
densities for E11 and E16 cohorts. However, females had greater hippocampal cell densities for 
E11 and E16-originating cells compared to males.  
 
Olfactory Bulb Cell Density  
Cell densities were also determined in the olfactory bulb of P8 samples for cells 
originating from E11 and E16 (Fig. 5-3A, 3B). Two-way ANOVA analysis on E11 cell density 
values (cells/mm2) were completed (Fig. 5-3C, F(3,14)=6.521, p=0.0055). PGE2-exposed males 
had significantly higher E11 cell density compared to WT males (Fig. 5-3C, p=0.009809; 
WT=1475.8±253.1, PGE2=3342.4±950.1). There was no statistical difference in E11 olfactory 
bulb cell densities between females (Fig. 5-3C, p=0.998; WT=725.1±67.3, PGE2=723.4±162.2). 
Sex differences were not seen between WT mice (Fig. 5-3C, p=0.249571) but were present 
between PGE2-exposed mice, where males had a greater cell density than females (Fig. 5-3C, 
p=0.001856).  
 Two-way ANOVA analysis on E16 cell density values were conducted (Fig. 5-3D, 
F(3,14)=5.389, p=0.011213). PGE2-exposed males also had significantly higher E16 cell density 
compared to WT males (Fig. 5-3D, p=0.005998; WT=4=16.1±734.0, PGE2=10963.6±3355.8). 
There was no difference in E16 olfactory bulb cell densities between females (Fig. 5-3D, 
p=0.906; WT=2887.5±238.4, PGE2=3169.1±505.0). Sex-dependent differences were not seen in 
WT mice (Fig. 5-3D, p=0.60800) but were apparent between PGE2-exposed mice, where males 
had a greater cell density than females (Fig. 5-3D, p=0.005135). 
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In short, PGE2-exposed males had greater olfactory bulb cell densities for E11 and E16 
cohorts compared to WT controls. Olfactory bulb cell densities were not affected in PGE2-
exposed females compared to female controls. Sex-dependent differences were seen in PGE2-
exposed mice for E11 and E16 olfactory bulb cell densities; males had greater cell densities 
compared to females.  
 
Neocortical Cell Density 
Cells originating from E11 and E16 were counted in the neocortex of P8 samples (Fig. 5-
4A, 4B). Two-way ANOVA analysis on E11 cell density values (cells/mm2) were performed 
(Fig. 5-4C, F(3,14)=6.706, p=0.004924). There were no significant differences in neocortical 
cell densities between PGE2-exposed mice compared to WT controls for males (Fig. 5-4C, 
p=0.848; WT=227.8±24.3, PGE2=238.7±23.8) and for females (Fig. 5-4C, p=0.475; 
WT=378.9±44.1, PGE2=417.8±47.8). Sex differences were seen between WT mice, where males 
had lower neocortical cell densities than WT females (Fig. 5-4C, p=0.007009). Similarly, PGE2-
exposed males also had lower cell densities than PGE2-exposed females (Fig. 5-4C, 
p=0.007009). 
 Two-way ANOVA analysis on neocortical E16 cell density values were also completed 
(Fig. 5-4D, F(3,12)=67.459, p=0.000000088). There were also no significant differences in E16 
neocortical cell densities between PGE2-exposed males compared to WT males (Fig. 5-4D, 
p=0.062815; WT=575.2±44.4, PGE2=442.5±28.4). In contrast, PGE2-exposed females had 
lower cell densities than WT females (Fig. 5-4D, p=0.001011; WT=1254.5±53.4, 
PGE2=984.3±36.2). Sex-dependent differences were observed in the WT and PGE2-exposed 
groups. WT males had a lower E16 neocortical cell density than WT females (Fig. 5-4D, 
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p=0.000000083). Similarly, PGE2-exposed males also had a lower cell density than PGE2-
exposed females (Fig. 5-4D, p=0.000004). 
To summarize, PGE2-exposure did not change the neocortical cell densities for E11 and 
E16 cell cohorts in males. However, PGE2-exposed females had lower neocortical cell densities 
than WT controls for the E16 cell cohort. Sex differences were observed in neocortical cell 
densities, males had lower cell densities for E11 and E16-originating cells compared to females.  
 
Neocortical Cell Migration 
The neocortex develops in an ‘inside-out’ order, where neurons that arise earliest form 
the deepest cortical layers and later-produced neurons migrate past the existing neurons to upper 
layers (Nadarajah et al. 2003). The migration distances in the neocortex of P8 brain samples 
were measured from the subplate to the cells labelled at E11 (CldU-labelled) and E16 (IdU-
labelled) (Fig. 5-5A). Migration percentages were calculated for each labelled cell as described 
in the methods. 
Two-way ANOVA analysis was conducted on the migration percentages for E11-born 
cells of males and females (Fig. 5-5B, F(3,7016)=76.79, p<0.00001). The migration percentage 
of E11 cells for PGE2-exposed males was not significantly different from WT males (Fig. 5-5B, 
p=0.132; WT=36.9±0.58, PGE2=35.4±0.65). In contrast, the migration percentage of E11 cells 
for PGE2-exposed females was statistically greater than WT females (Fig. 5-5B p=0.00000013; 
WT=43.5±0.62, PGE2=48.2±0.72). Sex differences were seen in both WT and PGE2-exposed 
animals. E11-labelled cells of WT males travelled a shorter distance than E11-labelled cells of 
WT females (Fig. 5-5B, p<0.00001). Similarly, E11 cells of PGE2-exposed males also migrated 
less than E11 cells of PGE2-exposed females (Fig. 5-5B, p<0.00001) 
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Two-way ANOVA analysis was conducted on the migration percentages for E16-born 
cells of males and females (Fig. 5-5C, F(3,16909)=85.32, p<0.00001). The migration percentage 
of E16 cells for PGE2-exposed males was significantly greater from WT males (Fig. 5-5C, 
p<0.00001; WT=81.4±0.30, PGE2=85.8±0.25). The migration percentage of E16 cells for PGE2-
exposed females was also significantly greater from WT females (Fig. 5-5C, p=0.01184; 
WT=79.3±0.26, PGE2=81.2±0.25). Sex differences were seen in both WT and PGE2-exposed 
animals. E16-labelled cells of WT males travelled a greater distance than those of WT females 
(Fig. 5-5C, p<0.00001). Similarly, E16 cells of PGE2-exposed males also migrated further than 
E16 cells of PGE2-exposed females (Fig. 5-5C, p<0.00001). 
In summary, PGE2-exposure led to increased migration of E11-born cells in females and 
E16-born cells in males and females. Sex differences were seen in E11-labelled and E16-labelled 
cells. E11-labelled cells in females had greater migration percentages than E11-labelled cells in 
males for WT and PGE2-exposed groups. In contrast, E16-labelled cells in males had greater 
migration percentages than E16-labelled cells in females for WT and PGE2-exposed groups. 
 
Abnormal expression of Spn and Actb in PGE2-exposed mouse offspring 
 The expression of cell proliferation and migration genes, including spinophilin (Spn), 
beta-actin (Actb), and cyclin D1 (Ccnd1), were quantified in PGE2-exposed male and female 
mice and compared to WT controls. Brain samples from postnatal day 8 were collected for 
analysis. Gene expression profiles were determined using quantitative RT-PCR analysis (Table 
5-1). 
In comparison to WT males (RQ=1), only the expression of Spn out of the three genes 
was significantly different in PGE2-exposed males (Table 5-2). Specifically, PGE2-exposed males 
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had decreased expression of Spn by half (t(4)=4.540, p=0.045; RQ=0.487±0.11) compared to 
controls. The expression of Actb (t(4)=1.721, p=0.227; RQ=0.753±0.14) and Ccnd1 (t(4)=2.875, 
p=0.103; RQ=0.725±0.10) were not statistically different in males. 
In contrast, the expression of Spn (t(4)=-4.371, p=0.049, RQ=1.525±0.12) and Actb 
(t(4)=-5.389, p=0.033, RQ=1.309±0.06) were both increased in PGE2-exposed females 
compared to WT females (RQ=1) (Table 5-2). No statistical differences were found in the 
expression of Ccnd1 (t(4)=-2.179, p=0.161; RQ=1.198±0.091). In summary, PGE2 exposure led 
sex-specific changes in the expression of Spn and Actb. 
 
5.5. Discussion 
The manifestation of ASD phenotypes is believed to result from a cascade of prenatal 
pathogenic processes, including irregular proliferation and migration of neural cells (Courchesne 
et al. 2019). Thus, in this study we aimed to determine how cell density and migration could be 
affected by prenatal exposure to PGE2. We found that a single maternal injection of PGE2 during 
pregnancy led to abnormalities in mouse offspring at P8. Specifically, PGE2-exposed offspring 
displayed aberrant cell density in ASD-associated brain regions including the cerebellum, 
hippocampus, olfactory bulb, and neocortex. Sex-dependent alterations in neocortical migration 
of cells originating at E11 or E16 and irregular expression of cell growth and motility genes 
(Spn, Actb) were also affected in PGE2-exposed offspring. Quantified cells are most probably 
neurons since neurogenesis occurs from E10 to E18, whereas astrocytes and oligodendrocytes 
are generated later in development (Reemst et al. 2016, Miller and Gauthier 2007, Bayer and 
Altman 1991). 
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We found that PGE2-exposed males and females had a lower density of E11-labelled 
cells in the cerebellum compared to sex-matched controls. PGE2-exposed males also exhibited a 
lower density of E16-labelled cerebellar cells than controls. The cerebellum is important in 
motor movement and perception (Manto et al. 2012) and is also involved with executive 
functioning and social cognition, indicating that the cerebellum has a predominant role in non-
motor processes relevant to ASDs (Van Overwalle et al. 2014, Buckner 2013, Tedesco et al. 
2011, Strick et al. 2009). One of the most consistently reported abnormalities of the brain in 
ASD cases is a decreased number of Purkinje cells in the cerebellum (Skefos et al. 2014, 
Whitney et al. 2009, Yip et al. 2007, Bauman and Kemper 2005, Bailey et al. 1998, Ritvo et al. 
1986). Moreover, cerebellar dysplasia and a reduction in total cerebellar volume in children and 
adults with an ASD have been reported (Wegiel et al. 2010, Hallahan et al. 2009, Carper and 
Courchesne 2000). Our findings showing decreased cerebellar cell density at E11 and E16 
complement previous studies that reported reduced Purkinje cell numbers and volume of the 
cerebellum in ASD patients. Moreover, anatomical deviations of the cerebellum may contribute 
to motor difficulties in ASDs (Esposito and Venuti 2008, Ming et al. 2007, Vernazza-Martin et 
al. 2005) and abnormal social cognition (Fishman et al. 2014). Interestingly, we have also 
previously found that an increase or decrease of PGE2 signalling during prenatal development 
can lead to atypical motor ability and sociability in mice (Wong et al. 2019, Wong et al. 2017). 
The hippocampus is important in learning and memory as well as cognitive flexibility and 
social behaviour (Rubin et al. 2014). We did not find a significant difference in hippocampal cell 
densities for E11 or E16 cell cohorts between PGE2-exposed and matched control mice. Cell 
densities have not been well investigated in ASDs but previous studies in infants and children 
have reported hippocampal shape deformation, increased or decreased hippocampal volume, 
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altered neuron morphology, decreased dendritic branching, and reduced hippocampal functional 
connectivity in individuals with an ASD (Cooper et al. 2017, Dager et al. 2007, Sparks et al. 
2002, Aylward et al. 1999, Raymond et al. 1996). We did find that females had greater 
hippocampal cell densities compared to males within PGE2-exposed and control groups. Sex 
differences have been recorded for decades in the general population in regards to spatial and 
object memory—males outperform in spatial memory while females outperform in object 
memory—however, the biological etiology of these sex differences is currently inconsistent or 
not well understood (Koss and Frick 2017). Future memory-based behavioural testing in PGE2-
exposed mice may determine potential correlations between altered hippocampal densities and 
behavioural outcomes. 
We also observed that PGE2-exposed males had greater E11 and E16 cell densities in the 
olfactory bulb compared to matched controls. In contrast, PGE2 exposure did not affect olfactory 
bulb cell densities in females. Although often overlooked, olfaction can affect one’s social life, 
behaviours, emotions, memory, and thought (Boesveldt et al. 2017, Kadohisa 2013, Sarafoleanu 
et al. 2009). The olfactory bulb is a large structure in the mouse and is important for processing 
many social signals (Lin et al. 2005). Perhaps abnormal cell densities in the olfactory bulb could 
be correlated to atypical sensory processing, particularly olfactory processing, present in ASDs 
(Tonacci et al. 2017, Wicker et al. 2016). Sex differences were specific to PGE2-exposed mice, 
with greater E11 and E16 olfactory bulb cell densities in males compared to females. No sex 
differences were observed in control mice. This pattern is dissimilar to the sexual dimorphism 
seen in general human samples, where women had a greater number of neurons and glia in the 
olfactory bulb than men (Oliveira-Pinto et al. 2014). 
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We also reported that PGE2 exposure in males and females were correlated with lower 
neocortical cell densities and increased cellular migration compared to matched controls. Sex 
differences were also observed: neocortical cell densities were greater in females compared to 
males in both control and PGE2-exposed groups. Interestingly, in both PGE2-exposed and 
controls groups, cells originating from E11 travelled a greater distance in females compared to 
males, while cells originating from E16 travelled a greater distance in males compared to 
females. Abnormal cell proliferation and migration measured in our study could lead to incorrect 
formation and circuitry of the neocortex, which may contribute to impairments in cognition and 
increased susceptibility to neurodevelopmental disorders (Rubenstein 2011, Valiente and Marin 
2010). Several anatomical irregularities in the cortex have been reported in ASDs: increased 
neuron numbers, decreased interneuron numbers, disorganization of neurons and layering, 
disrupted minicolumn cell organization, and abnormal neuronal migration (Hashemi et al. 2017, 
Stoner et al. 2014, Courchesne et al. 2011, Wegiel et al. 2010, Hutsler et al. 2007, Buxhoeveden 
et al. 2006, Casanova et al. 2002). Sex differences in the general human population are varied: 
cell density in cortical layer II and IV is higher in females than males (Witelson et al. 1995), 
while other studies have found greater cortical neuronal numbers in males than females 
(Rabinowicz et al. 2002, de Courten-Myers 1999). Similar to research in humans, our results also 
demonstrate abnormal migration and cell numbers in the cortex of PGE2-exposed mice as well as 
sex-dependent differences.  
In addition to atypical cellular densities and cortical migration, PGE2-exposed mice also 
exhibited altered gene expression of spinophilin (Spn) and beta-actin (Actb) in whole brain 
samples at postnatal day 8. Spn expression was decreased in PGE2-exposed males compared to 
sex-matched controls. In contrast, PGE2-exposed females had greater Spn expression than 
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controls. Actb expression was increased in PGE2-exposed females compared to sex-matched 
controls but not statistical difference was observed in PGE2-exposed males compared to controls. 
Spinophilin and beta-actin are both important components in the cytoskeleton and are involved 
in embryonic development of the nervous system. Spinophilin is required for various functions 
including dendritic spine morphology, cell adhesion, cell growth, and neuronal migration 
(Sarrouilhe et al. 2006, Feng et al. 2000). Similarly, beta-actin influences cell growth and 
motility, wiring of neuronal circuitry through growth cone development, and synaptogenesis 
(Tondeleir et al. 2014, Cheever et al. 2012, Bassell et al. 1998). Beta-actin may also play a role 
in cognitive and hyperactive behaviours (Cheever et al. 2012). Atypical sex-dependent 
expression of Spn and Actb observed in PGE2-exposed mice may contribute to sex-specific 
abnormal cell densities and migration also quantified in this study, and could lead to abnormal 
brain connectivity and synaptic plasticity, which have been observed in ASD cases (Alaerts et al. 
2016, Mottron et al. 2015). Gene expression analyses were conducted on whole brain samples 
but future investigations on region-specific expression of these genes will offer further details on 
how Spn and Actb may impact cell density and migration. 
 
5.6. Conclusions 
In conclusion, our results demonstrate that a single dose of maternal PGE2 exposure 
might affect the fate of current and later dividing cells in offspring by contributing to sex-
specific dysregulation of neocortical migration and cell densities in the cerebellum, 
hippocampus, olfactory bulb, and neocortex. Specific cell types—neurons, interneurons, or 
glia—that may be affected in PGE2-exposed mice remain to be determined. Moreover, the 
potential effect on synaptic density, spine morphology, and dendritic spine density, which have 
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all been implicated in ASDs (Tang et al. 2014, Hutsler and Zhang 2010), could also be 
investigated in PGE2-exposed mice. Overall, the findings of our study provide new evidence that 
prenatal PGE2 exposure during early development may disrupt important neuronal processes that 
could influence pathogenesis of neurodevelopmental disorders such as ASDs.  
 
5.7. Figures 
 
Fig. 5-S1: Methods timeline for cell density and migration quantification 
Females were inspected every morning for a vaginal plug. Appearance of vaginal plug was noted 
as embryonic day 1; females were separated and housed individually for the entirety of their 
pregnancy. CldU and IdU labelling technique was used to identify and quantify two separate cell 
cohorts. On E11, control and PGE2-exposed pregnant females were given a subcutaneous 
injection of 5-Chloro-2’- deoxyuridine (CldU) in saline.  PGE2-exposed pregnant females were 
given a single co-injection of CldU and 16, 16-dimethyl prostaglandin E2 (dmPGE2). On E16, 
control and PGE2-exposed pregnant females were given a subcutaneous injection of 5-Iodo-
2’deoxyurdine (IdU). Birth occurs on the 20th day of gestation (E20) also recorded as postnatal 
day 0 (P0) Left and right brain samples were extracted on P8 for fluorescent 
immunohistochemistry and qRT-PCR, respectively. 
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Fig. 5-1: E11 and E16 Cohort-labelled cell densities in the Cerebellum.  
(A) Greyscale image and (B) Immunoflourescent image of cerebellum indicated by yellow 
outline. (C) Decreased cell density of E11-labelled cells in the cerebellum of PGE2-exposed 
mice. Sex differences were only observed between control mice. (D) Decreased cell density of 
E16-labelled cells in the cerebellum of PGE2-exposed males. Cerebellar E16 cell densities were 
greater in females than males. Means represent at least 3 independent animals for each 
experimental group. Data are presented as mean ±SEM, *p<0.05, **p<0.01, ***p<0.001. Scale 
bar represents 500μM. 
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Fig. 5-2: E11 and E16 Cohort-labelled cell densities in the Hippocampus. 
(A) Greyscale image and (B) Immunoflourescent image of hippocampus indicated by yellow 
outline. (C) PGE2 exposure did not have a statistical effect on hippocampal cell density for E11-
labelled cells compared to controls. In the control group, there was a higher E11-labelled cell 
density in females compared to males. (D) PGE2 exposure did not have a statistical effect on 
hippocampal E16 cell density.  Within the control and PGE2-exposed group, there was a greater 
E16-labelled cell density in females compared to males.  Means represent at least 3 independent 
animals for each experimental group. Data are presented as mean ±SEM, *p<0.05, **p<0.01, 
***p<0.001. Scale bar represents 500μM.   
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Fig. 5-3: E11 and E16 Cohort-labelled cell densities in the Olfactory Bulb.  
(A) Greyscale image and (B) Immunoflourescent image of olfactory bulb indicated by yellow 
outline. (C) Increased cell density of E11-labelled cells in the olfactory bulb of PGE2-exposed 
males. In the PGE2-exposed group, olfactory bulb E11 cell density was greater in males than 
females. (D) Similarly, there was increased cell density of E16-labelled cells in the olfactory 
bulb of PGE2-exposed males. Olfactory bulb E16 cell density was greater in PGE2-exposed 
males than females. Means represent at least 3 independent animals for each experimental group. 
Data are presented as mean ±SEM, *p<0.05, **p<0.01, ***p<0.001. Scale bar represents 
500μM. 
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Fig. 5-4: E11 and E16 Cohort-labelled cell densities in the Neocortex.  
(A) Greyscale image and (B) Immunoflourescent image of a representative portion of the 
neocortex. (C) PGE2 exposed did not significantly affect cell density of E11-labelled cells in the 
neocortex. Within control and PGE2-exposed groups, females had a greater E11 cell density than 
males. (D) Decreased cell density of E16-labelled cells in the neocortex of PGE2-exposed 
females. Neocortical E16 cell densities were greater in females than males. Means represent at 
least 3 independent animals for each experimental group. Data are presented as mean ±SEM, 
*p<0.05, **p<0.01, ***p<0.001. Scale bar represents 500μM.  
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Fig. 5-5: E11 and E16 Cohort-labelled cell migration in the Neocortex.  
(A) Neocortical cell migration distances from the subplate to the labelled cells were measured in 
the cortex (E11-labelled cells shown here). The migration percentage for each cell was calculated 
by taking its migration distance (indicated by green lines) and dividing it by the total distance 
between the subplate/corpus callosum and pial surface (indicated by white lines). (B) Increased 
neocortical cell migration of E11-labelled cells in PGE2-exposed females. In the control and 
PGE2-exposed group, E11-labelled cell migration was greater in females than males. (C) 
Increased neocortical cell migration of E16-labelled cells in PGE2-exposed males and females 
compared to sex-matched controls. E16-labelled cells migrated further in males compared to 
females within control and PGE2-exposed groups. Means represent at least 3 independent 
animals for each experimental group. Data are presented as mean ±SEM, *p<0.05, **p<0.01, 
***p<0.001.     
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Table 5-2 : Growth and migration gene expression in PGE2-exposed mice. 
Gene expression analysis were completed on postnatal day 8 samples as shown as RQ units for 
male and female PGE2 groups relative to respective controls (RQ=1). Values represent the mean 
of at least 3 independent individuals. *p<0.05, **p<0.01, ***p<0.001 
 
PGE2-exposed compared to WT controls (RQ=1) 
Males RQ Mean Values p-values 
Spn 0.487 0.045* 
Actb 0.753 0.227 
Ccnd1 0.725 0.103 
Females RQ Mean Values p-values 
Spn 1.526 0.049* 
Actb 1.309 0.033* 
Ccnd1 1.198 0.161 
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CHAPTER 6.  
Study 4: Augmented microglial density and abnormal morphology in mice with defective 
cyclooxygenase-2/prostaglandin E2 signalling 
 
Manuscript 6 Citation (in preparation):  
Wong, C. T., Smith J., and Crawford DA. (in preparation, 2019). Augmented microglial density 
and abnormal morphology in mice with defective cyclooxygenase-2/prostaglandin E2 signalling. 
 
Contributions: Christine T. Wong designed and performed all experiments, collected samples, 
acquired and analyzed the data, made all figures and tables, and prepared the manuscript. Josee 
Smith assisted in the collection of mouse samples and helped with acquiring data. Dr. Dorota A. 
Crawford supervised the design of the study and was involved with editing the manuscript.  
 
Objectives and Hypotheses: The fourth study was comprised of in vivo experiments with the 
main purpose of studying the effect of elevated PGE2 and COX-2-deficiency on microglia. The 
objectives were to determine whether elevated PGE2 or COX-2-deficiency can influence 
microglial density and morphology. The cerebellum, hippocampus, olfactory bulb, prefrontal 
cortex, and thalamus were investigated. I hypothesized that both exposure to PGE2 or lack of 
COX-2 activity would disrupt microglial density, activation state, branch density, and process 
length in the mouse brain in a sex-dependent and region-specific manner. This was the first study 
to determine that aberrations to the COX-2/PGE2 signalling pathway during prenatal 
development could alter microglia in the brain. 
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6.1. Chapter Summary 
Cyclooxygenase-2 (COX-2) and its enzymatic product, prostaglandin E2 (PGE2), have 
key roles in inflammation and normal developmental processes in the brain, including synaptic 
plasticity and masculinization. The COX-2/PGE2 lipid signalling pathway is susceptible to 
numerous environmental agents associated with autism spectrum disorders (ASDs). Our recent 
studies in mice determined that an elevated level of maternal PGE2 during pregnancy or COX-2-
deficiency leads to autism-related behaviours in offspring that is sex-dependent. Our previous 
research has also provided some insight into possible molecular mechanisms by which defects in 
PGE2 signalling may affect brain development. In this study, we aim to further investigate the 
impact of abnormal signalling of the COX-2/PGE2 pathway on microglial density and 
morphology in the developing brain. In the healthy brain, microglia play a well-established role 
in inflammation but can also influence many neurodevelopmental processes including synaptic 
modification. We demonstrate that both maternal exposure to PGE2 or lack of COX-2 activity 
affect microglial density, activation state, branch density, and process length in the mouse brain 
at postnatal day 8 in a sex-dependent and region-specific manner. Overall, PGE2-exposed mice 
exhibited higher microglial density with a greater percentage of amoeboid microglia and fewer 
ramified microglia, which was further demonstrated by decreased branching and process lengths. 
COX-2-deficient mice also had an elevated microglial density but with a lower percentage of 
amoeboid microglial cells and more ramified microglia. Greater branching and increased process 
lengths were also found in COX-2-deficient mice. Our findings in two separate mice models of 
ASDs provide further evidence that abnormal COX-2/PGE2 signalling can contribute to brain 
pathology by disrupting microglial density and morphology. 
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6.2. Introduction 
Prostaglandin E2 (PGE2) is a bioactive signalling molecule derived from cell membrane 
lipids from the enzymatic activity of cyclooxygenase-1, and -2 (COX-1, 2). In the brain, COX-2 
expression is particularly important since it can be both constitutive and inducible. Its 
constitutive expression contributes to normal brain functions while its inducible expression 
results as a response to intrinsic and extrinsic stressors (Minghetti, 2004). COX-2 regulates the 
production of PGE2, which is best known as a potent inflammatory mediator but is also the main 
prostanoid in the developing nervous system, involved in synaptic plasticity, cerebellar 
development, and masculinization (Dean et al., 2012, Dean et al., 2012, Wright and McCarthy, 
2009, Chen and Bazan, 2005).  
Growing clinical and molecular research provides evidence that abnormal COX-2/PGE2 
signalling is linked to autism spectrum disorders (ASDs) (Wong et al., 2015, Wong and 
Crawford, 2014, Tamiji and Crawford, 2010). For instance, various genetic factors and 
environmental insults such as maternal infections, pollution, pesticides, and drugs capable of 
affecting the level of PGE2 have been linked to ASDs. Furthermore, prenatal use of common 
over-the-counter drugs that inhibit COX enzymatic activity, such as acetaminophen, has been 
linked to behavioural disorders including, ADHD and autism (Bauer et al., 2018, Ystrom et al., 
2017, Avella-Garcia et al., 2016). Current findings from our lab in murine models have 
determined for the first time that an elevated level of maternal PGE2 during pregnancy or COX-
2-deficiency leads to autism-related behaviours manifested in a sex-dependent manner (Wong et 
al., 2019, Wong et al., 2017). Our previous research has also revealed possible molecular 
mechanisms by which abnormal COX-2/PGE2 signalling may affect brain development 
including dysregulation of intracellular calcium level, proliferation and migration of neuronal 
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stem cells, neuronal differentiation, and expression of ASD-linked genes (Rai-Bhogal et al., 
2018, Davidson et al., 2016, Wong et al., 2016, Wong et al., 2014, Tamiji and Crawford, 2010). 
Moreover, we showed that COX-2-deficient mice exhibit differential expression of various ASD-
associated genes and deficits in pathways involved in synaptic transmission, dendritic spine 
formation, and immune response (Wong et al., 2019, Rai‐Bhogal et al., 2018)  
Interestingly, current research shows that in the healthy brain, PGE2 can also regulate 
neonatal microglia activation (Chen et al., 2018, Cantaut-Belarif et al., 2017, Quan et al., 2013). 
Microglia are major resident immune cells in the central nervous system and are key mediators 
of neuroinflammatory processes. Microglia are also essential in the development and wiring of 
synaptic circuitry (Ziebell et al., 2015, Paolicelli and Gross, 2011, Tremblay et al., 2010, Wake 
et al., 2009). In addition, dysfunction of microglia has been implicated in ASDs (Kim et al., 
2018, Edmonson et al., 2016, Koyama and Ikegaya, 2015, Takano, 2015, Rodriguez and Kern, 
2011). However, the molecular mechanisms that might affect microglial dysfunction in ASDs are 
not known.  
In this study, we aim to examine whether abnormal COX-2/PGE2 signalling can disrupt 
microglial density and morphology during early development. Two mouse model systems of 
ASDs recently established in our lab were used here: offspring exposed to PGE2 during 
pregnancy at embryonic day 11 (E11) and homozygous COX-2- knockin (KI) mice deficient in 
the PGE2-producing enzyme (Wong et al., 2019, Wong et al., 2017). Our data collected from 
pups on postnatal day 8 (P8) brains revealed that irregular COX-2/PGE2 signalling in both 
models alters microglial density and morphology in various neuroanatomic locations that have 
been previously implicated in ASDs, including the cerebellum, hippocampus, olfactory bulb, 
prefrontal cortex, and thalamus in a sex-dependent manner. These findings demonstrate that 
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abnormal PGE2 levels during prenatal development affects microglia in mouse offspring that 
display autism-relevant behaviours. These results add to our previous studies by providing 
evidence that abnormal COX-2/PGE2 signalling might lead to some cases of ASDs by affecting 
microglia function in the developing brain. 
 
6.3. Methods 
Animals in PGE2 -exposed model: C57bl/6 wildtype mice and maternal Injection of PGE2 
Wildtype C57bl/6 (WT-C57) mice were obtained from Charles River Laboratories. 
Animals were maintained on a 12-hour light/dark cycle at York University animal. Ethics 
guidelines of the York University Animal Care Committee were followed for all experiments 
and protocols, which were approved by the Research Ethics Board of York University. 
Overnight breeding was completed by housing male and female mice together. Females 
were inspected for a vaginal plug every morning, which was recorded as embryonic day 1 (E1). 
If a vaginal plug was found, females were separated and housed individually for their entire 
pregnancy. On E11, a single subcutaneous injection of 0.2 μg/g concentration of 16, 16-dimethyl 
prostaglandin E2 (dmPGE2; Cayman Chemical) diluted in saline or saline vehicle (for WT-C57 
mice) was administered to pregnant females, as done in previous studies (Rai-Bhogal et al., 
2018, Wong et al., 2017, Okamoto et al., 2011, Tessner et al., 2004). dmPGE2 has a slower 
metabolic rate and is a stable analogue of PGE2 (Ohno et al., 1985, Steffenrud, 1980). E11 marks 
the start of neurogenesis in mice and also corresponds with the time that misoprostol, a drug 
analogous to PGE2, was taken in human cases resulting in Moebius syndrome and autism 
characteristics (Bandim et al., 2003, Pastuszak et al., 1998). Maternal exposure of dmPGE2 at 
E11 has also been recently shown to result in autism-like behaviours and altered expression of 
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autism-linked genes in offspring (Rai-Bhogal et al., 2018, Wong et al., 2017). Mouse offspring 
exposed to maternal dmPGE2 will be referred to as “PGE2 mice”. 
 
COX-2- knock-in model:  129S6 Wildtype mice and COX-2- knock-in mice 
Ptgs2Y385F founder mice, also known as B6.129S6(FVB)-Ptgs2 tm1.1Fun/J mice or Ptgs2 
knockin (COX-2- KI) mice, were obtained from Jackson Laboratory (stock #008101; Queen’s 
University, laboratory of C. Funk) backcrossed for at least 5 generations to wild-type 
129S6/SvEvTac (WT-S6) mice acquired from Taconic Laboratory. Ptgs2Y385F mice are a genetic 
mouse model created by a targeted point mutation of the Ptgs2 gene, specifically a Y385F amino 
acid substitution. This results in complete inhibition of COX-2 activity but downstream 
peroxidase activity remains intact (Yu et al., 2006, Yu and Funk, 2006). Since homozygous 
COX-2- KI females are infertile, heterozygous females were bred with homozygous or 
heterozygous males to produce COX-2- KI male and female offspring for brain sampling. All 
WT-S6 and COX-2- KI mice were bred and maintained under the same conditions at York 
University on a 12-hours light/dark cycle.  
 
Genotyping 
Polymerase chain reaction (PCR) analysis was conducted for genotyping analysis of the 
COX-2 gene using primer sequences detailed by the Jackson Laboratory (Ptgs2; Table 6-1). 
DNA extraction was completed on individual tail samples, which were denatured in alkaline 
lysis buffer (25mM NaOH) at 95°C for 30 min, followed by addition of neutralization buffer 
(Tris-HCl). Standard PCR was performed in an Eppendorf Mastercycler according to the Jackson 
Laboratory Ptgs2tm1.1Fun protocol (The Jackson Laboratory, 2016). 
 
237 
 
Table 6-1: PCR Primer set for Ptgs2 Genotype Analysis 
Primer Name Primer Sequence (5’-3’) Base pairs COX-2- Wild-type 
Forward Mus Ptgs2IMR7834 ACCAGTCTCTCAATGAGTAC 20 bp 585 bp   493 bp 
Reverse Mus Ptgs2IMR7835 AGAATGGTGCTCCAAGCTCTAC 22 bp 
 
 
Brain Exaction 
Whole brain samples were extracted on postnatal day 8 (P8), where birth was considered 
postnatal day 0. P8 in mice is analogous to infanthood in humans (Pressler and Auvin, 2013, 
Semple et al., 2013), which is the time when ASD symptoms are first observed. Brain samples 
were collected and fixed in 4% (w/v) paraformaldehyde (PFA) in PBS at 4°C for 48 hours in 
preparation for histological staining. 
 
Immunohistochemistry  
P8 brain samples were carefully extracted, prepared, and then delivered to The Centre for 
Phenogenomics (Toronto, Canada) for paraffin-embedding and 4μm serial slicing from the mid-
sagittal plane. Paraffin removal from samples was completed by xylene incubation, followed by 
subsequent ethanol incubations for rehydration. Antigen retrieval was performed by boiling 
samples in 0.01M pH 6.0 sodium citrate buffer for 20 minutes in a microwave. To prevent 
endogenous peroxidase activity, slides were then incubated with 0.3% H2O2 in methanol for 30 
minutes. Next, sections were circled using a liquid blocking super PAP pen (Cedarlane). All 
subsequent steps were then performed in a hydration chamber.  Blocking was completed in 5% 
goat serum and 0.1% Triton X-100 diluted in PBS for 30 minutes. Slides were then incubated 
overnight at 4°C in primary antibody for Iba1 called Rabbit anti-Iba1 (1:1000, Wako, #019-
19741) diluted in 5% goat serum in PBS. Secondary antibody staining was completed with 
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biotinylated anti-rabbit IgG antibody (1:200, Vector Laboratories) for 1 hour, followed by 1 hour 
incubation with Elite ABC Reagent (Vectastain Avidin Biotin Complex kit, Vector laboratories). 
Immunostaining was developed by incubating samples with 3,3’-Diaminobenzidine (DAB) 
substrate solution (SIGMAFAST DAB tablets, D4168, Sigma) in 0.3% ammonium nickel sulfate 
hexahydrate and Milli-Q water.  Slides were then dehydrated in ascending EtOH washes 
followed by xylene incubation. Permount mounting medium was used to coverslip slides. 
 
Microglial Cell Density and Morphological Analysis 
Microglia-specific staining was captured using an Eclipse Ti microscope (Nikon). The 
cerebellum, hippocampus, olfactory bulb, prefrontal cortex, and thalamus were investigated 
using light microscopy and visualized at 20x magnification with automated image stitching (Fig. 
1). Estimated cell density measurements for each brain region were calculated by dividing the 
total number of cells by the area of interest. Microglial cells were characterized morphologically. 
Quiescent microglia are thought to have a ramified morphology with branches processes that are 
long and thin; while activated microglia have enlarged cell bodies that are characteristically 
round and amoeboid in shape (Kloss et al., 2001; Stence et al., 2001; Schwarz et al., 
2012; Schafer et al., 2012).  Activation state (Amoeboid or Ramified), number of primary 
branches and longest length of processes of each microglial cell were quantified using NIS-
Elements software (Nikon). Primary branches were defined as branches that protruded directly 
from the soma. Length of processes were measured from the surface of the soma. All analyses 
were completed blind to the condition. 
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Statistical Analysis 
Numerical data are reported as mean±standard error of the mean (SEM), which 
represents quantification from a minimum of three individuals from at least three separate litters. 
Two-way ANOVA followed by post-hoc Bonferroni pairwise comparisons were conducted to 
determine if there were significant differences in microglial characteristics between experimental 
groups of interest and respective wildtype (WT) control groups, and between males and females. 
Significance was determined for p values less than 0.05. 
 
6.4. Results 
Altered Microglial Density in PGE2-exposed offspring mice 
Changes in microglial density have been previously shown to influence key 
developmental processes including neurogenesis, neuron migration, formation of axons, and 
synaptic pruning (Askew 2018, Cunningham 2013, Squarzoni 2014, Rodriguez 2010, Antony 
2011, Paolicelli 2011). In this study, microglial density was quantified in the cerebellum, 
hippocampus, olfactory bulb, prefrontal cortex, and thalamus at postnatal day 8 (P8) (Fig. 6-1) to 
determine whether differences occurred between PGE2-exposed mice and wild-type C57bl/6 
(WT-C57) mice. Males and females were also examined independently. Two-way ANOVA 
analysis on microglial density values (cells/mm2) was conducted for each brain region. 
Results from the cerebellum (Fig. 6-2, F(3,8)=2.913, p=0.100727) show that the 
cerebellar microglial density of PGE2 mice (males and females combined) was statistically 
greater than WT-C57 mice (p=0.035251, WT=73.1±11.5, PGE2=116.1±12.9). Males and females 
of each group were also independently investigated. The cerebellum of WT-C57 males, PGE2 
males, WT-C57 females, and PGE2 females had microglial densities of 62.3±17.0, 101.2±4.0, 
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83.8±16.1, 131.0±24.3, respectively. Post hoc comparisons revealed no significant differences 
between groups within the same sex or between sexes (p>0.05). 
In the hippocampus (Fig. 6-2, F(3,8)=1.757, p=0.232827), there were no significant 
differences in microglial density between PGE2 mice as compared to WT-C57 mice (p=0.23429, 
WT=143.0±12.3, PGE2=161.3±9.1). The hippocampus of WT-C57 males, PGE2 males, WT-C57 
females, and PGE2 females had microglial densities of 129.0±23.4, 148.3±4.3, 157.0±4.2, 
174.4±15.0, respectively, with no significant sex-dependent differences between these groups 
(p>0.05).  
In the olfactory bulb (Fig. 6-2, F(3,8)=3.279, p=0.079612), microglial density of PGE2 
mice was statistically greater than WT-C57 mice (p=0.018863, WT=83.1±10.4, 
PGE2=174.3±28.0). No significant differences were observed in the olfactory bulb of WT-C57 
males, PGE2 males, WT-C57 females, and PGE2 females, which had microglial densities of 
69.5±12.7, 154.1±19.4, 96.7±13.8, 194.5±56.0, respectively (p>0.05). 
Results from the prefrontal cortex (Fig. 6-2, F(3,8)=2.148, p=0.172289) showed no 
statistical differences in microglial density between PGE2 mice and WT-C57 mice (p=0.324361, 
WT=88.8±11.3, PGE2=100.6±6.3). We also did not see significant sex differences. The 
prefrontal cortex of WT-C57 males, PGE2 males, WT-C57 females, and PGE2 females had 
microglial densities of 74.8±4.3, 88.9±3.8, 102.9±20.5, 112.3±6.8, respectively. Post hoc 
comparisons showed no significant differences between these groups (p>0.05).  
In the thalamus (Fig. 6-2, F(3,8)=4.686, p=0.035839), microglial density of PGE2 mice 
was statistically greater than WT-C57 mice (p=0.043477, WT=65.4±5.2, PGE2=86.0±6.6). The 
thalamus of WT-C57 males, PGE2 males, WT-C57 females, and PGE2 females had microglial 
densities of 50.1±5.2, 74.4±6.6, 80.7±2.2, 97.7±16.0, respectively. There were significantly 
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greater microglial density in the thalamus of WT-C57 females compared to WT-C57 males 
(p=0.044505) but this difference was not observed between PGE2 males and PGE2 females 
(p>0.05). 
 Overall, PGE2-exposed mice (males and females combined) at P8 had higher microglial 
densities in the cerebellum, olfactory bulb, and thalamus compared to WT-C57 mice. PGE2-
exposure did not affect microglial densities in the prefrontal cortex and hippocampus. When each 
sex was analyzed independently, statistical differences were generally not found between males 
and females, with the exception of WT-C57 males and females, where females had a greater 
microglial density than males in the thalamus. 
 
Altered Microglial Density in COX-2- KI mice 
Microglial densities were also investigated in the cerebellum, hippocampus, olfactory 
bulb, prefrontal cortex, and thalamus in COX-2- KI mice and wild-type 129S6 (WT-S6) mice at 
P8. Males and females were also examined separately. Two-way ANOVA analysis on microglial 
density values (cells/mm2) was conducted on each area. 
Similar to the PGE2-exposed animals (males and females combined), results for 
cerebellar microglial density (Fig. 6-3, F(3,8)= 5.200, p=0.027716) showed that COX-2- KI mice 
was statistically greater than WT-S6 mice (p=0.006634, WT=56.7±8.2, COX-2=87.5±8.0). 
Males and females of each group were also independently investigated. The cerebellum of WT-
S6 males, COX-2- males, WT-S6 females, and COX-2- females had microglial densities of 
50.7±3.0, 94.7±10.1, 62.6±3.4, 80.4±12.9, respectively. Interestingly, post hoc comparisons 
revealed that COX-2- males had a significantly higher density of microglia in the cerebellum than 
WT-S6 males (p=0.006417). No statistical difference was found between WT-S6 females and 
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COX-2- females (p=0.17641). Sex-dependent differences in microglial density were not found in 
the cerebellum (p>0.05). 
For hippocampal microglial density (Fig. 6-3, F(3,8)=0.301, p=0.823721), there were no 
significant differences between COX-2- KI mice  and WT-S6 mice (p=0.708032, 
WT=129.5±10.8, COX-2=134.8±7.1). The hippocampus of WT-S6 males, COX-2- males, WT-
S6 females, and COX-2- females had microglial densities of 132.4±18.0, 142.8±13.4, 
126.5±15.8, 126.9±3.0, respectively, with no significant differences within groups of the same 
sex or between sexes (p>0.05).  
In the olfactory bulb (Fig. 6-3, F(3,8)=5.536, p=0.023632), microglial density of COX-2- 
KI mice was statistically greater than WT-S6 mice (p=0.024542, WT=98.1±4.6, COX-
2=115.2±6.6). The olfactory bulb of WT-S6 males, COX-2- males, WT-S6 females, and COX-2- 
females had microglial densities of 105.8±6.3, 104.6±6.7, 90.4±3.0, 125.8±7.8, respectively. 
COX-2- females had a significantly higher density of microglia in the olfactory bulb than WT-S6 
females (p=0.003708). No statistical difference was found between WT-S6 males and COX-2- 
males (p=0.894199). Sex-dependent differences were seen in COX-2- mice, where females had a 
greater microglial density than males (p=0.041503) but a sex-dependent effect was not present in 
WT-S6 mice (p=0.116908). 
In the prefrontal cortex (Fig. 6-3, F(3,8)=24.377, p=0.000223), microglial density of 
COX-2- KI mice was statistically greater than WT-S6 mice (p=0.000077, WT=66.6±4.4, COX-
2=100.2±5.9). The prefrontal cortex of WT-S6 males, COX-2- males, WT-S6 females, and COX-
2- females had microglial densities of 73.5±5.2, 88.2±1.9, 59.7±4.9, 112.2±5.3, respectively. 
COX-2- females had a significantly higher density of microglia in the prefrontal cortex than WT-
S6 females (p=0.000038). No statistical difference was found between WT-S6 males and COX-
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2- males (p=0.052043). Sex-dependent differences were seen in COX-2- mice, where females had 
a greater microglial density than males (p=0.00574) but a sex-dependent effect was not present 
in WT-S6 mice (p=0.063866). 
In the thalamus (Fig. 6-3, F(3,8)=1.266, p=0.349611), microglial density of COX-2- KI 
mice was not statistically different than WT-S6 mice (p=0.415009, WT=63.1±6.4, COX-
2=70.1±5.8). The thalamus of WT-S6 males, COX-2- males, WT-S6 females, and COX-2- 
females had microglial densities of 71.6±10.0, 75.4±9.9, 54.5±5.3, 64.7±6.1, respectively, with 
no significant differences between these groups (p>0.05). 
 Overall, COX-2- KI mice at P8 had higher microglial densities in the cerebellum, 
olfactory bulb, and prefrontal cortex compared to WT-S6 mice. Disruption of COX-2 activity did 
not affect microglial densities in the hippocampus and thalamus. When each sex was analyzed 
independently, statistical differences were found in various regions between WT-S6 and COX-2- 
mice, including the cerebellum (males), olfactory bulb (females), and prefrontal cortex (females). 
Moreover, sex-dependent differences were not present in WT-S6 but were found in the olfactory 
bulb and prefrontal cortex of COX-2- KI mice, with greater microglial densities in females than 
males. 
 
Altered Amoeboid and Ramified Microglial Morphology in PGE2-exposed offspring mice 
Microglia were characterized into their two main morphological phenotypes—active 
amoeboid cells or quiescent ramified cells (Fig. 6-4)—in the cerebellum, hippocampus, olfactory 
bulb, prefrontal cortex, and thalamus at P8 brain samples of PGE2-exposed mice and wild-type 
C57bl/6 (WT-C57) mice.  
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Amoeboid Morphology Percentages 
The percentage of amoeboid microglia to total microglia identified in each specified areas 
was calculated. Two-way ANOVA analysis on active amoeboid microglia percentages was 
conducted on each brain region of interest. 
In the cerebellum (Fig. 6-4, F(3,8)=19.568, p=0.000484), active amoeboid microglia 
morphology percentages of PGE2 mice in general was not statistically different from WT-C57 
mice when males and females were averaged together (p=0.20356, WT=22.1±4.6, 
PGE2=25.0±2.7). Investigating males and females of each group separately showed that the 
cerebellum of WT-C57 males, PGE2 males, WT-C57 females, and PGE2 females had active 
microglia morphology percentage values of 32.0±0.9, 30.2±2.2, 12.1±2.6, 19.8±2.3, respectively. 
There were no difference between WT males and PGE2 males (p>0.05) but PGE2 females had 
significantly greater microglial activated morphology compared to WT females (p=0.033994). 
Moreover, females had statistically lower cerebellar microglial activated morphology than males 
within the WT groups (p=0.000158) and the PGE2 groups (p=0.007888). 
For hippocampal active amoeboid microglia percentages (Fig. 6-4, F(3,8)=0.351, 
p=0.789928), there were no significant differences between PGE2 mice and WT-C57 mice  
(p=0.73294, WT=9.6±2.7, PGE2=10.8±2.2). The hippocampus of WT-C57 males, PGE2 males, 
WT-C57 females, and PGE2 females had amoeboid morphology percentages of 11.8±3.6, 
9.7±4.5, 7.1±4.3, 11.8±1.7, respectively, with no significant differences between these groups 
(p>0.05).  
Olfactory bulb active amoeboid microglia percentages (Fig. 6-4, F(3,8)=2.961, 
p=0.097613) showed no significant differences between PGE2 mice and WT-C57 mice 
(p=0.286967, WT=17.5±4.0, PGE2=21.6±2.2). The olfactory bulb of WT-C57 males, PGE2 
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males, WT-C57 females, and PGE2 females had amoeboid morphology percentages of 23.6±5.2, 
25.3±1.5, 11.4±3.9, 18.0±3.0, respectively. WT-C57 males had greater microglial activation in 
the olfactory bulb compared to WT-C57 females (p=0.046131) but there were no other 
significant differences between these groups (p>0.05).  
There were no statistical differences in prefrontal cortex active amoeboid microglia 
percentages (Fig. 6-4, F(3,8)=4.546, p=0.038563) between PGE2 mice and WT-C57 when both 
sexes were combined (p=0.361248, WT=9.5±2.8, PGE2=12.3±3.1). The prefrontal cortex of 
WT-C57 males, PGE2 males, WT-C57 females, and PGE2 females had active microglia 
percentages of 14.5±3.7, 17.6±1.9, 4.5±0.2, 7.0±4.0, respectively. Post hoc comparisons 
confirmed no significant differences between WT and PGE2-exposed mice within the male or 
female groups (p>0.05). However, post hoc analysis showed that males had greater microglial 
activation compared to females within the WT groups (p=0.039795) and PGE2 groups 
p=0.032334). 
Interestingly, percentage of active amoeboid microglia morphology in the thalamus (Fig. 
6-4, F(3,8)=4.364, p=0.04247) were overall statistically greater in PGE2 mice than WT-C57 
mice (p=0.016325, WT=5.7±1.3, PGE2=11.5±1.7). The thalamus of WT-C57 males, PGE2 
males, WT-C57 females, and PGE2 females had active microglial percentages of 8.3±0.8, 
11.6±2.4, 3.0±0.6, 11.3±2.8, respectively. There was greater microglial activation in the 
thalamus of PGE2-exposed females compared to WT-C57 females (p=0.015239). There were no 
statistical differences between the remaining comparisons (p>0.05). 
 Overall, PGE2-exposed mice at P8 had higher percentages of active amoeboid microglia 
morphology in the cerebellum and thalamus compared to WT-C57 mice in a sex-dependent 
manner, with differences between females groups reaching significance. PGE2-exposure did not 
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affect overall microglial activation percentages in the olfactory bulb, prefrontal cortex and 
hippocampus. When each sex was analyzed independently, a general trend appeared where males 
had a greater percentage of active microglia compared to females in the cerebellum, olfactory 
bulb, and prefrontal cortex. 
  
Ramified Morphology Percentages 
The percentage of ramified microglia to total microglia identified in each specified areas 
was also calculated. Two-way ANOVA analysis on ramified microglia percentages was 
conducted on each brain region of interest. 
In the cerebellum (Fig. 6-4, F(3,8)=19.568, p=0.000484), ramified microglia morphology 
percentages of PGE2 mice was not statistically different from WT-C57 mice when males and 
females were combined (p=0.20356, WT=77.9±4.6, PGE2=75.0±2.7). Investigating males and 
females of each group separately showed that the cerebellum of WT-C57 males, PGE2 males, 
WT-C57 females, and PGE2 females had ramified microglia morphology percentage values of 
68.0±0.9, 69.8±2.2, 87.9±2.6, 80.2±2.3, respectively. There were no difference between WT 
males and PGE2 males (p>0.05) but PGE2 females had significantly less ramified morphology 
compared to WT females (p=0.033994). Moreover, females had statistically greater cerebellar 
microglial ramified morphology than males within the WT groups (p=0.000158) and the PGE2 
groups (p=0.007888). 
For hippocampal ramified microglia percentages (Fig. 6-4, F(3,8)=0.351, p=0.789928), 
there were no significant differences between PGE2 mice and WT-C57 mice (p=0.73294, 
WT=90.5±2.7, PGE2=89.2±2.2). The hippocampus of WT-C57 males, PGE2 males, WT-C57 
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females, and PGE2 females had ramified morphology percentages of 88.2±3.6, 90.3±4.5, 
92.9±4.3, 88.2±1.7, respectively, with no significant differences between these groups (p>0.05).  
For olfactory bulb ramified microglia percentages (Fig. 6-4, F(3,8)=2.961, p=0.097613), 
there were no significant differences between PGE2 mice and WT-C57 mice (p=0.286967, 
WT=82.5±4.0, PGE2=78.4±2.2). The olfactory bulb of WT-C57 males, PGE2 males, WT-C57 
females, and PGE2 females had ramified morphology percentages of 76.4±5.2, 74.7±1.5, 
88.6±3.9, 82.0±3.0, respectively. WT-C57 males had fewer ramified microglia in the olfactory 
bulb compared to WT-C57 females (p=0.046131) but there were no other significant differences 
between these groups (p>0.05).  
In the prefrontal cortex (Fig. 6-4, F(3,8)=4.546, p=0.038563), no differences were found 
for ramified microglia percentages between PGE2 mice and WT-C57 (p=0.361248, 
WT=90.5±2.8, PGE2=87.7±3.1). The prefrontal cortex of WT-C57 males, PGE2 males, WT-C57 
females, and PGE2 females had ramified microglia percentages of 85.5±3.7, 82.4±1.9, 95.5±0.2, 
93.0±4.0, respectively. Post hoc comparisons confirmed no significant differences between WT 
and PGE2-exposed mice within the male or female groups (p>0.05). However, post hoc analysis 
showed that males had fewer ramified microglia compared to females within the WT groups 
(p=0.039795) and PGE2 groups p=0.032334). 
For percentages of ramified microglia morphology in the thalamus (Fig. 6-4, 
F(3,8)=4.364, p=0.04247), it was statistically less in PGE2 mice than WT-C57 mice  
(p=0.016325, WT=94.3±1.3, PGE2=88.5±1.7). The thalamus of WT-C57 males, PGE2 males, 
WT-C57 females, and PGE2 females had ramified microglia percentages of 91.6±0.8, 88.4±2.4, 
97.0±0.6, 88.7±2.8, respectively. There was less ramified microglia in the thalamus of PGE2-
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exposed females compared to WT-C57 females (p=0.015239). There were no statistical 
differences between the remaining comparisons (p>0.05). 
 Overall, the results of ramified microglia percentages complimented the amoeboid 
percentages. PGE2-exposed mice at P8 had fewer ramified microglia compared to WT-C57 in the 
cerebellum (females) and thalamus (sexes combined and females only). PGE2-exposure did not 
affect overall ramified percentages in the olfactory bulb, prefrontal cortex and hippocampus but 
when each sex was analyzed separately, a general trend appeared where males had a lower 
percentage of ramified microglia compared to females in the cerebellum, olfactory bulb, and 
prefrontal cortex.  
  
Altered Amoeboid and Ramified Microglial Morphology in COX-2- KI mice 
Amoeboid Microglial Morphology 
The percentage of active amoeboid microglia morphology was also analysed in the 
cerebellum, hippocampus, olfactory bulb, prefrontal cortex, and thalamus at P8 in the COX-2- KI 
mice and wild-type 129S6 (WT-S6) mice. Two-way ANOVA analysis on active amoeboid 
microglia percentages was conducted on each brain area. 
In the cerebellum, there were no significant differences in active amoeboid microglia 
morphology percentages (Fig. 6-5, F(3,8)=0.9335, p=0.46807). The cerebellar active microglia 
percentages of WT-S6 mice, COX-2- mice, WT-S6 males, COX-2- males, WT-S6 females, and 
COX-2- females were 31.8±6.8, 22.1±4.9, 26.4±4.1, 27.3±8.9, 37.2±13.6, 17.0±3.5, respectively.  
In the hippocampus, there were also no significant differences in active amoeboid 
microglia morphology percentages (Fig. 6-5, F(3,8)=0.6900, p=0.583399). WT-S6 mice, COX-2- 
mice, WT-S6 males, COX-2- males, WT-S6 females, and COX-2- females had hippocampal 
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active microglia percentages values of 17.9±3.7, 10.8±4.0, 16.4±5.7, 13.8±8.2, 19.3±5.8, 
7.9±1.5, respectively.  
In the olfactory bulb, there were no significant differences in active amoeboid microglia 
morphology percentages (Fig. 6-5, F(3,8)=0.962, p=0.456247). WT-S6 mice, COX-2- mice, WT-
S6 males, COX-2- males, WT-S6 females, and COX-2- females had microglial activation values 
in the olfactory bulb of 22.8±3.8, 16.3±4.3, 20.0±6.7, 20.8±7.8, 25.7±4.3, 11.9±3.4, respectively. 
In the prefrontal cortex (Fig. 6-5, F(3,8)=4.832, p=0.033271), the microglial activation of 
COX-2- KI mice was statistically less than WT-S6 mice when both sexes were considered 
(p=0.028123, WT=15.2±1.8, KI=9.4±1.9). The prefrontal cortex of WT-S6 males, COX-2- 
males, WT-S6 females, and COX-2- females had active microglia percentages of 12.9±1.6, 
12.9±0.8, 17.4±3.1, 6.0±2.4, respectively. Post hoc comparisons showed that COX-2- KI females 
had a statistically lower percentage of active microglia than WT-S6 females (p=0.005492), but 
there were no other significant differences between the groups (p>0.05). 
In the thalamus, there were no significant differences in active amoeboid microglia 
morphology percentages (Fig. 6-5, F(3,8=0.814, p=0.521383). The thalamic active microglia 
percentages of WT-S6 mice, COX-2- mice, WT-S6 males, COX-2- males, WT-S6 females, and 
COX-2- females were 9.8±0.6, 9.6±2.5, 9.9±1.1, 12.3±4.4, 9.8±0.8, 6.8±1.9, respectively.  
 Overall, COX-2- KI mice at P8 had a lower percentage of active microglia only in the 
prefrontal cortex compared to WT-S6 mice, which was specific to female mice. Disruption of 
COX-2 did not statistically affect the percentage of amoeboid microglia in the cerebellum, 
hippocampus, olfactory bulb, and thalamus. COX-2- KI did not lead to sex-dependent effects on 
microglial activation. 
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Ramified Microglial Morphology 
The percentage of ramified microglia morphology was also determined in the cerebellum, 
hippocampus, olfactory bulb, prefrontal cortex, and thalamus at P8 in the COX-2- KI mice and 
wild-type 129S6 (WT-S6) mice. Two-way ANOVA analysis on ramified microglia percentages 
was conducted on each brain area. 
In the cerebellum, there were no significant differences in ramified microglia morphology 
percentages (Fig. 6-5, F(3,8)=0.9335, p=0.46807). The cerebellar active microglia percentages of 
WT-S6 mice, COX-2- mice, WT-S6 males, COX-2- males, WT-S6 females, and COX-2- females 
were 68.2±6.8, 77.9±4.9, 73.6±4.1, 72.7±8.9, 62.8±13.6, 83.0±3.5, respectively.  
In the hippocampus, there were also no significant differences in ramified microglia 
morphology percentages (Fig. 6-5, F(3,8)=0.6900, p=0.583399). WT-S6 mice, COX-2- mice, 
WT-S6 males, COX-2- males, WT-S6 females, and COX-2- females had hippocampal ramified 
microglia percentages values of 82.1±3.7, 89.2±4.0, 83.6±5.7, 86.2±8.2, 80.7±5.8, 92.1±1.5, 
respectively.  
In the olfactory bulb, there were no significant differences in ramified microglia 
morphology percentages (Fig. 6-5, F(3,8)=0.962, p=0.456247). WT-S6 mice, COX-2- mice, WT-
S6 males, COX-2- males, WT-S6 females, and COX-2- females had microglial activation values 
in the olfactory bulb of 77.2±3.8, 83.7±4.3, 80.0±6.7, 79.2±7.8, 74.3±4.3, 88.1±3.4, respectively. 
In the prefrontal cortex (Fig. 6-5, F(3,8)=4.832, p=0.033271) the percentage of ramified 
microglia in COX-2- KI mice was statistically greater than WT-S6 mice (p=0.028123, 
WT=84.8±1.8, COX-2=90.6±1.9). The prefrontal cortex of WT-S6 males, COX-2- males, WT-
S6 females, and COX-2- females had active microglia percentages of 87.1±1.6, 87.1±0.8, 
82.6±3.1, 94.0±2.4, respectively. Post hoc comparisons showed that COX-2- females had a 
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statistically more ramified microglia than WT-S6 females (p=0.005492), but there were no other 
significant differences between the groups (p>0.05). 
In the thalamus, there were no significant differences in ramified microglia morphology 
percentages (Fig. 6-5, F(3,8=0.814, p=0.521383). The thalamic active microglia percentages of 
WT-S6 mice, COX-2- mice, WT-S6 males, COX-2- males, WT-S6 females, and COX-2- females 
were 90.2±0.6, 90.4±2.5, 90.1±1.1, 87.7±4.4, 90.2±0.8, 93.2±1.9, respectively.  
 Overall, COX-2- KI mice at P8 had a greater percentage of ramified microglia only in the 
prefrontal cortex compared to WT-S6 mice, specifically in female mice. Disruption of COX-2 
did not statistically affect the percentage of ramified microglia in the cerebellum, hippocampus, 
olfactory bulb, and thalamus. No statistical differences in ramified microglial percentages were 
quantified between males and females within the WT-S6 or COX-2- KI groups. 
 
PGE2-exposed offspring mice display altered number of primary microglial branches 
It is well established that the morphology of microglia and their function are highly 
connected (Cho and Choi, 2017, Karperien et al., 2013). Although basic microglia function can 
be informed through the phenotypic categorization of cells as ramified or amoeboid, 
quantification of more subtle structural features including branching and process length could 
help explain the functional complexities of microglia, particularly during development 
(Karperien et al., 2013, Tremblay, 2011). To determine if PGE2 exposure could affect microglial 
morphology, we quantified branch density in microglia (defined as the number of primary 
branches directly protruding from the soma) in the cerebellum, hippocampus, olfactory bulb, 
prefrontal cortex, and thalamus at P8 (Fig. 6-6). Two-way ANOVA analysis on the number of 
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branches per microglia was conducted in each brain region comparing PGE2-exposed mice and 
wild-type C57bl/6 (WT-C57). 
In the cerebellum (Fig. 6-6, F(3,989)=8.538, p=0.000013), the number of branches per 
microglia in PGE2 mice was not significantly different than WT-C57 mice (p=0.291890, 
WT=1.8±0.1, PGE2=2.0±0.1). When males and females within each group were independently 
investigated, the average branch numbers per microglia in the cerebellum of WT-C57 males, 
PGE2 males, WT-C57 females, and PGE2 females were 1.6±0.1, 1.7±0.1, 1.9±0.1, 2.2±0.1, 
respectively. Post hoc comparisons revealed that PGE2 females had greater microglial branching 
compared to WT-C57 females (p=0.010423). Females also had a greater number of microglial 
branches than males within both the WT-C57 (p=0.031729) and PGE2 groups (p=0.000037).   
Hippocampal microglial branching (Fig. 6-6, F(3, 1026)=3.936, p=0.00831) was 
significantly less in PGE2 mice compared to WT-C57 mice (p=0.015154, WT=2.4±0.1, 
PGE2=2.2±0.1). The average number of microglia branches in the hippocampus of WT-C57 
males, PGE2 males, WT-C57 females, and PGE2 females were 2.3±0.1, 2.1±0.1, 2.5±0.1, 
2.3±0.1, respectively, but there were no significant differences between these groups (p>0.05). 
For olfactory bulb microglial branching (Fig. 6-6, F(3, 1043)=4.214, p=0.005659), there 
were no significant difference between PGE2 mice and WT-C57 mice (p=0.284694, 
WT=2.1±0.1, PGE2=2.0±0.1). The average number of branches per microglia in the olfactory 
bulb of WT-C57 males, PGE2 males, WT-C57 females, and PGE2 females were 1.8±0.1, 
1.8±0.1, 2.1±0.1, 2.0±0.1, respectively. WT-C57 females had greater microglial branching than 
WT-C57 males (p=0.015432). However, there were no other significant differences between 
these groups (p>0.05).  
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Prefrontal cortex microglial branch numbers (Fig. 6-6, F(3, 1267)=2.148, p<0.0001) 
showed no statistical differences between PGE2 mice and WT-C57 mice (p=0.203660, 
WT=2.1±0.1, PGE2=2.2±0.1). The prefrontal cortex of WT-C57 males, PGE2 males, WT-C57 
females, and PGE2 females had microglial branch numbers of 2.0±0.1, 2.0±0.1, 2.2±0.1, 2.5±0.1 
respectively. PGE2 females had greater microglial branching compared to WT-C57 females 
(p=0.000803), and also greater microglial branching when compared to PGE2 males (p<0.0001).  
For microglial branching in the thalamus (Fig. 6-6, F(3,1718)=2.786, p=0.039456), it was 
statistically less in PGE2 mice than WT-C57 mice (p=0.010983, WT=2.2±0.04, PGE2=2.1±0.04). 
The thalamus of WT-C57 males, PGE2 males, WT-C57 females, and PGE2 females had 
microglial branch numbers of 2.3±0.1, 2.1±0.1, 2.2±0.04, 2.1±0.1, respectively. There was 
decreased microglial branching in the thalamus of PGE2 males compared to WT-C57 males 
(p=0.027548). There were no statistical differences between the remaining comparisons 
(p>0.05). 
 Overall, PGE2-exposed mice at P8 had decreased microglial branching in the 
hippocampus and thalamus compared to WT-C57 mice. Within the thalamus, decreased 
microglial branching was prominent in PGE2 males compared to WT-C57 males. PGE2-exposure 
did not seem to statistically affect microglial branching in the cerebellum, olfactory bulb, and 
prefrontal cortex. However, when each sex was analyzed independently, PGE2 females had 
greater branching compared to WT-C57 females in the cerebellum and prefrontal cortex. 
Moreover, sex differences revealed that statistically greater microglial branching was seen in 
females compared to males in the cerebellum (WT-C57 and PGE2 groups), olfactory bulb (WT-
C57), and prefrontal cortex (PGE2).  
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COX-2- KI mice display increased microglial branch density 
To determine if deficient COX-2 activity could affect microglial branch density, the 
number of primary branches per microglia was quantified in the cerebellum, hippocampus, 
olfactory bulb, prefrontal cortex, and thalamus of P8 COX-2- KI mice. Whether differences 
occurred between COX-2- KI mice and wild-type 129S6 (WT-S6) mice, and between males and 
females, was evaluated. Two-way ANOVA analysis on the number of primary branches per 
microglia was conducted on each brain area. 
In the cerebellum (Fig. 6-7, F(3,1214)=15.631, p<0.0001), the number of branches per 
microglia in COX-2- KI mice was significantly greater than WT-S6 mice (p<0.0001, 
WT=1.3±0.04, COX-2=1.6±0.04). When males and females within each group were 
independently investigated, the average branch numbers per microglia in the cerebellum of WT-
S6 males, COX-2- males, WT-S6 females, and COX-2- females were 1.5±0.1, 1.6±0.1, 1.1±0.1, 
1.5±0.1, respectively. Post hoc comparisons revealed that COX-2- females had greater microglial 
branching compared to WT-S6 females (p<0.0001). Males had a greater number of microglial 
branches than females, which was statistically different in WT-S6 mice (p<0.0001).   
Hippocampal microglial branching (Fig. 6-7, F(3, 816)=5.368, p=0.001157) was 
significantly greater in COX-2- KI mice compared to WT-S6 mice (p=0.000079, WT=2.0±0.1, 
COX-2=2.3±0.04). The average number of microglia branches in the hippocampus of WT-S6 
males, COX-2- males, WT-S6 females, and COX-2- females were 2.0±0.1, 2.4±0.1, 2.0±0.1, 
2.3±0.1, respectively. Both COX-2- KI males (p=0.004880) and COX-2- females (p=0.005218) 
had statistically higher microglial branches compared to sex-specific WT-S6 controls.  
For olfactory bulb microglial branching (Fig. 6-7, F(3, 1487)=0.501, p=0.68191), there 
was no significant difference in between COX-2- KI mice and WT-S6 mice (p=0.29900, 
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WT=1.8±0.04, COX-2=1.9±0.03). The average number of branches per microglia in the 
olfactory bulb of WT-S6 males, COX-2- males, WT-S6 females, and COX-2- females were 
1.8±0.1, 1.9±0.1, 1.8±0.1, 1.9±0.1, respectively, with no significant differences between these 
groups (p>0.05).  
In the prefrontal cortex (Fig. 6-7, F(3, 1092)=6.817, p=0.000149), there was statistically 
higher microglial branching in COX-2- KI mice compared to WT-S6 mice (p=0.000060, 
WT=1.8±0.04, COX-2=2.1±0.04). The prefrontal cortex of WT-S6 males, COX-2- males, WT-
S6 females, and COX-2- females had microglial branch numbers of 1.9±0.1, 2.1±0.1, 1.7±0.1, 
2.0±0.1, respectively. COX-2- males (p=0.041613) and COX-2- females (p=0.000286) had 
greater microglial branching compared to sex-specific WT-S6 controls. Males had a greater 
number of microglial branches than females, which was statistically different in WT-S6 mice 
(p=0.02295).   
Microglial branching in the thalamus (Fig. 6-7, F(3, 1493)=8.165, p<0.0001) of COX-2- 
KI mice was not statistically different than WT-S6 mice (p=0.204093, WT=2.0±0.04, COX-
2=2.1±0.04). WT-S6 males, COX-2- males, WT-S6 females, and COX-2- females had microglial 
branch numbers of 2.2±0.1, 2.0±0.1, 1.8±0.1, 2.1±0.1, respectively. However, analyizing males 
and females independently revealed an increase in microglial branching in the thalamus of COX-
2- females compared to WT-S6 females (p=0.000186). WT-S6 males had greater microglial 
branches than WT-S6 females (p<0.0001).   
 Overall, COX-2- KI mice at P8 had increased microglial branching in the cerebellum, 
hippocampus, olfactory bulb, prefrontal cortex and thalamus compared to WT-S6 mice. COX-2-
deficiency did not seem to affect microglial branching in the olfactory bulb. Analysis on sex 
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differences revealed statistically greater microglial branching in WT-S6 males compared to WT-
S6 females in the cerebellum, prefrontal cortex, and thalamus.  
 
PGE2-exposed offspring mice display decreased microglial branch lengths 
In addition to the number of microglial branches, the length of microglial branches has 
also been shown to be indicative of their function and state (Cho and Choi, 2017, Karperien et 
al., 2013). The length of the longest process (μm) was measured for each identified microglia 
(Fig. 6-8). To determine if maternal exposure to PGE2 affects microglial branch lengths, 
measurements were conducted in the cerebellum, hippocampus, olfactory bulb, prefrontal cortex, 
and thalamus at P8. We examined differences between PGE2-exposed mice and wild-type 
C57bl/6 (WT-C57) mice, and between males and female using two-way ANOVA analysis on the 
microglial branch lengths in each brain region. 
In the cerebellum (Fig. 6-8, F(3,989)=14.754, p<0.0001), the branch lengths of microglia 
in PGE2 mice were not significantly different than WT-C57 mice (p=0.87625, WT=10.0±0.3, 
PGE2=9.6±0.3). Males and females within each group were also independently investigated. The 
average branch length per microglia in the cerebellum of WT-C57 males, PGE2 males, WT-C57 
females, and PGE2 females were 8.0±0.5, 8.4±0.4, 10.9±0.3, 10.6±0.3, respectively. Post hoc 
comparisons revealed that females had greater microglial branch lengths compared to males 
within the WT-C57 (p<0.0001) and PGE2 groups (p<0.0001). 
Hippocampal microglial branch lengths (Fig. 6-8, F(3,1026)=15.431 p<0.0001) were 
significantly less in PGE2 mice compared to WT-C57 mice (p<0.0001, WT=15.4±0.3, 
PGE2=13.2±0.3). The average microglial branch length in the hippocampus of WT-C57 males, 
PGE2 males, WT-C57 females, and PGE2 females were 14.0±0.4, 14.0±0.5, 16.4±0.4, 12.6±0.4, 
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respectively. PGE2 females had shorter hippocampal microglial branch lengths compared to WT-
C57 females (p<0.0001). WT-C57 females had greater branch lengths than WT-C57 males 
(p<0.0001). In contrast, PGE2 females had shorter branch lengths than PGE2 males 
(p=0.020297).   
In the olfactory bulb (Fig. 6-8, F(3, 1043)=7.627, p<0.0001), there was no significant 
difference in microglial branch lengths between PGE2 mice and WT-C57 mice (p=0.719, 
WT=10.8±0.3, PGE2=10.1±0.3). The average branch length per microglia in the olfactory bulb 
of WT-C57 males, PGE2 males, WT-C57 females, and PGE2 females were 8.9±0.5, 10.3±0.4, 
11.6±0.3, 9.9±0.4, respectively. PGE2 females had greater microglial branch lengths than WT-
C57 females (p<0.0001). WT-C57 females also had longer microglial branches compared to 
WT-C57 males (p<0.0001). 
For the average branch lengths of microglia in the prefrontal cortex (Fig. 6-8, F(3, 
1267)=13.563, p<0.0001), PGE2 mice had shorter branch lengths than WT-C57 mice (p<0.0001, 
WT=15.6±0.3, PGE2=13.6±0.3). The prefrontal cortex of WT-C57 males, PGE2 males, WT-C57 
females, and PGE2 females had microglial branch lengths of 14.0±0.5, 13.9±0.4, 16.9±0.5, 
13.3±0.4, respectively. PGE2 females had shorter microglial branch lengths compared to WT-
C57 females (p<0.0001) in the prefrontal cortex. WT-C57 females also had greater microglial 
branch lengths compared to WT-C57 males (p<0.0001).  
In the thalamus (Fig. 6-8, F(3,1718)=25.87, p<0.0001), microglial branch lengths of 
PGE2 mice was also statistically shorter than WT-C57 mice (p<0.0001, WT=16.8±0.3, PGE2 
=14.1±0.2). The thalamus of WT-C57 males, PGE2 males, WT-C57 females, and PGE2 females 
had microglial branch lengths of 15.3±0.5, 14.8±0.4, 17.6±0.3, 13.4±0.3, respectively. There 
were decreased microglial branch lengths in the thalamus of PGE2 females compared to WT-C57 
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females (p<0.0001). WT-C57 females also had longer microglial branch lengths compared to 
WT-C57 males (p<0.0001). In contrast, PGE2 females had shorter microglial branch lengths 
compared to PGE2 males in the thalamus (p=0.005841). 
 Overall, PGE2-exposed mice at P8 had decreased microglial branch lengths in the 
hippocampus, prefrontal cortex, and thalamus compared to WT-C57 mice. Closer examination of 
each group by independently investigating both sexes revealed that PGE2 females had shorter 
microglial branch lengths than WT-C57 females in the mentioned areas as well as in the 
olfactory bulb. PGE2-exposure did not seem to statistically affect average microglial branch 
length in the cerebellum. Sex difference analyses within the WT-C57 group showed that 
statistically longer microglial branch lengths were seen in females compared to males in all areas 
quantified: cerebellum, hippocampus, olfactory bulb, prefrontal cortex, and thalamus. Sex 
difference analyses within the PGE2 group also showed females had increased microglial branch 
lengths in the cerebellum compared to males. However, shorter microglial branch lengths were 
found in PGE2 females compared to PGE2 males in the hippocampus and thalamus. 
 
COX-2- KI mice show increased microglial branch lengths 
To determine if COX-2-deficiency could affect microglial morphological characteristics, 
the length of the longest branch (μm) of each microglia was quantified in the cerebellum, 
hippocampus, olfactory bulb, prefrontal cortex, and thalamus of COX-2- KI mice at P8. Potential 
differences between COX-2- KI mice and wild-type 129S6 (WT-S6) mice, and between males 
and female, were examined. Two-way ANOVA analysis on the microglial branch lengths was 
conducted on each brain area.  
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In the cerebellum (Fig. 6-9, F(3,1214)=17.405, p<0.0001) the longest branch length per 
microglia in COX-2- KI mice was significantly longer than WT-S6 mice (p<0.0001, 
WT=6.7±0.2, COX-2=9.6±0.3). Males and females within each group were also independently 
investigated. The average branch length per microglia in the cerebellum of WT-S6 males, COX-
2- males, WT-S6 females, and COX-2- females were 6.6±0.3, 9.1±0.3, 6.9±0.3, 9.3±0.4, 
respectively. Post hoc comparisons revealed that COX-2- males (p<0.0001) and COX-2- females 
(p<0.0001) had greater microglial branch lengths compared to sex-specific controls. Males and 
females did not have significant different cerebellar microglial branch lengths within the WT-S6 
or COX-2- KI groups (p>0.05). 
Hippocampal microglial branch lengths (Fig. 6-9, F(3,816)=18.592, p<0.0001) were 
significantly greater in COX-2- KI mice compared to WT-S6 mice (p<0.0001, WT=10.7±0.4, 
COX-2=13.6±0.3). The average microglial branch length in the hippocampus of WT-S6 males, 
COX-2- males, WT-S6 females, and COX-2- females were 9.5±0.5, 14.6±0.5, 13.0±0.8, 
12.8±0.4, respectively. COX-2- males had longer hippocampal microglial branch lengths 
compared to WT-S6 males (p<0.0001). WT-S6 females had greater branch lengths than WT-S6 
males (p=0.000046). In contrast, COX-2- females had shorter branch lengths than COX-2- males 
(p=0.005239).   
In the olfactory bulb (Fig. 6-9, F(3, 1487)=3.478, p=0.015456), microglial branch lengths 
were longer in COX-2- KI mice compared to WT-S6 mice (p=0.002238, WT=10.0±0.2, COX-
2=11.1±0.3). The average branch length per microglia in the olfactory bulb of WT-S6 males, 
COX-2- males, WT-S6 females, and COX-2- females were 9.6±0.6, 11.2±0.4, 10.6±0.3, 
11.0±0.3, respectively. COX-2- males had greater microglial branch lengths than WT-S6 males 
(p=0.003560). There were no other significant differences between the groups (p>0.05). 
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For average branch lengths of microglia in the prefrontal cortex (Fig. 6-9, F(3, 
1092)=19.742, p<0.0001), it was greater in COX-2- KI mice than in WT-S6 mice (p<0.0001, 
WT=11.5±0.3, COX-2=14.8±0.3). The prefrontal cortex of WT-S6 males, COX-2- males, WT-
S6 females, and COX-2- females had microglial branch lengths of 11.0±0.4, 15.0±0.5, 12.1±0.5, 
14.7±0.4, respectively. COX-2- males (p=0.000065) and COX-2- females (p<0.0001) had longer 
microglial branch lengths in the prefrontal cortex compared to sex-specific WT-S6 controls. 
There were no differences in prefrontal cortex microglial branch lengths between males and 
females in the COX-2- KI or WT-S6 control groups (p=0.05). 
In the thalamus (Fig. 6-9, F(3,1493)=10.983, p<0.0001), COX-2- KI mice had 
statistically longer microglial branches than WT-S6 mice (p=0.005908, WT=13.4±0.3, COX-
2=14.7±0.3). The thalamus of WT-S6 males, COX-2- males, WT-S6 females, and COX-2- 
females had microglial branch lengths of 12.2±0.4, 15.2±0.4, 14.9±0.5, 14.2±0.4, respectively. 
There were significantly increased microglial branch lengths in the thalamus of COX-2- males 
compared to WT-S6 males (p<0.0001). WT-S6 females also had longer microglial branch 
lengths compared to WT-S6 males (p<0.0001).  
 Overall, an opposite trend was seen in the COX-2- KI mouse model compared to PGE2-
exposed model. COX-2- KI mice had increased microglial branch lengths compared to WT-S6 
mice in all the areas examined: cerebellum, hippocampus, olfactory bulb, prefrontal cortex, and 
thalamus. Elevated microglial branch lengths were pronounced in COX-2- males. Sex difference 
analyses within the WT-S6 group showed that statistically longer microglial branch lengths were 
seen in females compared to males in the hippocampus and thalamus. However, shorter 
microglial branch lengths were found in COX-2- females compared to COX-2- males in the 
hippocampus. 
261 
 
6.5. Discussion 
In this study, using two distinct mice model systems we show for the first time that 
abnormal COX-2/PGE2 signalling during development affects microglial density and 
morphology in mice at P8. Offspring from the PGE2-exposed model, where a single maternal 
injection of PGE2 was administered during pregnancy at E11, elevated microglial density as well 
as an increase in amoeboid and decrease in ramified morphology, with region-specific alterations 
in the number of microglial branches and decreased process lengths. In the COX-2-deficient 
model, COX-2- KI mice also had a higher density of microglia but a lower percentage of cells 
were in the active amoeboid state and a higher percentage of cells were ramified. Microglia in 
COX-2- KI mice also showed increased branching and elevated process lengths compared to 
control mice in a region-specific and sex-dependent manner. 
These findings could have implications for brain development and pathologies of 
neurodevelopmental disorders such as autism spectrum disorders (ASDs). As previously 
mentioned, defects in the COX-2/PGE2 signalling pathway due to genetic or environmental risk 
factors have been documented in many clinical cases of ASDs, resulting in an increase or 
decrease in the level of PGE2 or its metabolites (Wong et al., 2015, Wong and Crawford, 2014, 
Tamiji and Crawford, 2010). Investigations into the molecular impact of abnormal PGE2 levels 
on neurodevelopment have only recently begun. For example, current in vitro and in vivo 
research from our lab (Rai-Bhogal et al., 2018, Rai‐Bhogal et al., 2018, Davidson et al., 2016, 
Wong et al., 2016, Wong et al., 2014, Tamiji and Crawford, 2010) and others (Hoffman et al., 
2016, Dean et al., 2012, Dean et al., 2012, Wright and McCarthy, 2009) provide insight on the 
impact disrupted PGE2 levels (high or low) have in the developing brain. More recently, we also 
confirmed that PGE2-exposed and COX-2-deficient mice both exhibit autism-like behaviours 
262 
 
that are sex-dependent (Wong et al., 2019, Wong et al., 2017). Below, we discuss the effect of 
abnormal PGE2 levels on microglial morphology in two model systems and potential  
physiological and pathological implications for the developing brain. 
 
PGE2 exposure and COX-2-deficiency led to increased microglial density 
 First, we showed that an abnormal level of PGE2 in either the PGE2-exposed or COX-2-
deficient model resulted in increased microglial density. Microglial density was increased in the 
cerebellum, olfactory bulb, and thalamus of PGE2-exposed mice and in the cerebellum, olfactory 
bulb, and prefrontal cortex of COX-2-deficient mice. In the healthy brain, microglial cells are 
present in all regions (Lawson et al., 1990) and their density may increase in response to immune 
mediators (Chan et al., 2007, Rezaie et al., 2005). In addition to its role in innate immunity, 
microglia also have developmental functions in the CNS including involvement in neuronal 
activity and communication with astrocytes (Eyo and Wu, 2013, Tremblay et al., 2010, Wake et 
al., 2009, Pocock and Kettenmann, 2007, Nimmerjahn et al., 2005). Research shows that an 
increase in microglial density was correlated with disrupted proliferation of neural progenitors 
and inhibition of neuronal differentiation in the early postnatal developing brain and adult brain 
(Appel et al., 2018, Smith et al., 2014). Elevated microglial density has also been previously 
linked to abnormal neuron dendrites with reduced dendritic spine density (Appel et al., 2018). 
Interestingly, greater microglial density was demonstrated in the cerebral cortex, prefrontal 
cortex and cerebellum in individuals with autism, from childhood to into early adulthood (Suzuki 
et al., 2013, Tetreault et al., 2012, Morgan et al., 2010, Vargas et al., 2005, Blaylock, 2004), 
which were also seen in our PGE2-exposed and COX-2-deficient models in this study.  
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PGE2-exposure changes morphological features of microglia: increased amoeboid phenotype, 
decreased branching, and decreased process lengths 
In addition to increased microglia density, the microglia in PGE2-exposed mice had 
increased amoeboid phenotype, decreased branching, and decreased process lengths in various 
brain regions. Retraction and thickening of processes represents a shift towards activated 
amoeboid microglial morphology (Ransohoff and Perry, 2009). These morphological changes 
have been associated with irregular genesis, development, and function of neurons (Appel et al., 
2018, Smith et al., 2014). Furthermore, amplified microglial activation along with decreased 
branching and process lengths have been morphologically characterized in autism (Suzuki et al., 
2013, Tetreault et al., 2012, Morgan et al., 2010, Vargas et al., 2005, Blaylock, 2004). These 
differences in microglial morphology may contribute to disrupted neuronal proliferation, 
migration, and differentiation we previously described in this abnormal PGE2 model (Wong et 
al., 2019), Rai-bhogal et al., unpublished). 
 
COX-2-deficient changes morphological features of microglia: increased ramified phenotype, 
increased branching, and increased process lengths 
In contrast, elevated microglial density in the COX-2-deficient model was accompanied 
by a lower percentage of microglia with amoeboid morphology. An increase in ramified 
morphology (with statistical significance in the prefrontal cortex), together with increased 
branching and process lengths was characterized in COX-2- KI mice compared to control mice in 
all regions investigated. 
Interestingly, ramified microglia previously categorized as “resting” microglia have 
emerged as one of the most functionally and structurally dynamic cells in the nervous system 
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(Tremblay, 2011). They have roles in neurogenesis, differentiation of astrocytes, 
oligodendrocytes, and neurons, synaptic development, as well as axonal pruning and myelination 
(Menassa and Gomez-Nicola, 2018, Ji et al., 2013, Miron et al., 2013, Schafer et al., 2012, 
Paolicelli et al., 2011, Sierra et al., 2010). Ramified microglial cells are highly motile; they 
continually survey the environment and screen the complete brain parenchyma once every few 
hours (Nimmerjahn et al., 2005). They are important effectors of neuronal circuit reorganization 
by interacting and eliminating neuronal synaptic structures (Tremblay, 2011). An abnormal 
increase in ramified microglia could contribute to deficiencies in normal neuron-microglia 
communication, leading to impaired functional brain connectivity and abnormal social behaviour 
(Zhan et al., 2014), which are hallmarks of ASDs (Ha et al., 2015, Kana et al., 2014). Moreover, 
under non-pathological conditions, there is a gradual decrease in amoeboid microglia with a 
concomitant increase in ramified microglia as postnatal brain development progresses (Kaur et 
al., 2017, Zusso et al., 2012, Prinz and Mildner, 2011, Schlegelmilch et al., 2011). An untypical 
elevated percentage of ramified microglia could signify accelerated microglial development, 
which has been associated with autism (Hanamsagar et al., 2017). Thus, the increase in ramified 
microglia and related morphological changes quantified in COX-2- KI mice could disturb the 
diverse, developmental functions of these cells. 
 
Sex differences in PGE2 exposure and WT-C57 mouse model 
Clear sex differences were observed in the PGE2-exposed and WT-C57 model system. In 
general, control males had a significantly higher percentage of morphologically active amoeboid 
microglia with less branch numbers and shorter process lengths compared to control females. 
Our findings are in line with past research that described greater amoeboid morphology in males, 
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indicative of increased microglial activation or possibly a more immature phenotype (Villa et al., 
2018, Hanamsagar et al., 2017, Werling et al., 2016, Lenz et al., 2013, Schwarz et al., 2012). 
Female microglia have been found to reach a more mature, ramified microglial phenotype earlier 
compared to males (Hanamsagar et al., 2017).  
Interestingly, microglial morphological differences were identified most frequently in 
PGE2-exposed females when compared to controls. In the cerebellum and thalamus, PGE2 
exposure to females resulted in a greater proportion of morphologically active amoeboid 
microglia, previously described as a more “male” microglial morphologic profile (Lenz et al., 
2013). This finding complements existing work completed in the preoptic area, which showed 
PGE2 treatment masculinized and increased the active microglial morphologic profile in females 
(Lenz et al., 2013). Our results offer new evidence that PGE2 levels could influence male 
specificity.  
 
Sex differences in COX-2-deficient and WT-S6 mouse model 
We found that COX-2-deficiency led to various effects on microglial density and 
morphology, which were both sex-dependent and region-specific. For example, COX-2- males 
displayed increased microglial density in the cerebellum and increased branch lengths in the 
hippocampus. On the other hand, COX-2- females had increased microglial density in the 
olfactory bulb and prefrontal cortex, as well as decreased amoeboid and increased ramified 
microglia in the prefrontal cortex. Our diverse findings allude to a complex interaction between 
sex and microglia. Indeed, the well-documented sexually dimorphic impact on microglia is 
multifaceted and encompasses differences in homeostatic and inflammatory-induced 
transcriptional and translational expression profiles, maturation, function, and immune reactivity 
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to environmental challenges (Dubbelaar et al., 2018, Guneykaya et al., 2018, Thion et al., 2018, 
Villa et al., 2018, Wood, 2018, Hanamsagar et al., 2017, Mangold et al., 2017, Crain et al., 
2013). How these sex-dependent differences are programmed remains to be determined. One 
explanation may be though the action of estradiol, an important steroid sex hormone that 
influences sex differentiation in the brain (McCarthy, 2008). COX-2/PGE2 signalling and 
estradiol can interact to effect neuron morphology and function, microglial activity, 
neuroinflammatory responses, and sex behaviour (Pedersen and Saldanha, 2017, Shridharan et 
al., 2016, Stacey et al., 2016, Lenz et al., 2013, Dean et al., 2012, Schwarz and McCarthy, 2008, 
Amateau and McCarthy, 2004, Ospina et al., 2004). It is possible that crosstalk between 
abnormal COX-2/PGE2 signalling and sex-dependent levels of estradiol might contribute to the 
sex-specific changes in microglial density and morphology observed in our study. 
 
6.6. Conclusions 
Although the role of microglia in neuroinflammation in the adult brain has been studied 
extensively, the involvement of microglia during neurodevelopment is being progressively 
recognized. Our study shows that modification of PGE2 levels results in augmented sex-
dependent differences in microglial density and altered microglial morphology in ASD-
associated brain regions including the cerebellum, hippocampus, olfactory bulb, prefrontal 
cortex, and thalamus. Our findings provide further evidence that microglia could respond to 
environmental and genetic insults in a sex-dependent manner. As described in our previous 
review articles, various genetic and environmental risk factors that influence the level of PGE2 
during prenatal development have been associated with ASDs (Wong et al., 2015, Wong et al., 
2014, Tamiji and Crawford, 2010). The results in this current study provide new evidence that 
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prenatal deviations in COX-2/PGE2 signalling can also disrupt microglial function, which in turn 
may affect normal brain development. 
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6.7. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6-1: Brain areas visualized and quantified. Sagittal slices of brain samples were used to 
quantify the (1) cerebellum, (2) hippocampus, (3) olfactory bulb, (4) thalamus, and (5) prefrontal 
cortex (outlined in red). Scale bar represents 500μm. 
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Fig. 6-2: Microglial cell densities in PGE2 -exposed mice.  
Microglial densities were quantified in the cerebellum, hippocampus, olfactory bulb, prefrontal 
cortex, and thalamus. Means represent at least 3 independent animals for each experimental 
group. Data are presented as mean ±SEM, *p<0.05, **p<0.01, ***p<0.001.   
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Fig. 6-3: Microglial densities in COX-2- mice.  
Microglial densities were quantified in the cerebellum, hippocampus, olfactory bulb, prefrontal 
cortex, and thalamus. Means represent at least 3 independent animals for each experimental 
group. Data are presented as mean ±SEM, *p<0.05, **p<0.01, ***p<0.001.   
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Fig. 6-4: Microglial amoeboid/ramified morphology percentages in PGE2 -exposed mice.   
Stained microglia were characterized as ramified or active amoeboid cells. The percentage of 
amoeboid microglia was determined in the cerebellum, hippocampus, olfactory bulb, prefrontal 
cortex, and thalamus. Amoeboid percentages for each area were calculated by taking the number 
of amoeboid microglia and dividing it by the total number of microglia counted.  Ramified 
percentages were also determined. Scale bars represent 10μm in examples of amoeboid and 
ramified microglia. Means represent at least 3 independent animals for each experimental group. 
Data are presented as mean ±SEM, *p<0.05, **p<0.01, ***p<0.001.   
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Fig. 6-5: Microglial amoeboid/ramified morphology percentages in COX-2- mice.  
The percentage of amoeboid microglia was determined in the cerebellum, hippocampus, 
olfactory bulb, prefrontal cortex, and thalamus. Amoeboid percentages for each area were 
calculated by taking the number of amoeboid microglia and dividing it by the total number of 
microglia counted. Ramified percentages were also determined. Scale bars represent 10μm in 
examples of amoeboid and ramified microglia. Means represent at least 3 independent animals 
for each experimental group. Data are presented as mean ±SEM, *p<0.05, **p<0.01, 
***p<0.001.    
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Fig. 6-6: Microglial branching in PGE2 -exposed mice.  
The average number of primary branches per microglia was determined in the cerebellum, 
hippocampus, olfactory bulb, prefrontal cortex, and thalamus. In the example of branch number 
quantification, arrows signify the number of branches counted; scale bar represents 10μm. Means 
represent quantifications from at least 3 independent animals for each experimental group. A 
total of 6063 cells were quantified. Data are presented as mean ±SEM, *p<0.05, **p<0.01, 
***p<0.001.    
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Fig. 6-7: Microglial branching in COX-2- mice.  
The average number of primary branches per microglia was determined in the cerebellum, 
hippocampus, olfactory bulb, prefrontal cortex, and thalamus. Means represent quantifications 
from at least 3 independent animals for each experimental group. A total of 6122 cells were 
quantified. Data are presented as mean ±SEM, *p<0.05, **p<0.01, ***p<0.001.    
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Fig. 6-8: Microglial branch lengths in PGE2 -exposed mice.  
The average of the longest branch length per microglia was determined in the cerebellum, 
hippocampus, olfactory bulb, prefrontal cortex, and thalamus. In the example of branch length 
quantification, yellow line signifies the longest branch quantified; scale bar represents 10μm. 
Means represent quantifications from at least 3 independent animals for each experimental 
group. A total of 6063 cells were quantified. Data are presented as mean ±SEM, *p<0.05, 
**p<0.01, ***p<0.001.     
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Fig. 6-9: Microglial branch lengths in COX-2- mice.  
The average of the longest branch length per microglia was determined in the cerebellum, 
hippocampus, olfactory bulb, prefrontal cortex, and thalamus. Means represent quantifications 
from at least 3 independent animals for each experimental group. A total of 6122 cells were 
quantified. Data are presented as mean ±SEM, *p<0.05, **p<0.01, ***p<0.001.    
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CHAPTER 7.  
Study 5: Autism-related Behaviours in the Cyclooxygenase-2-deficient Mouse Model 
 
Manuscript 7 Citation (Copyright Permission in Appendix B.):  
Wong, C. T., Bestard Lorigados I., Crawford DA. (2019) Autism-related behaviors in the 
cyclooxygenase-2-deficient mouse model. Genes Brain Behaviour. 18:e12506. 
 
Contributions: Christine T. Wong designed and performed experiments, collected samples, 
acquired and analyzed the data, and prepared the manuscript. Isabel Bestard Lorigados assisted 
in acquiring RNA samples and data. Dr. Dorota A. Crawford supervised the design of the study 
and was involved with editing the manuscript.  
 
Objectives and Hypotheses: The fifth study was completed in vivo and its main objective was 
to investigate whether COX-2-deficiency could contribute to autism-related behaviours. The 
aims of this study were to characterize the behaviours of young and adult COX-2-deficient mice 
in the open field test, marble test, inverted screen test, and three chamber sociability test. I 
hypotheizsed that COX-2-deficient mice would display autism-related behaviours in a sex- and 
age-specific manner. Specially, I hypothesized that COX-2-deficient mice would show elevated 
hyperactive, repetitive, and anxiety-linked behaviours, motor deficits, and social abnormalities. 
In addition, I hypothesized that COX-2-deficient mice would have altered expression of autism-
linked genes: Wnt2, Glo1, Grm5, and Mmp9. This was the first study to show that irregularities 
in the COX-2/PGE2 signalling pathway could lead to the manifestation of autism-associated 
behaviours. 
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7.1. Chapter Summary 
Prostaglandin E2 (PGE2) is an endogenous lipid molecule involved in normal brain 
development. Cyclooxygenase-2 (COX-2) is the main regulator of PGE2 synthesis. Emerging 
clinical and molecular research provides compelling evidence that abnormal COX-2/PGE2 
signalling is associated with autism spectrum disorder (ASD). We previously found that COX-2 
knockout mice had dysregulated expression of many ASD-implicated genes belonging to 
important biological pathways for neurodevelopment. The current study is the first to 
demonstrate the connection between irregular COX-2/PGE2 signalling and autism-related 
behaviours in male and female COX-2-deficient knockin, COX-2-, mice at young (4-6 weeks) or 
adult (8-11 weeks) ages. Autism-related behaviours were prominent in male COX-2- mice for 
most behavioural tests. In the open field test, COX-2- mice travelled more than controls and adult 
male COX-2- mice spent less time in the center indicating elevated hyperactive and anxiety-
linked behaviours. COX-2- mice also buried more marbles, with males burying more than 
females, suggesting increased anxiety and repetitive behaviours. Young male COX-2- mice fell 
more frequently in the inverted screen test revealing motor deficits. The three-chamber 
sociability test found that adult female COX-2- mice spent less time in the novel mouse chamber 
indicative of social abnormalities. In addition, male COX-2- mice showed altered expression of 
several autism-linked genes: Wnt2, Glo1, Grm5, and Mmp9. Overall, our findings offer new 
insight into the involvement of disrupted COX-2/PGE2 signalling in ASD pathology with age-
related differences and greater impact on males. We propose that COX-2- mice might serve as a 
novel model system to study specific types of autism. 
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7.2. Introduction 
Autism spectrum disorder (ASD) is a neurodevelopment disorder phenotypically 
characterized by difficulties in social interaction, abnormal communicatory behaviours, and the 
presence of restricted and repetitive behaviours. Many individuals with ASD also experience 
motor difficulties (Travers et al., 2017), sensory sensitivity (Posar and Visconti, 2017), and 
anxiety (Zaboski and Storch, 2018). Epidemiological data reveals that ASD is one of the most 
common neurodevelopment conditions in children, affecting 1 in 68 (Christensen et al., 2016, 
Christensen et al., 2018, Lyall et al., 2017, Xu et al., 2018). The prevalence of ASDs has a strong 
sex bias, with significantly higher diagnosis in males compared to females (Loomes et al., 2017). 
Sex also plays a role in the clinical presentation of ASDs through varied symptomology 
(Halladay et al., 2015, Mandy et al., 2012, Van Wijngaarden-Cremers et al., 2014). For example, 
in males with ASD, attention deficit-hyperactivity disorder (ADHD) is more prevalent (Willcutt, 
2012) and repetitive behaviours are more severe than females (Supekar and Menon, 2015, 
Szatmari et al., 2012, Tillmann et al., 2018). The manifestation of these deficient behaviours in 
ASDs likely arises from complex interactions between genes and environment that result in 
improper brain development (Chaste and Leboyer, 2012, Lai et al., 2014, Yu et al., 2015).  
Current research on the developing brain has provided substantial evidence for the link 
between ASDs and abnormal signalling of the lipid mediator, prostaglandin E2 (PGE2) (Tamiji 
and Crawford, 2010, Wong and Crawford, 2014, Wong et al., 2015). PGE2 is the major lipid 
molecule in the nervous system. In the healthy brain, it is synthesized from arachidonic acid 
(AA) that is released from cell membranes through the activity of phospholipase A2 (PLA2) 
(Sang and Chen, 2006). AA is further converted to PGE2 and other prostanoid metabolites by 
two enzymes, cyclooxygenase-1 and -2 (COX-1 and COX-2) (Figure 7-1). However, PGE2 is the 
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predominant metabolite of COX enzymatic activity. COX-1 is constitutively expressed in most 
tissues and in the brain primarily by microglia (Choi et al., 2006, Hoozemans, 2001, Schwab et 
al., 2000). In contrast, COX-2 expression is typically inducible in the periphery by inflammation, 
but has constitutive expression in the kidney, intestinal tract, female reproductive system, and 
brain, where it is mainly localized in neurons (Brock et al., 1999, Hoozemans, 2001, Kirkby et 
al., 2016, Maslinska et al., 1999, Rouzer and Marnett, 2009, Yang and Chen, 2008). COX-2 
expression levels are significantly higher in the whole brain, particularly in the hippocampus and 
cerebral cortex, compared to its expression in peripheral tissues (Kirkby et al., 2016). In COX-2-
deficient mice the endogenous level of PGE2 in the brain is reduced by half compared to wild-
type mice, indicating that COX-2 contributes significantly to PGE2 production in the nervous 
system (Ayoub et al., 2004, Bosetti et al., 2004, Engstrom et al., 2012, Li et al., 2010). Normal 
COX-2/PGE2-mediated signalling is involved in fundamental brain functions such as dendritic 
spine formation, synaptic plasticity, and memory and learning (Burks et al., 2007, Chen and 
Bazan, 2005, Chen et al., 2002, Sang and Chen, 2006, Yang and Chen, 2008).  
Various abnormalities in key components of the COX-2/PGE2 pathway due to both 
genetic and environmental influences have been implicated in clinical studies on ASDs (Wong 
and Crawford, 2014, Wong et al., 2015). For instance, increased and decreased ratios of AA to 
omega-3 and omega-6 fatty acids (Bell et al., 2010, El-Ansary et al., 2011, Jory, 2016), increased 
PLA2 activity (Tostes et al., 2013), decreased total AA, and increased PGE2 levels (Brigandi et 
al., 2015) have been reported in blood samples of human patients with ASD. Moreover, 
polymorphism of Ptgs2, the gene that encodes the COX-2 enzyme, has been associated with 
ASDs and its relevant behaviours (Yoo et al., 2008). Furthermore, misuse of the drug 
misoprostol—a PGE2 analogue —for the termination of pregnancy was linked to elevated risk of 
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ASD (Bandim et al., 2003). We also previously reported that PGE2 signalling in the developing 
brain is especially vulnerable to various environmental insults such as inflammation, oxidative 
stress, pollution, heavy metals, pesticides, and commonly used over-the-counter drugs like 
acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic 
acid (ASA), which all have been linked to ASD (Masarwa et al., 2018, Tamiji and Crawford, 
2010, Wong and Crawford, 2014, Wong et al., 2015).  
Emerging molecular evidence offers insight into possible mechanisms by which 
abnormal COX-2/PGE2 signalling may affect brain development and lead to autism. For 
example, in vitro studies in our lab have shown that elevated levels of PGE2 can modify 
intracellular calcium dynamics and increase neural proliferation, migration, and differentiation in 
neural stem cells and differentiating neurons (Davidson et al., 2016, Wong et al., 2014, Wong et 
al., 2016). The expression of autism-linked genes including Ptgs2, Mmp9, Ctnnb1, and Wnt3 was 
also altered as a result of increased PGE2 levels in these model systems (Wong et al., 2014, 
Wong et al., 2016). Time-sensitive postnatal elevation or reduction of PGE2 levels have been 
shown to disrupt normal dendritic arborization in the cerebellum (Dean et al., 2012) and lead to 
reduced reciprocal social behaviour in male rats under both circumstances (Dean et al., 2012, 
Hoffman et al., 2016, McCarthy and Wright, 2017). Our recent whole genome microarray study 
of gene expression in male COX-2-deficient knockout mice found differential expression of 
many ASD-associated genes and deficits in various biological pathways involved in neuronal 
function during prenatal development such as synaptic transmission, long term potentiation, axon 
guidance, and dendritic spine remodelling (Rai-Bhogal et al., 2017). Interestingly, earlier studies 
have shown that mice lacking COX-2 enzymatic activity, including knockin COX-2- and 
knockout COX‐2–/– mice, exhibit irregularities in kidney morphology, gastrointestinal function, 
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and fertility (Lim et al., 1997, Loftin et al., 2001, Seta, 2009). However, the phenotypical 
consequences of COX-2 deficits in the brain have not yet been tested. 
In this study, we use homozygous COX-2- knockin mice to investigate for the first time 
the behavioural manifestations of abnormal COX-2/PGE2 signalling. We provide further 
evidence to existing clinical and molecular research indicating the COX-2/PGE2 signalling 
pathway as a candidate autism pathway by demonstrating the relationship between abnormal 
COX-2/PGE2 signalling and autism-related behaviour in COX-2- mice. We used the open field, 
marble burying, inverted screen, and three-chamber sociability tests to characterize sex- and age-
dependent ASD behaviours. We observed significant differences in hyperactivity, anxiety, 
repetitive behaviour, motor ability, and social behaviour in male and female mice at young (4-6 
weeks) or adult (8-11 weeks) ages. Additionally, we found significant alterations in the 
expression of autism-linked genes including Wnt2, Glo1, Grm5, and Mmp9.  Our results suggest 
that the experimental COX-2- mouse model may be useful for studying the connection between 
abnormal lipid signalling and developmental disorders, such as autism. 
 
7.3. Methods 
Animals 
Ptgs2Y385F founder mice, also known as B6.129S6(FVB)-Ptgs2 tm1.1Fun/J mice, were 
purchased from Jackson Laboratory (stock #008101; Queen’s University, laboratory of C. Funk) 
and backcrossed for at least 5 generations to wild-type 129S6/SvEvTac (WT) mice purchased 
from Taconic Laboratory. Ptgs2Y385F mice are a genetic mouse model for selective COX-2 
inactivation, which was created by a targeted point mutation of the Ptgs2 gene, resulting in a 
Y385F amino acid substitution. Although this mutation results in the complete inhibition of 
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COX-2 activity, downstream peroxidase activity remains intact (Yu et al., 2006). Mice were bred 
to generate homozygous Ptgs2 knockin (COX-2- KI) mice for behavioural testing. Homozygous 
COX-2- KI females are infertile, thus heterozygous females were bred with homozygous or 
heterozygous males to generate COX-2- KI male and female offspring. All WT and COX-2- KI 
mice were bred and maintained in group housing under the same conditions at York University 
throughout the study on a 12-hours light/dark cycle. Behavioural testing was conducted during 
the light phase. Mouse subjects were divided into two separate age cohorts: young (4-6 weeks 
old) and adult (8-11 weeks old). All equipment was thoroughly cleaned with antiseptic clinicide 
for disinfection and deodorization, followed by water wipes between testing of individual mice. 
Whole brain samples from separate animals were collected at postnatal day 8 (where birth was 
denoted as postnatal day 0) for gene quantification. All experiments and protocols were approved 
by the Research Ethics Board of York University and completed according to the York 
University Animal Care Committee ethics guidelines. 
 
Genotyping 
Genotyping analysis was performed via polymerase chain reaction (PCR) analysis of the 
COX-2 gene using primer sequences provided by the Jackson Laboratory (Ptgs2; Table 7-1). 
DNA extraction was completed on individual ear punch samples, which were denatured in 
alkaline lysis buffer (25mM NaOH) at 95°C for 30 min, followed by addition of neutralization 
buffer (Tris-HCl). Standard PCR was performed in an Eppendorf Mastercycler according to the 
Jackson Laboratory Ptgs2tm1.1Fun protocol (The Jackson Laboratory, 2016).  
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Table 7-1: PCR Primer set for COX-2- KI Genotype Analysis 
Primer Name Primer Sequence (5’-3’) Base pairs COX-2-  Wild-type 
Forward Mus Ptgs2IMR7834 ACCAGTCTCTCAATGAGTAC 20 bp 585 bp   493 bp 
Reverse Mus Ptgs2IMR7835 AGAATGGTGCTCCAAGCTCTAC 22 bp 
 
 
 
Open Field Test 
Changes in activity and anxiety levels were evaluated using standard methods as 
described previously (Bailey and Crawley, 2009, Seibenhener and Wooten, 2015). Mice were 
individually placed in a novel open chamber (40 cm L x 40 cm W x 40 cm H) with a center 
region designated as a 10 x 10 cm2. The test mouse was placed in the center of the apparatus and 
allowed to roam freely for a testing duration of 10 min.  Mouse movements were recorded by a 
Sony Cyber-shot DSC-W800 20.1 MP camera. Ambulatory activity was defined as the total 
pathlength travelled and was analyzed by an automated tracking program (NIS Elements 
Advanced Research Software). Anxiety-linked behaviour, investigated by determining the time 
spent in the center, was manually measured with a stopwatch by replaying the recorded video at 
a later date. Manual measurements were completed blind to the condition. The open field test 
was conducted on a total of 82 animals. 
 
Marble Burying Test 
Changes in repetitive behaviour and anxiety levels were evaluated through the marble 
burying test in line with previously described methods (Angoa-Perez et al., 2013, Chang et al., 
2017, Deacon, 2006, Kazdoba et al., 2016, Wohr et al., 2013). The trials were recorded using a 
Sony Cyber-shot DSC-W800 20.1 MP camera. The apparatus was a clean standard 
polycarbonate mouse cage (28.5 cm L x 17.5 cm W x 12 cm H) filled with bedding measuring a 
height of 3.5 cm. Twenty black glass marbles (15 mm) were arranged in the cage in a 4 by 5 
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array. The test mouse was individually placed in the center of the apparatus and allowed to bury 
marbles freely for a duration of 30 minutes. Once the trial was completed, the quantity of 
marbles that were fully buried was determined. Videos were later analyzed manually for time 
spent digging and grooming, which were completed blind to the test condition. The marble 
burying test was conducted on a total of 104 animals. 56 animals were recorded for analysis of 
digging and grooming behaviour.  
 
Inverted Screen Test 
To measure changes in strength, mice were individually placed in the center of a 34 x 38 
cm rectangular made of a wire mesh grid (1 mm thickness) with 13 mm squares surrounded by a 
wooden perimeter frame with 1.5 cm in thickness and 4 cm in height (Bonetto et al., 2015, 
Deacon, 2013). The screen was then slowly inverted over a 55 cm tall container filled with 30 
cm of foam padding for a maximum duration of 10 min. Whether or not the mouse fell during 
the test was noted and recorded as a binary result (1 = mouse fell, 0 = mouse did not fall). The 
fall percentage in each experimental group was then calculated by averaging the values for each 
test subject and multiplying by 100: Fall percentage of experimental group = (sum of values for 
each experimental group) ÷ (number of test subjects in the group) x 100. The inverted screen test 
was conducted on a total of 87 animals. 
 
Three-Chamber Sociability Test 
The three-chamber test was used to measure sociability as previously described (Chang et 
al., 2017, Kaidanovich-Beilin et al., 2011, Kazdoba et al., 2016, Silverman et al., 2010, Wohr et 
al., 2013). The sociability apparatus (60 cm L x 45 cm W x 26 cm H) was made from clear 
acrylic walls and divided into three chambers equal in area. The two dividing walls had openings 
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(10 cm x 10 cm) with removable doors that restricted or permitted access into the adjacent 
chambers. Testing consisted of two phases. In the first phase, the test mouse was individually 
placed in the center chamber and allowed to explore only the center chamber for 5 minutes. An 
inverted black wire-mesh cylinder container (10.5 cm D x 16 cm H) was placed in the middle 
against the lateral edge of each outer chamber.  A weighted hockey puck was placed on top of 
each cylinder to prevent tipping. A novel mouse (4 weeks old, matched for sex) was placed 
inside one of the two cylinders. The second phase was recorded using a Sony Cyber-shot DSC-
W800 20.1 MP camera mounted overhead and initiated by the removal of the barrier doors, 
allowing the test mouse to freely roam and explore all three chambers for 10 minutes. Videos 
were later analyzed for time spent in each chamber and time spent sniffing or touching the 
cylinders, which were completed blind to the test condition. The three-chamber sociability test 
was conducted on a total of 59 animals.  
 
RNA Isolation and quantitative Real-Time 
RNA for gene expression experiments was isolated from whole brain tissues collected at 
the postnatal day 8, a stage analogous to the infant stage in humans (Pressler and Auvin, 2013, 
Semple et al., 2013) during which the earliest signs of ASD-related behaviours have been 
observed (Koterba et al., 2014, Wagner et al., 2018). Total RNA isolation was completed via 
standard Trizol (Sigma) method and reverse-transcribed into cDNA with MMuLV reverse 
transcriptase (New England Biolabs, Ipswich, MA) following manufacturer’s protocol. SYBER 
green quantitative real-time polymerase chain reaction (qRT-PCR) on a 7500 FAST RT-PCR 
system (Applied Biosystem, Foster City, CA) was conducted and the ΔΔCt method was used to 
calculate transcript expression (Wong et al., 2014). Autism-associated genes were selected based 
on our recent findings in prenatal COX-2 knockout mice (Rai-Bhogal et al., 2017) and previous 
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research completed in human studies (refer to discussion). Primer pairs for tested genes—Wnt2, 
Glo1, Grm5, Mmp9 (Table 7-2)—were designed using Primer Express v3.0 (ThermoFisher 
Scientific, Waltham, MA). Hypoxanthine phosphoribosyl transferase (Hprt) and 
phosphoglycerate kinase 1 (Pgk1) were used as housekeeping controls. Relative quantification 
(RQ) mean for each gene was calculated from the RQ values of three litters determined in three 
independent experiments. 
Table 7-2: qRT-PCR Primers for autism-associated genes in COX-2- KI mice 
 
 
Statistical Analysis 
All behavioural data are graphically presented as mean±standard error of the mean 
(SEM) representing individuals from a minimum of three separate litters for each condition and 
time point. Three-way ANOVA followed by Bonferroni-adjusted pair-wise comparisons was 
performed on the  open field test, marble burying test, and three-chamber sociability test to 
determine if behavioural changes were dependent on condition (wild-type vs. knockin), sex 
Name Primer Primer Sequence (5’-3’) Base pair Length 
Hprt Forward TCCATTCCTATGACTGTAGATTTTATCAG 29 
 Reverse AACTTTTATGTCCCCCGTTGACT 23 
Pgk1 Forward CAGTTGCTGCTGAACTCAAATCTC 24 
 Reverse GCCCACACAATCCTTCAAGAA 21 
Wnt2 Forward GCCCTGATGAACCTTCACAAC 21 
 Reverse TGACACTTGCATTCTTGTTTCAA 23 
Glo1 Forward GGATTTGGTCACATTGGGATTG 22 
 Reverse CGTCATCAGGCTTCTTCACA 20 
Grm5 Forward CATGGAGCCTCCGGATATAATG 22 
 Reverse GTATCCAAGAGGAGTGACAACC 22 
Mmp9 Forward TCGCGTGGATAAGGAGTTCTCT 22 
 Reverse ATAGGCTTTGTCTTGGTACTGGAAGA 26 
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(male vs. females), or age (young vs. adult). The Kruskal-Wallis H test followed by post hoc 
pair-wise comparisons was conducted on the inverted screen test. Independent t-test was used to 
analyze potential gene expression differences and have been reported as mean±SEM. P values 
less than 0.05 were considered significant. 
 
7.4. Results  
Hyperactive locomotor and Anxiety-linked Behaviours: Open Field Activity 
The open field test was used to evaluate ambulatory activity and anxiety-linked behaviour 
in a novel environment for 10 min duration (Fig. 7-1A). Ambulatory activity was determined by 
measuring total pathlength travelled (Fig. 7-1B), while anxiety-related behaviour was measured 
by the time spent in the center of the apparatus (Fig. 7-1C).  Three-way ANOVA analysis was 
completed on pathlength values (Fig. 7-1B, F(7,73)=13.645, p<0.001). Pair-wise comparisons 
revealed that COX-2- mice had significantly increased ambulatory activity compared to WT 
controls. Specifically, this increase in pathlength travelled (cm) by COX-2- mice compared to 
WT was seen in young males (Fig. 7-1B, p=0.0456), adult males (Fig. 7-1B, p=0.000003), young 
females (Fig. 7-1B, p=0.000056), and adult females (Fig. 7-1B, p=0.012).  
There were no male vs. female differences in pathlength travelled within the young WT 
(Fig. 7-1B, p=0.131) or adult WT groups (Fig. 7-1B, p=0.178). A sex difference was also not 
observed between young COX-2- males and females (Fig. 7-1B, p=0.964). However, adult COX-
2- males travelled a greater pathlength than adult COX-2- females (Fig. 7-1B, p=0.000039).   
Similarly, WT animals did not show age differences in pathlength travelled within the 
male groups (Fig. 7-1B, p=0.092). No age differences were seen in COX-2- males (Fig. 7-1B, 
p=0.204). Although no age differences were observed in WT females (Fig. 7-1B, p=0.121), age-
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dependent differences were seen in COX-2- females: young female COX-2- mice travelled a 
longer pathlength than adult female COX-2- mice (Fig. 7-1B, p=0.000428).  
Anxiety-linked behaviour was measured by the amount of time spent (s) in the center of 
the apparatus (Fig. 7-1C). Three-way ANOVA analysis was completed on the time spent in the 
center (Fig. 7-1C, F(7,73)=3.225, p=0.005). There was no difference for time in center between 
young WT and COX-2- males (Fig. 7-1C, p=0.559). However, adult COX-2- males spent 
significantly less time in the center than adult WT males (Fig. 7-1C, p=0.001). There was no 
apparent difference in young COX-2- females (Fig. 7-1C, p=0.249) or adult COX-2- females (Fig. 
7-1C, p=0.889) compared to respective WT controls. 
Sex differences in anxiety-like behaviour were seen in WT animals, specifically in the 
adult group, where WT males spent more time in the center than WT females (Fig. 7-1C, 
p=0.000191). No sex differences were observed between young WT males and females (Fig. 7-
1C, p=0.658). There were also no sex differences in COX-2- mice for the young (Fig. 2c, 
p=0.995) or adult groups (Fig. 7-1C, p=0.952).  
Age differences were observed in the WT male group; young mice spent less time in the 
center than adult mice (Fig. 7-1C, p=0.015117). In contrast, no age differences were found 
within COX-2- males (Fig. 7-1C, p=0.134). No age differences were seen within the WT female 
groups (Fig. 7-1C, p=0.804) or COX-2- female groups (Fig. 7-1C, p=0.064). 
In summary, ambulatory behaviour was significantly elevated in COX-2- mice compared 
to WT across all groups, with sex- and age-dependent differences only seen in COX-2- mice. 
Anxiety-linked behaviour was decreased only in adult COX-2- males compared to matched WT 
mice, with sex- and age-dependent differences only seen in WT groups.  
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Anxiety-linked and Repetitive Behaviours: Marble Burying Test Results 
The marble burying test was used to assess anxiety-linked and repetitive behaviour over 
30 min (Fig. 7-2A). Only the number of marbles completely buried was counted and the total 
time spent digging or grooming was also measured. Three-way ANOVA analysis was completed 
on marble burying counts (Fig. 7-2B, F(7,96)=11.125, p<0.001). Computed pair-wise 
comparisons determined that COX-2- mice fully buried significantly more marbles than WT 
controls. An increased number of marbles buried was seen in young COX-2- males (Fig. 7-2B, 
p=0.00157), adult COX-2- males (Fig. 7-2B, p=0.000345), young COX-2- females (Fig. 7-2B, 
p=0.0483), and adult COX-2- females (Fig. 7-2B, p=0.012) compared to respective controls. 
Sex differences were seen in the number of marbles buried in both the WT and COX-2- 
groups. In WT animals, no sex differences were seen between males and females in the young 
group (Fig. 7-2B, p=0.283), but adult males were found to bury more marbles than adult females 
(Fig. 7-2B, p=0.00458). Similarly, COX-2- males buried more marbles than COX-2- females and 
this was seen in young animals (Fig. 7-2B, p=0.0338) and adults (Fig. 7-2B, p=0.00468).  
Age-dependent differences were only seen in males, specifically, adult mice significantly 
buried more marbles than young mice and this was seen within WT males (Fig. 7-2B, 
p=0.00208) and within COX-2- males (Fig. 7-2B, p=0.002670). No significant difference was 
seen in marbles buried between young and adult females within WT (Fig. 7-2B, p=0.269) or 
COX-2- groups (Fig. 7-2B, p=0.079). 
Three-way ANOVA analysis was completed on digging behaviour (Fig. 7-2C, 
F(7,48)=4.874, p<0.001). The pattern seen in the time spent digging (s) corresponded with the 
number of marbles buried, whereby COX-2- mice spent significantly more time digging than WT 
controls. This increased digging behaviour was seen in young COX-2- males (Fig. 7-2C, 
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p=0.0254), adult COX-2- males (Fig. 7-2C, p=0.000329), and young COX-2- females (Fig. 7-2C, 
p=0.0446). No significant differences in digging behaviour were seen between WT and COX-2- 
mice in adult females (Fig. 7-2C, p=0.0682). There were no significant sex or age differences 
within test groups seen in time spent digging (Fig. 7-2C, p>0.05). Three-way ANOVA analysis 
was also completed on grooming behaviour (F(7,48)=1.325, p=0.260). There were no statistical 
differences in the time spent grooming (s) for all group comparisons (no figure shown, p>0.05; 
total mean=103.2±8.2).  
In overview, COX-2- mice buried significantly more marbles and spent more time 
digging than WT controls. Sex- and age-dependent differences were also seen in the number of 
marbles buried, with males and adults burying the most marbles. The greatest number of marbles 
were buried by adult COX-2- males. No differences were seen in time spent grooming. 
 
Motor Strength: Inverted Screen Test  
To assess changes in motor strength, mice were subjected to the inverted screen test, 
which ran for a duration of 10 min (Fig. 7-3A). Fall percentage (%) was determined for each 
experimental group as described in the methods (Fig. 7-3B). Kruskal-Wallis H test analysis was 
conducted on binary fall values (1 = mouse fell, 0 = mouse did not fall) (Fig. 7-3B, H(7)=19.867, 
p=0.00356). Young COX-2- males (KI) fell significantly more (86%) than young WT males 
(25%) (Fig. 7-3B, p=0.0231) but there was no statistical difference between adult WT and COX-
2- males (Fig. 7-3B, p=0.143). In the females groups, although there was a trend that COX-2- 
mice had a greater fall percentage than WT mice, differences did not reach statistical 
significance between young WT and COX-2- females (Fig. 7-3B, p=0.530) or between adult WT 
and COX-2- females (Fig. 7-3B, p=0.0674).  
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When investigating potential sex differences in fall percentages, males fell more often 
than females. No sex differences were seen in young WT male and female mice (Fig. 7-3B, 
p=0.819) but adult WT males (55%) fell more frequently compared to adult WT females (9%) 
(Fig. 7-3B, p=0.0253). Similarly no statistical sex differences in fall values were observed in 
young COX-2- mice (Fig. 7-3B, p=0.0679) but males (83%) fell more often than females (43%) 
in the adult COX-2- (Fig. 7-3B, p=0.0381). Fall percentage values were not significantly different 
between the age groups tested (p>0.05).  
To summarize, only young COX-2- mice had a higher fall percentage than age-matched 
WT mice. Sex differences were observed within adult WT and adult COX-2- groups, where 
males fell more frequently than females. No age differences in fall percentage were observed 
within WT or COX-2- mice. 
 
 
Social Behaviour: Three-Chamber Sociability Test  
Social behaviour was evaluated with the three-chamber sociability test for a duration of 
10 minutes (Fig. 7-4A). Regardless of sex or age, we found that both genotype groups spent the 
most time exploring the novel mouse chamber, indicative of their preference for social proximity 
(Fig. 7-4B, -4C). 
Three-way ANOVA analysis was conducted on the time spent (s) in the novel object 
chamber (Fig. 7-4B, -4C, F(7,51)=0.840, p=0.559). Pair-wise comparisons on the time spent in 
the novel object chamber revealed no significant differences between groups (p>0.05). Three-
way ANOVA analysis was also conducted on the time spent (s) in the novel mouse chamber 
(Fig. 7-4B,-4C, F(7,51)=2.085, p=0.062). There were no statistical differences in the time spent 
in the novel mouse chamber between young WT and COX-2- males (Fig. 7-4B, p=0.0.532) or 
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between young WT and COX-2- females (Fig. 7-4B, p=0.271). In the adult groups, there was 
also no significant difference between adult WT and COX-2- males (Fig. 7-4C, p=0.327) but 
adult COX-2- females spent statistically less time in the novel mouse compared to WT females 
(Fig. 7-4C, p=0.011). The time spent sniffing the novel mouse (F(7,51)=0.877, p=0.531) or the 
novel object (F(7,51)=0.659, p=0.705) was not statistically different between groups (data not 
shown).  
Overall, we observed that young and adult WT or COX-2- mice spent more time 
exploring the novel mouse chamber compared to the novel object chamber. A statistical 
difference was only seen in adult female mice spending less time in the novel mouse chamber 
compared to age-matched controls. There were no sex- or age-dependent differences observed. 
 
Abnormal expression of autism-linked genes in COX-2- mice 
Our previous microarray analysis study in COX-2-deficient mice at two prenatal stages 
and our past in vitro work collectively found differential expression of the following genes—
Wnt2  Glo1, Grm5, and Mmp9 (Rai-Bhogal et al., 2017, Rai-Bhogal et al., 2018, Wong et al., 
2014)—which were all previously linked to ASD (Abdallah et al., 2012, Junaid et al., 2004, 
Marui et al., 2010, Skafidas et al., 2014). The gene expression levels were determined in whole 
brain samples collected at postnatal day 8, which is analogous to the infant stage in humans 
(Pressler and Auvin, 2013, Semple et al., 2013), using quantitative RT-PCR analysis (Table 7-2).  
In comparison to WT males (RQ = 1), expression of all genes tested was significantly 
different in COX-2- males (Table 7-3). Specifically, COX-2- males had statistically elevated 
expression of Wnt2 (t(6)=-15.65, p=0.00057; RQ=1.423±0.027) and decreased expression of 
Glo1 (t(6)=4.187p=0.025; RQ=0.781±0.052), Grm5 (t(6)=4.835, p=0.017; RQ=0.727±0.056), 
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and Mmp9 (t(6)=12.508, p=0.009; RQ=0.540±0.044). In contrast, only one of the genes showed 
altered expression in COX-2- females compared to WT females (RQ = 1); Glo1 was also 
significantly decreased compared to controls (t(6)=3.445,  p=0.041, RQ=0.627±0.108) . Overall, 
our analyses revealed that the observed dysregulation of ASD gene expression was 
predominantly found in males. 
 
7.5. Discussion  
In this study, we describe for the first time autism-related behaviours in COX-2- KI male 
and female mice and propose that these mice may serve as a novel experimental model system 
for studying ASDs. We observed sex-specific and age-specific differences that have never been 
described before in this animal model. The results presented in this study along with published 
clinical data (Tamiji and Crawford, 2010, Wong and Crawford, 2014, Wong et al., 2015) as well 
as in vitro and in vivo molecular research (Dean et al., 2012, Hoffman et al., 2016, Rai-Bhogal et 
al., 2017, Rai-Bhogal et al., 2018, Wong et al., 2014, Wong et al., 2016) strengthen the evidence 
that abnormal COX-2/PGE2 signalling may influence brain development and contribute to ASD 
pathology. We determined that male and female COX-2- KI mice lacking activity from the PGE2-
producing enzyme display behaviours linked to autism, specifically in hyperactivity, anxiety, 
repetitive behaviours, motor strength, and social interaction (Table 7-4). For the majority of 
behavioural assessments conducted, autism-related behaviours were particularly pronounced in 
male COX-2- mice. 
Results from the open field test revealed that COX-2- mice have elevated ambulatory 
activity and adult COX-2- males spend less time in the center, which are analogous to greater 
hyperactivity and anxiety behaviours respectively (Seibenhener and Wooten, 2015). These 
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behaviours seem to be comparable to symptoms commonly reported in ASD cases (Matson et al., 
2013, van Steensel and Heeman, 2017). For example, a number of cross-sectional studies have 
reported that 40-55% of children with ASD also had attention deficit-hyperactivity disorder 
(ADHD) (Gadow et al., 2005, Gadow et al., 2004, Gordon-Lipkin et al., 2018) or anxiety 
disorders (de Bruin et al., 2007, Simonoff et al., 2008, van Steensel et al., 2011). Our analysis on 
sex differences in the open field test revealed that COX-2- males showed increased movement or 
hyperactivity compared to COX-2- females, which is reminiscent of a bias in the prevalence for 
ADHD in males with ASD (Willcutt, 2012). We also found that anxiety-linked behaviour, 
indicated by decreased time spent in the center of the open field test, was significantly elevated 
specifically in adult COX-2- males compared to sex- and age-matched controls. This relationship 
between increasing age and anxiety is also seen in clinical studies on ASDs and ADHD, where 
older patients had a higher prevalence of anxiety disorder than younger patients (Gordon-Lipkin 
et al., 2018). In contrast to our results, previous work utilizing postnatal subcutaneous injections 
of a COX-2 inhibitor in a rat model found no alterations in activity output in the open field test 
(Dean et al., 2012). This signifies that behavioural outcomes of COX-2-deficiency may manifest 
through aberrations of COX-2/PGE2 signalling that occur prenatally as opposed to postnatal time 
points. 
The marble burying test showed that COX-2- animals buried a higher number of marbles 
compared to wild-type controls representing increased repetitive and anxiety-related behaviours, 
which are characteristic symptoms of autism (Gotham et al., 2013, Matson et al., 2009, van 
Steensel and Heeman, 2017). Sex differences were also seen in control and COX-2- animals: 
males buried more marbles than females suggesting that males show higher levels of anxiety-
related and repetitive behaviours. This male-specific sex difference in anxiety and repetitive 
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behaviours has also been reported in general and ASD-affected human populations (Evans et al., 
2018, Supekar and Menon, 2015, Szatmari et al., 2012). Moreover, age-specific differences were 
only seen in males, where adult mice buried more than young mice. It appears differences in the 
marble burying test were seen predominately in COX-2- animals and particularly in males, which 
parallels the strong male prevalence in ASD (Loomes et al., 2017). 
We also found that young male COX-2- mice fell at a higher rate during the inverted 
screen test indicating that these animals have less motor strength compared to controls. Analyses 
reported by Kern et al. (2011) found that hand grip strength in children with ASD was correlated 
to the severity of the disorder. Motor deficits are also comorbid symptoms of autism (Deacon, 
2013, McPhillips et al., 2014). For example, hypotonia, defined as a decrease in muscle tone, has 
been commonly characterized in young children with ASD (Ming et al., 2007). Hypotonia also 
seems to improve across development since it is less prevalent in older children with ASD (Ming 
et al., 2007). Interestingly, this age-related motor impairment is also observed in our age-
dependent results, where only young COX-2- animals were affected but not adults. Impairments 
in motor function involving more complex motor skills such as reaching, grasping, precision 
gripping, and interpersonal motor coordination have also been reported in the autism population 
(Curioni et al., 2017, David et al., 2009, Kaur et al., 2018, Libertus et al., 2014, Sacrey et al., 
2014, Wang et al., 2015). Our results signify that COX-2- mice display motor abnormalities that 
might be akin to deficits observed in some cases of ASDs. 
Control and COX-2- mice both had a preference for social novelty in the three-chamber 
sociability test. However, adult female COX-2- mice spent less time in the novel mouse chamber 
compared to adult female controls. This suggests that COX-2- mice can have sex- and age-
specific social abnormalities, which have also been reported in human cases of ASD. For 
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example, a recent study by Lawson et al. (2018) found that females with ASD exhibited more 
social impairments compared to matched males. Females with Smith-Magenis syndrome, a 
complex genetic neurodevelopmental syndrome with autism features, also display a greater 
number of abnormal social symptoms (Nag et al., 2018).  
It is also important to note that in our study, upon weaning, animals were housed with 
litter mates of the same test group (genotype), which facilitates normal enriched social 
interaction. In contrast, previously published studies in other autism rodent models have shown 
that individually caged animals exhibit greater behavioural abnormalities compared to socially 
enriched animals caged with other animals (Depino et al., 2017, Toyoshima et al., 2018). This 
suggests that the differences we observed in the COX-2- mice are more conservative and that our 
results may represent a robust observation of autism-related behaviours in this model system.  
To follow-up on the observed autism-associated behaviours in COX-2- mice, we 
investigated the expression of autism-linked genes—Wnt2, Glo1, Grm5, and Mmp9 (Abdallah et 
al., 2012, Junaid et al., 2004, Marui et al., 2010, Skafidas et al., 2014). We previously reported 
that ASD-linked genes were affected in COX-2 knockout mice during prenatal development 
(Rai-Bhogal et al., 2017). All genes tested in our current study were differentially expressed in 
postnatal day 8 COX-2- KI mice compared to controls. Interestingly, we found an increased 
expression of Wnt2 and decreased expression of Glo1, Grm5, and Mmp9 predominantly in male 
offspring. 
Wnt2 was elevated in COX-2- male mice in comparison to wild-type mice. Wnt2 is an 
active signalling molecule of the Wnt pathway, which has been connected to ASDs (Kalkman, 
2012, Zhang et al., 2014). Wnt2 is found in an autism susceptibility locus (7q31-33) and 
mutations in Wnt2 have been found in patients with ASD, correlating to speech delay (Lin et al., 
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2012, Wassink et al., 2001). The elevated Wnt2 levels we measured in COX-2- mice may 
contribute to altered sociability also observed in this study. Furthermore, this finding provides 
additional support for an interaction between the COX-2/PGE2 and Wnt signalling pathways, 
which has already been demonstrated in our lab in neuronal cell cultures and prenatal COX-2-
deficient male mice (Rai-Bhogal et al., 2017, Wong et al., 2014, Wong et al., 2016).  
In contrast, transcript expression of glyoxalase 1 (Glo1), a detoxification enzyme (Distler 
and Palmer, 2012), was found to be decreased in COX-2- male and female mice. Single 
nucleotide polymorphisms in the Glo1 gene have been identified in ASD patients (Junaid et al., 
2004). Dysregulated Glo1 expression in mice has been associated with increased anxiety 
(Hovatta et al., 2005). Taking into account this correlation between Glo1, autism, and anxiety, 
the decreased Glo1 expression that we quantified in COX-2- mice may contribute to the 
increased anxiety-related behaviours found in this study. Glutamate metabotropic receptor 5 
(Grm5) expression was also decreased in COX-2- male mice. Abnormal Grm5 expression has 
been previously found in ASD (Skafidas et al., 2014). Moreover, a deletion within the Grm5 
gene has been linked to ADHD (Elia et al., 2010, Elia et al., 2011), which commonly occurs in 
children with autism (Antshel et al., 2013). It is feasible that the hyperactive behaviour displayed 
by COX-2- mice in our study may be resulting from reduced Grm5 expression in the brain. 
Lastly, expression of matrix metalloproteinase 9 (Mmp9) was found to be lower in COX-2- male 
mice. Mmp9 is important in synaptogenesis, axonal pathfinding, and cortical plasticity (Reinhard 
et al., 2015, Vafadari et al., 2016). Atypical Mmp9 levels have been quantified in amniotic fluid 
samples from ASD cases (Abdallah and Michel, 2013, Abdallah et al., 2012). Mmp9 also 
regulates the levels of a synaptic neuroligin-1 (Peixoto et al., 2012), a gene that has been 
associated with ASD cases (Glessner et al., 2009, O'Roak et al., 2012). Altered levels of Mmp9 
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found in COX-2- mice during infanthood would affect early developmental processes, which may 
contribute to autism-like behaviours observed in this study.  
This study reveals that the abnormal expression of autism-linked genes can persist in 
COX-2-deficient mice during postnatal development. This complements our existing results 
from a microarray study conducted on prenatal stages of COX-2 knockout animals (Rai-Bhogal 
et al., 2017). Our past study found that prenatal COX-2 knockout male mice (at both embryonic 
day 16 and 19) exhibit gene expression abnormalities and deficits in protein-interaction networks 
involved in a number of key biological processes including regulation of immune responses, 
synaptic transmission, cell morphogenesis, and the Wnt signalling pathway (Rai-Bhogal et al., 
2017). Building on this earlier finding, irregularities in these crucial processes may contribute to 
the autism-linked behaviours in the COX-2-deficient mice described here.  
Previous literature has also revealed additional atypical phenotypes in COX-2-deficient 
mice associated with the global inactivation of COX-2. For example, the differential expression 
of constitutive COX-2 in various peripheral tissues contributes to tissue-specific irregularities, 
including renal abnormalities, gastric dysfunction, and infertility (Kirkby et al., 2016, Rouzer 
and Marnett, 2009, Seta et al., 2009, Wallace and Devchand, 2005). COX-2-deficient mice also 
exhibit defects in inflammatory responses and skeletal muscle development (Bondesen et al., 
2004, Otis et al., 2005, Ricciotti and Fitzgerald, 2011, Rouzer and Marneet, 2009). The hindered 
formation of muscle in COX-2-deficient mice may explain the reduced motor strength in COX-2- 
KI mice observed in this study. All these reported phenotypes could be relevant to 
developmental disorders such as ASDs, and thus should be evaluated together in the future. 
Furthermore, our analysis of social behaviour was limited to the three-chamber sociability 
test. Behavioural assays in subsequent studies could include additional tests investigating 
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ultrasonic vocalizations, reciprocal social interactions, social novelty, and social approach. 
Moreover, gene expression analyses were completed on whole brain samples from postnatal day 
8 but examining region-specific expression of these affected autism-associated genes across 
other developmental stages may provide new details regarding their impact on behavioural 
outcomes. 
 
7.6. Conclusions 
In conclusion, the results from this study provide the first behavioural evidence that 
aberrant COX-2/PGE2 signalling in the developing brain may result in autism-related behaviours 
manifested in postnatal life. COX-2- mice exhibited increased hyperactivity, anxiety, repetitive 
behaviour, motor deficit, and social abnormality as seen in many clinical cases of ASDs. Prior 
research from clinical studies in ASD individuals and from in vitro and in vivo studies, have 
found that alterations in the COX-2/PGE2 pathway change neuronal cell behaviour as well as 
differential expression of ASD-related genes and proteins.  Our current study provides further 
proof that a connection between abnormal COX-2/PGE2 signalling and autism may exist. Our 
results suggest that mouse models with disrupted COX-2/PGE2 signalling, such as the COX-2-
deficient mouse model, may be of specific interest for the study of ASDs. This study also reveals 
the importance of including both sexes in molecular and behavioural experiments in order to 
obtain a complete picture of autism specific phenotypic changes. Moreover, behavioural 
differences are also specific to age and therefore should be a considered factor as well.  
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7.7. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7-1: Ambulatory activity and anxiety-linked behaviour in COX-2- mice in the open field 
test. (A) An automated tracking program determined the pathlength travelled indicated in red. (B) 
Pathlength results showed that COX-2- mice travelled more than WT controls in male and female 
groups. Sex- and age-dependent differences were only seen in COX-2- mice. Adult male COX-2- 
mice spent less time in the center than matched controls. (C)  Measurements for time spent in center 
revealed no differences in anxiety-linked behaviour in female mice. Sex- and age-dependent 
differences in anxiety-related behaviour were found only in WT groups. Animals from at least 3 
different litters were tested for each experimental group. Data are presented as mean ±SEM, *p<0.05, 
**p<0.01, ***p<0.001.   
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Fig. 7-2: Repetitive and anxiety-linked behaviour in COX-2- mice in the marble burying 
test.  (A) Video recordings were taken and total marbles buried were counted. (B) Male COX-2- 
mice buried more marbles than controls. Female COX-2- mice buried more marble than WT 
mice. Sex differences were seen in adult WT and COX-2- mice. Age differences were seen in 
WT and COX-2- males. (C) Male COX-2- mice spent more time digging than controls. Young 
female COX-2- mice spent more time digging than controls. No sex- or age-dependent 
differences were observed in digging times. Animals from at least 3 different litters were tested 
for each experimental group. Data are presented as mean ±SEM, *p<0.05, **p<0.01, 
***p<0.001.   
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Fig. 7-3: Motor ability was measured in COX-2- mice using the inverted screen test.  
(A) For the inverted screen test, whether or not the mouse subjects fell was recorded. (B) Young 
male COX-2- mice fell at a higher percentage than WT controls. No difference in motor strength 
in female mice. Males fell more frequently than females within adult WT, young or adult COX-
2- groups. Animals from at least 3 different litters were tested for each experimental group. Data 
are presented as mean ±SEM, *p<0.05, **p<0.01, ***p<0.001.   
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Fig. 7-4: Sociability behaviour was determined in COX-2- mice using the three-chamber 
test. (A) Video recordings were taken and the time spent in the novel object chamber and novel 
mouse chamber was recorded. (B) Young mice showed preference for social proximity indicated 
by spending the greatest amount of time in the novel mouse chamber. No significant differences 
were observed between groups for time spent within the novel object chamber or time spent 
within the novel mouse chamber. (C) Adult mice also preferred social proximity but adult female 
COX-2- mice spent significantly less time in the novel mouse chamber (orange bars) than 
matched WT controls. Animals from at least 3 different litters were tested for each experimental 
group. Data are presented as mean ±SEM, *p<0.05.   
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Table 7-3: Expression of autism-linked genes for COX-2- mice  
Gene expression analysis on autism-linked genes were completed on postnatal day 8 samples as 
shown as RQ units for male and female COX-2- groups relative to respective controls (RQ=1). 
Values represent the mean of individuals from at least 3 independent litters. *p<0.05, **p<0.01, 
***p<0.0001 
 
COX-2- compared to WT controls : Autism-Linked Genes 
Males RQ Mean Values p-values 
Wnt2 1.4231 0.00057*** 
Glo1 0.7814 0.025* 
Grm5 0.7268 0.017* 
Mmp9 0.5404 0.009** 
Females RQ Mean Values p-values 
Wnt2 1.1540 0.281 
Glo1 0.6274 0.041* 
Grm5 0.9096 0.588 
Mmp9 1.0623 0.815 
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Table 7-4 : Summary of behavioural findings for COX-2- mice  
Results represent the overall significant behavioural comparisons of COX-2- mice to respective 
WT controls, where ↑ = Increased; ↓ = Decreased; - = not significant. Each finding is a 
representation of individuals from at least 3 independent litters.  
 
COX-2-  mice compared to WT controls: Behavioural Results 
Behaviour COX-2
- Male COX-2- Female 
Young Adult Young Adult 
Open Field Test  
Hyperactivity  
(pathlength) 
↑ ↑ ↑ ↑ 
Open Field Test  
Anxiety-like Behaviour  
(time in center) 
- ↓ - - 
Marble Burying Test  
Anxiety-like & Repetitive Behaviour 
(marbles buried) 
↑ ↑ ↑ ↑ 
Marble Burying Test  
Anxiety-like & Repetitive Behaviour 
(digging time) 
↑ ↑ ↑ ↑ 
Inverted Screen Test  
Motor Deficits 
(fall percentage) 
↑ - - - 
3 Chamber Test  
Social behaviour  
(time spent in novel mouse chamber) 
- - - ↓ 
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Objectives and Hypotheses: The sixth study was completed in vivo and its main purpose was to 
investigate whether prenatal PGE2 exposure can influence autism-related behaviours. The aims 
of this study were to quantify the behaviours of young and adult PGE2-exposed mice in the three 
chamber test, open field test, marble test, and inverted screen test. I hypothesized that PGE2-
exposed mice would display social abnormalities, elevated hyperactive, repetitive, and anxiety-
related behaviours, and motor deficits in a sex- and age- specific manner. I also hypothesized 
altered expression of autism-linked genes (Wnt2, Tcf4, Glo1) in PGE2-exposed mice.  
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8.1. Chapter Summary 
Healthy brain development relies on important lipid molecules, such as Prostaglandin E2 
(PGE2). PGE2 signalling can influence key neurobiological processes including neuronal 
proliferation, differentiation, and synaptogenesis. Disruption of PGE2 levels by various 
environmental risk factors or genetic causes have been linked to Autism Spectrum Disorders 
(ASDs). Our recent study in mice lacking COX-2, the PGE2 producing enzyme, already revealed 
distinct sex- and age-specific autism-related behaviours in offspring. The current study is the first 
to demonstrate that a single maternal injection of PGE2 during pregnancy, can also lead to 
manifestation of different autism-related behaviours in male and female C57bl/6 mouse offspring 
at young (4-6 weeks) or adult (8-11 weeks) ages. In the three chamber test, only adult PGE2-
exposed males spent more time in the novel object chamber but both PGE2-exposed males and 
females interacted longer with the novel object as opposed to the novel mouse, indicative of 
social abnormalities. PGE2-exposed male and female mice buried more marbles and only young 
PGE2-exposed females spent the most time grooming, suggesting increased repetitive and 
anxiety-like behaviours. In the open field test, only young PGE2-exposed male and female mice 
travelled more and spent less time in the center than controls suggesting elevated hyperactive and 
anxiety-like behaviours. PGE2-exposed mice didn’t display differences in motor strength; 
however, young PGE2-exposed male and female mice had greater defecation during the inverted 
screen test revealing increased anxiety. In addition, we detected sex-dependent downregulation 
of key developmental genes associated with autism such as Wnt2, Tcf4 (in males), and Glo1 (in 
females). Overall, our findings add new evidence for the connection between abnormal COX-
2/PGE2 signalling and ASD pathology. This study demonstrates that changes in the level of 
PGE2 during a critical time in prenatal development can lead to appearance of distinct sex- and 
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age-dependent autism behaviours. We suggest that PGE2-exposed mice could be a useful 
experimental model system for studying certain types of autism disorders.  
 
8.2. Introduction  
The brain is composed of a high concentration of lipids, which are important for both 
structural integrity and biological processes. The major bioactive lipid mediator is prostaglandin 
E2 (PGE2). The PGE2 signalling pathway is typically known for its role in regulation of 
inflammation and immune responses (Ricciotti and FitzGerald, 2011). PGE2 also plays an 
essential role in the development of the nervous system, including processes such as cell 
proliferation, synaptogenesis, and learning and memory (Tassoni et al., 2008, Chen and Bazan, 
2005). PGE2 is synthesized from arachidonic acid (AA) that is released from cell membrane 
phospholipids through the enzymatic activity of phospholipase A2 (PLA2). AA is then converted 
to PGE2 by cyclooxygenase-1 or -2 (COX-1 or COX-2), enzymes constitutively expressed in the 
brain mainly in microglia or neuronal cells, respectively.  
Epidemiological, clinical, and molecular studies on humans and rodent models have 
provided convincing evidence that the PGE2 signalling pathway might be an autism candidate 
pathway (Wong et al., 2015, Wong and Crawford, 2014, Tamiji and Crawford, 2010). 
Individuals with autism have increased or decreased AA:Omega fatty acid ratios in blood 
samples, decreased total AA, increased PLA2 activity, and elevated COX-2 and PGE2 levels 
(Qasem et al., 2018, Yui et al., 2016, Brigandi et al., 2015, Tostes et al., 2013, El-Ansary et al., 
2011, Bell et al., 2010). Abnormalities in various components of the PGE2 signalling pathway 
due to genetic or environmental causes have also been associated with cases of Autism Spectrum 
Disorders (ASDs). For example, genetic abnormalities of key enzymes, including polymorphism 
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of the genes encoding PLA2 and COX-2, have been found in individuals with autism (Liu et al., 
2017, Yoo et al., 2008). Many environmental factors that affect PGE2 levels, including exposure 
to heavy metals, pollution, maternal infection, pesticides, or over the counter medications such as 
acetylsalicylic acid and acetaminophen, have all been associated with ASDs  (Masarwa et al., 
2018, Wong et al., 2015). Moreover, prenatal exposure to misoprostol, a synthetic analogue of 
PGE2, during early gestation to terminate pregnancy resulted in neurodevelopmental defects such 
as Möbius Syndrome and autism-related behaviour (Miller et al., 2004, Bandim et al., 2003, 
Stromland et al., 2002). Studies in human and animal models of autism show that these 
environmental risk factors, including misoprostol, are capable of modifying the expression of 
many genes involved in key developmental processes and lead to manifestation of autism-related 
behaviour (Dufour-Rainfray et al., 2011, Miller et al., 2009, Stromland et al., 2002). 
Interestingly, gene expression analysis on ASD patients have uncovered dysregulation in the 
immune response, cell communication, and neuronal differentiation (Gupta et al., 2014, Garbett 
et al., 2008), which are processes influenced by PGE2 signalling. 
Subsequent molecular studies conducted in cell lines and animal models complement the 
human studies by providing further evidence for a connection between the PGE2 signalling 
pathway and neuronal pathology that may lead to autism. For example, we found that in neuronal 
cell cultures, an elevated level of PGE2 increases calcium levels in the cytosol and growth cones, 
and affects neural stem cell proliferation, neuronal migration and differentiation (Davidson et al., 
2016, Wong et al., 2016, Wong et al., 2014, Tamiji and Crawford, 2010). Increased levels of 
PGE2 also led to altered expression of autism-linked genes such as Ptgs2, Mmp9, Ctnnb1, and 
Wnt3 in neural stem cells and differentiating neurons (Wong et al., 2016, Wong et al., 2014). 
Moreover, evidence from our recent study in mice has found that maternal exposure to 
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exogenous PGE2 during early pregnancy led to abnormal expression of autism-associated genes, 
including Wnt2 and Wnt3a, in offspring across crucial prenatal developmental time points (Rai-
Bhogal et al., 2018). Similarly, whole genome microarray analysis in male mice lacking the 
PGE2 producing enzymes (either COX-1 or COX-2) also found differential expression of 
numerous ASD-linked genes and defects in several biological processes that influence 
neurodevelopment including axonal pathfinding, synaptic transmission, synaptic plasticity, and 
learning and memory (Rai-Bhogal et al., 2017). Other researchers have reported that both an 
increase or decrease in PGE2 levels at specific postnatal time-points also result in irregular 
cerebellar development (Dean et al., 2012) and decreased reciprocal social behaviour in male rats 
(McCarthy and Wright, 2017, Hoffman et al., 2016, Dean et al., 2012). Interestingly, our recent 
behavioural study in COX-2-deficient mice revealed sex-and age-specific autism-related 
behaviours, including increased hyperactivity, anxiety, and repetitive behaviour, as well as 
defects in motor ability and social interaction (Wong et al., 2019). 
In the present study, we aimed to investigate the correlation between maternal exposure 
to exogenous PGE2 during a critical time in pregnancy and manifestation of sex-specific ASD-
like behaviour in young (4-6 weeks old) and adult (8-11 weeks old) mouse offspring. For this 
purpose, we characterized autism-associated behaviours using the three-chamber sociability, 
marble burying, open field, and inverted screen tests. We observed that PGE2-exposed offspring 
showed abnormal social behaviour, repetitive and anxiety-related behaviour, and hyperactivity. 
Additionally, we found significant alterations in the expression of autism-linked genes including 
Wnt2, Tcf4, and Glo1. Most importantly, in line with reports observed in clinical studies, our data 
shows that a single exposure to exogenous PGE2 at a critical time point in development can 
result in postnatal manifestation of ASD-like symptoms. Our findings also suggest that mice 
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prenatally exposed to an environmental risk factor that can affect the fetal level of PGE2 in the 
brain may serve as an important experimental model to investigate the pathogenesis of ASDs. 
This novel study provides evidence for the existence of distinct male and female behavioural 
traits and genetic markers at different developmental ages. The sex-and age-dependent 
differences are particularly important in research on ASDs and thus should always be examined 
independently. 
 
8.3. Methods 
Animals  
 Male and female C57bl/6 mice were purchased from Charles River Laboratories. All 
animals were bred and maintained via group housing at York University animal facility on a 12-
hour light/dark cycle. Mice were separated into groups by treatment, sex and age. Mouse 
subjects were divided into either treatment (see maternal injections under methods) or vehicle 
control groups, into male or female groups, and into young (4-6 weeks old) or adult (8-11 weeks 
old) groups. Between testing of individual mice, behavioural equipment was disinfected and 
deodorized with antiseptic clinicide and thoroughly cleaned with water. All behavioural tests 
were administered by the same female researcher to avoid increased stress levels in mice 
reported when handling is done by male experimenters (Sorge et al., 2014). For gene 
quantification experiments, brain samples were collected at postnatal day 8, where birth was 
considered postnatal day 0. Postnatal day 8 in mice is of particular interest since it is analogous 
to infanthood in humans (Pressler and Auvin, 2013, Semple et al., 2013), where symptoms of 
ASDs can be first detected. Subjects from each experimental group included mice from at least 3 
different litters. All experiments and protocols followed the York University Animal Care 
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Committee ethics guidelines and have been approved by the Research Ethics Board of York 
University. 
 
Maternal Injections 
Male and female mice were housed together overnight for breeding. Females were 
checked every morning for the presence of a vaginal plug. When a plug was observed, this was 
noted as embryonic day 1 and females were then housed individually for the duration of their 
pregnancies.  On embryonic day 11 (E11), pregnant females were weighed in the morning and 
given a single subcutaneous injection of 0.2 μg/g concentration of 16, 16-dimethyl prostaglandin 
E2 (dmPGE2; Cayman Chemical) diluted in saline as used in previous studies (Rai-Bhogal et al., 
2018, Okamoto et al., 2011, Tessner et al., 2004). dmPGE2 has a metabolic rate that is slower 
than PGE2, and is considered a stable analogue of PGE2 that stays active for a longer time 
period (Steffenrud, 1980, Ohno et al., 1978). Control animals were given saline-only injections. 
Administration of dmPGE2 exposure was conducted on E11 since this time-point marks the onset 
of neurogenesis in embryonic mice (Zhang and Jiao, 2015). E11 also corresponds to the time that 
the drug analogous to PGE2, called misoprostol, was taken in human cases resulting in Moebius 
syndrome and autism characteristics (Bandim et al., 2003, Pastuszak et al., 1998). Maternal 
exposure of dmPGE2 at E11 was also previously shown to result in altered expression of autism-
linked genes during prenatal development (Rai-Bhogal et al., 2018). Herein, mouse offspring 
subjected to maternal exposure of dmPGE2 as described above are referred to as “PGE2-exposed 
mice”. 
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Three-Chamber Sociability Test 
Sociability was evaluated using the three-chamber test as previously described 
(Kaidanovich-Beilin et al., 2011, Silverman et al., 2010). The sociability apparatus (60 cm L x 
45 cm W x 26 cm H) was constructed with clear acrylic walls creating three chambers that were 
equal in area. Access into adjacent chambers was restricted or permitted by removable doors that 
covered openings (10 cm x 10 cm) on the two dividing walls. There were two phases in the 
three-chamber test. The test mouse was placed in the centre chamber and allowed to explore only 
the centre chamber for 5 minutes in the first phase. An inverted black wire-mesh cylindrical 
container (10.5 cm D x 16 cm H) was placed in the middle against the lateral wall of each outer 
chamber.  A weighted hockey puck was placed on top of each cylinder to prevent tipping. A 
novel mouse (4 weeks old, sex matched) was placed inside one of the two cylinders. The second 
phase began with the removal of the barrier doors and the test mouse was then allowed to freely 
explore all three chambers for 10 minutes. Trials for the second phase were recorded by a Sony 
Cyber-shot DSC-W800 20.1 MP camera mounted overhead. Recorded videos were replayed and 
manually analyzed for time spent in each chamber and time spent interacting with (sniffing or 
touching) the cylinders. These measurements were completed blind to the experimental test 
groups. The three-chamber sociability test was conducted on a total of 53 animals.  
 
Marble Burying Test 
Anxiety and repetitive behaviour was investigated using the marble burying test as 
previously described (Angoa-Pérez et al., 2013, Deacon, 2006). A clean standard mouse cage 
(28.5 cm L x 17.5 cm W x 12 cm H) was used as the testing apparatus. Bedding measuring a 
height of 3.5 cm was added and twenty black glass marbles (15mm diameter) were placed in the 
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cage in a 4 by 5 arrangement. The mouse subject was placed in the centre of the apparatus and 
allowed to move freely for the duration of 30 minutes. The behaviour were recorded using a 
Sony Cyber-shot DSC-W800 20.1 MP camera. Upon completion of the test, the number of 
completely buried marbles was counted. Recorded videos were later manually analyzed to 
measure the time spent digging or grooming. Manual measurements were completed blind to the 
test condition of the mouse subject. The marble burying test was conducted on a total of 62 
animals. 56 animals were recorded for analysis of digging time behaviour. 
 
Open Field Test 
Ambulatory activity and anxiety-like behaviour was determined using standard open field 
test methods as previously described (Seibenhener and Wooten, 2015). The mouse subject was 
placed in the middle of an empty open chamber (40 cm L x 40 cm W x 40 cm H) with a centre 
region outlined by a 10 x 10 cm2 square. Overhead video recording of free roaming behaviour by 
the test mouse for a duration of 10 minutes was completed with a Sony Cyber-shot DSC-W800 
20.1 MP camera. Ambulatory activity was investigated by determining the total pathlength 
travelled, which was analyzed by an automated tracking program from the NIS Elements 
Advanced Research Software. Anxiety-like behaviour was observed by measuring the time spent 
in the centre. Times were quantified manually with a stopwatch by replaying the recorded video 
at a future date. These measurements were completed without given information on the 
experimental group of the mouse subject.  The open field test was conducted on a total of 58 
animals. 
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Inverted Screen Test 
Motor strength was evaluated using the inverted screen test. The mouse subject was 
placed in the centre of a 34 x 38 cm rectangular wire mesh grid (1 mm thickness) composed of 
13 mm squares and enclosed by a wooden frame of 1.5 cm thickness and 4 cm height (Bonetto et 
al., 2015, Deacon, 2013). The framed wire grid was then inverted slowly over a 55 cm tall 
container with foam padding (30 cm height) for a maximum duration of 10 minutes. The number 
of fecal boli produced during the test was noted. Whether or not the mouse fell was recorded as a 
binary result (1 = mouse fell, 0 = mouse did not fall). The fall percentage in each experimental 
group was then calculated as follows: Fall percentage of experimental group = (sum of values for 
each experimental group) ÷ (number of test subjects in group) x 100. The inverted screen test 
was conducted on a total of 54 animals. 
                                                                                 
RNA Isolation and quantitative Real-Time 
Whole brain samples were collected at postnatal day 8 and homogenized in Trizol 
(Sigma) using a Polytron power homogenizer. Standard Trizol (Sigma) method was followed to 
isolate total RNA, which was then reverse-transcribed into cDNA with MMuLV reverse 
transcriptase (New England Biolabs, Ipswich, MA) using manufacturer’s protocol. Quantitative 
real-time polymerase chain reaction (qRT-PCR) was conducted on the cDNA samples using 
SYBER green master mixes in a 7500 FAST RT-PCR system (Applied Biosystem, Foster City, 
CA). The ΔΔCt method was used to calculate transcript expression and determine relative 
quantification (RQ) values (described in Wong et al. 2014). Autism-implicated genes were 
chosen based on current findings from human studies (refer to discussion) and our recent study 
in embryonic COX-2-/- mice (Rai-Bhogal et al., 2018). Primer Express v3.0 (ThermoFisher 
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Scientific, Waltham, MA) was used to design the primers for genes investigated: Wnt2, Tcf4, 
Glo1, Grm5 (Table 8-1). Hypoxanthine phosphoribosyl transferase (Hprt) and phosphoglycerate 
kinase 1 (Pgk1) served as housekeeping controls for the qRT-PCR experiments. The RQ means 
were calculated from the RQ values of three different litters determined in three independent 
experiments.  
Table 8-1: qRT-PCR Primers for autism-linked genes in PGE2-exposed mice 
 
Statistical Analysis 
All numerical data are reported as mean±standard error of the mean (SEM), which 
encompasses the average of individuals from a minimum of three separate litters for each 
condition and time point. Three-way ANOVA followed by Bonferroni pair-wise comparisons 
was conducted for the open field test, marble burying test, and three-chamber sociability test to 
analyze potential behavioural differences dependent on condition (control vs. PGE2-exposed), 
sex (male vs. females), or age (young vs. adult). The Kruskal-Wallis H test followed by post hoc 
pair-wise comparisons was conducted on fall percentages in the inverted screen test. Independent 
Name Primer Primer Sequence (5’-3’) Base pair Length 
Hprt Forward TCCATTCCTATGACTGTAGATTTTATCAG 29 
 Reverse AACTTTTATGTCCCCCGTTGACT 23 
Pgk1 Forward CAGTTGCTGCTGAACTCAAATCTC 24 
 Reverse GCCCACACAATCCTTCAAGAA 21 
Wnt2 Forward GCCCTGATGAACCTTCACAAC 21 
 Reverse TGACACTTGCATTCTTGTTTCAA 23 
Tcf4 Forward GGGTTTGCCGTCTTCAGTCTAC 22 
 Reverse GCCTGGCGAGTCCCTGTT 18 
Glo1 Forward GGATTTGGTCACATTGGGATTG 22 
 Reverse CGTCATCAGGCTTCTTCACA 20 
Grm5 Forward CATGGAGCCTCCGGATATAATG 22 
 Reverse GTATCCAAGAGGAGTGACAACC 22 
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t-test was performed to determine if there were differences in gene expression. Significance was 
determined for p values less than 0.05. 
 
8.4. Results 
Three-Chamber Sociability Test of Social Behaviour 
The three-chamber sociability test was used to characterize changes in social behaviour 
(Fig. 8-1A). The time spent in the novel object, centre, or novel mouse chamber was recorded 
and reported in seconds. 
Three-way ANOVA analysis was completed on the total times spent inside the chamber 
with the novel object (Fig. 8-1B, F(7,45)=4.986, p=0.000309). Pair-wise comparisons on the 
time spent in the novel object chamber revealed no significant differences between young wild-
type (WT) and PGE2-exposed males (p=0.088). However, adult PGE2-exposed males spent 
significantly more time in the novel object chamber compared to adult WT males (p=0.000007; 
WT=191.3±6.10, PGE2=283.2±14.2). Female WT or PGE2 mice did not show differences in the 
time spent inside the novel object chamber (p>0.05). 
Three-way ANOVA analysis was also completed on the total times spent inside the  
chamber with the novel mouse (Fig. 8-1C, F(7,45)=3.806, p=0.002515). Similarly, significant 
differences were not found between young WT and PGE2-exposed males (p=0.261) but adult 
PGE2-exposed males occupied the novel mouse chamber for a significantly shorter duration than 
adult WT males (p=0.000562; WT=307.7±12.7, PGE2=203.0±13.0). Statistical analyses on 
female mice found that only young PGE2-exposed females spent significantly less time in the 
novel mouse chamber compared to young WT controls (p=0.0291; WT=306.9±15.8, 
PGE2=243.5±38.2).  
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Sex differences were only observed between adult PGE2-exposed mice: males spent more 
time in the novel object chamber (Fig. 8-1B, p=0.00348; Male (M)=283.2±14.2, Female 
(F)=222.5±7.11) and less time in the novel mouse chamber (Fig. 8-1C, p=0.01390; 
M=203.0±13.0, F=281.3±16.9) compared to females. 
Age-dependent comparisons were also completed and statistical differences were only 
seen between PGE2-exposed males, where adult males spent more time inside the novel object 
chamber (Fig. 8-1B p=0.00001; Young (Y)=185.5±23.8, Adult (A)=283.2±14.2) and less time in 
the novel mouse chamber than young males (Fig. 8-1C, p=0.000135; Y=330.8±27.3, 
A=203.0±13.0).  
The time spent interacting with the novel object or the novel mouse was also quantified 
by measuring the amount of time spent sniffing or touching. Three-way ANOVA analysis on the 
time interacting with the novel object was completed (Fig. 8-1D, F(7,45)=8.74, p=0.00000096). 
Pair-wise comparisons showed that all PGE2-exposed animals spent more time sniffing or 
touching the novel object compared to respective controls. This was seen in young PGE2-
exposed males (p=0.000825; WT=60.1±4.0, PGE2=95.0±8.5), adult PGE2-exposed males 
(p=0.000002; WT=48.7±4.5, PGE2=101.2±11.5), young PGE2-exposed females (p=0.006152; 
WT=53.7±7.1, PGE2=81.7±8.2), and adult PGE2-exposed females (p=0.010211; WT=51.4±6.2, 
PGE2=77.5±6.0). No sex- or age-dependent differences were found between groups for times 
spent sniffing or touching the novel object (p>0.05).  
Three-way ANOVA analysis on the time spent sniffing and touching the novel mouse 
was also conducted (Fig. 8-1E, F(7,45)=9.031, p= 0.00000065). PGE2-exposed animals spent 
less time interacting with the novel mouse than respective WT controls. This was seen in young 
PGE2-exposed females (p=0.000073; WT=140.1±9.3, PGE2=65.5±7.9), adult PGE2-exposed 
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males (p=0.000014; WT=119.4±13.4, PGE2=35.8±4.3), and adult PGE2-exposed females 
(p=0.00087; WT=111.0±11.6, PGE2=50.0±5.9). There were no statistical differences for time 
spent interacting with the novel mouse between young WT and PGE2-exposed males (p=0.1019; 
WT=115.7±18.6, PGE2=87.2±9.4). There were no sex- or age-dependent differences between 
experimental groups for the times spent sniffing and touching the novel mouse (p>0.05). 
In summary, the three-chamber sociability test revealed that both young and adult PGE2-
exposed animals displayed abnormal social behaviour, however, adult PGE2-exposed mice spent 
the most time in the object chamber. When compared to WT controls, adult PGE2-exposed mice 
spent overall significantly more time occupying the novel object chamber and interacting with 
(sniffing or touching) the novel object, while also spending significantly less time inside the 
novel mouse chamber and sniffing or touching the novel mouse. Some sex- and age-dependent 
differences were also found but only in the PGE2-exposed groups. 
 
Marble Burying Test of Anxiety-linked and Repetitive Behaviours  
To assess repetitive and anxiety-like behaviour, the marble burying test was administered 
(Fig. 8-2A). The number of marbles that were completed buried after the 30 minute trial was 
recorded. The total time spent digging and grooming were also measured. Three-way ANOVA 
analysis was conducted on marble burying counts (Fig. 8-2B, F(7,54)=9.623, p=0.000000105). 
Pair-wise comparisons determined that most PGE2-exposed groups buried significantly more 
marbles compared to matched WT controls including young PGE2-exposed males (p=0.000002; 
WT=1.6±0.625, PGE2=7.9±1.79), young PGE2-exposed females (p=0.000103; WT=0.6±0.400, 
PGE2=5.6±1.21), and adult PGE2-exposed females (p=0.0062; WT=2.1±0.588, 
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PGE2=5.1±0.581). No statistical differences were seen between adult PGE2-exposed and WT 
males (p=0.309; WT=4.4±0.0.766, PGE2=5.6±0.429). 
 There were no sex-dependent differences between males and females within the young 
WT (p=0.325) or young PGE2-exposed (p=0.0960) groups. Sex differences were seen between 
adult WT males and females, where males buried significantly more marbles than females 
(p=0.0270; M=4.4±0.0.766, F=5.6±0.429). However, there were no differences between adult 
PGE2-exposed males and females (p=0.694) indicating that in contrast to the sex difference seen 
in WT controls, adult PGE2-exposed females buried a similar number of marbles as PGE2-
exposed males. Age differences were found exclusively between young and adult WT males, 
with adults burying more marbles than young animals (p=0.0101; Y=1.6±0.625, 
A=4.4±0.0.766). This age-dependent difference was not observed across age groups between 
young and adult PGE2-exposed males (p=0.0673), as young PGE2-exposed males buried a large 
number of marbles and this was persistent in adult PGE2-exposed males. No statistical 
differences were seen across age groups between young and adult WT females (p=0.137) or 
PGE2-exposed females (p=0.703). 
Three-way ANOVA analysis was also completed on digging behaviour (Fig. 8-2C, 
F(7,48)=4.708, p=0.000441). The time spent digging (s) complemented our results regarding the 
number of marbles buried whereby PGE2-exposed mice spent more time digging than WT 
controls. Statistically increased time of digging behaviour was seen in young PGE2-exposed 
males (p=0.00104; WT=206.1±19.7, PGE2=390.3±49.6) and adult PGE2-exposed females 
(p=0.00133; WT=218.8±25.3, PGE2=387.9±24.3) in comparison to respective matched controls. 
No significant differences in digging time were seen between adult WT and PGE2-exposed males 
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(p=0.470; WT=343.3±49.2, PGE2=389.4±62.3) or between young WT and PGE2-exposed 
females (p=0.363; WT=220.8±46.2, PGE2=279.0±60.9).  
Sex-dependent differences in digging time were only seen between adult WT mice. 
Specifically, adult WT males spent more time digging than adult WT females (Fig. 8-2C, 
p=0.0348; M=343.3±49.2, F=218.8±25.3). Age-dependent differences were only found between 
young and adult WT males, with adult mice spending significantly more time digging than 
young mice (Fig. 2C, p=0.0229; Y=206.1±19.7, A=343.3±49.2).  
Three-way ANOVA analysis was also completed on grooming behaviour (Fig. 8-2D, 
F(7,48)=5.452, p=0.000120). Young PGE2-exposed females were found to spend statistically 
more time grooming than matched females (p=0.000485; WT=67.3±9.0, PGE2=129.4±8.3). No 
significant differences in grooming behaviour were found between respective controls and young 
PGE2-exposed males (p=0.546; WT=68.7±6.0, PGE2=77.3±8.5), adult PGE2-exposed males 
(p=0.159; WT=34.0±4.6, PGE2=57.8±8.3), or adult PGE2-exposed females (p=0.639; 
WT=52.8±12.4, PGE2=58.9±13.5).  
Sex-dependent differences in grooming behaviour were only seen in young PGE2-
exposed animals, where males spent statistically less time grooming than females (Fig. 8-2D, 
p=0.00205; M=77.3±8.5, F=129.4±8.3). Age-dependent differences in grooming behaviour were 
seen between young and adult WT males (p=0.0279; Y=68.7±6.0, A=34.0±4.6), with adult males 
spending less time grooming than young males. Grooming differences between age groups were 
also found in PGE2-exposed females. Young PGE-exposed females spent a greater time 
grooming than adult PGE2-exposed females (p=0.000042; Y=129.4±8.3, A=58.9±13.5). 
To summarize, the marble burying test revealed that PGE2-exposed mice buried more 
marbles and spent more time digging than WT controls. Sex and age differences were found in 
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WT groups for marble burying but were not present in PGE2-exposed mice. On average, young 
PGE2-exposed males buried the greatest number of marbles and spent the most time digging. The 
time spent grooming was greatest in young PGE2-exposed females and reached statistical 
significance when compared to young PGE2-exposed males and across age groups when 
compared to adult PGE2-exposed females. Young WT males spent significantly more time 
grooming than adult WT males. In contrast, the increased grooming behaviour seen in young 
PGE2-exposed males was persistent in the adult group. 
 
Open Field Test of Hyperactive locomotor and Anxiety-like Behaviours 
To evaluate ambulatory activity and anxiety-like behaviour in a novel environment, the 
open field test was used (Fig. 8-3A). Movement behaviour was assessed by measuring the total 
pathlength (cm) that was travelled (Fig. 8-3B), while anxiety-like behaviour was determined by 
quantifying the time spent in the centre of the apparatus (Fig. 8-3C).  
Pathlength values underwent three-way ANOVA analysis followed by pair-wise 
comparisons (Fig. 8-3B, F(7,50)=6.638, p=0.000015). Young PGE2-exposed males were found 
to travel a greater pathlength than WT male controls (p=0.000083; WT=4179±188, 
PGE2=5414±318). There was no significant difference in ambulatory activity between adult 
PGE2-exposed males and WT controls (p=0.835; WT=4308±148, PGE2=4247±142). Young 
PGE2-exposed females also travelled a longer pathlength than WT female controls (p=0.000083; 
WT=3720±68.4, PGE2=5079±70.0) and there were no statistical differences between adult WT 
and PGE2-exposed females (p=0.705; WT=4052±280, PGE2=3937±293). There were no 
statistical sex-dependent differences in pathlength travelled between males and females in all 
groups tested (p>0.05). Age-dependent differences in ambulatory activity were observed 
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between young and adult PGE2-exposed males (p=0.000411, Y=5414±318, A=4247±142) and 
PGE2-exposed females (p=0.000393, Y=5079±70.0, A=3937±293). In both comparisons, young 
mice travelled a greater pathlength than adult mice. In contrast, no age-dependent differences 
were seen within WT males (p=0.654) or WT females (p=0.301). 
Three-way ANOVA analysis was conducted on the amount of time spent in the centre of 
the apparatus (s) to evaluate anxiety-like behaviour (Fig. 8-3C, F(7,51)=2.586, p=0.02318). 
Young PGE2-exposed males spent less time in the centre than WT males (p=0.01496; 
WT=50.38±12.4, PGE2=20.89±2.86) and this pattern was also observed between young PGE2-
exposed females and WT females (p=0.00412; WT=52.67±11.9, PGE2=17.85±3.18). No 
significant differences were detected between adult PGE2-exposed males and WT controls 
(p=0.366; WT=24.89±5.34, PGE2=34.78±6.74) or between adult PGE2-exposed females and WT 
controls (p=0.840; WT=26.87±5.59, PGE2=29.19±7.12). There were also no sex-dependent 
differences for the time spent in the centre between all groups tested (p>0.05). Age-dependent 
differences in anxiety-like behaviour were only found between young and adult WT males 
(p=0.022573; Y=50.38±12.4, A=24.89±5.34) and between young and adult WT females 
(p=0.03727; Y=52.67±11.9, A=26.87±5.59). In both cases, young WT mice spent more time in 
the centre than adult WT mice. In contrast, this age-dependent difference was not seen in PGE2-
exposed males (p=0.241) or PGE2-exposed females (p=0.304), which is the result of decreased 
times in the centre for both young PGE2-exposed males and females. 
The main findings from the open field test were specific to the young cohorts: young 
PGE2-exposed males and PGE2-exposed females travelled a greater pathlength and spent less 
time in the centre compared to respective WT controls. This indicates that young PGE2-mice 
show increased hyperactivity and greater anxiety-linked behaviour in the open field test. 
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Ambulatory activity remained consistent across age groups in WT animals. However, 
ambulatory activity was decreased in adult PGE2-exposed animals compared to young PGE2-
exposed animals. Adult WT animals spent significantly less time in the centre compared to 
young WT animals indicating increased anxiety-linked behaviour in adults. In contrast, PGE2-
exposed animals exhibited constant elevated anxiety-like behaviour in both young and adult 
groups. No sex-dependent differences were characterized in the open field test.  
 
Inverted Screen Test of Motor Strength and Stress-linked Behaviour 
The inverted screen test was administered to assess changes in motor strength and stress-
related behaviour (Fig. 8-4A). To evaluate motor strength, fall percentages (%) were calculated 
for each experimental group as described in the methods section. The Kruskal-Wallis H test was 
conducted on fall percentage values to determine potential statistical differences (Fig. 8-4B, 
H(7)=19.271, p=0.00738).  Fall percentage was not statistically different between young WT and 
PGE2-exposed males (p=0.999; WT=50±18.9, PGE2=50±22.4) or adult WT and PGE2-exposed 
males (p=0.916; WT=75.0±25.0, PGE2=77.8±14.7). Similarly, differences in fall percentage 
were no statistically significant between young WT and PGE2-exposed females (p=0.429; 
WT=12.5±12.4, PGE2=0.0±0.0) or adult WT and PGE2-exposed females (p=0.089; 
WT=33.3±21.1, PGE2=0.0±0.0). Sex differences in fall percentages were only observed in adult- 
PGE2-exposed animals, where males fell more often (78%) than females (0%) (p= 0.001604; 
M=77.8±14.7, F=0.0±0.0). No significant differences in fall percentages were found between the 
age groups tested (p>0.05). 
The number of fecal boli produced by the mouse subject during the inverted screen test 
was recorded to assess stress-related behaviour (see methods). Three-way ANOVA analysis was 
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completed on fecal boli values (Fig. 8-4C, F(7,46)=3.269, p=0.00769).  Young PGE2-exposed 
males defecated more frequently than WT controls (p=0.00379; WT=1.3±0.42, PGE2=3.6±0.60). 
The number of fecal boli were not statistically different between adult WT or PGE2-exposed 
males (p=0.752; WT=2.5±0.65, PGE2=2.3±0.49). There were also no significant differences 
between young WT and PGE2-exposed females (p=0.140; WT=1.3±0.42, PGE2=2.5±0.50) or 
adult WT and PGE2-exposed females (p=0.575; WT=3.2±0.60, PGE2=3.6±0.53). No significant 
sex differences were observed (p>0.05). Comparisons between age groups revealed that young 
WT females had fewer fecal boli than adult WT females (p=0.0121; Y=1.3±0.42, A=3.2±0.60). 
There were no other differences in defecation between age groups (p>0.05). 
Overall, PGE2-exposure did not statistically affect fall outcomes in the inverted screen 
test. However, adult PGE2-exposed males were found to fall more often than adult PGE2-
exposed females suggesting potential abnormality in motor strength in adult PGE2-exposed 
males. The increased number of fecal boli in young PGE2-exposed males compared to WT 
controls implies a potential for elevated stress levels in young PGE2-exposed males during the 
inverted screen test. Adult WT females produced higher number of fecal boli than young WT 
females suggesting that WT females may experience more stress with increased age. In contrast, 
it was found that young and adult PGE2-exposed females had an elevated number of fecal boli 
across both age groups.  
 
Abnormal expression of Wnt2 and Glo1 in PGE2-exposed mouse offspring 
Our previous in vitro study and in vivo studies on abnormal PGE2/COX signalling mouse 
models collectively found differential expression of the genes: Wnt2, Tcf4, Glo1, and Grm5 (Rai-
Bhogal et al., 2018, Rai-Bhogal et al., 2017, Wong et al., 2014), which have all been previously 
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associated with ASDs (Skafidas et al., 2014, Abdallah et al., 2012, Marui et al., 2010, Junaid et 
al., 2004). The expression of these autism-linked genes was quantified in PGE2-exposed mice 
and compared to WT controls. Total brain samples from postnatal day 8, the time analogous to 
infanthood in humans (Pressler and Auvin, 2013, Semple et al., 2013), were collected for 
analysis. Gene expression profiles were determined using quantitative real-time RT-PCR 
analysis (Table 8-1). 
In comparison to WT males (RQ = 1), the expression of Wnt2 and Tcf4 was significantly 
different in PGE2-exposed males (Table 8-2). Specifically, PGE2-exposed males had statistically 
decreased expression of Wnt2 (t(4)=6.282, p=0.02441; RQ=0.8859±0.018) and Tcf4 (t(4)=4.803, 
p=0.00862; RQ=0.5781±0.087) compared to controls. The expression of Glo1 (t(4)=1.739, 
p=0.15702; RQ=0.8618±0.079), and Grm5 (t(4)=1.831, p=0.20863; RQ=0.8575±0.078) were 
not statistically different. In contrast, only one of the genes showed altered expression in PGE2-
exposed females compared to WT females (RQ = 1); Glo1 was also significantly decreased 
compared to controls (t(4)=35.563, p=0.00079, RQ=0.6259±0.011) (Table 3). No statistical 
differences were found in the expression of Wnt2 (t(4)=-1.266, p=0.33298; RQ=1.1072±0.085), 
Tcf4 (t(4)=-2.067, p=0.17462; RQ=1.3067±0.148), and Grm5 (t(4)=I2.072, p=0.17402; 
RQ=1.2689±0.130)  between PGE2-exposed females and WT controls. Overall, we found sex-
dependent dysregulation of ASD gene expression in PGE2-exposed offspring. 
 
8.5. Discussion 
Our present study demonstrates for the first time that autism-like behaviours can result 
from a maternal injection of PGE2 at a single time-point during pregnancy in mice. We propose 
that prenatally PGE2-exposed mice may serve as a novel experimental model system for studying 
357 
 
specific types of ASDs. The findings described in this study add new and convincing evidence 
that abnormal PGE2 signalling may impact brain development and contribute to autism 
symptomatology. We report that offspring of PGE2-injected mice exhibit complex behavioural 
alterations linked to autism at different postnatal ages, including abnormal sociability, increased 
repetitive behaviours, hyperactivity, and anxiety (Table 8-3). We also provide novel evidence for 
distinct sex- and age-specific behavioural differences in this animal model and emphasize the 
importance of such analyses in research related to disorders such as autism. 
The three-chamber sociability test showed that PGE2-exposed male mice spent more time 
in the novel object chamber than the novel mouse chamber, suggesting object preference over 
social preference. This behaviour manifested at a later age during adulthood. PGE2-exposed 
males and females also spent more time interacting with the object and less time interacting with 
the novel mouse compared to respective controls. These results are comparable to the tendency 
of children with autism to show preference for solitary object play over social play (Memari et 
al., 2015, Volkmar et al., 2014). Similar to the male bias for decreased social interaction 
observed in the three-chamber test, clinical studies have reported that male individuals with ASD 
are less likely to engage in social interactions (Hiller et al., 2016, Lai et al., 2015, McLennan et 
al., 1993) while females with ASD are thought to be more socially motivated (Sedgewick et al., 
2016, Lai et al., 2015, Head et al., 2014). Although PGE2-exposed and control females displayed 
social preference by spending the most time inside the novel mouse chamber, PGE2-exposed 
females spent significantly less time interacting with the novel mouse and more time interacting 
with the novel object. This social discrepancy between PGE2-exposed and control females was 
only made apparent through the analysis of object and social interaction. This might be akin to 
the finding that girls with autism stay in close proximity to peers, masking their social 
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challenges, while boys with autism tended to play alone (Dean et al., 2017, Lai et al., 2015). 
Similarly, women with ASD have also been described to have better superficial socio-
communicatory abilities, which may conceal their social difficulties (Lai et al., 2011). 
Results from the marble burying test demonstrated that PGE2-exposed mice buried a 
greater number of marbles and spent more time digging than WT controls. In particular, young 
PGE2-exposed males buried the most marbles and spent the most time digging, analogous to 
increased ASD-associated repetitive and anxiety-like behaviours. Studies on children and 
adolescents with ASD have also found that restrictive and repetitive behaviours are more 
prominent in males with ASD than their female counterparts (Mandy et al., 2012, Sipes et al., 
2011). We also observed that young PGE2-exposed females exhibited the most grooming 
behaviour among all groups. Increased grooming behaviour is an indication of elevated stress 
and anxiety (Smolinsky et al., 2009). Anxiety disorders are a common comorbidity of ASDs (van 
Steensel et al., 2011). Moreover, young children with ASD, especially girls, have more anxiety 
symptoms than older children and boys (Wijnhoven et al., 2018). The increased anxiety-like 
behaviour observed in young PGE2-exposed mice appears to resemble these clinical findings of 
co-occurring anxiety symptoms with higher risk in young females with ASD.  
The open field test revealed that both males and females PGE2-exposed mice at young 
age displayed increased ambulatory activity, indicative of hyperactivity (Seibenhener and 
Wooten, 2015). Our age-dependent finding seems to parallel studies on attention deficit 
hyperactivity disorder (ADHD) and ASDs, which have reported that symptoms of ADHD are 
often exhibited by individuals with ASD, particularly young children (Leitner, 2014, Sikora et 
al., 2012). Additionally, young PGE2-exposed mice also spent a decreased amount of time in the 
centre during the open field test suggestive of greater anxiety (Seibenhener and Wooten, 2015). 
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As mentioned above, young children with ASD show more symptoms of anxiety compared to 
older children with ASD (Wijnhoven et al., 2018). This age-dependent difference was also seen 
in the open field test, where young PGE2-exposed mice exhibited elevated anxiety-like 
behaviour. 
There were no significant differences in fall percentages between PGE2-exposed and 
control mice for the inverted screen test, demonstrating that motor strength of offspring was not 
affected by maternal PGE2 exposure. Motor deficits are comorbid symptoms to ASDs (Travers et 
al., 2017, Ming et al., 2007) but irregularities in motor strength were not found in PGE2-exposed 
mice. However, young PGE2-exposed males and females mice produced a significantly greater 
number of fecal boli during the inverted screen test. Increased defecation in mice has been shown 
to be induced by elevated levels of psychological stress or anxiety (Monnikes et al., 1993). We 
found that the age-dependent difference of anxiety-like behaviour, specific to young PGE2-
exposed mice, was also demonstrated in the inverted screen test as well as the marble burying 
test and open field test discussed earlier. Our behavioural results signify that the offspring of 
PGE2-exposed mother mice display social abnormalities, repetitive behaviours, hyperactivity, 
and elevated anxiety that might be analogous to atypical behaviours observed in ASDs. 
In addition to investigating behaviours of PGE2-exposed mice, we also examined the 
expression of known autism-associated genes including Wnt2, Tcf4, Glo1, and Grm5 (Gabriele et 
al., 2014, Skafidas et al., 2014, Sweatt, 2013, Kalkman, 2012). Interestingly, the expression of 
three of these key developmental genes, Wnt2, Tcf4, and Glo1, was affected in postnatal day 8 in 
PGE2-exposed mice, with different effects in males and females. Specifically, we found 
decreased expression of Wnt2 and Tcf4 in PGE2-exposed males and decreased Glo1 expression 
in PGE2-exposed females compared to respective controls.  
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The Wnt2 (Wingless/integrated 2) ligand is an important activator of the Wnt signalling 
pathway, which is crucial in brain development (Noelanders and Vleminckx, 2017, Sousa et al., 
2010) and has been associated with ASDs (Kalkman, 2012). Tcf4, short for transcription factor 
4, is a key protein initiated through canonical Wnt signalling (Cadigan and Waterman, 2012) and 
has been linked to ASDs and schizophrenia (Kwan et al., 2016, Sweatt, 2013). Various genetic 
knockout mouse models targeting Wnt pathway molecules have ASD-related behavioural 
deficits, such as impaired sociability and repetitive behaviours (Belinson et al., 2016, Dong et al., 
2016, Kwan et al., 2016, Lugo et al., 2014). Decreased Wnt2 and Tcf4 levels measured in PGE2-
exposed male mice may contribute to abnormal sociability and repetitive behaviours that were 
also prominent in PGE2-exposed males. Moreover, these results provide further evidence for an 
interaction between the PGE2 and WNT signalling pathways in the brain, which has been 
previously shown in our lab in cell and animal model systems (Wong et al., 2019, Rai-Bhogal et 
al., 2018, Wong et al., 2016, Wong et al., 2014). 
Glo1 (Glyoxalase 1) expression and its translated protein is important for the enzymatic 
detoxification of reactive oxygen species (Distler and Palmer, 2012). A specific GLO1 allele, 
C332 (Ala111), which results in the reduction of glyoxalase activity, has been associated with 
increased autism vulnerability (Gabriele et al., 2014). Decreased Glo1 expression in PGE2-
exposed females could result in elevated oxidative stress, which has been linked to ASDs 
(Rossignol and Frye, 2014, Meguid et al., 2011, Chauhan and Chauhan, 2006). Oxidative stress 
has also been implicated in the genesis of anxiety (Hassan et al., 2014). In line with the 
connection between oxidative stress and anxiety, irregular Glo1 transcript and protein expression 
has been associated with anxiety-like behaviour in mice (Distler et al., 2012, Hovatta et al., 2005, 
Kromer et al., 2005). It may be possible that the diminished expression of Glo1 in PGE2-exposed 
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females may have influenced the increase of anxiety-like behaviours characterized in these mice 
(demonstrated in the marble burying test, open field test, and inverted screen test). 
Lastly, it is interesting that the abnormal behaviours manifested in prenatally PGE2-
exposed mice resemble those from our previous study in a decreased PGE2 model, namely, in 
COX-2-deficient mice (Wong et al., 2019).  The PGE2-exposure and COX-2-deficient 
experimental models resulted in social defects, repetitive behaviours, hyperactivity, and anxiety-
like behaviour. Social abnormalities and anxiety-like behaviours were more distinct in PGE2-
exposed mice of this current study, while motor deficits were exclusive to COX-2-deficient 
mice. Collectively, these studies suggest that elevated or decreased PGE2 signalling might lead to 
consequent ASD-like pathologies. Other studies have reported that postnatal increase or decrease 
in PGE2 levels also contribute to social irregularities in male rodents (Hoffman et al., 2016, Dean 
et al., 2012). The findings from our study and others’ are comparable to evidence from clinical 
studies, where increased PGE2 signalling—for example, from exposure to maternal inflammation 
(Madore et al., 2016) or pesticides (De Felice et al., 2016, Holzman, 2014, Shelton et al., 
2014)—or diminished PGE2 signalling—from acetaminophen use (Masarwa et al., 2018, Parker 
et al., 2017, Schultz and Gould, 2016)—have been associated with increased risk for ASDs. 
Altogether, results from these various studies strengthen the evidence that the COX-2/PGE2 
signalling pathway is an autism candidate pathway.  
 
8.6. Conclusions 
In conclusion, our study found that prenatally PGE2-exposed mice exhibit abnormal 
sociability, repetitive behaviour, anxiety, and hyperactivity, as well as aberrant expression of 
ASD-linked genes in a sex- and age-dependent manner. We provide novel evidence that 
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disrupted COX-2/PGE2 signalling, which could occur through different environmental or genetic 
causes, may influence the development of ASD-like behaviours. Moreover, our study highlights 
that the maternal environment or prenatal exposure to risk factors that can affect the level of 
PGE2 during critical stages of development may result in a spectrum of ASD symptomatology. 
Our study also shows that it is imperative that molecular and behavioural research be conducted 
in both males and females at various developmental ages, which is currently underrepresented in 
the literature. 
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8.7. Figures 
 
 
 
Fig. 8-1: Sociability behaviour was determined in PGE2-exposed mice using the three-
chamber test. (Figure description on following page). 
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Fig. 8-1: Sociability behaviour was determined in PGE2-exposed mice using the three-
chamber test. (A) Video recordings were taken and the time spent in the chambers or interacting 
with the novel object or novel mouse was measured. (B) Adult PGE2 -exposed males spent 
significantly more time in the object chamber. (C) Young PGE2-exposed males and females 
spent significantly less time in the novel mouse chamber than controls. Sex differences were 
only observed between adult PGE2-exposed mice. Age-dependent differences were only seen in 
PGE2-exposed males. (D) PGE2-exposed animals spent more time interacting with the object 
than WT controls. (E) PGE2-exposed mice spent less time interacting with the mouse compared 
to WT controls. n represents the number of animals tested in each experimental group, 
originating from at least 3 different litters. Data are presented as mean ±SEM, *p<0.05, 
**p<0.01, ***p<0.001.   
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Fig. 8-2: Repetitive and anxiety-linked behaviour in PGE2-exposed mice in the marble 
burying test. (Figure description on following page). 
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Fig. 8-2: Repetitive and anxiety-linked behaviour in PGE2-exposed mice in the marble 
burying test. (A) Video recordings were taken and total marbles buried were counted. (B) PGE2-
exposed mice buried more marbles than WT controls. (C) Young PGE2-exposed males and adult 
PGE2-exposed females spent more time digging than controls. Sex differences were seen in adult 
WT mice. Age differences were seen in WT males. (D) Young PGE2-exposed females spent the 
most time growing. Sex differences were seen in young PGE2-exposed mice. Age differences 
were seen in WT males and PGE2-exposed females. n represents the number of animals tested in 
each experimental group, originating from at least 3 different litters. Data are presented as mean 
±SEM, *p<0.05, **p<0.01, ***p<0.001.   
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Fig. 8-3: Ambulatory activity and anxiety-linked behaviour in PGE2-exposed mice in the 
open field test. (A) An automated tracking program determined the pathlength travelled. (B) 
Pathlength results showed that young PGE2-exposed mice travelled more than WT controls in 
male and female groups. Age-dependent differences were only seen in PGE2-exposed mice. (C)  
Measurements for anxiety-like behaviour revealed that young PGE2-exposed mice spent less 
time in center than controls. Age-dependent differences in anxiety-related behaviour were found 
only in WT groups. n represents the number of animals tested in each experimental group.Data 
presented as mean±SEM, *p<0.05, **p<0.01, ***p<0.001.   
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Fig. 8-4: Motor ability and anxiety-like behaviour was measured in PGE2-exposed mice 
using the inverted screen test. (A) For the inverted screen test, whether or not the mouse 
subjects fell was recorded. (B) There was no significant difference in fall percentage between 
PGE2-exposed mice and WT controls. Sex differences were seen between Adult PGE2-exposed 
mice; males fell more frequently. (C) Young PGE2-exposed males and females displayed greater 
anxiety-like behaviour by producing increased number of fecal boli. n represents the number of 
animals tested in each experimental group, originating from at least 3 different litters. Data are 
presented as mean ±SEM, *p<0.05, **p<0.01.   
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Table 8-2 : Expression of autism-linked genes in PGE2 -exposed mice. 
Gene expression analysis on autism-linked genes were completed on postnatal day 8 samples as 
shown as RQ units for male and female PGE2 groups relative to respective controls (RQ=1). 
Values represent the mean of individuals from at least 3 independent litters. *p<0.05, **p<0.01, 
***p<0.001 
PGE2 -exposed compared to WT controls : Autism-Linked Genes 
Males RQ Mean Values p-values 
Wnt2 0.8859 0.02441* 
Tcf4 0.5781 0.00862** 
Glo1 0.8618 0.15702 
Grm5 0.8575 0.20863 
Females RQ Mean Values p-values 
Wnt2 1.1072 0.33298 
Tcf4 1.3067 0.17462 
Glo1 0.6259 0.00079*** 
Grm5 1.2689 0.17402 
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Table 8-3. Summary of behavioural findings for PGE2 -exposed mice. 
Results represent the overall significant behavioural comparisons of PGE2 -exposed mice to 
respective WT controls, where ↑ = Increased; ↓ = Decreased; - = not significant. Each finding is 
a representation of individuals from at least 3 independent litters.  
 
PGE2 -exposed  mice compared to WT controls: Behavioural Results 
Behaviour PGE2 Male PGE2 Female 
Young Adult Young Adult 
3 Chamber Test  
Social-related behaviour  
(time spent in novel object chamber) 
- ↑ - - 
3 Chamber Test  
Social-related behaviour  
(time spent in  novel mouse chamber) 
- ↓ - - 
3 Chamber Test  
Social-related behaviour  
(interaction with novel object) 
↑ ↑ ↑ ↑ 
3 Chamber Test  
Social-related behaviour  
(interaction with novel mouse) 
- ↓ ↓ ↓ 
Marble Burying Test  
Anxiety-like & Repetitive Behaviour 
(marbles buried) 
↑ - ↑ ↑ 
Marble Burying Test  
Anxiety-like & Repetitive Behaviour 
(digging time) 
↑ - - ↑ 
Marble Burying Test  
Anxiety-like Behaviour  
(grooming time) 
- - ↑ - 
Open Field Test  
Hyperactivity  
(pathlength) 
↑ - ↑ - 
Open Field Test  
Anxiety-like Behaviour  
(time in center) 
↓ - ↓ - 
Inverted Screen Test  
Motor Deficits 
(fall percentage) 
- - - - 
Inverted Screen Test  
Stress-like Behaviour 
(defecation) 
↑ - ↑ - 
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CHAPTER 9.   
 
GENERAL DISCUSSION 
 
9.1. Dissertation Objectives Revisited 
Although clinical and epidemiological evidence have revealed a correlation between 
disrupted COX-2/PGE2 lipid signalling and risk for the development of ASDs, literature 
surrounding the molecular mechanisms of this connection is sparse. Therefore, the global aim of 
this dissertation was: To discover the molecular mechanisms by which abnormal signalling of 
lipid mediators, specifically prostaglandin E2 (PGE2), may affect brain development and 
contribute to ASDs-related pathologies. Another important objective was to describe sex 
differences in mouse studies, which are often overlooked although critical for understanding 
disorders such as ASDs. I hypothesized that abnormal COX-2/PGE2 lipid signalling can disrupt 
healthy brain development and lead to molecular characteristics and behaviours associated with 
ASDs in a sex-dependent manner.  
From our research studies, we first found in our cell model that PGE2 treatment could 
affect important brain developmental processes including cell movement, proliferation and 
differentiation in neuroectodermal (NE-4C) stem cells, while also interfering with the Wnt 
signalling pathway by disrupting Wnt-target gene expression. Our investigations in vivo then 
determined that an increase or decrease of PGE2 during development could also lead to changes 
in cell density, cell migration, microglial density and morphology, as well as expression of 
autism-linked genes and the manifestation of autism-like behaviours.  
Sex-dependent differences are typically underrepresented in research. We observed sex-
differences in all in vivo studies. Irregular COX-2/PGE2 signalling via COX-2-deficiency or an 
increased level of PGE2 led to sex-specific changes in cell density, neocortical cell migration, 
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microglial density, microglial morphology, expression of various developmental and autism-
linked genes, and manifestation of autism-related behaviours. 
Based on the results of the six presented research studies, we report that disturbances to 
normal COX-2/PGE2 signalling could be detrimental to the developing brain due to the 
molecular, cellular, and behavioural conseuqences mentioned above. Our studies are the first to 
show that these changes are manifested differently in males and females at various 
developmental ages, which are consistent with clinical findings. We propose that the COX-
2/PGE2 signalling pathway may influence the pathogenesis of ASDs and is an autism-candidate 
pathway. Furthermore, PGE2-injected and COX-2- KI animals may serve as two new 
experimental model systems for studying specific types of ASDs. 
 
9.1.1 Key Findings of Specific Objectives 
In this section, the specific objectives outlined in this dissertation and respective results 
will be summarized. The implications of these major findings emerging from this collection of 
studies are discussed in further detail in the next section: “9.2. Discussion and Future 
Directions”.  
 
Objective 1) to study the effects of PGE2 exposure on the proliferation and migration of early 
neuroectodermal (NE-4C) stem cells. 
We showed that an elevated level of PGE2 can influence the function of NE-4C cells by 
promoting cell proliferatory behaviour (Study 1 and 2) and increasing their final distance, 
pathlength, and average speed (Study 1). 
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Objective 2) to determine if an elevated level of PGE2 influences the differentiation of NE-4C 
stem cells.  
 In Study 2, we found that increased levels of PGE2 could increase the proliferation of 
NE-4C stem cells in a dose-dependent manner and could also promote their differentiation. 
Specifically, PGE2 accelerated the progression of NE-4C cells into neurons through earlier 
expression of a neurosphere adhesion molecule (Cdh2) and modification of neurosphere 
characteristics (area, perimeter, roundness). Furthermore, PGE2 increased the protein expression 
of β-catenin (signal transducer of Wnt canonical pathway) and altered the expression of Wnt-
target genes Wnt3, Tcf4, and Ccnd1 during differentiation. 
 
Objective 3) to investigate the possible interaction between the PGE2 pathway and a major 
developmental pathway of the nervous system called the Wnt signalling pathway. 
In Study 1 and 2, we demonstrated for the first time that cross-talk exists between the 
PGE2 and Wnt/β-catenin canonical signalling pathways, which was mediated through kinases, 
protein kinase A (PKA) and phosphatidylinositide 3-kinase (PI-3K). Furthermore, we also 
determined that in response to PGE2, the levels of β-catenin as well as the expression of 
downstream Wnt-target genes previously associated with ASDs can be altered.  
 
Objective 4) to verify our in vitro findings by studying the consequences of elevated maternal 
levels of PGE2 on cell proliferation and neuronal migration in the developing brain of offspring 
mice. 
 In Study 3, a single subcutaneous maternal injection of PGE2 during development at 
embryonic day 11 (E11) resulted in long-term changes at postnatal day 8 (P8); the densities of 
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cells originating from E11 and E16 were altered (increased in olfactory bulb and decreased in 
cerebellum and neocortex) and E11 and E16 cells displayed further neocortical migration. PGE2 
exposure also led to changes in the expression of cell growth and motility genes (Spn, Actb). 
 
 Objective 5) to describe if altered COX-2/PGE2 signalling can disrupt microglial density and 
morphology. 
 In Study 4, prenatal PGE2 exposure or COX-2-deficiency changed the density and 
morphology of microglia in P8 offspring. Both conditions led to higher microglial densities in 
the cerebellum, olfactory bulb, thalamus (PGE2-exposed mice), and prefrontal cortex (COX-2-
deficient mice). PGE2-exposed mice had a greater percentage of amoeboid microglia and fewer 
ramified microglia, which was further demonstrated by decreased branching and process lengths. 
In contrast, COX-2-deficient mice displayed a lower percentage of amoeboid microglial cells 
and more ramified microglia. Greater branching and process lengths were also found in COX-2-
deficient mice.  
 
Objective 6) to examine the behavioural outcomes of COX-2-deficient and PGE2-exposed mice. 
 In Study 5 and 6, autism-related behaviours were observed in both COX-2-deficient and 
PGE2-exposed mice, respectively. COX-2-deficient mice displayed elevated hyperactive, 
repetitive, and anxiety-linked behaviours, motor deficits, and social abnormalities. PGE2-
exposed mice displayed distinct social abnormalities as well as increased hyperactive, repetitive, 
and anxiety-linked behaviours. At P8, COX-2-deficient mice displayed changes in the expression 
of ASD-associated genes: Wnt2, Glo1, Grm5, Mmp9. PGE2-exposed mice at P8 also showed 
altered expression of ASD-associated genes: Wnt2, Tcf4, Glo1. 
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9.2. Discussion and Future Directions 
 
Key topics emerging from our results that span across multiple in vitro and in vivo studies 
will be discussed further: the effect of PGE2 on neurogenesis, the convergence of the PGE2 and 
Wnt signalling pathways, the sex-dependent effects of COX-2/PGE2, implications for increased 
or decreased levels of PGE2, and their contributions to literature on Autism. 
 
9.2.1. The effect of PGE2 on Neurogenesis  
Neurogenesis involves the stages of proliferation, migration, differentiation, and 
functional integration (Lazarov and Demars, 2012). In study 1 through 3, we show that PGE2 can 
affect the proliferation, migration, and differentiation of neural cells.  
Our investigations into the effect of PGE2 on proliferation and cell density demonstrated 
that in vitro PGE2 can promote the proliferation behaviour (increased percentage of cells 
splitting, Study 1, Fig. 3-4) and increase the total number of NE-4C stem cells (Study 2, Fig. 4-
1). Interestingly, Study 3 showed that in vivo prenatal exposure to PGE2 at E11 led to i) a 
decrease in the density of E11-born and E16-born cells at P8 in the cerebellum of both sexes, ii) 
a decrease in E16-born cells in the neocortex of females, and iii) an increase in E11-born and 
E16-born cells in the olfactory bulb of males.  E11-born and E16-born cells likely represent 
neuronal cells since neurons are largely generated from E10 to E18 in rodents, while astrocytes 
and oligodendrocytes appear at later time points around E18 and postnatally, respectively 
(Reemst et al., 2016, Miller and Gauthier, 2007, Bayer and Altman, 1991). Although our in vitro 
studies revealed an increase in neuronal proliferation in response to PGE2 treatment, our findings 
in vivo portrayed a more complex picture demonstrating that an elevated level of PGE2 during 
prenatal development results in sex-dependent, region-specific, and time-sensitive changes. This 
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may be explained by the fact that neurogenetic processes are governed by both intrinsic and 
extrinsic factors (Calof, 1995). Extracellular signals that influence the microenvironmental 
conditions inside the brain (Navarro Quiroz et al., 2018), which are present in vivo (but are 
absent in vitro), are likely the cause for the distinct differences in how PGE2 affects cell density 
in a region- and sex-dependent manner. We show that the COX-2/PGE2 signalling pathway 
converges with the Wnt signalling pathway to regulate proliferation in NE-4C stem cells in vitro. 
Future studies are needed to further explore the potential cross-talk that happens between these 
two pathways that regulate cell proliferation in vivo. Additionally, subsequent investigations into 
whether a connection exists between the COX-2/PGE2 pathway and other important cell growth 
and proliferation pathways such as the Notch and BMP signalling pathways (Jovanovic et al., 
2018, Navarro Quiroz et al., 2018, Zhou et al., 2010) will help uncover the extent in which PGE2 
may impact key developmental processes. 
 An elevated level of PGE2 can also alter the migration of cells in vitro and in vivo, and 
promote the differentiation of cells in vitro. Our in vitro study determined that an elevation in 
PGE2 level can increase the final distance, pathlength, and speed of NE-4C stem cells (Study 1, 
Fig. 3-3, 3-4). Similarly, we also found that prenatal exposure to PGE2 can also result in greater 
neocortical migration of cells originating from E11 and E16 (Study 3, Fig. 5-5). Alterations in 
the position of each neuron in the brain may have more significant consequences compared to 
other cells in the body since the functions of neurons rely on the precise connections made 
between neurons and target cells (Purves et al., 2011). The final location of a neuron will 
influence its differentiation and development, including the orderly organization of neural 
circuits that are responsible for processing information (Yuste, 2015). Furthermore, we showed 
that increased PGE2 can also accelerate the differentiation of NE-4C stem cells into neurons 
389 
 
(Study 2, Fig. 4-2). Irregular migration or differentiation of neurons, resulting from an increase 
in PGE2 level, could lead to disrupted connectivity of neural networks including those underlying 
complex social and emotional information processing (Zikopoulos and Barbas, 2013, Wegiel et 
al., 2010). 
Overall, Study 1 through 3 demonstrated that PGE2 can alter various stages of 
neurogenesis, including proliferation, migration, and differentiation. How PGE2 affects the 
function of neurons, such as its influence on the formation of axons, synapses, and cell circuitry 
will need to be addressed in future experiments.  
 
9.2.2. Convergence of PGE2 and Wnt Signalling Pathways  
 Wnt molecules are morphogenic signals that are essential to the proper development of 
the nervous system (Wang et al., 2012). Anterior-posterior patterning, cell proliferation, neuronal 
maturation, and synaptogenesis are examples of some of the many processes regulated by Wnt 
signalling (Rosso and Inestrosa, 2013, Hirabayashi et al., 2004). PGE2 signalling is also involved 
with brain development and maturation, including neurite outgrowth, synaptic plasticity, and 
synaptic transmission (Nango et al., 2017, Dean et al., 2012, Alix et al., 2008, Sang et al., 2005). 
Previous research identified that cross-talk between the PGE2 and Wnt signalling pathways in 
diverse cell types including hematopoietic stem cells, gastric progenitor cells, and embryonic 
kidney cells (Goessling et al., 2009, Oshima et al., 2006, Fujino et al., 2002). However, the 
possible interaction between these two developmental pathways had not been investigated in 
neural cell types and the brain.  
Our studies 1, 2, 5, and 6 demonstrated that altered levels of PGE2 can influence Wnt 
signalling and its expression of gene targets. Our in vitro studies revealed that PGE2 can alter 
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Wnt-induced proliferation and movement behaviour of NE-4C stem cells by increasing β-catenin 
protein expression through kinases (PKA and PI3K) downstream in the PGE2 pathway (Study 1, 
Fig. 3-1, 3-2, 3-3). An elevated level of PGE2 also increased the expression of Wnt target genes 
Ctnnb1, Ccnd1, Mmp9, Wnt3, and Tcf4 but decreased expression of Ptgs2 (Study 2, Fig. 4-4, 4-
5). Interestingly Ptgs2 encodes for the COX-2 enzyme, which is responsible for the production 
of PGE2. Thus, we reported for the first time that cross-talk occurs between the PGE2 and Wnt 
pathways in neural stem cells. Our results indicated that PGE2 may promote the expression of 
Wnt-target genes, although feedback regulation likely also exists between these two pathways. 
This is in line with previous studies, which have predominately reported that PGE2 activates the 
Wnt signalling pathway in various tissues (Nam et al., 2018, Goessling et al., 2009, Castellone et 
al., 2005), while a negative feedback loop between PGE2 and the Wnt pathway has also been 
described (Gonzalez et al., 2010). Our investigations in vivo showed that prenatal exposure to 
PGE2 led to a decrease in postnatal Wnt2 and Tcf4 expression (Table 8-2), while COX-2-
deficiency resulted in an increase in Wnt2 expression (Table 7-3). Our in vivo findings support a 
negative feedback loop whereby an increase in the level of PGE2 may contribute to a future 
decrease in Wnt target gene expression. Similarly, this feedback regulation between the PGE2 
and Wnt pathways may be the reason that a decrease in PGE2 level (via COX-2-deficiency) led 
to an increase in Wnt2 expression at a later time point.  
What remains to be determined are the mechanisms by which cross-talk occurs between 
the PGE2 and Wnt pathways in vivo—perhaps through PKA, PI-3K, and/or β-catenin as seen in 
vitro. Furthermore, our studies focused on the canonical Wnt pathway since it is the most well-
established of the Wnt pathways and because of its involvement in the control of gene expression 
and cell behaviour. Importantly, future investigations need to be made into the effect of PGE2 on 
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non-canonical Wnt pathways, such as the Wnt/Ca2+ and Planar Cell Polarity (PCP) pathways. 
These pathways can act independently of β-catenin and also regulate key neurodevelopmental 
processes such as cell migration and cell polarization (McQuate et al., 2017, Gomez-Orte et al., 
2013, De, 2011, Sugimura and Li, 2010, Komiya and Habas, 2008). A connection between PGE2 
and non-canonical Wnt signalling has been reported in osteoblasts and chondrocytes (Doroudi et 
al., 2014) but have yet to be examined in brain tissue cells.   
 
9.2.3. The Sex-dependent effects of COX-2/PGE2 
Human diseases and disorders, including ASDs, can affect males and females differently. 
The sex of an individual can influence their susceptibility, development, and progression of a 
disorder (Pollitzer, 2013, Wald and Wu, 2010). Therefore, it was important for us to examine the 
sex-specific outcomes of abnormalities to the COX-2/PGE2 signalling pathway. We identified 
various differences between males and females in our in vivo studies (Study 3, 4, 5, and 6): 
deviations to normal COX-2/PGE2 levels (an increase or decrease) can lead to sex-dependent 
changes in cell density, neocortical cell migration, microglial density and morphology, and 
autism-related behaviours.  
The sexually dimorphic physiology and behaviour observed in our studies perhaps could 
be explained by the interaction between sex hormones and PGE2. The PGE2-driven sex 
differences in the brain and in behaviours likely involved the molecular mechanisms behind the 
potent estrogen called estradiol. Estradiol is made from the androgen, testosterone, through the 
enzymatic activity of aromatase (Wright et al., 2010). In the rodent brain, estradiol has been 
shown to play a key role in physiological and behavioural masculinization (Wright et al., 2010, 
Wu et al., 2009). A burst of testosterone occurs in the male testes during early development, and 
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it is the subsequent conversion of testosterone, which enters the brain, into estradiol that drives 
the formation of male-specific neural circuitry (Wu et al., 2009). Perinatal up-regulation of 
COX-2 and consequent synthesis of PGE2 can be induced by estradiol to mediate various 
functions including formation of dendritic spines, masculinization of microglial number and 
morphology, and development of male sex behaviour (Lenz et al., 2013, Wright et al., 2010, 
Amateau and McCarthy, 2004). Conversely, an increase in PGE2 has also been found to cause an 
elevation of testosterone (Wade and Van der Kraak, 1993), while aromatase activity and 
estradiol level can also be regulated by PGE2 (Pedersen and Saldanha, 2017, Subbaramaiah et al., 
2011, Richards and Brueggemeier, 2003). Moreover, a positive feedback loop between estradiol 
and PGE2 has been described in endometrial tissue (Waclawik et al., 2009). Interestingly, PGE2 
has been found to induce an increase in estradiol content following brain injury through a sex-
dependent mechanism: PGE2 acts through EP3 receptors in males, while PGE2 binds to EP4 
receptors in females (Pedersen and Saldanha, 2017).  A similar sex-dependent mechanism 
between specific PGE2 EP receptors and estradiol signalling may also exist during brain 
development and requires future attention.  
Taken altogether, aberrations in the COX-2/PGE2 pathway during early development, 
resulting in an increase or decrease in PGE2 levels, could disrupt the careful coordination 
between estradiol and PGE2 that orchestrates sex-specific development of the brain. Our research 
highlights the importance of analyzing males and females separately in order to uncover sex-
specific differences, which may provide better insight into the neural underpinnings of the 
molecular mechanisms responsible for the effects of abnormal COX-2/PGE2 signalling. Studying 
sex differences in mice models may provide clues into the origins of human brain disorders that 
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disproportionately affect one sex over the other, including ASDs which appears in more males 
than females (Baio et al., 2018).  
 
9.2.4. Increased and Decreased levels of PGE2 
We studied the effect of increased and decreased levels of PGE2 on autism-associated 
behaviours (Study 5 and 6) and on microglia (Study 4) and determined that either condition of 
excess or deficient levels of PGE2 could disrupt normal neurodevelopmental outcomes. We 
found that mice prenatally exposed to PGE2 through a single maternal injection displayed 
abnormal behaviours that resembled those observed in COX-2-deficient mice (Study 5 and 6). 
PGE2-exposure and COX-2-deficiency led to social defects and an increase in repetitive, 
hyperactive, and anxious behaviours. Together, these two studies suggest that either an elevation 
or decrease in the level of PGE2 may contribute to behavioural pathologies related to ASDs. Our 
findings correspond with other research in mice and humans revealing that either an increase or 
decrease of PGE2 during development could contribute to the manifestation of ASDs and their 
behavioural outcomes (Masarwa et al., 2018, Parker et al., 2017, Cortelazzo et al., 2016, 
Hoffman et al., 2016, Madore et al., 2016, Holzman, 2014, Shelton et al., 2014, Dean et al., 
2012). This has been discussed in greater detail in Chapter 8. Interestingly, in our microglial 
study (Study 4), we found that microglial density was generally increased in both PGE2-exposed 
and COX-2-deficient mice compared to respective controls. However, PGE2-exposure and COX-
2-deficiency led to contrasting results on microglial morphology: overall, PGE2-exposed mice 
had a greater percentage of morphologically “active” amoeboid microglia, while COX-2-
deficient mice had a greater percentage of morphologically “resting” ramified microglia from the 
norm. This indicates that the COX-2/PGE2 signalling pathway can regulate divergent functions 
of microglia.  
394 
 
Considering our collective findings from our studies on microglia and autism-associated 
behaviours, a careful balance of COX-2/PGE2 molecules is necessary for normal development. 
Deviations from the typical concentrations of COX-2/PGE2 during sensitive periods of prenatal 
development can drive different cellular mechanisms that could contribute to similar autism-
related behavioural consequences.  
The versatile responses of increased or decreased levels of PGE2 may be explained by 
investigating the four EP receptor subtypes that PGE2 binds to, including EP1 through EP4. Each 
EP receptor activates a unique signal transduction pathway, which can yield activation of distinct 
second messenger systems including cAMP, Ca2+, and inositol phosphate, and subsequent 
downstream kinases (Sugimoto and Narumiya, 2007). For example, we previously determined in 
Neuro-2A cells that PGE2 can promote an elevation of intracellular calcium through EP2 
receptor and downstream kinase, PKA, but PGE2 can also be involved with the inhibition of 
intracellular calcium through EP4 receptor and PI-3K (Tamiji and Crawford, 2010). 
Furthermore, PGE2 can induce differential desensitization and internalization of its EP receptors 
(Dey et al., 2006, Bilson et al., 2004, Desai et al., 2000, Nishigaki et al., 1996). This suggests 
that deviations to the level of PGE2 could affect the EP receptors in which they interact with and 
their resulting functions. Future studies utilizing agonists and antagonists of specific EP 
receptors will elucidate the mechanisms for the diverse responses of PGE2. 
 
9.2.5. Contribution to literature on ASDs   
  
Autism was historically believed to originate during life after birth, with the previous 
thought that the primary cause was poor parental nurturing (Evans, 2013, Kanner, 1954, Kanner, 
1943). This drove autism research to adopt a postnatal-focused research approach for decades 
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(Cohmer, 2014). Although the debate into the etiology of autism has existed for some time 
(Stein, 1966), it was only recently that there has been true acknowledgement for the need of a 
greater understanding of the prenatal pathogenic processes that result in the highly heterogeneous 
phenotypes of ASDs (Courchesne et al., 2019). Evidence for the prenatal origins of ASDs has 
come from clinical research, which determined that of the 72 high-confidence genes identified as 
being recurrent and most penetrant in individuals with ASD, 94% of them are highly active 
during the prenatal stages of development (Courchesne et al., 2019, Kosmicki et al., 2017). 
These genes regulate cell proliferation, differentiation, migration and early organization, and 
may also impact synaptogenesis and early learning experiences that occur postnatally 
(Courchesne et al., 2019, Kosmicki et al., 2017). Moreover, a new retrospective study in humans 
utilizing fetal ultrasound parameters has confirmed that the pathogenesis of autism begins 
prenatally (Bonnet-Brilhault et al., 2018).   
The series of studies presented in this dissertation was aimed at addressing this gap in 
knowledge and provide possible mechanisms by which autism pathogenesis may occur. Due to 
the clinical heterogeneity of ASDs, we believed it was important to approach their complex 
etiology from different angles and thus we investigated the influence COX-2/PGE2 signalling 
may have from the molecular, cellular, and behavioural perspective. Our behavioural studies 
provided novel proof that the COX-2/PGE2 signalling pathway can influence autism-associated 
behavioural outcomes, including social abnormalities, repetitive behaviours, hyperactivity, and 
anxiety (Study 5 and 6). Our other studies also showed that irregular levels of PGE2 affect 
cellular processes involved with proliferation, migration, and microglial density and morphology 
(Study 1-4). This suggests that improper development of these particular biological processes 
may contribute to the autism-related behaviours displayed in our studies. Changes in cell density 
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and migration can have direct consequences on the structure, organization, and connectivity of 
the brain; abnormalities in these areas have been reported in autism patients (Stoner et al., 2014, 
Abrams et al., 2013, Ecker et al., 2013, Wegiel et al., 2010, Schumann and Amaral, 2006, 
Redcay and Courchesne, 2005, Belmonte et al., 2004, Herbert et al., 2003). Moreover, a number 
of autism-associated genes were affected in our model systems, providing further confirmation 
that the level of PGE2 is likely involved in autism pathogenesis.  
Our research in mice offers new information on the developmental roles of COX-2/PGE2 
signalling that could not otherwise be investigated in humans. Our findings provide insight into 
the potential mechanisms contributing to the pathologies of ASDs seen in human cases. 
Altogether, all our studies provide new evidence that COX-2/PGE2 signalling can significantly 
impact neurodevelopment and support a relatively new hypothesis that the beginnings of ASDs 
occur prenatally (Courchesne et al., 2019, Donovan and Basson, 2017, Kaushik and Zarbalis, 
2016).  
 
9.3. Conclusions 
This dissertation encompassed a compilation of molecular, cellular, and behavioural work 
that aimed to expand our understanding of how the endogenous lipid signalling pathway, namely 
the COX-2/PGE2 pathway, may affect the developing brain. 
Our in vitro studies provided the first evidence that PGE2 can interfere with the signalling 
and function of key developmental morphogen, Wnt, by disrupting proliferation and 
differentiation while also causing irregular expression of Wnt-target autism-candidate genes. Our 
findings gave us confidence to pursue our investigations at the molecular, cellular, and 
behavioural level in vivo. The presented collection of in vivo studies determined that 
perturbations to this pathway, whether through increased PGE2 exposure or decreased PGE2 
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levels through a genetic defect, led to differences in cortical neuronal migration, cell density, 
microglial density and morphology, and autism-related behavioural outcomes. Moreover, our 
distinct sex-dependent findings indicate the etiological importance of studying both males and 
females, and also support the need for a personalized approach when treating ASDs. Althogether, 
our findings provide convincing evidence that the COX-2/PGE2 signalling pathway is an autism 
candidate pathway that deserves further investigation. We propose that the PGE2-injected and 
COX-2- KI mice used in these studies could be considered as new experimental model systems 
for studying ASDs-related pathologies.  
In closing, the COX-2/PGE2 signalling pathway is important for crucial 
neurodevelopmental processes. Exposure to environmental risk factors that can disrupt the levels 
of PGE2—such as immunological agents, air pollution, heavy metals, prolonged use of drugs like 
NSAIDs and acetaminophen, and particular consumer products—may be detrimental for the 
developing brain. Precautions taken to minimize exposure to these environmental risk factors 
during prenatal development are warranted. 
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